2012N155299_05 CONFIDENTIA L
The GlaxoSmithKline group of companies BMA117159
1TITLE PA GE
Division: World wide Development
Information Type: Protocol Amendment
Title: DREAMM -1: A Phase I Open -label, Dose Escalation Study  to 
Investigate the Safety , Pharmacokinetics, Pharmacody namics, 
Immunogenicit y and Clinical Activity  of the Antibody Drug 
Conjugate GSK2857916 in Subjects with Relapsed/Refractory  
Multiple My eloma and Other Advanced Hematologic 
Malignancies Expressing BCMA
Compound Number: GSK2857916
Development Phase:PHASE I
Effective Date: 02-NOV-2017
Protocol Amendment Number: 5
Author (s):
Clinical Research Group, R&D Oncology , UP, US
Value Evidence Outcomes, UP, US
Bioanal, Immunogenicity, & Biomarkers, IVIV T, PTS, UM, US
CPSSO , UP, US
Oncology  Clinical Statistics, UP, US
Oncology  Clinical Statistics, UP, US
Clinical Research Group, R&D Oncology , UP, US
R&D Oncology , UP, US
Clinical Pharmacol Modeling & Simulation, Stockley  Park, UK
Genetics, Stevenage, UK
Global Clinical Safety and Pharmacovigilance, UP, US
Safety , Ware, UK
Copy right 2017 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised cop ying or use of this inf ormation is prohibited.
PPD
2012N155299_05 CONFIDENTIA L
The GlaxoSmithKl ine group of companies BMA117159
2Revision Chronology
GlaxoSmith Kline
Document NumberDate Version
2012N155299_00 2013 -DEC -26 Original
2012N155299_01 2014 -MAR -01 Amendment No. 1
Country  specific Amendment for the United Kingdom to address required changes per 
MHR A.  Updated Exclusion Criteria to exclude subjects with current corneal disease or 
history  of corneal disease.  Updated QTc withdrawal criterion to modify  QTc withdrawal 
for QTc >500msec and to include > 60 msec increase from baseline.  Updated Data 
Manage ment Section 12 to include details on dissemination of data and communication 
plan.  
2012N155299_02 2014 -MAR -20 Amendment No. 2
Global Amendment to address required changes per the FDA.  Updated Inclusion Criteria 
with minimum weight requirement.  Updat ed Blood Volumes.  Revised Time and Events 
Tables. Corrected t ypographical errors.
2012N155299_03 2014 -MAY -05 Amendment No. 3
Country  specific Amendment for Canada to address required changes per Health Canada.  
Updated preparation instructions of GSK2857916.
2012N155299_04 2016 -MAY -05 Amendment No. 4
Global Amendment to include patient reported outcome instruments in the Part 2 multiple 
myeloma cohort and refine the ly mphoma histologies eligible in Part 2 BCMA -
expressing l ymphoma c ohort. Additionally ,the requirement for 60% of tumor cells 
staining positive for BCMA expression was removed. The total number of subjects that 
may be enrolled is presented by  a range of 80 to 95 to provide an updated estimate based 
on the number of subjects who enrolled at the time of the amendment.  Additional 
modifications include: changing the time -point specific blood specimens are collected for 
baseline/pre -treatment immunogenicit y and biomarker measurements, and the visit 
window for certain assessments.
2012N155299_05 2017 -NOV-02 Amendment No. 5
Global amendment to include additional follow up of multiple my eloma subjects for 
ocular exams (for those whose corneal signs or symptoms have not resolved), additional 
patient reported outcome instruments, addition of time -to-event endpoints as exploratory  
objectives. Subjects who have completed treatment or the 3 month follow up visit (end of 
study ) prior to amendment 5 will be reconsented for further follow up and survival status. 
Other administrative changes are also included
PPD
PPD
2012N155299_05 CONFIDENTIA L
BMA117159
4SPONSOR/MEDICAL MONI TOR INFORM ATION PA GE
Medical Monitor and Sponsor Contact Information:
Role Name Day Time 
Phone 
NumberAfter -hours 
Phone/C ell/
Pager 
NumberGSK Address
Primary 
Medical 
Monitor 
 
MDGlaxoSmithKline
1250 South Collegeville Road
Mailstop UP -4300
Collegeville, PA 19426, USA
Secondary 
Medical 
Monitor 
 MD, 
PhDGlaxoSmithKline
1250 South Collegeville Road
Mailstop UP4300
Collegeville, PA 19436, USA
Sponsor Registered Address:
GlaxoSmithKline
Iron Bridge Road
Stockley  Park West, Uxbridge, Middlesex, UB11
1BU, UK
Telephone:  
GlaxoSmithKline
Five Moore Drive 
P.O. 13398
Research Triangle Park, NC 27709- 3398, USA
Telephone: 
GlaxoSmithKline
1250 South Collegeville Road
Collegeville, PA 19426, USA
Telephone Number:
In some countries, the clinical trial sponsor may  be the local GlaxoSmithKline affiliate 
compan y (or designee).  Where applicable, the details of the Sponsor and contact person 
will be provided to the relevant regulatory  authority  as part of the clinical trial 
submission.
Regulatory  Agency  Identify ing Number(s):
Compound Number IND Number EudraCT Number
GSK2857916 119333 2013 -004549 -18
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
2012N155299_05 CONFIDENTIA L
BMA117159
5INVESTIGA TOR PROTOCOL AGREEMENT PA GE
For protocol number BMA117159
Iconfirm agreement to conduc t the study  in compliance with the protocol, as amended by  
this protocol amendment.
I acknowledge that I am responsible for overall study  conduct. I agree to personall y 
conduct or supervise the described stud y.
I agree to ensure that all associates, collea gues and employ ees assisting in the conduct of 
the study  are informed about their obligations. Mechanisms are in place to ensure that site 
staff receives the appropriate information throughout the study . 
Investigator Name:
Investigator Address:
Inves tigator Phone Number:
Investigator Signature Date
2012N155299_05 CONFIDENTIA L
BMA117159
6TABLE OF CONTENTS
PAGE
LIST OF ABBREVIATION S........................................................................................... 12
PROTOCOL SYNOPSIS ............................................................................................... 16
1.INTRODUCTION .................................................................................................... 32
1.1. Background ................................................................................................ 32
1.2. GSK2857916 .............................................................................................. 33
1.2.1. Background ................................................................................. 33
1.2.2. Preclinical Pharmacology ............................................................. 33
1.2.3. Preclinical Pharmacokinetics and Metabolism of 
GSK2857916 ............................................................................... 35
1.2.3.1. Single dose pharmacokinetics .................................... 35
1.2.3.2. Repeat dose pharmacokinetics ................................... 35
1.2.3.3. Distribution, Metabolism, and Excretion ...................... 37
1.2.3.4. Pharmacokinetic drug interactions .............................. 37
1.2.3.4.1. Victim interaction potential ...................... 37
1.2.3.4.2. Perpetrator interaction potential .............. 38
1.2.4. Toxicology of GSK2857916 (anti-BCMA MMAF) .......................... 38
1.2.5. Repeat dose toxicity .................................................................... 38
1.2.5.1. Rat............................................................................. 38
1.2.5.2. Cynomolgus monkey .................................................. 40
1.2.6. Genotoxicity ................................................................................. 43
1.2.6.1. Route assessment for genotoxic impurities ................ 43
1.2.7. Local tolerance ............................................................................ 43
1.3. Benefit:R isk Assessment ............................................................................ 44
1.3.1. Risk Assessment ......................................................................... 44
1.3.2. Benefit Assessment ..................................................................... 46
1.3.3. Overall Benefit:Risk Conclusion ................................................... 46
2.OBJECTIVE(S), ENDP OINT(S) AND HYPOTHES IS ............................................. 46
3.INVESTIGATIONAL PLAN ..................................................................................... 49
3.1. Discussion of Study Design ........................................................................ 49
3.2. Study Schematic ......................................................................................... 51
3.3. Part 1: Dose -Escala tion Phase ................................................................... 51
3.3.1. Dose Escalation on Schedule 1 (GSK2857916 
administered once every three weeks; 21 days = 1 cycle) ........... 52
3.3.1.1. Single Subject Cohort Run -in (Schedule 1 only) ......... 52
3.3.1.2. Description of N -CRM f or Schedule 1 ......................... 54
3.3.1.2.1. Planned Dose Levels .............................. 54
3.3.1.2.2. Implementation of N -CRM ...................... 55
3.3.1.2.3. Bayesian Prior ........................................ 56
3.3.2. Dose Escalation on Schedule 2 (GSK2857916 
administered once weekly x3, 1 week rest; 28 days = 1 
cycle) ........................................................................................... 57
3.3.3. Dose -Limiting Toxicity -Part 1 only .............................................. 58
3.3.4. Maximum Tolerated Dose ............................................................ 59
3.4. RP2 Dose and Administration Schedule Selection for Part 2 ...................... 59
2012N155299_05 CONFIDENTIA L
BMA117159
73.5. Intra-Subject Dose Escalation ..................................................................... 61
3.6. Rationale .................................................................................................... 61
3.6.1. Rationale for Study ...................................................................... 61
3.6.2. Rationale for Population ............................................................... 61
3.6.3. Rationale for Starting Dose .......................................................... 62
3.6.3.1. Human PK prediction .................................................. 62
3.6.3.2. Starting dose determination ........................................ 64
3.6.3.3. Potential therapeutic dose determination .................... 67
3.6.4. Rationale for Endpoints ................................................................ 68
3.7. Study Treatment ......................................................................................... 68
3.7.1. Treatment Assignment ................................................................ .68
3.8. Dosage and Administration of Study Treatment(s) ...................................... 69
3.8.1. Blinding ........................................................................................ 69
3.9. Safety Management Guidelines .................................................................. 69
3.9.1. Liver Chemistry Stopping Criteria ................................................ 69
3.9.1.1. Liver Chemistry Follow -up Procedures ....................... 69
3.9.2. QTc Stopping Criteria .................................................................. 71
3.9.3. Troponin Evaluation and Stopping Criteria ................................... 72
3.9.4. Left Ventricular Ejection Fraction (LVEF) ..................................... 72
3.9.4.1. LVEF Stopping Criteria ............................................... 72
3.9.4.2. Valvular Toxicity Stopping Criteria .............................. 73
3.9.5. Infusion -related Reactions and Cytokine Release 
Syndrome .................................................................................... 74
3.9.6. Allergic and Anaphylactic reaction ............................................... 75
3.9.7. Tumor Lysis Syndrome (TLS) Preventi on and Treatment 
Recommendations ....................................................................... 75
3.9.8. Ocular Toxicity and Stopping Criteria ........................................... 76
3.10. Guidelines for Events of Special Interest and Dose Modifications ............... 76
3.10.1. Guidelines for Events of Special Interest ..................................... 76
3.10.2. Predicted Toxicities and Proposed Dose 
Adjustments/Stopping Criteria ...................................................... 77
3.10.3. Dose Modifications ...................................................................... 82
4.INVESTIG ATIONAL PRODUCT(S) ........................................................................ 83
4.1. Description of Investigational Product ......................................................... 83
4.2. Preparation/Handling/Storage of GSK2857916 Investigational 
Product ....................................................................................................... 83
4.3. Product Accountability ................................................................................ 84
4.4. Treatment Compliance................................................................................ 85
4.5. Treatment of Investigational Product Overdose .......................................... 85
5.STUDY POPULATION ........................................................................................... 85
5.1. Number of Subjec ts .................................................................................... 85
5.2. Subject Selection Criteria ............................................................................ 86
5.2.1. Inclusion Criteria .......................................................................... 86
5.2.2. Exclusion Criteria ......................................................................... 89
6.COMPLETION OR WITHDRAW AL OF SUBJEC TS............................................... 90
6.1. Screen and Baseline Failures ..................................................................... 90
6.2. Subject Completion Criteria ........................................................................ 91
6.3. Permanent Discontinuation from Study Treatment ...................................... 91
6.4. Subject W ithdrawal ..................................................................................... 92
2012N155299_05 CONFIDENTIA L
BMA117159
86.5. Study Completion ....................................................................................... 92
6.6. Treatment after the End of Study ................................................................ 92
7.STUDY ASSESSMENTS AND PROCEDURES ..................................................... 92
7.1. Time and Events Tables ............................................................................. 93
7.1.1. Dose Escalation ........................................................................... 94
7.1.1.1. Every 3 W eeks Dosing Schedule for Multiple 
Myeloma ..................................................................... 94
7.1.1.2. Weekly Dosing Schedule (Dose Escalation) fo r 
Multiple Myeloma ....................................................... 97
7.1.2. Dose Expansion ......................................................................... 102
7.1.2.1. Every 3 W eeks Dosing Schedule for Multiple 
Myeloma ................................................................... 102
7.1.2.2. Dose Expansion W eekly Dosing Schedule for 
Multiple Myeloma ..................................................... 107
7.1.2.3. Dose Expansion Every 3 W eeks Dosing 
Schedule for Lymphomas ......................................... 111
7.1.2.4. Dose Expansion W eekly Dosing Schedule for 
Lymphomas .............................................................. 115
7.2. Demogr aphic/Medical History and Baseline Assessments ........................ 118
7.2.1. Critical Baseline Assessments ................................................... 118
7.3. Safety Evaluations .................................................................................... 118
7.3.1. Physical Examinations ............................................................... 119
7.3.2. ECOG Performance Status ........................................................ 119
7.3.3. Vital Signs .................................................................................. 119
7.3.4. Electrocardiogram ...................................................................... 119
7.3.5. Echocardiogram ......................................................................... 120
7.3.6. Ocular Exam .............................................................................. 120
7.3.7. Laboratory Assessments ........................................................... 120
7.3.8. Pregnancy Testing and Reporting .............................................. 122
7.3.9. Immunogenicity .......................................................................... 122
7.3.10. Visual Functioning Questionnaires ............................................. 122
7.3.10.1. National Eye Institute Visual Functioning 
Questionnaire -25...................................................... 123
7.3.10.2. Ocular Surface Disease Index Questionnaire ........... 123
7.4. Pharmacokinetics ..................................................................................... 123
7.4.1. Blood Sample Collection for Pharmacokinetics .......................... 123
7.4.2. Urine Sample Collection for Pharmacokinetics .......................... 124
7.4.3. Pharmacokinetic Sample Anal ysis............................................. 124
7.5. Translational Research ............................................................................. 124
7.5.1. Pharmacodynamics ................................................................... 124
7.5.1.1. BCMA Receptor Occupancy in bone marrow 
plasma cells .............................................................. 125
7.5.1.2. sBCMA Analysis ....................................................... 125
7.5.1.3. Activated TBNK cells ................................................ 125
7.5.1.4. Cytokine and Chemokine Analysis ........................... 125
7.5.2. Subject stratification/predictive biomarkers ................................ 125
7.5.3. Tumor Biomarker Analysis ......................................................... 126
7.5.3.1. Circulating cell free DNA (cfDNA) analysis ............... 126
7.6. Genetics ................................................................................................... 127
7.7. Evaluation of Anti -Cancer Activity ............................................................. 127
7.8. Health Outcomes: Quality of Life .............................................................. 128
2012N155299_05 CONFIDENTIA L
BMA117159
97.8.1. Bone Pain/Fatigue Assessment (eDiary) ................................... 128
7.8.2. Exit Interview and Follow -up Interview ....................................... 129
8.ADVERSE EVENTS AND S ERIOUS ADVERSE EVENT S................................... 129
8.1. Definition of an AE .................................................................................... 129
8.2. Definition of an SAE .................................................................................. 130
8.2.1. Sentinel Events .......................................................................... 131
8.3. Laboratory and Other Safety Assessment Abnormalities Reported 
as AEs and SAEs ..................................................................................... 132
8.3.1. Cardiovascular Events ............................................................... 132
8.4. Disease -Related Events and/or Disease- Related Outcomes Not 
Qualifying as SAEs ................................................................................... 133
8.5. Time Period and Frequency of Detecting AEs and SAEs .......................... 133
8.5.1. Method of Detecting AEs and SAEs ........................................... 133
8.5.2. Prompt Reporting of SAEs a nd Other Events to GSK ................ 134
8.5.3. Regulatory reporting requirements for SAEs .............................. 135
9.LIVER CHEMISTRY FOLL OW-UP PROCEDURES ............................................. 135
9.1. Liver Chemistry Testing Procedures ......................................................... 135
9.2. Liver Chemistry Monitoring Criteria ........................................................... 136
9.3. Drug Restart/Rechallenge Following Liver Events that are Possibly 
Related to Study Drug ............................................................................... 136
9.4. Drug Restart Fol lowing Transient, Resolving Liver Events Not 
Related to Study Drug ............................................................................... 137
10.CONCOMITANT MEDICATI ONS AND NON -DRUG THE RAPIES ....................... 138
10.1. Permitted Medication(s) ............................................................................ 138
10.2. Prohibited Medication(s) ........................................................................... 138
10.3. Permitted Non -Drug Therapies ................................................................ .138
10.4. Prohibited Non- Drug Therapies ................................................................ 138
11.LIFESTYLE AND/OR DIE TARY RESTRICTIONS ................................................ 139
11.1. Contraception ........................................................................................... 139
11.1.1. Female Subjects ........................................................................ 139
11.1.2. Male Subjects ............................................................................ 140
11.2. Lactation Restrictions ................................................................................ 140
12.DATA MANAGEMENT ......................................................................................... 140
12.1. Data Dissemination and Communication Plan .......................................... 141
13. DATA ANALYSIS AND STATISTICAL CONSIDERATIONS ................................ .142
13.1. Hypothesis(es) .......................................................................................... 142
13.1.1. Part 1: Dose -Escalation Phase .................................................. 142
13.1.2. Part 2: Expansion Cohort ........................................................... 142
13.2. Sample Size Determination ...................................................................... 142
13.2.1. Part 1: Dose -Escalation Phase .................................................. 142
13.2.2. Part 2: Expansion Cohort ........................................................... 143
13.3. Sample Size Sensitivity ............................................................................. 144
13.3.1. Sample Size Re- estimation ........................................................ 144
13.4. Data Analysis Consi derations ................................................................... 144
13.4.1. Analysis Populations .................................................................. 144
13.5. Treatment Comparisons ........................................................................... 145
2012N155299_05 CONFIDENTIA L
BMA117159
1013.5.1. Primary Comparisons of Interest ................................................ 145
13.5.1.1. Primary Comparison of Interest ................................ 145
13.5.2. Other Comparisons of Interest ................................................... 145
13.6. Interim Analysis ........................................................................................ 147
13.6.1. Part 1 ......................................................................................... 147
13.6.2. Part 2 ......................................................................................... 147
13.7. Key Elements of Analysis Plan ................................................................ .149
13.7.1. Anti-Cancer Activity Analyses .................................................... 149
13.7.2. Safety Analyses ......................................................................... 150
13.7.2.1. Extent of Exp osure ................................................... 150
13.7.2.2. Adverse Events ........................................................ 150
13.7.2.3. Clinical Laboratory Evaluations ................................ 150
13.7.2.4. Immunogenicity Analyses ......................................... 151
13.7.2.5. Other Safety Measures ............................................. 151
13.7.3. Pharmacokinetic Analyses ......................................................... 152
13.7.3.1. Raw Plasma Concentrations .................................... 152
13.7.3.2. Statistical Analysis of Pharmacokinetic Data ............ 153
13.7.4. Pharmacokinetic/Pharmacodynamic Analyses ........................... 154
13.7.4.1. Translational Research Analyses ............................. 154
13.7.4.2. Novel Biomarker(s) Analyses ................................... 154
13.7.5. Genetic Analyses ....................................................................... 154
13.7.6. Pharmacodynamic Biomarkers and Exploratory Response 
Prediction Biomarkers ................................................................ 154
13.7.6.1. Exploratory analyses of DNA, and Protein ................ 155
13.7.7. Clinical Activity Analyses ........................................................... 155
13.7.8. Health Outcome Analyses ......................................................... 156
14.STUDY CONDUCT CONSIDERATIONS ............................................................. 157
14.1. Posting of Information on Clinicaltrials.gov ................................................ 157
14.2. Regulatory and Ethical Considerations, Including the Informed 
Consent Process ...................................................................................... 157
14.3. Urgent Safety Measures ........................................................................... 157
14.4. Quality Control (Study Monitoring) ............................................................ 157
14.5. Quality Assurance ..................................................................................... 158
14.6. Study and Site Closure ............................................................................. 158
14.7. Records Retention .................................................................................... 159
14.8. Provision of Study Results to Investig ators, Posting of Information 
on Publicly Available Clinical Trials Registers and Publication .................. 159
15.REFERENCES ..................................................................................................... 160
16.APPENDICES ...................................................................................................... 163
16.1. Appendix 1: Internationa l Myeloma W orking Group Uniform
Response Criteria for Multiple Myeloma ................................................... 163
16.2. Appendix 2: Revised Response Criteria for Malignant Lymphoma ............ 166
16.3. Appendix 4: NYHA Functional Classification S ystem ................................ 168
16.4. Appendix 5: Modified Diet in Renal Disease Formula ................................ 169
16.5. Appendix 6: ECOG Performance Status1 ................................................. 170
16.6. Appendix 7: Genetics ................................................................................ 171
16.7. Appendix 8: Liver Safety Drug Restart Guidelines .................................... 174
16.8. Appendix 9: Urine Protein Creatinine (UPC) Ratio Clinical meaning 
of UPC ...................................................................................................... 178
2012N155299_05 CONFIDENTIA L
BMA117159
1116.9. Appendix 10: Blood Requirements ............................................................ 179
16.9.1. Blood Requirements for All Lab Tests, Except PK ..................... 179
16.9.1.1. Dose Escalation: Every 3 W eeks for Multiple 
Myeloma ................................................................... 179
16.9.1.2. Dose Escalation:  Weekly for Multiple Myeloma ....... 179
16.9.1.3. Dose Expansion:  Every 3 W eeks for Multiple 
Myeloma ................................................................... 180
16.9.1.4. Dose Expansion:  W eekly for Multiple Myeloma ....... 181
16.9.1.5. Dose Expan sion:  Every 3 W eeks for 
Lymphomas .............................................................. 181
16.9.1.6. Dose Expansion:  W eekly for Lymphomas ............... 182
16.9.2. Blood Requirements for PK ....................................................... 182
16.9.3. Total Blood Requirements ......................................................... 183
16.10. Appendix 11:  Pgp Inhibitors ..................................................................... 184
16.11. Appendix 12: Protocol Amendment Changes ............................................ 185
16.11.1. Amendment 1 ............................................................................ 185
16.11.2. Amendment 2 ............................................................................ 192
16.11.3. Amendment 3 ............................................................................ 231
16.11.4. Amendment 4 ............................................................................ 232
16.11.5. Amendment 5 ............................................................................ 253
2012N155299_05 CONFIDENTIA L
BMA117159
12LIST OF A BBREVIATIONS
ABC Airway  breathing and circula tion
ADA Anti- drug antibody
ADC Antibody  drug conjugate
ADCC Antibody  dependent cellular cy totoxicity
AE Adverse event
ALP Alkaline phosphatase
ALT Alanine aminotransferase
APRIL A proliferation -inducing ligand
AST Aspartate aminotransferase
AUC Area under the concentration- time curve
AUC (0 -∞) Area under the concentration-time curve to infinity
AUC (0 -) Area under the concentration time curve over the dosing 
interval
AV Atrioventricular
BAFF/BLy S B-cell activating factor/B -lymphocy te stimulat or
BAL Bronchoaveolar lavage
BCMA B cell maturation antigen
BCRP Breast cancer resistant protein
BCVA Best corrected visual acuity
BED Biologically  Effective Dose
BNP B-type natriuretic peptide
BSA Body surface area
BWT Body weight
CBC Complete bl ood count
CBR Clinical benefit rate
CDISC Clinical Data Interchange Standards Consortium
cfDNA Cell-free deox yribonucleic acid
CI Confidence interval
CK Creatine kinase
CK-MB Creatine kinase MB- isoenzy me
CL Clearance
CLL Chronic ly mphocy tic leukemi a
Cmax Maximum plasma drug concentration
CPMS Clinical Pharmacology Modeling and Simulation
CPR Cardio- pulmonary  resuscitation
CR Complete response
CRM Continual Reassessment Method
CRP C-reactive protein
CT Computer tomograph y
cTn Cardiac troponin
Ctrough Trough plasma concentration
CYP Cytochrome P450
CV% Coefficient of variation percent 
Cys-mcMMAF cys Monomethy l auristatin F 
2012N155299_05 CONFIDENTIA L
BMA117159
13DIC Disseminated intravascular coagulation
DOR Duration of response
DLBCL Diffuse large B -cell ly mphoma
DLT Dose limiting toxicity
DMPK Drug metabolism and pharmacokinetics
DNA Deox yribonucleic acid
EC50 Concentration associated with 50% maximal effect
ECL Electrochemiluminescence
ECOG Eastern Cooperative Oncology  Group
eCRF Electronic case report form
eDiary Electronic Diary
EM Extramedullary
EOI End of infusion
FACTS Fixed and adapted clinical trials simulator
FLC Free light chain
FSH Follicle stimulating hormone
FTIH First time in human
GLDH Glutamate deh ydrogenase
GLP Good laboratory  practice
GSK GlaxoSmithKline
GSK2857914 GlaxoSmithKline anti -BCMA antibody  (CA8 J6M0 
Potelligent)
GSK2857916 GlaxoSmithKline anti -BCMA antibody  drug conjugate (CA8 
J6M0 Potelligent MMAF)
HBs-Ag Hepatitis B surface antigen
HBc Hepatitis B core
HBV Hepatitis B
HCV Hepatitis C
HNSTD Highest non -severel y toxic dose
HPL C High performance liquid chromatograph y
HRT Hormone replacement therap y
IC50 Concentration associated with 50%  inhibition of maximal 
effect 
IDSL Integrated Data Standards L ibrary
Ig Immunoglobuli n
IHC Immunohistochemistry
IMIDs Immunomodulators
IMWG International M yeloma Working Group
INR International normalized ratio
IP Intraperitoneal
IV Intravenous
IVRS Integrated voice response sy stem
KIM-1 Kidney  injury  molecule -1
LBC L Large B -cell ly mphoma
LDH Lactate deh ydrogenase
MABEL Minimum anticipated biological effect level
2012N155299_05 CONFIDENTIA L
BMA117159
14mc Maleimidocapro yl
MDRD Modified diet in renal disease
MI Myocardial infarction
MM Multiple My eloma
MMAF Monomethy l auristatin F
MR Minimal response
MRI Magnetic resonance Imaging
MTD Maximum Tolerated Dose
NAG N-Acety l-β-D- glucosaminase
NCI-CTCAE National Cancer Institute –Common Terminology Criteria 
for Adverse Events
N-CRM A modification of the Continual Reassessment Method 
(CRM) proposed b y Neuenschwander et al.
NEI-VFQ -25 National Ey e Institute Visual Functioning Questionnaire - 25
NF-B Nuclear factor kappa light- chain enhancer of activated B 
cells
NK Natural killer
NONMEM Non linear mixed effects modelling
OAT Organic anion transporter
OATP Organi c anion transporter poly peptide
ORR Overall response rate
OSDI Ocular Surface Disease Index
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PD Pharmacod ynamic
PET Probability  of earl y termination
PFS Progression- free survival
PFT Pulmonary  function test
Pgp P-glycoprotein
PK Pharmacokinetic(s)
PR Partial response
PRO Patient reported outcome
PT Prothrombin time
PTS Platform technologies and sciences
PTT Partial thromboplastin time
QID 4 times a day
QoL Quality  of life
RAP Reporting and anal ysis plan
RAMOS Registration and medication ordering s ystem
REML Restricted maximum likelihood
RIBA Recombinant immunoblot assay
RNA Ribonucleic acid
Ro Observed accumulation ratio
RO Receptor occupancy
RPA -1 Renal papillary  antigen -1
RP2 Recommended Phase 2 
2012N155299_05 CONFIDENTIA L
BMA117159
15SAE Serious adverse event
sBCMA Soluble B -cell maturation antigen
sCR Stringent complete response
SD Stable disease
SOI Start of infusion
SPEP Serum protein electrophoresis
SPM Study  procedure manual
SPR Surface p lasmon resonance
t½ Half-life
TBNK T-cell, B-cell and N atural Killercells
Tlast Time of last quantifiable concentration
TLS Tumor ly sis sy ndrome
Tmax Time to maximum drug concentration
TTP Time to progression
ULN Upper limit of normal
UPEP Urine protein electrophoresis
VGPR Very  good partial response
Vd Volume of distribution
Vss Volume of distribution at steady  state
WM Waldenstrom’s macroglobulinemia
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companiesTrademarks no t owned by the 
GlaxoSmithKline group of companies
NONE FACTS
SAS
WinNonlin
2012N155299_05 CONFIDENTIA L
BMA117159
16PROTOCOL SYNOPSIS
TITLE A Phase I Open -label, Dose Escalation Study  to Investigate the 
Safety , Pharmacokinetics, Pharmacody namics, 
Immunogenicit y and Clinical Activity  of the Antibody  Drug 
Conjugate GSK2857916 in Subjects with Relapsed/Refractory  
Multiple My eloma and  Other Advanced  Hematologic 
Malignancies Expressing BCMA
PROTOCOL NUMBER BMA117159
CLINICAL PHASE I
COMPOUND(S) GSK2857916
STUDY RATIONALE This is a FTIH study  that will assess the safet y, 
pharmacokinetics (PK), pharmacod ynamics (PD) and 
therapeutic potential of GSK2857916 in multiple my eloma 
(MM) and lymphomas that express BCMA. GSK2857916 is a 
humanized immunoglobulin (IgG1) antibod y drug conjugate 
(ADC) which binds specifically  to B cell maturation antigen 
(BCMA). The parent anti -BCMA antibod y (J6M0) is 
conjugated to the microtubule inhibitor monomethy l auristatin -
F (MMAF) via a protease resistant maleimidocaproy l (mc) 
linker to produce the GSK2857916 ADC molecule.  Upon 
binding to the cell surface, GSK2857916 is rapidly internalized 
and active drug (cy s-mcMMAF) is released inside the cell.
GSK2857916 has been produced in an afucos ylated form to 
generate an enhanced antibody  dependent cellular cy totoxicity
(ADCC) response upon binding to Fc RIIIa receptors on the 
surface of human effector cells. This dual mechanism of action 
may improve efficacy  by targeting dividing through ADC and 
non-dividing tumor cells through ADCC. I mportantly , BCMA 
expression is maintained at the cell surface over time following 
GSK2857916 binding and internalization due to rapid BCMA 
receptor recy cling and/or new protein s ynthesis.  GSK2857916 
has demonstrated dose -dependent cytotoxic activity  in 
myeloma cell lines, ex vivo primary  myeloma tumor samples, 
as well as preclinical m yeloma mouse tumor models.  
GSK2857916 has also shown activity in B cell l ymphoma cell 
lines that express BCMA.
The hy pothesis is that GSK2857916 can be safely  administered 
to subjects with BCMA positive malign ancies at doses where 
target engagement can be demonstrated.  This study will 
determine if adequate target engagement of BCMA receptors 
translates into clinical benefit for subjects with MM and 
2012N155299_05 CONFIDENTIA L
BMA117159
17BCMA positive lymphomas . 
STUDY OBJECTIVES, 
ENDPOINTS AND 
HYPOTHESESHypothesis:  GSK2857916 can be safel y administered to 
subjects with MM and with BCMA positive lymphomas at 
doses where target engagement can be demonstrated.
Objective Endpoint
Primary
To determine safet y, 
tolerability , maximum 
tolerated dose (MT D), 
and recommended phase 
(RP2) dose and schedule 
of GSK2857916 
administeredAdverse events (AE) and 
changes in clinical signs 
and laboratory  
parameters 
Secondary 
To evaluate the 
pharmacokinetic (PK) 
profile of GSK2857916 
and the breakdown 
product cy s-mcMMAF) 
after intravenous (IV) 
single and repeat dose 
administration in subjects 
with relapsed/refractory  
MM and BCMA 
expressing ly mphomasGSK2857916 and cy s-
mcMMAF PK 
parameters following IV 
single and repeat dose 
administration during 
dose escalation as data 
permit (e.g., AUCs 
Cmax, tmax, CL , VSS, t½ 
[single dose], Cmax and 
Ctrough [repeat dose]).
GSK2857916 population 
PK parameters in 
expansion cohorts at the 
RP2 dose (e.g. clearance 
(CL), volume of 
distribution (Vd), and 
relevant covariates 
which may  influence 
exposure (e.g. age, 
weight, or disease -
related covariates e.g. 
BCMA expression) 
To assess anti -drug 
antibody  (ADA)
formation after IV single 
and repeat dose 
administration of 
GSK2857916ADA incidence and 
titers after single and 
repeat IV dosin g of 
GSK2857916
2012N155299_05 CONFIDENTIA L
BMA117159
18To explore the initial 
anti-tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and BCMA 
expressing ly mphomasClinical activity  
measured as Overall 
Response Rate (ORR) 
which is defined as 
follows:
oFor MM: the 
percentage of 
subjects 
achieving 
confirmed partial 
response or better 
(PR) 
oIn addition, the 
percentage of 
subjects with 
minimal response 
(MR) will be 
assessed for 
clinical benefit 
rate (CBR) 
(Appendix 1 )
oFor Lymphomas: 
the perc entage of 
subjects 
achieving PR or 
better ( PR) 
(Appendix 2 )
Exploratory 
To evaluate PD markers 
in MM after treatment 
with GSK2857916sBCMA levels, BCMA 
receptor occupancy  and 
cell death markers in 
subjects with M M. 
To explore relationships 
of GSK2857916 plasma 
concentrations/exposure 
with pharmacod ynamics 
(PD), safet y and clinical 
activity  Relationship between 
receptor occupancy , 
tumor cell death 
markers, sBCMA and 
GSK2857916 plasma 
PK parameters;
Relationship between 
safet y/clinical activity  
(e.g. ORR) and 
GSK2857916  PK 
parameters 
2012N155299_05 CONFIDENTIA L
BMA117159
19To characterize the 
relationship between 
clinical response and 
other biologic tumor 
characteristics (DNA, 
protein anal ysis)BCMA expression levels 
on malignant cells as 
measured b y IHC and/or 
flow cy tometry  in tumor 
tissue, serum sBCMA 
levels and their 
relationship to clinical 
response
To investigate the 
relationship between 
genetic variants in the 
host and response to 
study  medicine, or 
susceptibility , severit y 
and progression of
diseaseRelationship between 
host genetic variation 
and response to study  
medicine or 
susceptibility , severit y 
and progression of 
disease
To explore the effect of 
GSK2857916 on 
symptoms (including 
bone pain, fatigue and 
visual sy mptoms) and 
impacts on H RQoL  in 
subjects with 
relapsed/refractory  MM
(Part 2)Changes from baseline 
in bone pain/fatigue and 
analgesic use as 
measured b y the eDiary
Interviews with subjects 
to further characterize 
changes in sy mptoms
(including bone pain, 
fatigue and visual 
symptoms) and impacts 
on HRQoL
To explore changes in 
visual sy mptoms and 
function following 
discontinuation of 
treatment with 
GSK2857916Changes in visual 
symptoms and impacts 
as measured b y the 
OSDI  and NEI -VFQ -25 
following treatment 
discontinuation
Follow -up telephone 
interview s conducted to 
further understand 
subjects experience with 
visual sy mptoms and 
changes in s ymptoms 
and related impacts 
following treatment 
discontinuation 
2012N155299_05 CONFIDENTIA L
BMA117159
20To explore the initial 
anti-tumor activity  of 
GSK2857916 in subjects 
with rela psed/refractory  
MM in terms of time -to-
event (TTE) endpoints 
(Part 2 MM)Time to progression 
(TTP), defined as: the 
time from first dose until 
the earliest date of PD 
per International 
Multiple My eloma 
Working Group
(IMWG), or death due to 
PD.
Duration of response 
(DOR), defined as: the 
time from first 
documented evidence of 
PR or better; until the 
time when disease 
progression (PD) is 
documented per IMWG; 
or death due to PD 
occurs in participants 
who achieve a response, 
i.e. confirmed PR or 
better.
Time to response (TTR), 
defined as: the time 
between the date of first 
dose and the first 
documented evidence of 
response (PR or better).
Progression- free 
survival (PFS), defined 
as: the time from first 
dose until the earliest 
date of disease 
progression (PD) per
IMWG, or death due to 
any cause.
Number of deaths
STUDY DESIGN This study  is an open- label, dose escalation Phase I FTIH study  
to determine the RP2 dosing regimen of GSK2857916.  The 
recommended dose and schedule will be selected based on the 
safet y, pharmacokinetic (PK), and pharmacody namic (PD) 
profiles observed after administering the study  drug to subjects 
with multiple my eloma (MM).  The study  will consist of two 
parts and will enroll approximately  80-95subjects.  The Part 1 
dose escalation phase will characterize the safet y and 
2012N155299_05 CONFIDENTIA L
BMA117159
21tolerability  of respective dosing regimen for GSK2857916 
utilizing the model based on the Neuenschwander continual 
reassessment method (N-CRM).  Initially , GSK2857916 will 
be administered via 60 min intravenous (IV) infusio n once 
every  three weeks (21 day s = 1 cy cle). After a MTD or 
recommended phase 2 dose (RP2D) has been established on 
the once every  three weeks schedule, the safet y, tolerability , 
and PK of once -weekly  dosing of GSK2857916 for three 
consecutive weeks with 1 week rest (28 day s = 1 cy cle) may  be 
explored in an additional cohort(s). Part 2 will explore the 
safet y, tolerabilit y, PK, PD, and clinical activity of the RP2
dose of GSK2857916 identified in Part 1.  Subjects with MM 
(n=40) ,and lymphomas expressing B CMA (n=10) will be 
enrolled in expansion cohort in Part 2. Futility  analy ses will be 
performed on the MM cohort after approximately  15, 22, 30 
subjects have been enrolled. Sparse PK sampling will be 
collected to further characterize GSK2857916 exposures fo r 
the selected dose schedule.  Although not required for MM, 
subjects with lymphomas will be enrolled in Part 2 based upon 
the detection of positive BCMA staining of tumor cells in a 
prospective immunohistochemistry  screening assay  performed 
at a central l aboratory .
NUMBER OF SUBJECTS Approximately  80-95 subjects will be enrolled.
Up to 30 subjects with relapsed/refractory  MM will be enrolled 
in Part 1, Schedule 1; Schedule 2, if explored, will enroll up to 
15 additional subjects in Part 1.
Up to 40 subjec ts with relapsed/refractory  MM and up to 10 
subjects with lymphomas expressing BCMA will be enrolled in 
Part 2.
INCLUSION/EXCLUSION 
CRITERIAInclusion Criteria:
1.Provide signed written informed consent, which includes 
compliance with the requirements and r estrictions listed 
in the consent form.
2.Male or female, 18 years or older (at the time consent is 
obtained)
3.Eastern Cooperative Oncology  Group (ECOG) 
performance status of 0 or 1 ( Appendix 6 )
4.Part 1/dose escalation:
Histologicall y or c ytologically  confirmed diagnosis 
of: Multiple My eloma in a subject who fulfills all 
of the following: 
2012N155299_05 CONFIDENTIA L
BMA117159
22has undergone stem cell transplant, or is considered 
transplant ineligible, 
has been pretreated with at least the 3 following 
classes of anti -myeloma drugs: alk ylators, 
proteasome inhibitors and immunomodulators, 
has demonstrated progression on, or within 60 days 
of completion of the last therap y. 
Part 2 /MM cohort:
Histologicall y or c ytologically  confirmed diagnosis 
of: Multiple My eloma in a subject who fulfills all 
of the following: 
has undergone stem cell transplant, or is considered 
transplant ineligible, 
has been pretreated with at least the 3 following 
classes of anti -myeloma drugs: alk ylators, 
proteasome inhibitors and immunom odulators, 
and has demonstrated progression on, or within 60 
days of completion of the last therapy . 
AND has measurable disease with at least one of the 
following:
a.Serum M -protein  0.5 g/dL ( 5 g/L)
b.Urine M -protein  ≥200 mg/24h
c.Serum FLC assay : Involved FLC level ≥5 
mg/dL ( ≥50 mg/L) and an abnormal serum free 
light chain ratio (<0.26 or >1.65)
d.Biopsy  proven plasmacy toma (should be 
measured within 28 day s of Screening Visit)
or
Part 2/ BCMA positive Lym phoma cohort: 
a.Subject with one of the following 
lymphomas : Diffuse Large B -cell 
Lym phoma ( DLBCL) or follicular 
lymphoma (FL) that exhibits positive 
BCMA expression on tumor cells as 
determined by a central laboratory  using a 
validated IHC assay . Eligible subjects with 
BCMA positive lymphomas must also 
fulfill the prior treatment requirements as 
follows:
b.DLBCL: at least 2 prior lines of sy stemic 
2012N155299_05 CONFIDENTIA L
BMA117159
23therap y containing at least one line of 
chemo -immunotherap y with anti- CD20 
antibody , and either has undergone ste m 
cell transplant or is considered transplant 
ineligible
c.FL: at least 2 prior lines of sy stemic therapy  
5.Subjects with a history  of autologous stem cell 
transplant are eligible for study participation 
provided the following eligibility  criteria are met:
a.transplant was > 100 days prior to study  
enrolment
b.no active infection
c.subject meets the remainder of the eligibility  
criteria outlined in this protocol
6.Adequate organ s ystem functions as defined in 
Table below:
System Laboratory Values
Hematologic
Absol ute neutrophil count (ANC)11.0 X 109/L
Hemoglobin 8.0 g/dL
Platelets 50 X 109/L
Coagulation
INR 1.5 
PTT 1.5 x ULN
Hepatic
Total bilirubin ≤1.5 X ULN (isolated 
bilirubin >1.5xULN is 
acceptable if bilirubin 
is fractionated and 
direct bi lirubin <35%)
AST and ALT 1.5 X ULN
Renal
Serum creatinine or
Calculated creatinine clearance2
Albuminuria <1.2XULN
≥ 60 mL/min for Part 
1;
50 mL/min for Part 
2 if data supports 
loosening criteria
500mg/24hr
Cardiac
LVEF (Echo)
Troponin 50%
1xULN
2012N155299_05 CONFIDENTIA L
BMA117159
241. Without Growth factor support for the past 14 days, excluding erythropoietin
2. As calculated by Modified Diet in Renal Disease (MDRD) formula  
(Appendix 5 )
NOTE:  Laboratory results obtained during Screening should 
be used to determine eligibility  criteria.  In situations where 
laboratory  results are outside the permitted range, the 
investigator may  opt to retest the subject and the subsequent 
within range screening result may be used to confirm 
eligibility .
7. A female subject is eligible to participate if she is of:
Non-childbearing potential (i.e. ph ysiologically  
incapable of becoming pregnant) defined as pre -
menopausal females with a documente d tubal ligation 
or hy sterectom y; or postmenopausal defined as 12 
months of spontaneous amenorrhea [in questionable 
cases a blood sample with simultaneous follicle 
stimulating hormone (FSH) > 40 MIU/mL and estradiol 
< 40 pg/mL (<147 pmol/L) is confirmatory ].  Females 
on hormone replacement therap y (HRT) and whose 
menopausal status is in doubt will be required to use 
one of the contraception methods specified if they wish 
to continue their HRT during the stud y.  Otherwise, 
they must discontinue HRT to allow confirmation of 
post-menopausal status prior to study  enrollment.  For 
most forms of HRT, at least 2 -4 weeks will elapse 
between the cessation of therap y and the blood draw; 
this interval depends on the ty pe and dosage of HRT.  
Following confirmation of th eir post -menopausal 
status, they  can resume use of HRT during the study  
without use of a contraceptive method.
Women of childbearing potential must have a negative 
serum pregnancy  test within 72 hours of first dose of 
study  treatment and agree to use effec tive 
contraception, as defined in Section 11.1.1 , during the 
study  and for 60 day s  following the last dose of study  
treatment.
8.Men with a female partner of childbearing potential must 
have either had a prior vas ectomy  or agree to use 
effective contraception as described in Section 11.1.2
from the time of first dose of study  until 60 day s after 
the last dose of study  treatment to allow for clearance of 
any altered sperm .
9.All prior treatment- related toxicities (defined by  
National Cancer Institute- Common Toxicity  Criteria for 
Adverse Events (NCI -CTCAE), version 4) must be 
2012N155299_05 CONFIDENTIA L
BMA117159
25≤Grade 1 at the time of enrollment except for alopecia, 
and grade 2 neuropathy .
Exclusion Criteria:
1.Systemic anti -tumor therapy  within 14 days, or 
plasmapheresis within 7 day s prior to the first dose of 
study  drug.
2.Use of an investigational drug within 14 day s or five 
half-lives, whichever is shorter, preceding the first dose 
of study  drug.  Prior treatment with a monoclonal 
antibody  within 30 day s of receiving the first dose of 
study drug. 
3.History  of an allogeneic stem cell transplant.  Subjects 
with a history  of an autologous stem cell transplant are 
NOT excluded if they  meet I nclusion Criterion #5. 
4. Presence of active renal condition (infection, 
requirement for dial ysis or an y other condition that 
could affect subject’s safety). Subjects with isolated 
proteinuria resulting from MM are eligible, provided 
they fulfil criteria given in Table 14 .
5.Evidence of active mucosal or internal bleedin g.
6.Any major surgery  within the last four weeks.
7.Any serious and/or unstable pre -existing medical, 
psychiatric disorder or other conditions (including lab 
abnormalities) that could interfere with subject’s safet y, 
obtaining informed consent or compliance t o the study  
procedures. 
8.Known active infection requiring antibiotic treatment.
9.Evidence of severe or uncontrolled sy stemic diseases 
(e.g., unstable or uncompensated respiratory , hepatic, 
renal or cardiac disease)
10.Subjects with previous or concurrent malig nancies are 
allowed only  if the second tumor is not contributing to 
the subject’s illness.  The subject must not be receiving 
active therap y, other than hormonal therap y for this 
disease and the disease must be considered medically  
stable for at least 2 y ears.
11.Evidence of cardiovascular risk including an y of the 
following:
a.QTc interval ≥ 470 msecs.
b.Evidence of current clinically  significant 
2012N155299_05 CONFIDENTIA L
BMA117159
26uncontrolled arrh ythmias;
i.including clinicall y significant ECG 
abnormalities including 2nd degree 
(Type II) or 3rd deg ree atrioventricular 
(AV) block.
c.History  of m yocardial infarction, acute coronary  
syndromes (including unstable angina), 
coronary  angioplasty , or stenting or by pass 
grafting within six months of Screening.
d.Class III or IV heart failure as defined b y the 
New York Heart Association functional 
classification s yst em (Appendix 4 )
e.Uncontrolled h ypertension
f.Subjects with intra -cardiac defibrillators or 
permanent pacemakers;
g.Abnormal cardiac valve morphology  
(≥Grade 2) documented by  echocardiogram 
(subjects with grade 1 abnormalities [i.e., mild 
regurgitation/stenosis] can be entered on 
study ).  Subjects with moderate valvular 
thickening should not be entered on stud y.
12.Known immediate or delay ed hy persensitivit y reaction or 
idiosy ncras y to drugs chemically related to GSK2857916 
or an y of the components of the study treatment.
13. Pregnant or lactating female.
14.Known HIV infection.
15.Subjects with positive test for Hepatitis B surface (HBS -
Ag) or Hepatitis B core (HBc)a ntigen  
16.Subjects with positive test for hepatitis C (HCV) infection 
are excluded regardless of viral load.  If hepatitis C 
antibody  test is positive, a confirmatory  polymerase chain 
reaction (PCR) or recombinant immunoblot assay ( RIBA)
test should be perf ormed.  If the PCR or RIBA test is
negative, subject is eligible for this trial.
17. Current active liver or biliary  disease (with the exception of 
Gilbert's s yndrome or asymptomatic gallstones, liver 
metastases or otherwise stable chronic liver disease per 
investigator’s assessment).
18.Current corneal disease or a history  of corneal disease. 
2012N155299_05 CONFIDENTIA L
BMA117159
27STUDY TREATMENT 
DOSE/ROUTE/REGIMEN Product name :GSK2857916 Solution, 20 
mg/mL, 1.5mL anti -BCMA- ADC 
Formulation 
description:Solution containing 20mg/mL 
GSK2857916
Dosage form :Supplied as frozen liquid.  
Recommended storage condition 
is -50C to - 15C. 
Unit dose 
strength(s)/Dose 
Level(s):20mg/mL, 1.5mL (Refer to Section 
3.3.1.2.1 for dose levels)
Physical Description:GSK2857916 Solution for Infusion 
is clear or opalescent; colorless, 
yellow to brown liquid 
Route/
Administration/ 
Duration:Delivered as IV solution (see 
Section 3.8)
Dosing instructions:Dilute GSK2857916 solution in 
normal 0.9% saline to the 
appropriate concentration for the 
dose.  See Section 4.2for 
compatible administration 
materials.  Doses of GSK2857916 
are to be administered as an IV 
infusion via an infusio n pump that 
can ensure precision to the 
decimal point of a mL for the 
infusion rate at lower doses. It is 
recommended to prime the tubing 
with at least 15 mL prior to dosing.
Manufacturer/ Source 
of Procurement:GSK
Manufacturer Lot 
number132373860
SAFETY 
ASSESSMENTSMeasurements to evaluate safety will include height, weight, heart 
rate (HR), blood pressure (BP), temperature, echocardiogram, 
troponin I, 12- lead ECG, clinical chemistry, hematology, and other 
laboratory tests listed in Table 15 standard disease assessments 
for MM including bone marrow aspirate (cy tology  and flow 
2012N155299_05 CONFIDENTIA L
BMA117159
28cytometry ) and M protein anal ysis,ECOG performance status, 
and complete physical examination. AEs and laboratory results will 
be grade d according to the NCI -CTCAE v4.0 [ NCI, 2009]. Planned 
time points for all safety assessments are listed in the Time and 
Events Tables (Section 7.1 ).
PHARMACOKINETIC/ 
PHARMA CODYNAMIC 
ASSESSMENT(S)In Part 1 on Schedule 1 (i.e., GSK2857916 administered once 
every  21 day s) PK samples will be taken in all subjects for 
both GSK2587916 and cy s-mcMMAF measurement according 
to the Time and Events Tables in Section 7.1
In Part 1 on Schedule 2 (i.e., GSK2857916 administered once 
weekl y for 3 consecutive weeks, 1 week rest) PK samples will 
be taken in all subjects for both GSK2857916 and cy s-
mcMMAF measurement according to the Time and Event s 
Tables in Section 7.1. 
In the Part 2 dose expansion phase in subjects with MM PK 
samples will be taken for both GSK2587916 and cys -
mcMMAF measurement according to the Time and Events 
Tables in Section 7.1. 
In the Part 2 dose expansion phase in subjects with BCMA 
positive lymphomas PK samples will be taken for both 
GSK2587916 and cy s-mcMMAF measurement according to 
the Time and Events Tables in Section 7.1. 
Pharmacod ynamic markers will be collected according to the 
schedule outlined in the Time and Events Tables in Section 
7.1.
Samples for immunogenicity  assessment will be coll ected as 
outlined in the Time and Events Tables in Section 7.1.
CLINICAL ACTIVITY 
ASSESSMENTClinical activity  will be measured as Overall Response Rate 
(ORR) which is defined as follows:
For MM: the percentag e of subjects with confirmed stringent 
complete response (sCR), complete response (CR), very  good 
partial response (VGPR), and partial response (PR) as assessed 
by 2011 recommendation of the International My eloma 
Working Group (IMWG) Panel I .   Clinical be nefit rate (CBR), 
including minimal response (MR), may  be considered in 
addition to ORR ( Appendix 1 ).  
For Lymphomas: the percentage of subjects with confirmed 
CR, PR, as described in the Revised Response Criteria for 
Malignant Lymphoma (Appendix 2 )
2012N155299_05 CONFIDENTIA L
BMA117159
29TRANSLATIONAL 
RESEARCHPharmacod ynamic assessments will include evaluation of 
tumor tissue by  flow cy tometry  and immunohistochemistry  
(IHC) for plasma cell expression of free BCMA receptors and 
GSK2857916 bound receptors, cell cy cle markers, as well as 
apoptosis markers on tumor cells, to understand anti- tumor 
responses. IHC markers may  include but will not be limited to 
BCMA, Blimp1, CD38, CD45, cy s-mcMMAF, CC3, PH3, and 
MPM -2.  Additionally , tumor tissue may be evaluated for any  
DNA /RNA changes correlating with response.  Serum levels 
of free and GSK2857916 bound sBCMA will be assessed by  
Meso -Scale Discovery  immunoassay  and correlated with 
clinical outcome to treatment with GSK2857916.  Cytokines
and chemokines will be measured ; cell- free deoxy ribonucleic 
acid (cfDNA) may  be measured.  
Leukocy tepopulation willbe characterized and may be 
correlated with clinical outcome.
A genetics samples will be collected in Part 2 and ma y be used 
to investigate variability  in response that may  be attributable to 
host genetic variation, if it emerges during this clinical study  or 
a series of clinical studies of GSK2857916 ( Appendix 7 ).
Further, the genetic sample may be used to investigate the 
relationship between genetic variation and disease 
(susceptibility , severity  or progression).
PATIENT REPORTED 
OUTCOMESPart 2/ MM cohort : changes in sy mptoms and health -related 
qualit y of life (HRQoL) will be assess ed with the use of the 
Bone Pain/Fatigue diary .
Changes in visual s ymptoms and impacts with the use of the 
OSDI  and NEI -VFQ -25
2012N155299_05 CONFIDENTIA L
BMA117159
30STATISTICAL 
METHODSPart1: After each dosing cohort, the N -CRM will be used to 
recommend the next dose level based on ob served dose -
limiting toxicities (DL Ts).  The dose escalation decisions will 
be based on this recommendation as well as the totality  of the 
safet y, pharmacokinetic, and pharmacod ynamic data.
Part 2: Futility  anal yses will be performed on the MM cohort 
after approximately  15, 22, and 30 evaluable subjects have 
been enrolled. The methodology  utilized is based on the 
predictive probability  of success if enrollment continues to 40 
subjects [ Lee, 2008].
Clinical Activity
The ex act 95% confidence interval (CI) for overall response 
rate (ORR) and clinical benefit rate (CBR) will be provided. 
Subjects with unknown or missing response will be treated as 
non-responders, i.e., these subjects will be included in the 
denominator when ca lculating percentages of response.
For the Part 2 MM population, additional exploratory  time -to-
event (TTE) endpoint will include TTP, DOR, TTR, and PFS, 
as data permits. For all the TTE endpoints listed above, median 
TTE with 95% CI  will be estimated empl oying the Kaplan-
Meier method as data permits. A Kaplan -Meier survival curve 
will be generated. The number and percentage of subject s who 
had the event or were censored will also be reported.
Adverse Events : Adverse events will be summarized by  
frequency  and proportion of total participants, by  system organ 
class and preferred term. Separate summaries will be given for 
all AEs, treatment -related AEs, SAEs, and AEs leading to 
discontinuation of study  treatment.
The incidence of deaths and the primary  cause of death will be 
summarized.
Clinical Laboratory Evaluation : The evaluation of clinical 
laboratory  tests will focus on selected laboratory  analy tes from 
the hematology  and blood chemistry  panel.
Descriptive statistics (mean, standard deviation, median, range) 
will be used to summarize observed laboratory  values and 
change from baseline in observed value at each scheduled visit 
or worst -case post baseline, as appropriate.
The worst -case-toxicity  grade in hematology  and chemistry  
result during the treatment will be summarized. Shift tables 
from baseline to the worst toxicity  grade during treatment will 
2012N155299_05 CONFIDENTIA L
BMA117159
31be provided for each laboratory  analy te.
Other Safety Measures : Data for vital signs, 
electrocardiograms (ECGs), and echocardiograms (ECHOs) 
will be summa rized. For continuous variables, these summaries 
will include sample size, mean, median, standard deviation, 
minimum, and maximum.  For categorical variables, the 
summaries will include frequencies and corresponding 
percentages.  
2012N155299_05 CONFIDENTIA L
BMA117159
321. INTRODUCTION
1.1. Background
Multiple my eloma (MM) accounts for 1% of all cancers and for 10% of all hematologic 
malignancies.  Approximately  20,000 people will be diagnosed with MM each year in the 
United States [Rajkumar , 2011a]. The median age at diagnosis is approximately  70 y ears.  
Newl y  diagnosed patients less than 60 years of age have a 30% probability for 10 -year 
survival [ Palumbo , 2011].  Recent progress in understanding the biology of the diseas e 
has resulted in significant improvements in treatment strategies for MM.  Drugs that are 
currentl y approved for MM fall into three separate classes of agents:  alkylating agents 
(melphalan, cy clophosphamide), proteasome inhibitors (bortezomib, carfilzomib), and 
immunomodulators (I MIDs: thalidomide, lenalidomide, pomalidomide).  These highl y 
active agents used in combination are providing tangible benefits for patients with MM 
[Rajkumar , 2011b].  I mportantly , improvements in survival outcomes have been noted in 
patients with MM and current treatment strategies provide a very  good chance for 
response in the first line. Unfortunatel y, duration of response and response rates decline 
dramaticall y in each subsequent line of treatment for this malignancy . MM remains 
incurable and the need for new treatment modalities is well recognized. 
The normal function of B cell maturation antigen (BCMA) is to promote cell survival by  
transduction of signals from two known ligands (BA FF/BLy S and APRIL).  The 
expression is restricted to B cells at later stages of differentiation, with expression on 
germinal center B cells in tonsil, blood plasma blasts and long lived plasma cells [ Darce , 
2007].  
BCMA is expressed in various B -cell malignancies, including MM.  The expression 
levels in MM vary  from patient to patient, but our studies demonstrate that all patients 
tested express detectable levels of BCMA protein on their tumor cells. BCMA expression 
varies between MM patients and GlaxoSmithKline (GSK) studies have shown that in 
samples taken from MM patients (N=45), 31% have low expression, 38% moderate 
expression and 31% high expression of BCMA as detected b y immunohistochemistry 
(IHC).  BCMA was also analyzed by flow cy tometry  in tumor cells from 48 MM patients 
which aligned well with IHC results. In addition, other B -cell malignancies including 
Follicular Ly mphoma (FL) [ Basso, 2005; GSKin -house data], Diffuse Lar ge B-Cell 
Lym phoma (DLBCL), L arge B -Cell Ly mphoma (LBC L), Chronic Lymphocytic 
Leukemia (CLL) and Waldenstrom’s Macroglobulinemia (WM) [ Montes -Moreno , 2012] 
[Elsawa , 2006] [ Endo, 2007] were reported to express BCMA at vary i ng frequencies; 
DLBCL and FL were among the B -cell hematologic malignancies exhibiting the highest 
frequency  of BCMA expression.
A soluble form of BCMA has also been rep orted [ Sanchez , 2012].  Higher amounts of 
this soluble form were found in supernatants isolated from cultures of MM -containing 
peripheral blood and bone marrow mononuclear cells compared to normal cells.  
Moreover, s oluble BCMA (sBCMA) was higher in the sera of MM patients (n=209) 
compared to sera from age -matched, health y controls (n=40; P< 0.0001).  Measurement 
of serum levels of BCMA was conducted b y immunoassay to confirm the prevalence and 
level of sBCMA express ion in MM.  Soluble BCMA is present in serum at a median 
2012N155299_05 CONFIDENTIA L
BMA117159
33concentration of 9.28 ng/mL  (range 6.10- 14.09 ng/mL ) in healthy  volunteers (N=38) and 
is elevated in the serum of MM patients (N = 44) to median of 148.64 ng/mL (range 2.40 -
1062.48 ng/mL). 
The rest ricted normal tissue expression profile of BCMA, along with its upregulation and 
survival function in MM and other BCMA -positive cancers makes it an attractive target 
for a therapeutic antibody with direct cell killing activity . 
1.2. GSK2857916
1.2.1. Background
GSK2 857916 is a humanized IgG1 antibod y drug conjugate (ADC) which binds 
specificall y to BCMA. The parent anti- BCMA antibody  (J6M0) is conjugated to the 
microtubule inhibitor monomethy l auristatin -F (MMAF) via a protease resistant 
maleimidocapro yl (mc) linker to produce the GSK2857916 ADC molecule.  Upon 
binding to the cell surface, GSK2857916 is rapidly internalized and active drug (cy s-
mcMMAF) is released inside the cell. 
GSK2857916 has been produced in an afucos ylated form to generate an enhanced 
antibody  dependent cellular cy totoxicity  (ADCC) response upon binding to Fc RIIIa 
receptors on the surface of human effector cells. The rationale for this dual mechanism of 
action is to improve efficacy  by targeting dividing and non- dividing tumor cells. 
Importantly , BCMA expression is maintained at the cell surface over time following 
GSK2857916 binding and internalization due to rapid BCMA receptor recycling and/or 
new protein s ynthesis.  GSK2857916 has demonstrated dose- dependent cy totoxic activity  
in my eloma cell lines, ex vivo primary  myeloma tumor samples, as well as preclinical 
myeloma mouse tumor models.
1.2.2. Preclinical Pharmacology
J6M0, the parent antibody  for GSK2857916 binds specificall y to human BCMA with an 
affinity  of 1.61 nM as defined by  surface plasmon resonance (SPR), and the binding 
properties were maintained following drug conjugation. J6M0 competes for binding to 
BCMA with bot h known ligands BAFF/BlyS and APRIL, and inhibits ligand -induced 
NF-ĸB signalling with an I C50 of 0.91 g/mL and 2.43 µg/mL ,respectively. However, in 
cell proliferation assay s, GSK2857916 failed to inhibit cell growth directly .
A total of 16 cell lines we re used to demonstrate the antitumor activity  of GSK2857916 
via the ADC mechanism in BCMA expressing cells and to investigate the relationship 
between BCMA expression and potency . The IC50of GSK2857916 was determined for 
each cell line tested ( Table 1). In general, the highest BCMA expressing cell lines (NCI -
H929, MM.1R and JJN3) were most sensitive to GSK2857916 and the lowest expressing 
cell lines (ARH -77, MC/CAR and HuNS1) were least sensitive. In the 4 negative control 
cell lines (KU812, Raji, HUT78 and MOLT -4) where no expression or only  trace 
expression of BCMA was observed b y flow cy tometry , there was no detectable growth-
inhibitory  activity  at any  of the concentrations tested. This demonstrates the specificity  of 
GSK2857916 for BCMA expressing cells.
2012N155299_05 CONFIDENTIA L
BMA117159
34Table 1 Mean IC 50Values for GSK2857916
Cell Line IC50(ng/mL) 95% CI
U266 3.0 1.4 to 6.5
ARH77.10B5 3.4 2.5 to 4.8
MM.1R 11.5 10.9 to 12.1
NCI-H929 13.8 13.2 to 14.3
JJN3 26.0 24.1 t o 28.1
MM.1S 53.2 49.5 to 57.0
LP1 55.7 44.3 to 70.1
ARH77 72.7 58.8 to 89.7
RPMI8226 79.1 60.1 to 104.1
L363 93.7 74.3 to 118.2
OPM2 114.3 97.0 to 134.9
KMS128M 148.4 124.1 to 177.5
HUNS1 244.2 198.4 to 300.5
MC/CAR >1000
Negative Control Cell Lines
KU812 >1000
Raji >1000
HUT78 >1000
MOLT4 >1000
GSK2857916 also had ADCC activity  when tested against a panel of MM target cell lines 
using a fresh human PBM effector cells from healthy  donors. The ADCC EC 50values 
were NCI -H929 [0.57 ng/mL ], RPMI -8226 [4.09 ng/mL ], JJN -3 [14.42 ng/mL ], OPM-2 
[4.15 ng/mL ] and U266 [9.04 ng/mL ], respectively .
GSK2857916 demonstrated dose dependent ADCC and ADC activity  against primary  
CD138+ my eloma tumor cells from nine m yeloma patients. These results demons trate 
that GSK2857916 is capable of killing primary  myeloma cells with potency  similar to 
that observed in cell lines.
2012N155299_05 CONFIDENTIA L
BMA117159
35Myeloma tumor models in mice were also tested to ensure that GSK2857916 has activity  
in vivo . The cell lines selected for subcutaneous xenograft studies were NCI -H929 and 
OPM2. GSK2857916 administration resulted in complete tumor regression in both 
models at 4 mg/kg dosed by  intraperitoneal (I P) route twice weekl y for 4 weeks. In an 
orthotopic, bone marrow dissemination mouse model usin g MM.1S cells, treatment with 
GSK2857916 dosed at 0.4mg/kg or 4.0 mg/kg I P 9 times over the course of 1 month 
resulted in complete reduction of tumor burden and significantl y increased survival of 
mice. These results demonstrate the anti -tumor activity  of GSK2857916 at achievable in 
vivo dose levels.
1.2.3. Preclinical Pharmacokinetics and Metabolism of GSK2857916
1.2.3.1. Single dose pharmacokinetics
The pharmacokinetics of GSK2857916 (ADC) and cys-mcMMAF has been investigated 
following IV (bolus) administration to the r at and cy nomolgus monkey .  Plasma 
concentrations were quantifiable over the entire sampling period (144 hours in rat and 
504 hours in cy nomolgus monkey ) at doses of 10, 30 and 100 mg/kg for the rat and 3, 10, 
and 30 mg/kg for the cy nomolgus monkey .  The ma ximum concentrations were observed 
at 0.25 hours (first sampling occasion) in the rat and between 0.25 and 6 hours in the 
cynomolgus monkey .  Systemic exposure (C maxand AUC 0-t) for ADC and total increased 
approximately  proportionally  with increasing dose and there was no notable sex 
difference.  Similar concentrations between ADC and total antibody  suggest that 
GSK2857916 remains largel y intact in circulation.  This is further confirmed with the 
relativel y low levels of cys -mcMMAF observed in both plasma a nd urine.  GSK2857916 
was cleared slowl y (total plasma clearance; rat 0.333ml/hr/kg and cynomolgus monkey 
1.07 ml/hr/kg).  The mean steady  state volume of distribution (V ss) was low in both the 
rat and monkey  being 97.6 mL /kg and 105 mL/kg, respectivel y; suggesting GSK2857916 
is mainly  confined to the sy stemic circulation.
1.2.3.2. Repeat dose pharmacokinetics
Rat
The pharmacokinetics of GSK2857916 and cy s-mcMMAF has been investigated 
following IV infusion administration to male and female rats over 3 -weeks (once we ekly 
at 3, 10 or 30 mg/kg on Day s 1, 8 and 15), followed by  a 12 -week off -dose period.
Systemic exposure (AUC 0-168 and C max) increased proportionally with increasing dose and 
there were no notable differences in the s ystemic exposure between sexes.  The sy stemic 
exposure on Day  15 was slightly  higher (up to 2.4 -fold) than that on Day  1.  T maxwas 
observed at 0.25 hours, the first sampling point.
The AUC for ADC and total antibody  were similar to one another at each dose level on 
Day 1 and was generall y higher for total antibody  on Day  15.  The C maxwas generall y 
lower for total antibod y than ADC on Day  1, but similar on Day  15. The average half -life 
was 11 day s.
2012N155299_05 CONFIDENTIA L
BMA117159
36For cy s-mcMMAF, there was insufficient data available to determine AUC on Day  1 in 
the low dose g roup (3 mg/kg). The s ystemic exposure increased proportionally  with 
increasing dose and there were no notable differences in sy stemic exposure between 
sexes.  The sy stemic exposure on Day  15 was higher (up to 6.4 -fold) than that on Day  1.  
Tmaxranged from 0.25 to 48 hours.
There were quantifiable concentrations of cy s-mcMMAF in the urine samples collected 
on Day 7, 14, 22, 43R, 64R, 85R and 106R from toxicology  animals.  The mean total 
amount of cy s-mcMMAF recovered in urine generally  increased proportiona lly with 
increasing dose of GSK2857916.   Cys-mcMMAF was not quantifiable in the urine 
samples collected on Days -6, -5 and - 1 (pre -treatment) at an y dose or in control group 
samples.
Cynomolgus Monkey
The pharmacokinetics of GSK2857916 and cy s-mcMMAF has b een investigated 
following IV bolus administration to male and female cynomolgus monkey s over 3 -
weeks (once weekl y at 1, 3 or 10 mg/kg on Day s 1, 8 and 15), followed by  a 12 -week off -
dose period.
Gender -averaged s ystemic exposure increased proportionally  with increasing dose and 
there were no notable differences in the s ystemic exposure between sexes.  The gender -
averaged s ystemic exposure increased 1.2 -to 2.1 -fold, respectivel y, from Week 1 to 
Week 3.  Following IV bolus administration of GSK2857916, T maxwas observed at 0.25 
hour (the first sampling time point) in the majority of animals. 
The sy stemic exposures for ADC and total antibody  were similar, with total antibody  
consistently  being slightly  higher than ADC.  The average half -life was 4 day s.
For cys-mcMMAF, the gender averaged s ystemic exposure (AUC 0-48hr) increased 
proportionally  with increasing dose and there were no notable differences in sy stemic 
exposure between sexes. The changes in gender -averaged s ystemic exposure from 
Week 1 to Week 3 we re less than 2- fold. Tmaxwas variable, although in most animals 
Tmaxwas achieved within 6 hours after dosing during Weeks 1 and 3.
2012N155299_05 CONFIDENTIA L
BMA117159
37Table 2 Gender A veraged Pharmacokinetic Values for GSK2857916 (A DC) 
Follo wing IV A dministration to Cynomolgus Monkey s
PK Parameters AUC 0-167 
(g.h/mL)Cmax (g/mL) Tmax (h) t½ (h)
Week
Dose 
(mg/Kg/week)1 3 1 3 1 3 3
1865 1240 22.3 27.5 0.25 0.25 N/A
3 2330 3760 58.8 63.3 0.25 0.25 96.4
10 11200 21500 249 292 0.25 0.25 N/A
1.2.3.3. Distribution, Metab olism, and Excretion
No studies have been performed at GSK specifically  to evaluate the distribution, 
metabolism and excretion of GSK2857916.
A study  performed on a similar antibody  linked to MMAF has been performed [ Alley , 
2009] [ Alley , 2010].  Distribution has shown using radio- labeled ADC that accumulation 
is rapid in the tumor with the proportion of released drug relative to conjugated drug 
increased over time in the tumor.  In most normal tissues, both the mAb and drug 
decreased over time in conjunction with the serum concentrations, except in organs 
involved in hepatobiliary clearance where there was a 4 hour peak post dose followed b y 
a rapid decrease.  The difference between tumor versus normal biodistribution and 
release kinetics yielded a tumor exposure to released drug tens to hundreds of times 
higher than that of normal tissue.
Metabolism studies have shown the directl y conjugated drug linker releases cys -
mcMMAF after ADC catabolism, consistent with proteoly tic degradation of the mAb to 
release the drug.
Cys-mcMMAF was detected in rat urine between 7 and 106 day s following IV 
administration.  However, it was not possible to make a quantitative assessment of renal 
excretion.
1.2.3.4. Pharmacokinetic drug interactions
1.2.3.4.1. Victim interaction potential
Victim PK interactions occur when a co -administered drug changes the PK of the
investigational agent. 
2012N155299_05 CONFIDENTIA L
BMA117159
38Elimination pathway s (metabolism/catabolism and/or drug transporter) for GSK2587916 
or cy s-mcMMAF in humans have not been characterised. As a consequence, care should 
be exercised when GSK2857916 is co- administered with potent cy tochrome P450 (CYP) 
inhibitors, CYP inducers, and transporter modulators. In vitro cys-mcMMAF was shown 
to be a subs trate of P -glycoprotein (P -gp) with an efflux ratio of 31 -fold in the presence 
of verapamil. As cy s-mcMMAF has low permeability  (<10 nm/s) changes in P -gp 
activity  could potentiall y affect the pharmacokinetics of cy s-mcMMAF in vivo . 
Concomitant dosing of GSK2857916 with strong Pgp inhibitors should be avoided unless 
considered medicall y necessary ( See Appendix 11 :  Pgp Inhibitors for list of relevant Pgp 
inhibitors).
1.2.3.4.2. Perpetrator interaction potential
Perpetrator interactions are chan ges in the PK of a co- administered drug caused by  the 
investigational agent. 
No clinical studies have been performed b y GSK to evaluate the potential for cy s-
mcMMAF or GSK2587916 to interact with substrates of cytochrome P450 or drug 
transporters P -gp, OA TP, BCRP or OAT.  In vitro, Cy s-mcMMAF did not appear to be a 
direct, time- or metabolism -dependent inhibitor of CYP1A2, CYP2B6, CYP2C8, 
CYP2C9, CYP2C19, CYP2D6 or CYP3A4/5 and no induction of CYP 1A2, 2B6 or 
3A4/5 enzy me activity  or gene expression was ob served.  Therapeutic proteins have been 
shown to cause suppression of cy tochrome P450 and drug transporter activities and 
expression however GSK2587916 is unlikely  to modulate the cy tokines which are known 
to elucidate this mechanism. Together these data s uggest cy s-mcMMAF and 
GSK2587916 have a low risk of being perpetrators of drug interactions. 
1.2.4. Toxicology  of GSK2857916 (anti -BCMA  MMA F)
The potential toxicity  of GSK2857916 [aBCMA antibody  drug conjugate (CA8 J6M0 
Potelligent MMAF)] has been evaluated in r at and cy nomolgus monkey s in single dose 
range toxicity  studies and in repeat dose studies of 3- weeks duration b y the intravenous 
route of administration. An in vitro cross -reactivity  study  was conducted to evaluate the 
binding of GSK2857916 to human tissu es. 
1.2.5. Repeat dose toxicity
In the definitive 3 week rat and monkey  toxicity  studies, GSK2857916 was administered 
by the intravenous route formulated as a solution in 25mM aqueous Citrate buffer 
containing 0.05mM EDTA, 200mM Trehalose and 0.02% Polysorbate 80 (pH 6), and 
administered to rats at a dose volume of 10 mL /kg (10 minute infusion) and to monkey s 
at a dose volume of 4 mL/kg/dose (bolus, slow push).
1.2.5.1. Rat
GSK2857916 [0 (vehicle), 3, 10 or 30 mg/kg] was given once weekl y for 3 weeks b y IV 
infusion to mal e and female rats followed b y a 12 week off dose period (0, 3 and 
30mg/kg/week). All changes presented are times control values.
2012N155299_05 CONFIDENTIA L
BMA117159
39One female given 30 mg/kg died in the restraint tube prior to dosing on Day 8; however, 
as 1control animal died immediately  after removal from the restraint tube on completion 
of dosing on Day 1, this death was considered not to be test article-related.
Adverse microscopic changes in the testes were noted at 10 mg/kg/week (degeneration 
and atroph y of seminiferous tubules which correlated with macroscopic findings of 
reduced size/flaccid testes and lower testes weights (down to 0.50X control). At 
30mg/kg/week, adverse microscopic changes were also noted in the kidney  (tubular 
degeneration, characterised by  basophilia, single ce ll necrosis and often, with hy aline cast 
formation) with associated increases in urine albumin (up to 549X), total protein (up to 
14X), NAG (up to 1.3X), GST (up to 5.4X), lipocalin-2 (up to 58X), KIM- 1 (up to 
3.4X) and RPA -1 (up to 2.4X); and plasma urea (up to 1.22X) and calcium 
concentrations (up to 1.13X) and sternum/bone marrow, decreased cellularity  (minimal to 
moderate) accompanied by  single cell necrosis with associated changes in red cell 
parameters [decreased red blood cells (down to 0.81X)], hem oglobin and hematocrit 
(down to 0.75X), mean cell volume and mean cell hemoglobin (down to 0.92X) and 
increased high absorption reticulocy tes (1.97X) and decreased medium and low 
absorption reticulocy te counts (down to 0.45X)] at the end of the treatment p eriod. In 
addition, in the lung, eosinophilic material (tubular- myelin) accompanied by multifocal 
macrophage aggregates, frequentl y subpleural, with alveolar wall thickening and in some 
foci, perivascular mononuclear inflammatory  cell infiltration, was noted at the end of the 
off-dose period. Macroscopically  man y pale areas were noted in the lungs of these 
animals. 
Non adverse microscopic and clinical pathology  changes were noted at 30 mg/kg in the 
mandibular and mesenteric ly mph nodes (multinucleate giant cells), femur/femorotibial 
joint (bone remodelling, characterised b y osteoblast hy pertrophy /hyperplasia, 
scalloped/uneven bone surfaces, fibrosis or earl y hyperostosis), and male mammary  gland 
(epithelial single cell necrosis) as well as lower body  weight gain (0.53X) and food 
consumption (0.91X) and increased total protein (1.29X), immunoglobulin A (1.78X) and 
higher alpha 1 and beta electrophoresis (up to 2.1X), cholesterol and potassium (1.47X) 
concentrations, changes in trigl yceride concentrations, dec reased bilirubin (0.59X) and 
lower WBCs (down to 0.47X), reflecting lower neutrophil, ly mphocy te, monocy te, 
eosinophil and basophil counts. 
At 10mg/kg non- adverse findings were noted in the epididy mides 
(aspermia/h ypospermia, reduced size, mixed interst itial inflammatory  cell infiltration), 
ovaries (luteinized nonovulatory  follicles), spleen (ly mphocy tolysis, increased pigmented 
macrophages, congestion, higher weights), sternum/bone marrow (decreased cellularit y/ 
single cell necrosis/ bone remodelling, c haracterised by  osteoblast 
hypertrophy /hyperplasia, scalloped/uneven bone surfaces, fibrosis or earl y hyperostosis), 
liver (extramedullary  haematopoeisis, increased weights), injection site (local epidermal 
hyperplasia/perivascular inflammation/skeletal mu scle degeneration/necrosis), and 
thymus (l ymphocy tolysis accompanied by  decreased cellularit y and mixed inflammatory  
cell infiltration the interstitial and surrounding connective tissue and lower weights) as 
well as higher platelet counts (2.1X) and red ce ll distribution width (1.37X) higher 
neutrophil and basophil counts (2.5X) and increases in AST (6.8X), aldolase (3.4X), 
2012N155299_05 CONFIDENTIA L
BMA117159
40creatinine kinase (2.8X), ALP (up to 3.0X), ALT(3.5X), glutamate dehy drogenase 
(GLDH) (8.6X), alpha 1 acid gly coprotein and IgM. 
At al l doses findings non -adverse findings were noted in the lung (eosinophilic material 
(tubular -myelin) accompanied with prominent alveolar macrophages) and ey e (minimal 
bilateral corneal single cell necrosis, without ophthalmology  findings) as well as higher
albumin (1.13X), lipcalin -2 (7.5X) and alpha 2 macroglobulin (1.76X) concentrations.
In addition, increases in cy tokine levels from 24 hours after the start of dosing on Day 1 
was observed with higher monocyte chemoattractant protein -1 (up to 3.1X), IL -1(up to 
1.93X), IL -6 (up to 3.9X) and TNF -concentrations (up to 3.1X) noted at 30 mg/kg, and 
IL-6 (up to 1.74X) and TNF -(up to 2.3X) concentration in females onl y noted at 
10mg/kg. No associated treatment- related changes in body  temperature or associa ted 
clinical signs were noted. 
Following the 12 week off dose period, in animals previously  given 30 mg/kg/week, 
there was recovery  of the changes in all tissues except the lungs and testes/epididy mides 
(seminiferous tubular atrophy  and aspermia) together with additional clinical 
(discoloration, unevenl y/abnormally  worn, appearing longer, thicker or shorter) and 
microscopic changes (degeneration of ameloblast lay er) in continuousl y growing incisor 
teeth. Bod y weight gain increased between Day s22R and 39R (1.21X) and lower from 
Day 39R (0.82X) onwards, food intake (0.94X) continued to be lower in males. Liver 
(1.14X) and spleen weights (1.23X) were still increased in males, thy mus weights 
(0.78X) were reduced and some clinical pathology parameters were sti ll altered in some 
animals after the off -dose period including increased urine albumin excretion levels (up 
to 40X), cholesterol (up to 1.27X), higher reticulocyte counts (up to 1.98X), red cell 
distribution width (up to 1.14X), WBC (up to 1.39X) and l ymphocyte (up to 1.56X) 
counts.
Findings of uncertain relationship to treatment comprised a diffuse decrease in 
vacuolation in the brown adipose tissue of 1 female given 30 mg/kg at the end of the 
treatment period, and an increase in the incidence of hy aline casts in the kidney s of off -
dose animals previousl y given 30 mg/kg. 
There were no changes considered related to GSK2857916 administration in the stage 
dependent evaluation of spermatogenesis following treatment at 3 mg/kg/week. Changes 
in the testes at hi gher doses precluded sperm staging evaluation in these animals.
Due to the adverse microscopic changes in the testes at 10mg/kg, the no observed 
adverse effect level (NOAEL) was 3 mg/kg [mean AUC 0-168h: 6100  g.h/mL , range: 5960 
to 6240  g.h/mL, and mean Cmax: 103 g/mL, range: 101 to 105 g/mL (based on gender 
averaged Day 15 values for GSK2857916 ADC)].
1.2.5.2. Cynomolgus monkey
In the 3 -week definitive study  in cy nomolgus monkey , GSK2857916 was given to 
monkey s (3/sex/group) at 0 (vehicle), 1, 3 and 10 mg/kg/w eek once weekl y for 
approximately 3 weeks by  intravenous injection (bolus, slow push).  An additional 2 
2012N155299_05 CONFIDENTIA L
BMA117159
41monkey s/sex/group were added at doses of 0 and 3 mg/kg/week to evaluate the 
reversibility  of potential test article related effects following a 12 -week off-dose period. 
Test article -related microscopic inflammatory  changes were noted in the spleen and bone 
marrow.  In the spleen and bone marrow, an increase in macrophages, characterized by 
increased numbers of vacuolated macrophages containing variable a mounts of brown 
pigment, engulfed cellular and/or nuclear debris, was present in the red pulp of monkeys 
given ≥3mg/kg/week (minimal to mild) or in the bone marrow of monkeys given 
10 mg/kg/week (mild to moderate).  These microscopic effects in spleen and bone 
marrow at  3mg/kg/week were reflective of a sy stemic inflammatory  response at 
increasing doses and were not noted following the off- dose period.  
The inflammatory  microscopic changes in spleen and bone marrow noted at terminal 
necrops y correlated w ith clinical pathology  findings at Day  22 consistent with an 
inflammatory  response including dose responsive increases in mean serum C -reactive 
protein concentrations (up to 36X baseline) at 3mg/kg/week, decreased serum albumin 
concentrations for individ ual monkey s given  3 mg/kg/week, and increases in mean total 
white blood cells, principally  neutrophils, monocytes and large unstained cell counts, at 
10mg/kg/week.  The s ystemic inflammatory  response was also associated with a mild 
decrease in red cell mass parameters (to 0.82X baseline) and platelet counts (to 0.70X 
baseline), with evidence of regenerative responses in individual monkey s including 
reticulocy tosis and release of nucleated red blood cells at 10 mg/kg/week.  These changes 
were noted with hi stologic splenic and marrow macrophage changes which, upon 
cytologic evaluation of bone marrow smears, were suggestive of hemophagocy tosis.  
These clinical pathology  changes noted in monkeys given 3 mg/kg/week were not noted 
at the end of the off -dose period.
In the liver, Kupffer cell effects characterized by  an overall increase in visible Kupffer 
cells and with occasional presence of mitotic figures were noted in monkeys given 
3mg/kg/week.  In the kidney , minimal increases in mitotic figures of mesangia l cells 
were present in renal glomeruli of monkey s given 10 mg/kg/week.  Also associated in 
some of the affected kidney s, was an increase in mitotic figures within interstitial 
histiocy tic cells of the renal cortex.  
In the kidney  of a single male given 10 mg/kg/week, a mild glomerulopathy  was noted 
microscopicall y, characterized by  expansion of the mesangium by  a homogenous 
eosinophilic matrix.  Also present in the same monkey , there was mild 
degeneration/regeneration of the distal nephron, characterized by clustered distal tubules 
that were dilated and with basophilic cy toplasm and euchromatic nuclei.  Single cell 
necrosis was present in the collecting duct epithelium.  Rare tubules contained 
proteinaceous fluid or blood.  These findings correlated with s ignificantly  elevated urine 
albumin and total protein excretion values in this animal on Day  22 and were considered 
an effect of the test article.   The constellation of clinical pathology  and microscopic 
findings are consistent with a primary , test articl e-related injury to glomeruli, with 
subsequent tubule/duct injury .
Increased tingible bod y macrophages were microscopically  present in the thy mic cortex 
of monkey s given ≥3mg/kg/week and were often associated with intracy toplasmic 
2012N155299_05 CONFIDENTIA L
BMA117159
42phagocy tized cellular an d nuclear debris (l ymphocy tolysis) or decreased cortical 
thickness.  Several monkey s given 10 mg/kg/week additionally  had decreased cellularit y 
of the cortex associated with the tingible bod y macrophage finding and variable thymic 
weights at 10 mg/kg/week. These findings were not considered to be adverse. 
Decreases in absolute number and percentage of natural killer (NK cells) were observed 
on Day  22 in monkey s given 10 mg/kg/week, as well as in individual monkey s given 
3mg/kg/week.  There was evidence of reversibility  at the end of the 12 -week off -dose 
period in monkey s given 3 mg/kg/week.  Additionally , minimal increases in absolute 
number and percentage of activated (CD69+) Bcells were observed on Day  22 in 
monkey s given 10 mg/kg/week; however, activated B cells represent a small proportion 
of total B cells (0.6 and1.1% CD69+mean for males and females, respectively , at 
baseline) and changes were not detected in the absolute number or percentage of total 
B cells.  There were no test article- related cha nges in absolute number or percentage of 
Tcells, CD4 andCD8 Tcell subsets, or NK T cells following administration of 
GSK2857916.
Mean serum immunoglobulin M (IgM) concentrations were decreased (0.77X to 0.48X 
baseline) for males given 3mg/kg/week and females given 1mg/kg/week on Day 22 
and were also decreased (0.54 to 0.66X baseline) following the off -dose period.  Mean 
serum immunoglobulin G (IgG) concentrations for individual females given 
10mg/kg/week were decreased (0.78X baseline) on Day 22.  These decreases in IgM and 
IgG were expected changes consistent with the pharmacologic activity  of the test article 
on plasma cells.
Mean serum aspartate aminotransferase (AST) (to 13X baseline), glutamate 
dehy drogenase (GLDH) (up to 3.3X baseline), gamma g lutam yltransferase (GGT) (to 
2.0X baseline), total bilirubin (to 1.7X baseline) and/or alanine aminotransferase values 
(ALT) (to 2.2X baseline) for male and female monkey s given 10 mg/kg/week were 
increased on Day 22, but were not associated with correlative hepatocy te or biliary  
microscopic findings.  
The mean serum cholesterol concentration for males given 10 mg/kg/week was increased 
(1.52X baseline) and mean serum trigly ceride concentration for females given 
10mg/kg/week was increased (2.2X baseline) o n Day 22.  
Increased mean activated partial thromboplastin times for males and females given 
10mg/kg/week were noted on Day 22 and were considered test article -related but 
non-adverse based on low magnitude and lack of correlate clinical findings.  
Reduced eating (greater than half the dail y allotment of food remaining) was noted 
sporadicall y throughout the dosing phase in monkeys given 10 mg/kg/week with a 
decrease in the consumption of citrus fruit in females given 3mg/kg/week.   Body  
weight loss was noted by 4 day s following the last dose in 1 female at each dose level 
(non-fasted).  A fasted terminal body  weight prior to necrops y (8 day s following the last 
dose) showed a slight increase from the previous weight for the female given 
1mg/kg/week, whi le that for the female given 10 mg/kg/week remained unchanged.  The 
affected female given 3 mg/kg/week was maintained throughout the off -dose period and, 
2012N155299_05 CONFIDENTIA L
BMA117159
43in the beginning of this phase, bod y weight continued to decrease.  The body weight for 
this female ge nerall y increased throughout the remainder of the off -dose period and was 
comparable to Day  1 values by  the end of the off -dose period.
Stage dependent qualitative evaluation of spermatogenesis in the testes was not 
performed on male monkey s due to immatur ity of testes.  
Based on glomerulopathy and degeneration/regeneration noted in the distal nephron in 
the kidney  of the male given 10 mg/kg/week, the highest non -severely  toxic dose was 
3mg/kg/week.
Based on adverse findings noted at 3mg/kg/week and the transient nature of the body  
weight change noted in the monkey  given 1 mg/kg/week, the no -observed- adverse effect 
level was 1 mg/kg/week [GSK2857916 (ADC): AUC 0-167  1240 g.h/mL, range 893 to 
1470 g.h/mL ; Cmax27.5g\mL, range 22.7 to 32.9 g/mL ; GSK2857916 (Total) AUC 0-
1671520 g.h/mL , range 1210 to 1700 g.h/mL; C max27.3g\mL, range 22.4 to 31.7 
g/mL; cy s-mcMMAF: AUC 0-167  12.1 ng.h/mL, range 6.01 to 23.1 ng.h/mL ; Cmax0.499 
ng\mL, range 0.341 to 1.03 ng/mL (gender -averaged based on Week 3 values) ].
1.2.6. Genotoxicity
Intact biopharmaceutical therapeutics, such as monoclonal antibodies and antibody  drug 
conjugates, do not directly  interact with DNA or other chromosomal material.  Therefore, 
genetic toxicology  studies with GSK2857916 were not performed. T he active moiety  of 
GSK2857916 is MMAF cy totoxin which is expected to be genotoxic in mammalian 
systems given it is a microtubule disrupting agent.
1.2.6.1. Route assessment for genotoxic impurities
An assessment of the route of sy nthesis for GSK2857916 has been ca rried out to 
determine the likelihood of mutagenic impurities being present in the drug substance. 
This indicated that there are no impurities of known or potential mutagenic concern that 
are considered likel y to be present in final drug substance at a lev el that would exceed the 
threshold of toxicological concern at the planned clinical dose range. 
1.2.7. Local tolerance
Clinical and histopathological anal ysis of injection sites was incorporated into the dose 
range toxicity  and 3- week definitive repeat dose toxi city studies in rats and cy nomolgus 
monkey s.
In the rat dose range toxicity  study  mild epidermal hy perplasia with single cell necrosis 
and mild degeneration/necrosis of skeletal muscle with inflammatory  cell infiltrate was 
noted at the injection site in animals intravenously administered a bolus injection of 
GSK2857916 at  ≥ 30 mg/kg (dose concentrations 6 and 16.1 mg/mL). In the rat 3-week 
study  intravenous infusion of GSK2857916 at doses ≥ 10 mg/kg (dose concentrations 1 
and 3 mg/mL) caused localised epid ermal h yperplasia at the injection site. Focal skeletal 
muscle degeneration/necrosis was also observed in 1 male given 30 mg/kg. I n addition, 
2012N155299_05 CONFIDENTIA L
BMA117159
44the incidence of perivascular inflammation at the injection site was increased in 
GSK2857916 treated animals at do ses of ≥3 mg/kg (dose concentration 0.3 mg/mL). 
In the monkey  dose range toxicity  study  mild to minimal hemorrhage with minimal to 
moderate subcutaneous inflammation characterised by  necrosis, mixed inflammatory  cell 
infiltrate including l ymphocy tes and l arge histiocy tes/fibroblastic cells occasionally  with 
multinucleation and mitotic figures and/or fibrosis was observed at ≥3 mg/kg (dose 
concentration 16.1 mg/mL) following bolus intravenous injection. In the female given 30 
mg/kg epidermal squamous cell h yperplasia was also seen. No treatment related changes 
at the injection site were observed in the 3 -week monkey  study  following repeated bolus 
intravenous administration of GSK2857916  at doses of 1, 3 and 10 mg/kg (dose 
concentrations 0.25, 0.75 and 2.5 m g/mL).
1.3. Benefit:Risk A ssessment
Summaries of findings from non clinical studies conducted with GSK2857916 can be 
found in the Investigator’s Brochure [GlaxoSmithKline Document Number 
2013N175128_02].   The following section outli nes the risk assessment and mitigation 
strategy  for this protocol:  
1.3.1. Risk A ssessment
Nephrotoxicity
Non clinical safety  experiments have demonstrated primary  glomerular injury  and tubular 
degeneration (in rat at doses 30mg/kg, and in monkey  at doses 10mg /kg). The 
morphologic changes were accompanied b y large molecular proteinuria (albuminuria). 
The renal changes were dose dependent and reversible. 
To minimize the risk of nephrotoxicity , only subjects with well -preserved kidney  
function will be allowed on study . During the study  subjects will be monitored for 
kidney function by  assessing creatinine value and clearance, electrol ytes (Potassium, 
Calcium, Phosphorus, and Magnesium), protein and albumin excretion in 24 hr urine 
collection at every  cycle, or more frequentl y if clinically indicated. Subjects will be 
educated about the need of maintaining adequate urinary  output. Treatment will be 
implemented according to clinical practice. Dose reductions and treatment stopping 
criteria will be applied according to Section 3.10.
Hepatotoxicity
Non clinical safety  experiments demonstrated increased liver weight and elevated liver 
enzy mes at doses of 30 mg/kg in rats. Elevations in liver enzy mes were also observed in 
monkey s at doses of 10 mg/kg, in addition at 3 mg/kg increased mitotic figures in 
Kupffer cells were also observed in monkey s. All of these changes were dose dependent 
and reversible. 
Only  subjects with well preserved liver function will be allowed on study . Subjects with 
Hepatitis B (HBV) and C will be excluded from the trial.  L iver function tests will be 
frequentl y monitored in all subjects on study  and in case of liver abnormalities 
2012N155299_05 CONFIDENTIA L
BMA117159
45management will be implemented according to clinical practice. Subjects that meet liver 
stopping criteria (Section 3.9.1 ) will be withdrawn from the study .
Hematologic toxicity
Slight hemoglobin and platelet decrease together with an increase in numbers of 
neutrophils and monocy tes have been noted in monkey s at doses of 10mg/kg. In rats, 
decrease in hemoglobin, white cells, ly mphocy tes and neutrophils were noted at doses of 
30mg/kg.  However, rats given 10mg/kg showed higher neutrophil counts, and 
increased platelets at doses of 10mg/kg. 
The complete blood count (CBC) will be assessed frequentl y to monitor for hematologic 
toxicity . Supportive therapy  (growth factors, transfusions, antibiotics, monitoring and 
active treatment of infections) will be provided according to standard med ical practice 
and dose reductions or treatment discontinuations will follow recommendations in 
Section 3.10.1 .
Immunosuppression
In non clinical studies GSK2857916 has been associated with decrease in 
immunoglob ulins in monkey s (IgM at doses 1mg/kg, and IgG at >10 mg/kg).  An 
increase in immunoglobulins was seen in rats (IgM 10mg/kg and IgA at 30 mg/kg).  
Note that rats are not an antigen specific species for GSK2857916. 
Lym phocy te counts will be followed thro ughout the study  by CBC and lymphocy te sub -
population analy sis. Subjects will be activel y monitored for immunoglobulin levels and 
treated for infections according to standard practice.
Pulmonary toxicity
Preliminary  non clinical safet y experiments have demonstrated the presence of 
microscopic changes in the lungs (prominent alveolar macrophages associated with 
flocculent eosinophilic material; mixed perivascular inflammation) in rats at all doses 
tested. 
Subjects will be monitored for clinical signs and sy mptoms potentially  related to 
pulmonary  toxicity .  Further diagnostic tests and management will be implemented 
immediately  according to recommendations provided in Section 3.10.1 .
Ocular toxicity
There were no e ye related findings in monkey s.  Minimal corneal single cell necrosis was 
noted in rats treated at 3mg/kg.  
Subjects will be actively  monitored for ocular toxicity  and will be instructed to use 
preventive steroid ey e  drops as outlined in Section 3.9.8.  I n case of developing ey e-
related s ymptoms, subjects will be evaluated by  an ophthalmologist and appropriate 
management will be initiated immediately .  Dose reduction and treatment stopping 
2012N155299_05 CONFIDENTIA L
BMA117159
46recommendations will be followed according to recommendations provided in Section 
3.10.
1.3.2. Benefit A ssessment
Currently  there is no clinical evidence that treatment with GSK2857916 will result in any  
benefit to subjects.  However, base d on data from non clinical studies there is a 
possibility  that GSK2857916 might reduce tumor burden in subjects with MM and 
BCMA positive lymphomas .
1.3.3. Overall Benefit:Risk Conclusion
Overall, due to limited clinical experience with GSK2857916 benefit/risk cannot be 
asseesesed at this time.  The safet y of subject is the primary objective of this study  and 
adequate monitoring and guidance for dose reductions/stopping criteria are provided in 
the protocol to minimize risks associated with exposure to GSK285791 6. 
2. OBJECTIVE(S), ENDPOI NT(S) A ND HYPOTHESIS
Hypothesis
GSK2857916 can be safely  administered to subjects with MM and with other BCMA 
positive malignancies at doses where target engagement can be demonstrated.
Objective Endpoint
Primary
To determine safe ty, 
tolerability , maximum 
tolerated dose (MTD), and 
recommended phase (RP2) 
dose and schedule of 
GSK2857916 administeredAdverse events (AE) and changes in clinical signs 
and laboratory  parameters 
Secondary 
To evaluate the 
pharmacokinetic (PK) 
profile of GSK2857916 and 
the breakdown product cys -
mcMMAF) after 
intravenous (IV) single and 
repeat dose administration 
in subjects with 
relapsed/refractory  MM and 
BCMA expressing 
lymphomasGSK2857916 and cy s-mcMMAF PK parameters 
following IV single and repeat d ose administration 
during dose escalation as data permit (e.g., AUCs 
Cmax, tmax, CL , VSS, t½ [single dose], Cmax and 
Ctrough [repeat dose]). GSK2857916 population 
PK parameters in expansion cohorts at the RP2 
dose (e.g. clearance (CL), volume of distribution 
(Vd)), and relevant covariates which may  
influence exposure (e.g. age, weight, or disease-
related covariates e.g. BCMA expression) 
2012N155299_05 CONFIDENTIA L
BMA117159
47Objective Endpoint
To assess anti -drug 
antibody  (ADA) formation 
after IV single and repeat 
dose administration of 
GSK2857916ADA inciden ce and titers after single and repeat 
IV dosing of GSK2857916
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and BCMA expressing 
lymphomasClinical activity  measured as Overall Response 
Rate (ORR) which i s defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minimal response (MR) will be assessed 
for clinical benefit rate (CBR) ( Appendix 
1)
oFor Lymphomas: the percentage of subjects 
achieving PR or better ( PR) ( Appendix 2 ) 
Exploratory 
To evaluate PD markers in 
MM after treatment with 
GSK2857916sBCMA levels, BCMA recep tor occupancy  and 
cell death markers in subjects with MM. 
To explore relationships of 
GSK2857916 plasma 
concentrations/exposure 
with pharmacod ynamics 
(PD), safet y and clinical 
activity  Relationship between receptor occupancy , tumor 
cell death markers, sBCMA and GSK2857916 
plasma PK parameters;
Relationship between safety /clinical activity  (e.g. 
ORR) and GSK2857916  PK parameters 
To characterize the 
relationship between 
clinical response and other 
biologic tumor 
characteristics (DNA, 
protein anal ysis)BCMA expression levels on malignant cells as 
measured b y IHC and/or flow cy tometry  in tumor 
tissue, serum sBCMA levels and their relationship 
to clinical response
To investigate the 
relationship between genetic 
variants in the host and 
response to study  medicine 
or susceptibility , seve rity 
and progression of diseaseRelationship between host genetic variation and 
response to study  medicine or susceptibility , 
severit y and progression of disease
2012N155299_05 CONFIDENTIA L
BMA117159
48Objective Endpoint
To explore the effect of 
GSK2857916 on symptoms
(including bon e pain, 
fatigue and visual 
symptoms) and impacts on 
HRQoL  in subjects with 
relapsed/refractory  MM
(Part 2)Changes from baseline in bone pain/fatigue and 
analgesic use as measured by  the eDiary
Interviews with subjects to further characterize 
changes in sy mptoms (includi ng bone pain, 
fatigue and visual s ymptoms) and impacts on 
HRQoL
To explore changes in visual 
symptoms and function 
following discontinuation of 
treatment with 
GSK2857916Changes in visual s ymptoms and impacts as 
measured b y the OSDI and NE I-VFQ -25 
following treatment discontinuation
Follow -up telephone interview s conducted to 
further understand subjects experience with visual 
symptoms and changes in sy mptoms and related 
impacts following treatment discontinuation
To explore the initial anti-
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM in terms of time -to-
event (TTE) endpoints (Part 
2 MM)Time to progression (TTP), defined as: the time 
from first dose until the earliest date of PD per 
International Multiple Myeloma Wo rking Group 
(IMWG), or death due to PD.
Duration of response (DOR), defined as: the time 
from first documented evidence of PR or better; 
until the time when disease progression (PD) is 
documented per IMWG; or death due to PD occurs 
in subject s who achieve a response, i.e. confirmed 
PR or better.
Time to response (TTR), defined as: the time 
between the date of first dose and the first 
documented evidence of response (PR or better).
Progression-free survival (PFS), defined as: the 
time from first dose until t he earliest date of 
disease progression (PD) per IMWG, or death due 
to any  cause.
Number of deaths
2012N155299_05 CONFIDENTIA L
BMA117159
493. INVESTIGA TIONAL PLA N
3.1. Discussion of Study  Design
Table 3 Study  Design
Part 1 Dose Escalation (n=up to 30 subjects )
Population:   relapsed/refractory MM
Characterize safety, PK, PD, immunogenicity and establish RP2 dose of GSK2857916
Schedule 1 : GSK2587916 once every 3 weeks (21 -day cycle) (n=~20)
Schedule 2 : GSK2587916 once weekly for 3 consecutive weeks, 1 -week rest (28- day cycle) 
(n=~9)
Serial PK samples will be collected from all subjects in Part 1
Part 2 Expansion Cohort(s)  (n=~50 subjects)
Population:
1) Subjects with relapsed/refractory MM (up to 40 subjects)
2)Subjects with  lymphomas expressing BCMA (up to 10 subjects)
Cohor t Expansion groups : Further evaluate the safety, PK, immunogenicity, and activity of 
GSK2857916 at the RP2 dose identified in Part 1
A futility analysis based on ORR data will be performed after approximately 15, 22 and 30  
subjects have been evaluated fo r response in MM cohort
Both Expansion groups will be analyzed separately
Sparse PK samples will be collected from all subjects
Genetics research samples will be collected predose from all subjects
This is a First Time in Human (FTIH), open -label, d ose escalation trial consisting of two 
parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safet y, and clinical 
activity  testing ( Table 3and Section 3.2). The study will enroll a total of approximately  
80-95subjects with relapsed/refractory  MM or other BCMA- expressing ly mphomas.  
The maximum dose to be administered in this trial will not exceed 5 mg/kg.
Part 1 : Dose -escalation cohorts will characteriz e the safet y, tolerability , PK, and PD of 
GSK2857916 given on a once every  21 day s or a once weekl y schedule. Only  subjects 
with MM will be enrolled in Part 1 based on an N -CRM dose escalation model until 
MTD(s) or RP2D is/are established on an appropriate schedule(s). GSK2857916 and cy s-
mcMMAF PK parameters derived from extensive PK sampling and PD biomarkers (e.g. 
2012N155299_05 CONFIDENTIA L
BMA117159
50target engagement/tumor cell killing) will be estimated/measured during dose escalation 
to inform the next cohort dose and the selection of a R P2 dose [Biologically  effective 
dose (BED) or maximum tolerated dose (MTD)].  In case of insufficient sample quality  
or due to high variability  in the measurement of PD biomarkers, up to 6 additional 
samples from subjects in expansion cohort might be colle cted for PD analy sis.  I nitially , 
GSK2857916 will be administered (IV) via 60 min infusion once every  three weeks (21 
days = 1 cy cle) on Schedule 1. Once an MTD1 or RP2D has been established on the once 
every  21-day (Schedule 1), the safet y, tolerability, PK, and PD of once -weekly  dosing 
(Schedule 2) of GSK2857916 may  be explored asan additional cohort(s). Dose 
escalation decisions on each of these two dosing schedules will utilize a separate N- CRM 
model.  The information gained from evaluation of Schedul e 1 (once every  three weeks; 
21-day cy cle) will be utilized to inform the model for Schedule 2 (once weekly  for three 
consecutive weeks, 1 week rest; 28- day cycle).
Part 2 : Expansion cohorts will assess the safet y, tolerability , PK (sparse sampling), and 
clinical activity  of the GSK2857916 dose regimen identified in Part 1.  A total of 
approximately  50 subjects will be enrolled in Part 2. A MM cohort (up to 40 subjects) 
will be enrolled with no prospective BCMA screening required (BCMA expression data 
colle ction and retrospective anal ysis will be performed).  In addition, futility  analy ses 
will be performed on the MM cohort after approximately  15, 22 and 30 evaluable patients 
have been assessed for response.  For more detailed information on the futility  analysis, 
see Section 13.6.2. Sparse PK sampling will be collected to further characterize 
GSK2857916 exposure for the selected dose schedule.  
A smaller cohort of subjects with BCMA positive lymphomas (up to 10 s ubjects) will be 
enrolled based upon prospective detection of positive BCMA tumor cell expression as 
determined b y a central laboratory using a validated IHC assay .  
Protocol waivers or exemptions are not allowed.  Therefore, adherence to the study  
design requirements, including those specified in the Time and Events Tables 
(Section 7.1) are essential.
Supplementary  study  conduct information not mandated to be present in this protocol is 
provided in the accompan ying Study  Procedures Manual (SPM).  The SPM will provide 
the site personnel with administrative and detailed technical information that does not 
impact subject safet y.
2012N155299_05 CONFIDENTIA L
BMA117159
513.2. Stud y Schematic
MTD1
4
3
12
25% of MTD1 /RP2 D1MTD 2/RP2D2BCMA -positive Lymphomas (n =≈10)Multiple myeloma  (n ≈ 40)PART 1: Dose Escala tion
(n≈30)PART 2: Expa nsion Coho rts 
(n≈50)
23
1
*Cohort s ize to i ncrease, n≈3 i f ≥Grade 2 
drug related toxi city reported5-9
4RP2D1
Abbreviations: MTD=maximum tolerated dose; N- CRM= Neuenschwander Continual Reassessment 
Method ; RP2D=recommended phase 2 dose
1.Part 2 to initiate after  once every  3 week recommended dose is determined
2.Dose escalation with once week lyschedule may commence in parallel to Part 2 expansion
3.3. Part 1: Dose- Escalation Phase
Only  subjects with MM will be enrolled in Part 1, and no prospective selection by  BCMA 
expression level will be required.  The MTD of GSK2857916 will be established first on 
Schedule 1; the once every  three weeks (21 day s ) schedule as described in Section 3.3.1. 
Subjects on Schedule 1 will be enrolled into dose escalation cohorts based on an N -CRM 
dose escalation model generated for each schedule.  
After the MTD1 or RP2D is established for the once every  three weeks Schedule 1, once 
weekl y dosing of GSK2857916 (Schedule 2) may be evaluated prior to, or in parallel 
with the expansion phase as described in Section 3.3.2 .  A weekl y dosing regimen may be 
chosen for further eval uation if toxicity  is felt to be related to Cmax and that equivalent 
or greater exposures in terms of AUC can be safely achieved with weekl y dosing 
compared with the once every  3weeks dosing regimen.  
2012N155299_05 CONFIDENTIA L
BMA117159
52Note:  For details on data dissemination and communic ation with sites (dose escalation 
meetings and safet y  update meetings), refer to Section 12.1.
3.3.1. Dose Escalation on Schedule 1 (GSK2857916 administered once 
every three weeks; 21 day s = 1 cy cle)
(Note: For details on scheduled procedures in subjects given GSK2857916 on 
Schedule 1 in Part 1 refer to Time and Events Section 7.1.1.1 )
3.3.1.1. Single Subject Cohort Run -in (Schedule 1 only)
A single subject will be enrolled at each do se level as outlined in Table 4 until 
occurrence of a ≥ Grade 2 toxicity  for which relationship to the investigational 
agent cannot be ruled out.
Initiall y, GSK2857916 will be administered (IV) via 60 min infusion once every 
three weeks (21 day s = 1 cy cle) on Schedule 1. One subject or the sentinel 
subject i.e., the very  first subject on the study ; will initially  be enrolled at the 
starting dose of 0.03 mg/kg in Cohort 1 (Refer to Section 3.6.4 for starting dose 
rationale).  The initial dose will be given to the sentinel subject.  Serial blood 
samples will be collected for PK.  The sentinel subject must remain under 
observation for at least 24 hours after dosing before discharge.  GSK2857 916 
(intact and total [intact + unconjugated antibod y]) and cy s-mcMMAF plasma 
concentrations will be analy zed and reviewed together with the safet y data (DL T 
period). If the first dose is considered tolerated, the sentinel subject will be 
allowed to stay  on the study  and receive subsequent doses at the same dose level 
(i.e., 0.03 mg/kg) as scheduled, every  three weeks (21 day s interval) for up to 16 
doses (or until disease progression, toxicity  or withdrawal of consent). 
If the sentinel subject does not ex perience a ≥ Grade 2 toxicity  for which 
relationship to the investigational agent cannot be ruled out during the first cy cle 
(within 21 day s), the next subject will be allowed to enroll in the next cohort at a 
dose increased b y ≤100% of the starting dose. Dose escalation with increments 
up to 100% of the previous dose will continue with enrolment of 1 subject per 
cohort until the occurrence of the first ≥ Grade 2 toxicity  for which relationship 
to the investigational agent cannot be ruled out. (run in proc edure outlined in 
Table 4 )
The single subject (small cohort) run -in will be halted when the first ≥ Grade 2 
toxicity  for which relationship to the investigational agent cannot be ruled out
occurs in one subject in Cy cle 1 (21 day s).  At this point, the cohort will be 
expanded to 3 or more subjects at the same dose level and the escalation will 
continue to follow the N -CRM procedure as outlined in Table 4
2012N155299_05 CONFIDENTIA L
BMA117159
53Table 4 Single Subject (Sma ll Cohort) Run -InProcedure for GSK2857916 
given on Schedule 1 (once every  21 day s)
Dose Level Number of subjects 
with ≥G2 toxicityDose Escalation/Action
Dose Level 1/Cohort 1 0 out of 1 subject
(Sentinel subject)Predicted starting dose 0.03 mg/kg every 21 
days
Dose Level 2/Cohort 2 0 out of 1 subject Escalate to the next dose level with increase   
≤100%  of the starti ng dose
Dose Level 3 and 
beyond/Cohort 3 and 
beyond0 out of 1 subject Escalate to the next dose level with increase of 
≤100% of the dose tested in the previous cohort 
1 out of 1 subject* Switch to Cohort size of 3 or more subjects 
*Increase of doses up to 100% of the previous dose may continue until the first ≥Grade 2 
toxicity  for which relationship to the investigational agent cannot be ruled out occurs in 
one subject in Cycle 1 (21 days).  At this point the single subject (small cohort) run -in is halted.  
Continue with N -CRM, with cohort sizes of 3 or more subjects.  Increase of doses 100% will be 
considered for subsequent cohorts of 3 or more subjects. 
Dose escalation/de-escalations decisions will take into account all available data, 
includin g but not limited to the safet y parameters, PD and PK data of all cohorts 
assessed.  Dose escalation/de- escalation decisions will be informed by  the N -
CRM [ Neuenschwander , 2008].  The N -CRM model used for Sche dule 1 is 
described in detail in Section 3.3.1.2 .  The method is fully  adaptive and makes use 
of all DLT information available at the time of each dose assignment.  The Fixed 
and Adaptive Clinical Trial Simulato r (FACTS) will be used to conduct the N-
CRM.  Dose -related decisions will occur following review of these data b y the 
investigator(s), GSK medical monitor, clinical pharmacology  modelling and 
simulation (CPMS) representative, and statistician. The decision and rationale 
will be documented in written format and distributed to the investigator(s), GSK 
medical monitor, CPMS representative, and statistician.
The MTD will be defined as that dose which has the highest probability  of having 
a DLT rate within the target toxicity  interval, and for which the probability  that 
the DLT rate lies within the excessive toxicity  or the unacceptable toxicity  
window is less than 25% (see Section 3.3.3 for DLT definitions).  The DLT
assessment period on Schedule 1 will be 21 day s.
Dose adjustments/stopping criteria will adhere to guidelines provided in Section 
3.10.1 .
Selected dose escalation cohorts may  enroll additional subjects in ord er to further 
assess safet y, PK and/or PD.  The frequency  and schedule of dosing may  be 
adjusted based on emerging safet y, PK and PD data e.g., a recovery period may 
be incorporated into the dosing. Additional, intermediate dose levels may  also be 
explored. 
2012N155299_05 CONFIDENTIA L
BMA117159
54Subjects will receive GSK2857916 treatment until disease progression, 
unacceptable toxicity , withdrawal of consent, or until they  have reached the end 
of the treatment period, which has been pre- specified as 16 cy cles (48 weeks) for 
Schedule 1 (GSK28579 16 given once every  three weeks; 1 cy cle = 21 day s).
3.3.1.2. Description of N -CRM for Schedule 1
3.3.1.2.1. Planned Dose Levels
Prior to the start of the study , projected dose levels on Schedule 1 (in mg/kg) are 0.03, 
0.06, 0.12, 0.24, 0.48, 0.96, 1.92, 2. 8, 3.6, and 4.5 mg /kg; actual dose levels will be 
determined b y N-CRM ( Neuenschwander -Contin uous Reassessment Method ).  
Additional doses and schedules may  be explored based on emerging safet y, PK, and PD 
data. The maximum dose to be administered in this trial will not exce ed 5 mg/kg.
Description of the New Contin uous l Reassessment Method : After each cohort, a 
dosing recommendation for the next cohort will be made using the N-CRM 
[Neuenschwander , 2008].  All available data, including safet y, PK and PD data from 
current and prior cohorts will be reviewed at the dose escalation meeting (see Section 
12.1). Although the N -CRM will be used to recommend the next dosing level, clinical 
judgment by  the Medical Monitor and internal dose -escalation committee in consultation 
with the investigators can halt enrolment into lower dose cohorts as deemed appropriate 
at an y time during the trial. 
The N -CRM design is a ty pe of Bay esian adaptive dose e scalation scheme that assumes a 
two-parameter logistic model for the toxicity  rate based on dose.  It is a modified version 
of the original Contin uous Reassessment Method [ O’Quigley , 1990]. A CRM -based 
design uses a statistical model for dose and toxicity , and is expected to locate the MTD 
efficientl y while minimizing the number of subjects exposed to pharmacologically 
inactive dose levels. 
The method is fully  adaptive and makes use of all the DLT information availa ble at the 
time of each dose assignment.  I n contrast, the 3+3 method only  uses information from 
one dosing cohort at a time.  
At the time of each dose escalation decision, the Fixed and Adaptive Clinical Trial 
Simulator (FACTS) will be used to obtain, for each potential dose, the posterior 
probabilities that the DLT rate for that dose lies in each of four toxicity  intervals (under 
dosing, target dose range, excessive toxicity , and unacceptable toxicity ).  The four DLT 
toxicity  intervals are defined as fol lows:
[0%, 16%) Underdosing 
[16%, 33%) Target toxicity  
[33%, 60%) Excessive toxicity  
2012N155299_05 CONFIDENTIA L
BMA117159
55[60%, 100%) Unacceptable toxicity
The recommended dose will be the dose with the highest posterior probability  of ly ing in 
the target toxicity  interval with the addit ional requirement that the sum of the posterior 
probabilities of the DLT rate l ying in the excessive toxicity  or unacceptable toxicity  
range is less than 25%.  Selection of the next dose cohort to be enrolled is also subject to 
the constraint that the next dose level can be no more than two times that of the current 
dose level. An updated estimate of the toxicity  curve will be provided at the time of each 
dose escalation meeting (see Section 12.1).
Note that de -escalation as well as escalation is possible using this method.
Dose escalation will continue until:
i) Six subjects have been treated at the current target dose 
AND
For the current dose level, the posterior probabilities of the DLT rate l ying 
within the ex cessive toxicity interval or within the unacceptable toxicity  
interval sum to less than 25%.
AND
For the next higher dose, the posterior probabilities of the DLT rate ly ing 
within the excessive toxicity  interval or within the unacceptable toxicity  
interval sum to less than 25%.
OR
ii) No doses are usable (i.e.  For ALL doses, the posterior probabilities of the 
DLT rate l ying within the excessive toxicity  interval or within the 
unacceptable toxicity  interval sum to more than 25%
AND
At least two DLTs have been observed.
The N -CRM model used to determine the MTD for Schedule 1 will utilize a single 
subject/cohort run -in phase.
3.3.1.2.2. Implementation of N-CRM
The N-CRM model implementation will be performed using Fixed and Adaptive Clinical 
Trial Simulator (FACTS) ( Version 2.3 or higher) from Tessella .
2012N155299_05 CONFIDENTIA L
BMA117159
563.3.1.2.3. Bayesian Prior
The N -CRM methodology  requires that a Bay esian prior for the toxicity  curve be pre -
specified.    
The proposed prior probabilities of DL T are an approximation on the potential toxicity  
profile based on t he available non clinical toxicology  package, dosing range being 
considered, and literature data available from clinical trials with other ADCs. 
Additionally , the prior is considered a ‘weakl y informative prior’ and is defined with a 
fairly wide credible i nterval. This allows the model the freedom to estimate the observed 
probabilities of toxicity  with minimal restriction.
The initial Bay esian prior used for this design is determined by  using the quantile 
method.  For each dose, an estimate of the median pr obability  of DLT was specified, 
along with a 95% credible interval.  The 95% credible intervals are intentionally  wide 
due to limited information about the toxicity  profile of GSK2857916 in humans.  Table 5
shows t he median prior probability  of experiencing a DLT at the given dose along with a 
95% credible interval around the median:
Table 5 Table of Specified Prior Probability of DLT (with 95% Credible 
Interval)
Anticipated Dose
(mg/kg)2.5% Quantile for 
Probability  of 
ToxicityMedian 
Probability of 
Toxicity97.5% Quantile for 
Probability  of Toxicity
0.03 0 0.001 0.80
0.06 0.01 0.02 0.82
0.12 0.02 0.05 0.84
0.24 0.03 0.1 0.86
0.48 0.05 0.15 0.88
0.96 0.07 0.2 0.90
1.92 0.1 0.225 0.92
2.8 0.11 0.275 0.94
3.6 0.12 0.35 0.96
4.5 0.13 0.425 0.98
A graphical presentation of the initial prior is displayed in Figure 1.  Doses are the 
projected doses.  Actual doses used during the conduct of the trial may  vary .An 
intermediate prior will be derived based on the initial prior by  FACTS (Version 2.3 or 
higher) from Tessella. The final prior is determined based on the intermediate prior and 
all available data.
2012N155299_05 CONFIDENTIA L
BMA117159
57Figure 1 Graphic al display  of the prior distribution for the probability  of DLT 
given dose
3.3.2. Dose Escalation on Schedule 2 (GSK2857916 administered once 
weekly  x3, 1 week rest; 28 day s = 1 cy cle)
(Note: For details on scheduled procedures in subjects given GSK2857916 on Schedule 2 
in Part 1, refer to Time and Events Table in Section 7.1.1.2)
The MTD (MTD1) or RP2D (RP2D1) established for GSK2857916 on Schedule 1 i.e., 
once every  three weeks schedule, will inform selection of th e starting dose for Schedule 2 
i.e., the once weekl y schedule.  Additional cohort(s) may be enrolled to evaluate the 
safet y, PK, and PD of GSK2857916 for the once weekl y dosing schedule to establish an 
MTD2.  GSK2857916 will be dosed once weekly  for 3 cons ecutive weeks, followed by  1 
week off (Schedule 2 = 28- day cy cle). 
The once weekl y dosing cohorts may  be explored prior to, or in parallel with, 
enrollment to the expansion cohorts (Part 2).
The dose escalation of the once weekl y schedule will utilize a s eparate N -CRM 
model from the model used for the once every  three week schedule. The 
information gained from the evaluation of the once every  three week schedule 
(Schedule 1) will be utilized to more accuratel y define the N -CRM model used 
for dose escalation on the once weekl y schedule (Schedule 2).
Depending on emerging safet y signals, the proposed weekl y starting dose will be 
25% of MTD1 or RP2D1 .  If the initial dose of 25% of MTD1 or RP2D1 is not 
tolerated, dose escalation on the weekly schedule will be terminated and 
enrollment into Schedule 2 will be closed.  If the starting dose is tolerated, 
escalation on the weekl y schedule will continue at increments of 30% and will 
follow the N -CRM procedure until MTD2 or RP2D2 is reached. 
The MTD will be defin ed as that dose which has the highest probability  of having 
a DLT rate within the target toxicity  interval and for which the probability  that the 
2012N155299_05 CONFIDENTIA L
BMA117159
58DLT rate lies within the excessive toxicity  or the unacceptable toxicity  window is 
less than 25% (see Section 3.3.3 for DLT definitions).  The DLT assessment 
period on Schedule 2 will be 28 day s.
The N -CRM procedure for the weekl y schedule will not utilize a single 
subject/cohort run -in phase. Schedule 2 dose escalatio n cohorts will consist of 3 
or more subjects due to higher starting dose and greater probability  of toxicity .
Dose escalation decisions will a lso take into account all availab le data. This 
includes, but is not limited to the safet y and PK characteristics of all cohorts 
assessed.  In addition, dose escalation decisions will be determined by  the N -
CRM [ Neuenschwander , 2008].  The FACTS will be used to conduct the N- CRM.  
These decisions will occur following revi ew of these data b y the investigator(s), 
GSK medical monitor, CPMS representative, and statistician.  The decision and 
rationale will be documented in written format and distributed to the 
investigator(s), GSK medical monitor, CPMS representative, and stat istician.  
Dose adjustments/stopping criteria will adhere to guidelines provided in Section 
3.10. 
Subjects will receive GSK2857916 in this weekly dosing cohort until disease 
progression, unacceptable to xicity,withdrawal of consent, or completion of the 
pre-specified treatment period of 48 doses (16 cy cles on Schedule 2).
If a subject misses a dose on the weekl y schedule, the dose will be recorded as 
missing and the next dose will be administered according to t he current cycle.  
The counting of day s and cy cles will continue regardless of whether or not the 
subject received the dose.  Dose delay s of + 3 days are allowed in order to 
accommodate scheduling conflicts/holiday s, etc.
Additional alternative schedules may be evaluated based on emerging data. If an 
alternative schedule other than the weekly  dosing schedule is evaluated, details on 
dosing and Time and Events will be updated in the Study  Procedures Manual (SPM).
3.3.3. Dose -Limiting Toxicity -Part 1 only
Any subject in Part 1 (Dose Escalation) who received at least one dose of the drug 
(regardless of schedule) will be evaluated for DLTs.  Safety data together with DL Ts will 
be reviewed during the dose escalation meetings prior to opening enrollment into 
subsequen t cohorts (see Section 12.1). 
Subjects who have been withdrawn from the study  for reasons other than toxicity  but 
prior to completion of DLT observation period will be replaced. An event will be 
considered a DLT if its relationship to the investigational agent cannot be ruled out 
occurs within the DLT reporting period (first 21 day s of treatment for schedule 1, and 
first 28 day s for schedule 2) and meets one of the following criteria:
2012N155299_05 CONFIDENTIA L
BMA117159
59Albuminuria ≥2000 mg/24 hr which has been confirmed by  repeat test at least 7 
days apart and is not considered to be related to disease progression based on 
consultation of investigator with GSK medical monitor
Grade 4 neutropenia (without fever) lasting 7 day s 
Febrile neutropenia lasting 72 hours 
Grade 3 thrombocy topenia associated  with bleeding where estimated blood loss 
is > 10mL  or Grade 4 thrombocy topenia lasting >7 day s and not responding to 
platelet transfusions 
Any Grade 3 or greater non- hematologic toxicity  as described in Common 
National Cancer Institute- Terminology  Criteria for Adverse Events (NCI -
CTCAE) version 4.0 [ NCI, 2009]  with the exception of the following Grade 3 
events that can be controlled within 48 hours with routine supportive measures
oNausea and vomiting that can be controlled with anti -emetics
oDiarrhea that can be controlled with anti- diarrheals
oRash or other skin reactions that can be controlled with antihistamines and 
steroids
oClinically asymptomatic electrol yte abnormalities which can be corrected 
within 48 hours)
Liver toxicity meeting pre -specified GSK liver stopping criteria (see Liver in 
Section 3.9.1 )
Tumor ly sis sy ndrome does NOT constit ute a DLT (Section 3.9.7).
A subject who develops a DLT will be allowed to stay  on study  only if the toxicity  did 
not meet stopping criteria and recovered to Grade 1 within 14 day s, or after a longer 
recovery  time if benefit to subject can be demonstrated and if the investigator and 
medical monitor agree that for a given subject the benefits may  outweigh the risks.
3.3.4. Maximum Tolerated Dose
The MTD will be defined as that dose which has the highest probability  of having a DLT 
rate within the target toxicity  interval and for which the probability  that the DL T rate lies 
within the excessive toxicity  or the unacceptable toxicity  window is less than 25%.
3.4. RP2 Dose and A dministration Schedule Selection for Part 2
All ava ilable safet y, PK, and PD data from the once every  3 weeks schedule, and if 
available, the once weekly  dosing schedule ,will be anal yzed. If a consistent level of 95-
100% receptor occupancy is observed in evaluable subjects at a dose lower than the 
determi ned MTD with no evidence of target mediated disposition in the PK profile and 
where emerging signs of clinical activity  can be demonstrated, a dose level below MTD 
may be defined as the biologicall y effective dose (BED).
This lower dose level, or an intermediate dose considered the BED, may  be tested as the 
RP2 dose for further evaluation in Part 2.  Part 2 may start enrolling once Part 1 has 
2012N155299_05 CONFIDENTIA L
BMA117159
60completed enrollment of Schedule 1 (once every  three weeks) and after the preliminary  
PK and relevant PD data ha ve been anal yzed.The once weekl y schedule may be explored 
prior to or in parallel with the expansion cohorts. Data considered will include, but not be 
limited to,  relationships between safet y and exposure, the PK profiles, as well as an y 
emerging PD infor mation, and earl y signs of clinical activity observed for each schedule 
evaluated in Part 1. If the once weekl y schedule is explored prior to initiating Part 2, the 
chosen dosing regimen would need to provide evidence of the following in order to be 
the pr eferred schedule in Part 2:  a better safet y and tolerability profile at an equivalent or 
higher dose, or greater clinical activity , or a more desirable PK profile (i.e. no evidence 
of target -mediated disposition observed over the dosing interval).  A pref erence might be 
given to the weekl y schedule if at MTD1, the receptor occupancy  levels are considered 
sub-optimal and/or saturation of soluble sBCMA is not maintained long enough on the 
every  3 weeks dosing schedule .
Part 2: Expansion Cohort :
(Note: For de tails on scheduled procedures in subjects given GSK2857916 in Part 2, refer 
to Time and Events Tables Section 7.1.2 .The Time and Events Table for GSK2857916 
administered to MM subjects on Schedule 1 is represented in Section 7.1.2.1 , and the 
Time and Events Table for GSK2857916 administered to MM subjects on Schedule 2 is 
represented in Section 7.1.2.2 . Refer to Time and Events Tables Section 7.1.2.3 and 
Section 7.1.2.4 for GSK2857916 administered to subjects with lymphomas on Schedule 1 
or Schedule 2, respectively ).
Once the RP2 dose and schedule ha vebeen selected , expansion cohort swill be enrolled 
in order to better characterize the safet y profile of the selected dose and schedule.  
The Part 2 expansion will enroll up to 50 subjects as summarized below:
oMultiple My eloma cohort (up to 40 subjects)- no prospective screening of 
BCMA is required for enrollment
Futility anal yses based on ORR will take place after approximately  
15, 22 and 30 subjects have been evaluated for response. Full 
details can be found in Section 13.6.2   
BCMA expression data and retrospective anal ysis will be 
performed on samples collected in the MM population
PRO will be collected via eDiary  in the MM population in Part 2 
only
BCMA positive lymphomas (defined as BCMA positive staining 
by IHC)  (up to 10 subjects) – prospective screening of  BCMA 
expression is required for enrollment
Sparse PK sampling will be collected from all subjects in Part 2 to explore exposures 
of GSK2857916 at the RP2 dose (BED or MTD) and schedule.  Genetics research
2012N155299_05 CONFIDENTIA L
BMA117159
61samples will also be collected as outlined in Section 7.6and in the Time and Events 
Table in Section 7.1.2 .
Note:  For details on data dissemination and communication with sites (safety  update 
meetings), refer to Section 12.1.
3.5. Intra-Subject Dose Escalation
Forthesubjects enrolled in Part 1 ,intra-subject dose escalations may  be considered on a 
case-by-case basis, provided that the subject completed at least 2 cy cles at original ly 
assigned dose, still fulfils eligibility  criteria, has tolerated treatment well, and did not 
experience Grade 3 or higher toxicity . A subject’s dose may  be increased to that of a 
completed cohort that has not exceeded the MTD. Approval must be obtained from a 
GSK Medical Monitor. Dose -escalation decisions will be documented on a Dose 
Escalation/De -escalation Decision Form (see SPM).
3.6. Rationale
3.6.1. Rationale for Study
This study  will assess the safety, PK, PD and the therapeutic potential of GSK2857916 in 
subjects with MM and lymphomas that express BCMA. GSK2857916 is a humanized 
IgG1 antibody drug conjugate (ADC) which binds specificall y to BCMA. The parent 
anti-BCMA antibod y (J6M0) is conjugated to the microtubule inhibitor monomethyl 
auristatin -F (MMAF) via a protease resistant maleimidocaproyl (mc) linker to produce 
the GSK2857916 ADC molecule.  Upon binding to the cell surface, GSK2857916 is 
rapidly  internalized and active drug (cy s-mcMMAF) is released inside the cell.
GSK2857916 has been produced in an af ucosylated form to generate an enhanced 
antibody  dependent cellular cy totoxicity  (ADCC) response upon binding to Fc RIIIa 
receptors on the surface of human effector cells. This dual mechanism of action may  
improve efficacy  by targeting dividing and non- dividing tumor cells. Importantly , BCMA 
expression is maintained at the cell surface over time following GSK2857916 binding 
and internalization due to rapid BCMA receptor recy cling and/or new protein sy nthesis.  
GSK2857916 has demonstrated dose- dependent cy totoxic activity  in my eloma cell lines, 
ex vivo primary  myeloma tumor samples, as well as preclinical myeloma mouse tumor 
models.  GSK2857916 has also shown activity in B cell l ymphoma cell lines that express 
BCMA.
The hy pothesis is that GSK2857916 can be sa fely administered to subjects with BCMA 
positive malignancies at doses where target engagement can be demonstrated.  This study  
will determine if adequate target engagement of BCMA receptors translates into clinical 
benefit for subjects with MM and BCMA po sitive lymphomas. 
3.6.2. Rationale for Population
The anti -tumor activit y of GSK2857916 relies strictly  on its binding to the BCMA cell 
surface receptor. Following binding to receptor the drug will be internalized and the toxin 
(MMAF) will be released inside the cell to cause cell cy cle arrest and subsequent death.  
2012N155299_05 CONFIDENTIA L
BMA117159
62In addition, the antibody  on the cell surface will recruit effector cells via the ADCC 
mechanism to kill the tumor cells.  I t is prudent that the target population for this study  is 
required to expres s BCMA.  The MM population has been selected for this FTIH trial 
because this population has the highest likelihood of expressing BCMA.  BCMA 
expression levels in MM vary  from patient to patient, but our studies demonstrate that all 
MM patients tested expr ess detectable levels of BCMA protein on their tumor cells.  
Specificall y, GlaxoSmithKline (GSK) studies have shown that in samples taken from 
MM patients (N=45), 31% have low expression, 38% moderate expression and 31% high 
expression of BCMA as detected by immunohistochemistry  (IHC).  Subjects with 
lymphomas that exhibit BCMA expression have been selected as an exploratory  cohort in 
this FTIH study ; the frequency  of BCMA expression in ly mphomas is lower than that 
observed in MM, therefore prospective sele ction is required.  
The target population for this study  includes subjects with relapsed/refractory MM to 
establish the dose and characterize safety , PK and PD of GSK2857916.  Subjects with 
BCMA expressing ly mphomas will also be allowed on study  after pro spective screening 
by IHC demonstrates that BCMA is expressed on tumor cells. Potential subjects with B-
cell ly mphomas that will be tested for BCMA expressi on prior to study  entry  include
subjects with the following diseases:  Diffuse Large B -Cell Ly mphom a (DLBC L),or
Follicular Ly mphoma (FL), that have progressed after 2 prior lines of s ystemic therap y 
for a given disease.  
3.6.3. Rationale for Starting Dose
The dose selection of GSK2857916 in this proposed first time in human study  (FTIH) 
took into considerat ion both the ADC and enhanced ADCC mechanisms that are 
combined in this molecule and was based on estimations derived from different 
approaches that included non clinical biology , toxicology  as well as pharmacokinetic data 
collected in two species in parti cular mouse and monkey .
The following methods were used to support the determination of the starting dose:
methods specific for oncology compounds based on results of toxicology  studies 
(for ADC mechanism)
Minimum Anticipated Biological Effect Level (MABEL ) (for ADCC mechanism)
3.6.3.1. Human PK prediction
The human PK profile of GSK2857916 was predicted using the monkey  pharmacokinetic 
data collected during the pre- clinical development of GSK2857916. Anal ysis of the 
monkey  pharmacokinetic data using a 2- compartment PK model provided estimates of 
PK parameters in this species. In these conditions, the clearance of GSK2857916 in the 
monkey  was 0.00242 L/h or 19.6 mL /day/kg, the volume of distribution was 0.310 L  or 
105 mL /kg and the half -life was approximately  5 day s.An allometric scaling approach 
was used to predict the PK parameters in humans, with powers of unit y for volume and 
0.75 for clearance. Assuming a bod yweight of 70 kg for humans, the predicted human 
clearance (CL) is 0.0259 L/h or 8.89 mL/day /kg, the volu me of distribution (Vss) is 7.33 
L or 105 mL/kg and the plasma elimination half -life is approximately  12 day s in the 
2012N155299_05 CONFIDENTIA L
BMA117159
63absence of target.  Predicted human exposure at different doses with the predicted safet y 
cover in relation to the monkey  (cross -reactive species) and rat (non -target specific) 
exposure was determined assuming no target mediated disposition and in the absence of 
soluble BCMA (most conservative case), therefore human predicted exposure (i.e. AUC 
and Cmax) as well as the ratio predicted Cmax/I C50 will be likely  over -estimated in 
particular at the lower doses (i.e. <1 mg/kg) ( Table 6and Table 7 ).
Table 6 Safety  margins when comparing monke y NOAEL data (cross -
reactive species) with predicted human data for various doses of 
GSK2857916 administered IV (‘safety  cover’)
Predicted Human Cmax and AUC Safety cover (vs. Monkey NOAEL)
Ratio of predicted 
humanCmax/IC501Dose 
(mg/kg)Cmax (µg/mL) AUC (µg*h/mL) Dose cover Cmax coverAUC 
cover
0.03 0.593 81.0 33x 46.4x 15.3x 6.03x
0.05 0.988 135 20x 27.8x 9.2x 10.1x
0.1 1.98 270 10x 13.9x 4.6x 20.1x
0.2 3.95 540 5.0x 7.0x 2.3x 40.2x
1 19.8 2700 1.0x 1.4x 0.5x 201x
2 39.5 5400 0.5x 0.7x 0.2x 402x
5 98.8 13500 0.2x 0.3x 0.1x 1006x
1. IC50 = 0.1 μg/mL for depletion of CD19+/CD27hi/CD38hi plasmablasts in whole blood 
(ADCC mechanism)
Table 7 Safety  margins when comparing rat NOA EL data (non -target 
specific) with predicted human data for various doses of 
GSK2857916 administered IV (‘safety  cover’)
Predicted Human Cmax and AUC Safety cover (vs.rat NOAEL)
Dose (mg/kg) Cmax (µg/mL) AUC (µg*h/mL) Dose Cover Cmax Cover AUC Cover 
0.03 0.593 81.0 100x 174x 75x
0.05 0.988 135 60x 104x 45.2x
0.1 1.98 270 30x 52.1x 22.6x
0.2 3.95 540 15x 26.1x 11.3x
1 19.8 2700 3x 5.2x 2.3x
2 39.5 5400 2x 2.6x 1.1x
5 98.8 13500 1x 1.0x 0.5x
2012N155299_05 CONFIDENTIA L
BMA117159
643.6.3.2. Starting dose determination
A summary of the in-vitro and in-vivo IC50s for both the ADC and ADCC mechanisms 
are summari zed below ( Table 8 ).
Table 8 GSK2857916 in -vitro –in-vivo IC50 Values
Mechanism SystemIC50 (ng/mL)
(range)
ADCC
(In vitro )H929 target cells (n=8 PBMC donors) GSK 1.631 (0.57 -4.79)
JJN3 target cells (n=8 PB MC donors) GSK 9.421(1.01 -111.3)
primary  human MM CD138+ tumor cells (n=10 
donors) Farber~100
depletion of CD19+/CD27hi/CD38hi plasmablasts in 
whole blood (n=4 donors) GSK981(34-221)
H929 in presence of sBCMA 116
Cytokine induction 
from effector cells 
in vitroCytokines induction from PMBC in presence of H929 
target cells and GSK2857914 (ADCC enhanced only)< 1002
ADC
(In vitro )Across various expressing cells lines (n=12) 45.61(3-244)
H929 target cells GSK 8.9 (8.0 –9.8)3
JJN3 target cells GSK 25.1 (18.2 –34.8)3
ADC
(in vivo )Mouse xenograft 2540
1. Geometric mean
2. value reported is not an IC50, please refer to Section 5.6.3 of the IB for full description
3. (95%  CI) The values reported are for GSK2857916
Based on in-vitro H929 cell lines exper iments, the ADCC mechanism appears to be 
approximately  5.5-fold more potent than the ADC mechanism (1.63 ng/mL versus 8.9 
ng/mL).  The same pattern is observed with the JJN3 cell lines where the ADCC 
mechanism appears to be approximately  2.7-fold more pote nt than the ADC mechanism 
(9.42 ng/mL versus 25.1 ng/mL).   Additionally , from the receptor occupancy  curve and 
the killing activity  curves for the ADCC and ADC mechanisms, it can be noted that 
maximum killing activity can be achieved at low binding.
Based on results of toxicology studies (ADC mechanism)
2012N155299_05 CONFIDENTIA L
BMA117159
65Several methods were applied to look at the toxicologic aspect of GSK2857916 for the 
estimation of the starting dose based on the toxicology  findings from the GLP toxicology  
studies conducted in both the ra t and monkey  species (refer to Section 1.2.4 for more 
details). A summary  of the calculated starting dose from the different methods is 
provided in Table 9 below.
Table 9 Calculated starting dose from different approaches based on 
findings of toxicology  studies
Methods Starting dose
1/10thSTD 10 rat (BW T based) 1 mg/kg
1/6thHNSTD in monkey  (BW T 
based)0.5 mg/kg
1/6thHNSTD in monkey  (BSA
based)0.15 mg/kg
1/10thNOAEL in monkey  
(BWT based)0.1 mg/kg
1/10thNOAEL in monkey  (BSA
based)0.03 mg/kg
Based on MABEL determination (ADCC mechanism)
In order to investigate the pharmacology  aspect of GSK2857916, predicted receptor 
occupancy  (RO), based on the binding affinity  of the drug for its target and BCMA 
receptor concentration, at the predicted Cmax (assuming no target mediated disposition 
and in the absence of soluble BCMA) of various doses were estimated and summarised in 
Table 10 below.
Table 10 Predicted receptor occupancy  at Cmax for various doses
Dose (mg/kg) Cmax (µg/mL) RO
0.03 0.593 36%
0.05 0.988 55%
0.1 1.98 81%
0.2 3.95 93%
1 19.8 99%
2 39.5 99%
5 98.8 100%
To assess the excess of drug over target, the ratio of predicted Cmax at different doses to 
the BCMA receptor concentration in the bone marrow ( Table 11 ) was also estimated 
2012N155299_05 CONFIDENTIA L
BMA117159
66based on a published estimate of the number o f multiple my eloma cells [ Sullivan , 1972] 
an in-house determination of the number of BCMA receptor per cell.
Table 11 Ratio of predicted Cmax to the BCMA  receptor concentration in the 
bone ma rrow  at various doses of GSK2857916
Dose (mg/kg) Cmax (nM)Ratio of predicted human 
Cmax/BCMA Receptor 
concentration
0.03 3.95 0.45
0.05 6.58 0.74
0.1 13.2 1.49
0.2 26.3 2.97
1 132 15
2 263 30
5 658 74
Additionally , to incorporate the d ynamic aspec t, a drug- receptor binding PKPD model  
was developed that incorporates the major elements believed to be involved in the drug 
disposition process (e.g. tumor load, number of BCMA receptors on multiple my eloma 
cells, internalisation rate of the complex of d rug-BCMA receptor formed, shedding rate 
of the BMA receptors (soluble BCMA) based on pre- clinical data ( in-vitro as well as in -
vivo) generated in house, and assumptions supported by  published data in the literature. 
The model simulates the predicted level of receptor occupancy  achieved over time, the 
accumulation of the molecul e intracellularly via internaliz ation of the ADC -receptor 
complex formed and consequently  cys-mcMMAF, as well as the tumor regression. 
Mouse xenograft data generated during the pre -clinical development of GSK2857916 for 
which PK samples were also collected were modeled in order to derive an IC50 for tumor 
regression in relation to the cy totoxic agent (MMAF) of the molecule (ADC mechanism). 
This information was used in the drug-receptor binding PKPD model.  Predicted Cmax 
and receptor occupancy  assuming a high and low tumor burden at various doses are 
presented below. Prediction incorporates target -mediated disposition and presence of 
soluble BCMA.
Table 12 Predic ted Cmax and receptor occupancy  assuming a high and lo w 
tumor burden at various doses
High tumor loadLow tumor load 
(10-fold lower)
Dose (mg/kg)Cmax 
(µg/mL) ROCmax 
(µg/mL) RO
0.03 0.037 2% 0.30 22%
0.1 0.21 8% 1.7 52%
1 15.7 91% 21 96%
5 104 99% 108 99%
2012N155299_05 CONFIDENTIA L
BMA117159
67Selection of starting dose:
In light of the potent ADCC mechanism in this unprecedented combination of enhanced 
ADCC and ADC mechanism in GSK2857916 and the novelty  of the target (BCMA 
receptor), the MABEL approach to determine the starting dose was felt more appropriate. 
This is further supported by  the fact that the monkey  GLP toxicology  study was 
conducted in healthy  monkey  (i.e. with no tumor) and that the mouse xenograft 
experiments did not fully  explore the enhanced ADCC mechanism (human tum or but 
mouse effector cells). Furthermore, with both GSK2857916 (ADC molecule) and 
GSK2857914 (ADCC enhanced onl y) a general s ystemic inflammatory response was 
observed which could be attributable to the ADCC mechanism or related to the target 
binding.  An increase in cy tokine levels was observed with GSK2857914 which again 
could be attributed to the ADCC mechanism or to target binding. Finall y, in the agonism 
assay , cross -linking with GSK2857914 induced NFκB signaling in H929 cells (with an 
EC50 in the ran ge of 0.65-1.67 g/mL ). Taking into consideration all this information 
and the information derived from different methods looking at both the toxicology  and 
pharmacology  aspects of GSK2857916, a starting dose of 0.03 mg/kg is proposed to 
account for the AD CC mechanism of the molecule that is anticipated to occur first and is 
believed to be the most important mechanism to consider in the determination of the 
starting dose. This dose is lower than the 1/6thHNSTD in the monkey , the most relevant 
species for t his molecule as it cross -reacts with monkey  BCMA, based on body  surface 
area. Assuming no target mediated disposition and absence of soluble BCMA, this dose 
is predicted to provide 36% receptor occupancy .  From a drug -receptor binding PKPD 
model that incorporates target mediated disposition and the presence of sBCMA, this 
dose is anticipated to confer between 2 -22% receptor occupancy , depending on the tumor 
load.
3.6.3.3. Potential therapeutic dose determination
From the drug-receptor binding PKPD model (considering target mediated disposition 
and soluble BCMA) ,doses in the range 1 -5 mg/kg (depending on tumor load) are 
anticipated to confer maximal therapeutic activity  with an average predicted receptor 
occupancy  of approximately  90% over the interval between two d oses (i.e. 21 day s) 
following the first dose and maximal anti -tumor effect afforded b y the drug. This is also 
aligned with the in-vivo IC90 (approximately  20 g/mL) for tumor regression in relation 
to the cy totoxic agent of the molecule (ADC mechanism) derived from the mouse 
xenograft data in the presence of soluble BCMA and the in-vitro IC90 for the ADCC 
mechanism of 0.5 g/mL (depletion of CD19+/CD27hi/CD38hi plasmablasts in whole 
blood) or approximately  10 g/mL  (primary  human MM CD138+ tumor cells).
Of note, c ompetitor ADC molecules using MMAF as the cy totoxic agent have identified 
3 mg/kg every  3 weeks as the MTD SGN -75 [ Thompson, 2013] and AGS -16M8F doses 
up to  4.8 mg/kg every  3 weeks have been reported with no MTD identified y et [Beck, 
2012].
2012N155299_05 CONFIDENTIA L
BMA117159
683.6.4. Rationale for Endpoints
The endpoints of this study  are designed to evaluate the safet y, PK and PD of 
GSK2857916 in subjects with MM. Safety assessments will detect emerging safet y 
signals and identify  DLTs for determination of MTDs and a recommended dose and 
schedule of GSK2857916 for further exploration in expansion cohorts.
The collection of PK samples for determination of GSK2857916 plasma (intact, total 
antibody  and cy s-mcMMAF) conc entrations will allow characterization of the PK profile 
and support investigation of its pharmacology .
Tumor biomarker selection was based on the dual mechanism of action of GSK2857916 
(ADCC and ADC activity ), the need for BCMA receptor expression for GSK 2857916 to 
execute its action, and preclinical evidence that BCMA is a relevant therapeutic target.  
The study  will seek to characterize the PD effects of GSK2857916 and to obtain 
preliminary  data on the relationship between BCMA expression and other potential 
biomarkers (e.g., sBCMA, immune associated markers, etc) that may  influence clinical 
response.
Markers showing significant correlation between baseline levels and c linical outcome 
may have predic tive value and maybe further explored for utility  in pat ient selection in 
future trials .
Anti- tumor activity  will be explored to evaluate the potential for clinical benefit from 
GSK2857916 treatment. In addition, patient report outcomes will also be studied in Part 2 
(MM subjects only )
3.7. Stud y Treatment
3.7.1. Treatment Assignment
Dose level allocation will be performed b y GSK after subjects have given their written 
informed consent and have completed the necessary  screening assessments.  
The site staff will fax and/or email a complete Registration Form to the 
designate d GSK study  team member.  
Subjects will be identified by a unique subject number that will remain consistent 
for the duration of the study .  The subject number will be used on all Case Report 
Form (CRF) pages and other trial -related documentation or corre spondence 
referencing that subject.
Upon completion of all the required screening assessments, eligible subjects will 
be registered into RAMOS (Registration and Medication Ordering S ystem), the 
GSK interactive voice response sy stem (IVRS), by  the investiga tor or authorized 
site staff.  All enrolled subjects will receive GSK2857916.
Additional details are outlined in the SPM.
2012N155299_05 CONFIDENTIA L
BMA117159
693.8. Dosage and A dministration of Study Treatment(s)
GSK2857916 will be administered intravenousl y over 60 minutes.  Subjects enrolled in 
Schedule 1 will receive one dose every  3 weeks (21 day s) for a maximum of 16 cy cles 
(16 doses).  Subjects enrolled in Schedule 2 will receive one dose per week for 3 
consecutive weeks followed b y 1 week rest (28 day cycle) for a maximum of 16 cycles 
(48 dos es). 
The maximum dose to be administered to subjects in this trial is 5 mg/kg.
Refer to Section 4for details on preparation and handling, and administration instructions 
of GSK2857916.
3.8.1. Blinding
This is an open -label study .
3.9. Safet y Management Guidelines
3.9.1. Liver Chemistry Stopping Criteria
Liver chemistry  threshold stopping criteria have been designed to assure subject safet y 
and to evaluate liver event etiology  during administration of study  treatment(s) and the 
follow-up period.  Study treatment(s) will be stopped if any  of the following liver 
chemistry  stopping criteria is/are met:
1.Alanine aminotransferase (ALT) 3 X (times) upper limit of normal (ULN) and 
bilirubin 2 Xs UL N (or AL T 3 X ULN and international nor malization ratio 
[INR] >1.5)
NOTE: Serum bilirubin fractionation should be performed. 
2.ALT 5 X ULN.
3.ALT 3 X ULN if associated with the appearance or worsening of rash or hepatitis 
symptoms (fatigue, nausea, vomiting, right upper quadrant pain or tenderne ss, or 
jaundice) or h ypersensitivity  ( such as fever, rash or eosinophilia).
4.ALT 3 X ULN persists for 4 weeks.
5.ALT 3 X ULN and cannot be monitored weekl y for 4 weeks.
Subjects with AL T 3 X ULN and <5 Xs ULN and bilirubin <2 X UL N, who do not 
exhibit he patitis sy mptoms or rash, can continue study  treatment(s) as long as they  can be 
monitored weekl y for 4 weeks.  See following section for details on weekly follow -up 
procedures for these subjects.
3.9.1.1. Liver Chemistry  Follow -up Procedures
Refer to the diagram in Appendix 8 for a visual presentation of the procedures listed 
below.
2012N155299_05 CONFIDENTIA L
BMA117159
70The procedures listed below are to be followed if a subject meets the liver chemistry 
stopping criteria defined in Section 3.9.1:
Immediately  and permanently  withdraw the subject from study  treatment 
Notify  the GSK Medical Monitor within 24 hours of learning of the abnormality  to 
confirm the subject’s study  treatment(s) cessation and follow -up
Complet e the “Safet y Follow -Up Procedures” listed below
Complete the liver event electronic case report forms (eCRFs).  If the event also 
meets the criteria of a serious adverse event (SAE) (see Section 8.2), the SAE data 
collection tool will be completed separatel y  with the relevant details
Upon completion of the safet y follow- up permanently  withdraw the subject from the 
study  and do not rechallenge with study  treatment(s)
Safety Follow -Up Procedures for subjects with ALT 3 times ULN:
Monitor subjects weekly until liver chemistries (ALT, aspartate aminotransferase 
[AST], alkaline phosphatase [ALP], and bilirubin) resolve, stabilize or return to 
within baseline values
Safety Follow -Up Procedures for subjects with ALT 3 times ULN and bilirubin 2 
times ULN (or ALT 3 times ULN and INR >1.5):
This event is considered an SAE (see Section 8.2).  Serum bilirubin fractionation 
should be performed. 
Make every  reasonable attempt to have subjects return to the clinic within 24 hours 
for repeat liver chemistries, additional testing, and close monitoring (with specialist 
or hepatology  consultation recommended)
Monitor subjects twice weekly until liver chemistries (ALT, AST, alkaline 
phosphatase, bilirubin) resolve, stabilize or return to within baseline values
In addition, for allsubjects with ALT 3 times ULN, every attempt must be made to 
also obtain the following:
Viral hepatitis serology  including:
Hepatitis A I mmunoglobulin M (IgM) antibody
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM)
Hepatitis C ribonucleic acid (RNA)
Cytomegalovirus IgM antibody
Epstein -Barr viral capsid antigen IgM antibod y (or if unavailable, obtain 
heterophile antibod y or monospot testing)
Hepatitis E IgM antibody (if subject resides outside the United States (US) or 
Canada, or has traveled outside US or Canada in past 3 months)
2012N155299_05 CONFIDENTIA L
BMA117159
71Blood sample for PK analy sis.  Record the date/time of the PK blood sample draw 
and the date/time of the last dose o f study  treatment(s) prior to blood sample draw on 
the eCRF.  If the date or time of the last dose is unclear, provide the subject’s best 
approximation.  I f the date/time of the last dose cannot be approximated ORa PK 
sample cannot be collected within 48 hours of learning of the abnormalit y, do not 
obtain a PK sample .  Instructions for sample handling and shipping are included in 
the SPM.
Serum creatine phosphokinase and lactate deh ydrogenase
Fractionate bilirubin, if total bilirubin 2 times ULN
Obtain complete blood count with differential to assess eosinophilia
Record the appearance or worsening of clinical s ymptoms of hepatitis or 
hypersensitivity , such as fatigue, nausea, vomiting, right upper quadrant pain or 
tenderness, fever, rash or eosinophilia, o n the AE eCRF
Record use of concomitant medication(s), acetaminophen, herbal remedies, other 
over-the-counter medication(s), or putative hepatotoxins on the Concomitant 
Medications eCRF
Record alcohol use on the L iver Events eCRF
The following are required for subjects with ALT 3 times UL N andbilirubin 2 times 
ULN but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver kidney  
microsomal antibodies
Liver imaging (ultrasound, magnetic resonance imaging [MRI ] or computed 
tomograph y [CT] scan) to evaluate liver disease
Liver Imaging and/or Liver Biops y eCRFs are also to be completed if these tests are 
performed
Serum acetaminophen adduct HPL C assay  (quantifies potential acetaminophen 
contribution to liver injury  in subjects with definite or likely  acetaminophen use in the 
preceding week [ James, 2009]). 
Only  in those with underly ing chronic hepatitis B at study  entry  (identified by  
positive hepatitis B surface antigen):  quantitative hepatitis B DNA and hepatitis delta 
antibody .  NOTE :  if hepatitis delta antibody  assay  cannot be performed, it can be 
replaced with a PCR of hepatitis D RNA virus (where needed) – as outlined in: 
http://www.ncbi.nlm.nih.g ov/pmc/articles/PMC1153793 .
3.9.2. QTc Stopping Criteria
Study  treatment will be withheld in a subject who meets the corrected QT (QTc)1 interval 
duration criteria below.  
QT interval corrected for heart rate b y Fridericia’s formula (QTcF) >500 msec
or
2012N155299_05 CONFIDENTIA L
BMA117159
72Increase in QTc of > 60 msec from baseline
1Based on average QTc value of triplicate electrocardiograms (ECGs) to include manual 
over-read.  For example, if an ECG demonstrates a prolonged QT interval, obtain 2 
additional ECGs over a brief period (e.g., within appr oximately  10 minutes of the 
abnormal ECG, if possible, and approximately  10 minutes apart from each other), and 
then use the averaged QTc values of the 3 ECGs to determine whether the subjects 
should have study  treatment withheld.
3.9.3. Troponin Evaluation and S topping Criteria
If post -screening, the local cTn is >Institutional ULN it is recommended that subjects 
undergo urgent evaluation of cardiac ischemia s ymptoms and ECG should be performed 
to rule out cardiac ischemia.  An urgent repeat of cTn value and col lection of sample for 
central lab evaluation should be obtained within 24 hours.
Asymptomatic subject:
If the second value of cTn is ≤ULN the subject can continue on study  with close follow 
up of sy mptoms, ECG, and further cTn measurements as clinicall y indicated
If the second value of cTn remains >ULN treatment with GSK2857916 should be 
interrupted.  The s ubject should undergo cardiac evaluation including ECHO testing for 
cardiac function. An y re-start of study  treatment must be discussed with the GSK medical 
monitor who will consult with a member of the internal cardiotoxicity  panel prior to re -
start.
If the second value of cTn exceeds the threshold for MI according to local lab parameters, 
obtain cardiology  consultation immediately .  Permanently  discontinue GSK2857916 and 
withdraw the subject from the study .  
Symptomatic subject : 
Obtain cardiology  consul tation immediately . Permanently  discontinue GSK2857916 and 
withdraw the subject from the study .
3.9.4. Left Ventricular Ejection Fraction (LVEF)
3.9.4.1. LVEF Stopping Criteria
Echocardiograph y (ECHO) must be performed at Screening and as outlined in the Time 
and Events T ables (Section 7.1). Subjects who have an as ymptomatic, absolute decrease 
of >15% in LVEF compared with baseline or an absolute decrease of >10% in L VEF 
compared with baseline andthe ejection fraction is below 50% should temporaril y 
interrupt GSK2857916 and have a repeat evaluation of LVEF within 1 week. ECHO 
should be repeated every  1 to 2 weeks for 4 weeks or until L VEF recovery  to within 15% 
of baseline or to above 50% and within 10% of baseline depending on which stopping 
criteria above were met.
2012N155299_05 CONFIDENTIA L
BMA117159
73If the LVEF recovers (defined as absolute decrease 15% compared to baseline 
or 50% and absolute decrease 10% compared with baseline) at an y time 
during the next 4 weeks, after consultation and approval of the GSK Medical 
Monitor , the subject may be restarted on GSK2857916 at a reduced dose. For 
such subjects, monitoring of LVEF will be performed 2, 4, and 8 weeks after 
rechallenge, and then per protocol
If LVEF does not recover within 4 weeks, treatment with GSK2857916 should 
be permanently  discontinued. Ejection fraction should be monitored every  
4weeks for a total of 16 weeks or until resolution
Subjects with Grade 3 or 4 sy mptomatic left ventricular s ystolic dy sfunction must 
discontinue treatment with GSK2857 916. Ejection fraction should be monitored every  
4weeks for a total of 16 weeks or until resolution. 
Copies of all ECHOs and cardiology  consultations performed on subjects who experience 
a >15% decrease in LVEF from baseline or >10% decrease in LVEF fro m baseline and 
whose cardiac ejection fraction is <50% will require review b y a GSK medical monitor.
Instructions for submitting qualify ing ECHOs/MUGAs are provided in the SPM.
3.9.4.2. Valvular Toxicity  Stopping Criteria
Subjects who develop a new as ymptomatic, m oderate regurgitation or stenosis by  
echocardiogram (ECHO) (Grade 2 mitral/tricuspid/aortic valvular toxicity  per National 
Cancer Institute -Common Toxicity  Criteria for Adverse Events [ NCI-CTCAE], version 
4.0) should temporaril y discontinue GSK2857916 and have a repeat evaluation by  ECHO 
within 1 week.  ECHO should be repeated every  1 to 2 weeks for 4 weeks or until valve 
recovery  to baseline.
If the valve recovers to baseline an y time during the next 4 weeks after 
consultation and approval of the GSK Medi cal Monitor , the subject may  be 
restarted on GSK2857916 at a reduced dose(s).  For such subjects, monitoring of 
the valve via ECHO will then be performed 2 and 4 weeks after rechallenge, and 
every  4 weeks thereafter for 8 weeks and then per protocol.
If repeat ECHO does not reveal valve recovery  to baseline within 4 weeks, then 
the subject should permanently  discontinue GSK2857916.  The valve should 
continue to be monitored via ECHO every  4 weeks for 8 weeks or until 
resolution.
Subjects with a Grade 3 or 4 (symptomatic, severe regurgitation/stenosis by  imaging with 
symptoms controlled by  medical intervention) valvular toxicity  must discontinue 
GSK2857916.  Valvular toxicity  should continue to be monitored every  4weeks for 
12 weeks or until resolution.  If recovery  occurs (return to baseline via imaging AND 
symptom resolution) within 4 weeks, the subject may  restart GSK2857916at a reduced 
dose after consultation and approval of the GSK Medical Monitor.
ECHO must be performed at baseline and at the final stud y visit.  Copies of all ECHO(s) 
and cardiology  consultations performed on subjects who experience valvular toxicity  will 
2012N155299_05 CONFIDENTIA L
BMA117159
74be required b y GSK for review.  Instructions for submitting qualifying ECHOs are 
provided in the Study  Procedures Manual (SPM).
3.9.5. Infusio n-related Reactions and Cy tokine Release Sy ndrome
Premedication is not allowed prior to first infusion unless deemed medically  appropriate 
by the GSK Medical Monitor in consultation with investigators following evaluation of 
infusion related reactions acro ss cohorts. Premedication should be considered in any  
subject who experienced an infusion related reaction at first or an y subsequent infusion 
with GSK2857916.
If an infusion- related reaction occurs during administration, the infusion rate may  be 
reduced o r halted at the discretion of the investigator and/or GSK medical monitor 
depending on the severity of the s ymptoms.  The subject will receive appropriate medical 
treatment.  When the subject’s condition is stable, the infusion may  be restarted 
according t o the judgment of the investigator.  Upon restart, the infusion rate should be 
half of the infusion rate at the time the infusion was paused.
Blood for serum cy tokines should be collected in each subject who developed infusion 
related reaction regardless w hether the infusion has been completed or not. The time of 
serum collection will be documented in eCRF.
Grade 1 allergic reactions or cy tokine release s yndrome
oIf infusion is ongoing, it may  continue but subject should be monitored 
carefully  to ensure that ongoing signs and s ymptoms do not progress and 
worsen warranting intervention as described below
Grade 2 allergic reactions and/or cy tokine release sy ndrome 
oStop the infusion, follow subject frequently  for clinical sy mptoms
oInitiate s ymptoms treatment as clinicall y indicated 
oOnce subject has recovered to baseline and if in the opinion of the 
investigator the safet y/risk benefit is favorable, consideration can be given 
to restarting the infusion at 50% of the original rate after pre -medication 
with H1 rec eptor antagonist and acetaminophen
oIf treatment is continued, the subject should be pre -medicated prior to each 
subsequent dose and the infusion will be administered at 50% of the 
original rate
Grade 3 or higher allergic reactions and/or cytokine release s yndrome 
oStop infusion immediately
oInitiate s ymptoms treatment as clinicall y indicated 
oDo not resume infusion with GSK2857916
2012N155299_05 CONFIDENTIA L
BMA117159
75oFollow the subjects for safet y as clinically indicated until toxicity  resolves
oComplete safet y documentation
oSubjects who experie nce Grade 3 allergic reaction will be withdrawn 
from study  
oFurther treatment with GSK2857916 in subjects who experience a Grade 
3 infusion related reaction needs to be discussed with MM prior to next 
dose administration. Those subjects will be allowed to continue on study  
after recovery  of the reaction to Grade 1 but will have to receive pre -
medication prior to each subsequent dose of GSK2857916, and their 
infusion time will be extended to 2- 4 hours (depending on severity  of the 
reaction).  
3.9.6. Allergic and A naphylactic reaction
As GSK2857916 is a fully  humanized ADC, it is considered unlikel y for acute allergic 
reactions to occur in response to GSK2857916 exposure; however, all subjects will be 
monitored carefully  for evidence of allergic response. A su bject that exhibits signs or 
symptoms of severe hy persensitivity  or anaphy laxis will receive appropriate medical 
treatment and be withdrawn from the study .
In accordance with the preparedness for treatment of anaph ylaxis, emergency  
resuscitation equipment , advanced cardiac life support equipment, and medications must 
be readil y accessible during GSK2857916 administration.
It is important to recognize early signs of an anaphylaxis reaction and appropriate 
treatment must begin immediately  to prevent progress ion to severe anaphy laxis. Subjects 
will be closely  monitored in an appropriate setting for early  signs of dy spnea and edema. 
Antihistamines, such as diphenhy dramine; and corticosteroids such as prednisone may  be 
given to reduce s ymptoms.
If more severe cl inical signs arise, immediate assessment of the ABC's (airway , 
breathing, and circulation from Basic L ife Support) will be done in all suspected 
anaph ylactic reactions. Cardio -Pulmonary  Resuscitation (CPR) will be initiated if 
needed. Epinephrine will be g iven by  injection without delay . Emergency  interventions 
may include endotracheal intubation or tracheostomy . Treatment for shock will include 
IV fluids and medications that support the actions of the heart and circulatory  system. 
3.9.7. Tumor Ly sis Sy ndrome (TL S) Prevention and Treatment 
Recommendations
Subjects with a high tumor burden with a high proliferative rate might be at risk for TL S 
and should be monitored for clinical and laboratory  signs of tumor l ysis. Specificall y, all 
subjects with elevated uric ac id (>8mg/dL, or >476mmol/L) should receive prophy laxis 
with allopurinol, or rasburicase. All subjects should be hy drated to reduce risks for renal 
toxicity  and tumor l ysis syndrome (TLS) with GSK2857916 treatment. Adequate fluid 
volume status should be maintained throughout treatment and blood chemistries should 
2012N155299_05 CONFIDENTIA L
BMA117159
76be monitored as indicated in the Time and Events Tables in Section 7.1or more 
frequentl y if clinically indicated.  Prior to the first dose in Cy c le 1, a ll subjects should 
receive at least 250 -500 mL  of intravenous normal saline or other appropriate
intravenous fluid. Additionally , 250 -500 mL of intravenous fluid should be given as 
needed following GSK2857916 administration. I ntravenous hy dration should b e 
continued, as needed, in subsequent cy cles and subjects should be monitored for fluid 
overload during this period.
If the constellation of clinical and/or laboratory  signs tested on C ycle 2 Day 1 indicates a 
possibility  of developing TL S, subjects should be hospitalized with frequent monitoring 
of clinical signs and clinical chemistries and treated accordingl y.
3.9.8. Ocular Toxicity and Stopping Criteria
All subjects will be advised to use prednisolone phosphate 1% or dexamethasone 0.1% 
eye drop 4 times a day  (QID) for 4 day s starting 1 day  prior to each dose. Additional use 
of lubrication ey e drops (artificial tears) QID PRN throughout the trial is recommended, 
especiall y if subject develops any ocular s ymptoms. Subjects who develop Grade 3 
ocular or corneal to xicity  will be allowed to continue study  treatment after resolution to 
Grade 1; each case will be discussed individually  between the investigator and the
Medical Monitor .Subjects who develop Grade 4 ocular or corneal toxicity  will be 
permanentl y remov ed from study .  Refer to Section 3.10.2 for further guidance.
3.10. Guidelines for Events of Special Interest and Dose 
Modifications
3.10.1. Guidelines for Events of Special Interest
The severit y of adverse events (AEs) will be graded utilizi ng the National Cancer 
Institute -Common Toxicity  Criteria for Adverse Events (NCI -CTCAE), version 4.  
Guidelines for dose modifications and interruptions for management of common 
toxicities associated with the study  treatment are provided in this section.
2012N155299_05 CONFIDENTIA L
BMA117159
773.10.2. Predicted Toxicities and Proposed Dose A djustments/Stopping Criteria
Toxicity Grade/symptoms Recommendations
Creatinine  elevation which 
cannot be explained by 
concomitant sepsis, other 
severe infection with fever 
or dehydrationIf absolute serum cre atinine 
increase from baseline of > 0. 3 
mg/dL (26 mol/L) but 0.5 
mg/dL (44 mol/L)Repeat within 48 hours
If creatinine returns to 0. 3 mg/dL (26  mol/L) above baseline
oContinue GSK2857916 at current dose 
If creatinine remains elevated:  > 0. 3 mg/d L (26  mol/L) but 0.5 mg/dL 
(44 mol/L) from baseline
oContinue GSK2857916 
oMonitor creatinine at least weekly 
oConsider 25% dose reduction if creatinine remains elevated (after 
discussion with Medical Monitor)
If absolute serum creatinine 
increase fro m baseline of >0. 5 
mg/dLRepeat within 48 hours: 
If confirmed: withhold therapy, institute treatment and monitoring as 
clinically indicated, and follow for resolution
Discuss any further dosing with Medical Monitor*
* Medical Monitor should consult GSK’s nephrotoxicity panel about plans to 
continue therapy
Serum creatinine Grade 3 >3.0mg/dL from baseline
or
3.0-6.0xULNProvide appropriate medical treatment. 
Permanently discontinue treatment with GSK2857916
2012N155299_05 CONFIDENTIA L
BMA117159
78Toxicity Grade/symptoms Recommendations
Albuminuria >2000mg/24 hr Re-test (at least 7 days apart). 
oIf not confirmed, continue GSK2857916 at 100% dose
oIf confirmed on re -test and no clear evidence of disease progression*
Interrupt treatment with GSK2857916
Repeat testing within 4 weeks
If albuminuria ≤2000mg/24hr may restart 
GSK2857916 with 25% dose reduction
If albuminuria remains >2000mg/24hr  after 4 
weeks; Permanently discontinue GSK2857916  and 
withdraw subject from study; provide treatment as 
clinically indicated and  follow for resolution
* Medical Monitor should consult GSK’s nephrotoxicity panel about plans to 
continue therapy
Thrombocytopenia Grade 3: >25 and <50x109/L Where estimated blood loss is 10 mL : withhold the treatment :
No bleeding: continue treatment with  25% dos e reduction 
Grade 4: ≤25x109/L Withhold the dose. Consider restarting with 25% dose reduction if recovered to 
>25x x109/L  , only if there is no active bleeding at time of treatment re -start   
If thrombocytopenia is considered disease related, is not accompanied by 
bleeding, and recovers with transfusion to >30 x109/L within 14 days, restarting 
treatme nt at 50% dose reduction may be considered after discussion with the 
GSK Medical Monitor 
Febrile neutropenia >38.3oC for> 1 hr AND ANC < 
1000/mm3Withhold  GSK285791 6, implement treatment with antibiotics, antivirals and 
antifungals, as clinically indicated, 
If resolved  14 days, may restart GSK2857916 treatment at 25% dose 
reduction
2012N155299_05 CONFIDENTIA L
BMA117159
79Toxicity Grade/symptoms Recommendations
INR prolongation > 1.5 Evaluate liver function and other possible causes fo r INR elevation (use of 
anticoagulants, work up for DIC and provide treatment as clinically indicated 
–If subject meets liver stopping criteria:   Withdraw from study treatment
as per liver stopping criteria 
–If subject has evidence of DIC: withdraw subject from study treatment
–If isolated INR elevation and subject does not meet liver stopping 
criteria 
•Withhold the dose and re- test INR within 48hrs
•Discuss the case with M edical Monitor and consider 25% dose 
reduction  
> 2.0 Evaluate possible reasons as above, treat adequately if underlying condition has 
been identified
Restart treatment with GSK2857916 at 25 -50% dose reduction if toxicity 
resolved to 1.5 baseline and after discussing the case with GSK Medical 
Monitor
>2.5 Evaluate and provide medical treatment if necessary
If INR prolongation is not related to use of anticoagulants withdraw subject 
from study treatment
Ocular/corneal  toxicity Grade 1 Continue treatment with current dose of GSK2857916.  
Consult ophthalmologist within 7 days
Grade 2 First occurrence:
oInterrupt treatment with GSK2857916
oConsult ophthalmologist immediately
oWhen recovered to G 1 Restart treatment with GSK2857916 at 
25%  dose reduction upon resolution to G1 
Second occurrence:
oInterrupt treatment with GSK2857916
oCons ult ophthalmologist immediately
oOnce resolved to G1 or less: Restart treatment with GSK2857916 
2012N155299_05 CONFIDENTIA L
BMA117159
80Toxicity Grade/symptoms Recommendations
at additional 25% dose reduction
Third occurrence:
oFurther treatment with GSK2857916 only allowed after discussion 
and in agreement with medical monitor
Grade 3 First occurrence
oConsult ophthalmologist immediately
oInterrupt treatment with GSK2857916
oOnce resolved to G1: Restart treatment with GSK2857916 at 
25% - 50% dose reduction if the investigator and Medical Monitor 
agree that the potential benefits ou tweigh the risks
Second occurrence
oConsult ophthalmologist immediately
oPermanently discontinue treatment with GSK2857916
Grade 4 Consult ophthalmologist immediately
Permanently discontinue treatment with GSK2857916
Pneumonitis Grade 1 Withhold dose and follow recommendations below:
Obtain high resolution chest CT if possible.
CT scan (high- resolution with lung windows) recommended
Clinical evaluation and laboratory work -up for infection
Monitoring of oxygenation via pulse -oximetry recommended
Consult ation with pulmonologist recommended
If resolved: Retreatment at the full dose is possible
Grade 2 Withhold  treatment with GSK2857916
Follow recommendations below:
Obtain high resolution chest CT if possible.
CT scan (high- resolution with lung windows)
Clinical evaluation and laboratory work -up for infection
Consult pulmonologist
2012N155299_05 CONFIDENTIA L
BMA117159
81Toxicity Grade/symptoms Recommendations
Pulmonary function tests (PFT) –if abnormal, repeat every 8 weeks until back 
to baseline 
Bronchoscopy with biopsy and/or bronchoalveolar lavage (BAL) recommended
Symptomatic t herapy including corticosteroids if clinically indicated
If resolved: Restart treatment with 50% dose reduction
Grade 3/Grade 4 Permanently discontinue treatment with GSK2857916, and follow 
recommendations below.
Obtain CT scan (high-resolution with lun g windows)
Clinical evaluation and laboratory work -up for infection
Consult pulmonologist
PFT –if abnormal, repeat every 8 weeks until back to baseline Bronchoscopy 
with biopsy and/or BAL if possible
Symptomatic therapy including corticosteroids as clinic ally indicated
2012N155299_05 CONFIDENTIA L
BMA117159
823.10.3. Dose Modifications
For GSK2857916 toxicities not specificall y addressed in the protocol follow the 
guidelines outlined in Table 13.  
Table 13 Dose A djustment/Stopping Crit eria
Toxicity GradeaDose Modification of GSK2857916
Grade 1Continue at current dose level. Consider supportive care 
recommendations 
Grade 2If toxicity is considered not clinically relevant, continue with 100% 
scheduled dose
If toxicity is considered clinically relevant withhold the dose until 
toxicity resolves to Grade 1 or baseline. If resolved within 14 days, 
then restart at current dose level. Consider supportive care 
recommendations
If not resolved within 14 days, discuss with GSK Medical Monit or 
Grade 3Withhold dose until toxicity resolves to Grade 1 or baseline, unless 
condition fits exceptions noted below. If resolved within 14 days, 
resume treatment at dose reduced by 25% (first dose reduction), or 50% 
(second dose reduction). Consider supportive care recommendations.  
If toxicity is resolved within period longer than 14 days, continuation of 
treatment may be considered on an individual basis if benefit to 
subject can be demonstrated and if the investigator and medical 
monitor agree th at for a given subject the benefits may  outweigh 
the risks   
Exceptions :
Subjects who develop G3 toxicities which respond to standard treatment 
and resolve to G1 within 48 hours may continue treatment at 
scheduled or reduced dose
Permanently discontinue for grade 3 or greater QTc prolongation i.e., 
QTcF >500 msec or QTcF increase by > 60 msec from baseline
Troponin elevations: See Section 3.9.3 for troponin stopping criteria
Grade 4Permanently discontinue s tudy medication
Exceptions:
G4 thrombocytopenia with no sign of bleeding, if recovered within 
14 days.  For dose reductions see Section 3.10
G4 lymphopenia (dose reductions by 25 -50% may be considered )
a.Possibl yrelated to investigational drug.
2012N155299_05 CONFIDENTIA L
BMA117159
834. INVESTIGA TIONAL PRODUCT(S)
The term ‘stud y treatment’ is used throughout the protocol to describe GSK2857916 as 
the investigational product (I P) received by  the subject as per the protocol design.  
4.1. Description of In vestigational Product
Product name :GSK2857916 Solution, 20 mg/mL, 1.5mL anti -BCMA -
ADC 
Formulation description: Solution containing 20mg/mL GSK2857916
Dosage form :Supplied as frozen liquid.  Recommended storage 
condition is -50C to -15C. 
Unit do se strength(s)/Dose Level(s):20mg/mL, 1.5mL (Refer to Section 3.3.1.2 .1for dose 
levels)
Physical Description:GSK2857916 Solution for Infusion is clear or opalescent; 
colorless, yellow to brown liquid 
Route /
Administration/ Duration:Delivered as IV solution (see Section 3.8)
Dosing instructions:Dilute GSK2857916 solution in normal 0.9% saline to the 
appropriate concentration for the dose.  See Section 4.2
for compatible administration materials.  Doses of 
GSK2857916 are to be administered as an IV infusion 
via an infusion pump that can ensure precision to the 
decimal point of a mL for the infusion rate at lower 
doses .It is recommended to prime the tubing with at 
least 15 mL prior to dosing.
Manufacturer/ Source of Procurement: GSK
Batch Lot number 132373860
GSK2857916 will be provided to sites by  GSK.  Only Batch Lot# 132373860 of drug 
product will be used for this trial. The contents of the label will be in accordance with 
all applicable regulatory  requirements. The lot number indicated on the label refers to 
labelled lot number ; the batch Lot# 132373860 may not be provided on the label.
4.2. Preparation/Handling/Storage of GSK2857916 
Investigational Product
Preparation
GSK2857916 Solution for Infusion, 20 mg/mL is supplied as a frozen liquid (Lot# 
132373860) .  Before use, thaw each vial of GSK2857916 for Infusion, 20mg/mL , 1.5mL 
for up to 4 hours under refrigerated c onditions (2-8C), protected from light.  Following 
thawing, gently  swirl the vial to ensure uniformit y.  GSK2857916 should be diluted in 
normal saline (0.9%) to no more than 2 mg/mL and no less than 0.2 mg/mL. Refer to the 
Study  Procedures Manual (SPM) fo r further details on preparation of GSK2857916.
The dosing solution of GSK2857916 can be held under refrigerated conditions (2-8 C), 
for up to 24 hours ( NOTE : For centers in Canada up to 8 hours only ) or4hours at 
2012N155299_05 CONFIDENTIA L
BMA117159
84ambient temperature (diluted drug product in bag) from a stability  perspective, but should 
be used as soon as possible as the product does not contain an antimicrobial preservative.
Handling
Under normal conditions of handling and administration, investigational product (I P) is 
not expected to po se significant safet y risks to site staff.  A Material Safet y Data Sheet 
(MSDS) describing the occupational hazards and recommended handling precautions will 
be provided to site staff if required b y local laws or will otherwise be available from GSK 
upon r equest.
In the case of unintentional occupational exposure notify  the study  monitor, the GSK 
Medical Monitor and/or the study  manager.
Refer to the SPM for detailed procedures for the disposal and/or return of unused study  
treatment(s).
Administration
GSK2 857916 is compatible with poly vinylchloride -lined or pol yolefin -lined intravenous 
infusion administration sets, 0.2 micron poly ethersulfone filters, or optionally  a 
polyurethane catheter.   Doses of GSK2857916 are to be administered as an IV infusion 
via an infusion pump that can ensure precision to the decimal point of a mL for the 
infusion rate at lower doses. It is recommended to prime the IV tubing with at least 15 
mL prior to dosing.
Administration of drug product in this trial is restricted to Manufact urer Batch
Lot#132373869.
Storage
GSK2857916 must be stored in a secure area under the appropriate ph ysical conditions 
for the product.  Access to and administration of the GSK2857916 will be limited to the 
investigator and authorized site staff.  GSK2857 916 must be dispensed or administered 
only to subjects enrolled in the study  and in accordance with the protocol.  
GSK2857916 is to be stored at a temperature range of -50C to -15C.  Maintenance of a 
temperature log is required. 
The expiry  date, where required, is stated on the product label.
4.3. Product A ccountability
In accordance with local regulatory  requirements, the investigator, designated site staff, 
or head of the medical institution (where applicable) must document the amount of 
investigational product (IP) dispensed and/or administered to study  subjects, the amount 
returned b y stud y subjects, and the amount received from and returned to GSK, when 
2012N155299_05 CONFIDENTIA L
BMA117159
85applicable.  Product accountability  records must be maintained throughout the course of 
the study .  Refer to the SPM for further detailed instructions on product accountability .
4.4. Treatment Compliance
GSK2857916 will be intravenousl y administered to subjects at the study site.  The dose 
to be administered is based on body  weight calculation, and may  be reduced for toxicity  
according to protocol guidelines. Only  two dose reductions are allowed per subject; the 
first dose reduction by  25%, and the second by  an additional 25%.  If subject is not 
tolerating treatment at 50% of scheduled dose the subject will be withdrawn from study .  
Additional dose reductions (bey ond 50% of the original scheduled dose) may  be possible 
only for subjects who have been enrolled during dose escalation in Part 1 at the highest 
dose, which was subsequently  deemed as exceeding the MTD .
The actual bod y weight in kg will be used for dose calculation in all subjects whose body 
weight is  100kg.  For subjects with body  weight >100kg, the dose to be administered 
should be the same as that calculated for a subject weighing 100kg.  Administra tion will 
be documented in the source documents and reported in the electronic case report form 
(eCRF). The time of start and end of infusion will be documented in eCRF.
4.5. Treatment of Investigational Product Overdose
In the event of an overdose (defined as administration of more than the protocol- specified 
dose) of GSK2857916, the investigator should:
contact the GSK Medical Monitor immediately
closely  monitor the subject for adverse events (AEs)/serious adverse events 
(SAEs) and laboratory  abnormalities unt il GSK2857916 can no longer be 
detected s ystemically  (at least 3 months for GSK2857916)
obtain a plasma sample for pharmacokinetic (PK) anal ysis within 24 hours of 
the event if requested b y the GSK Medical Monitor (determined on a case -by-
case basis)
docum ent the quantity  of the excess dose as well as the duration of the 
overdosing in the eCRF
Decisions regarding dose interruptions or modifications will be made by  the investigator 
in consultation with the GSK Medical Monitor based on the clinical evaluation of the 
subject
5. STUDY POPULA TION
5.1. Number of Subjects
The number of dose levels and the level at which the maximum tolerated dose (MTD) is 
reached cannot be determined in advance.  An adequate number of subjects will be 
enrolled into the study  to establish t he recommended dose(s) for further study.  It is 
estimated that approximately  30 subjects will be enrolled into Part 1 , Schedule 1 (dose -
2012N155299_05 CONFIDENTIA L
BMA117159
86escalation) of the study .  Up to 40 subjects with MM and up to 10 subjects with BCMA 
positive lymphomas ( 50 subjects t otal) will be enrolled in Part 2 (expansion cohort).  
The number of subjects in the expansion cohort has been estimated based on expected 
variable expression of BCMA in those subjects (about 1/3 low, 1/3 medium, 1/3 high 
expression; approximately 13 subjects/group).  The level of BCMA expression in a given 
subject is expected to impact target -mediated clearance, which as a consequence might be 
reflected in the PK/PD variability  and safet y profile of individual subjects.  I n addition, 
the sample size of 40 subjects in the MM cohort will allow for assessment of earl y signals 
of clinical activit y and relationship s(if any ) to variable target expression levels.  A total 
of approximately  80 subjects will be enrolled in the study .If Part 1, Schedule 2 (once 
weekl y schedule) is explored , up to 15 additional subjects will be enrolled; then a total of 
approximately  95 subjects will be enrolled in the study .
In Part 1 (dose -escalation) of the stud y, if a subject has been withdrawn prior to 
expiration of the DLT observation period OR received less than 2/3 of the scheduled dose 
and is not evaluable for DL T, additional subjects may be enrolled as replacement subjects 
and assigned to the same treatment sequence at the discretion of the Sponsor in 
consultation with the inv estigator.
5.2. Subject Selection Criteria
5.2.1. Inclusion Criteria
Specific information regarding warnings, precautions, contraindications, adverse events 
(AEs), and other pertinent information on the GSK study  treatment that may impact 
subject eligibility  is provid ed in the Investigator Brochure (IB)/IB supplement(s).  
Deviations from inclusion criteria are not allowed because they  can potentially  jeopardize 
the scientific integrity of the study, regulatory acceptability or subject safety.  Therefore, 
adherence to t he criteria as specified in the protocol is essential.
Subjects eligible for enrolment in the study  must meet all of the following criteria:
1.Provide signed written informed consent, which includes compliance with the 
requirements and restrictions listed in the consent form
2.Male or female, 18 years or older (at the time consent is obtained )
3.Eastern Cooperative Oncology  Group (ECOG) performance status of 0 or 1 
(Appendix 6 )
4.Part 1/dose escalation:
Histologicall y or cytologically  confirmed diagnosis of: Multiple My eloma in a 
subject who fulfills all of the following: 
has undergone stem cell transplant, or is considered transplant ineligible, 
has been pretreated with at least the 3 following classes of anti -myeloma 
drugs: alk ylators, proteasome inhibitors and immunomodulators, 
2012N155299_05 CONFIDENTIA L
BMA117159
87has demonstrated progression on, or within 60 days of completion of the last 
therap y. 
Part 2 /MM cohort:
Histologicall y or c ytologically  confirmed diagnosis of: Multiple My eloma in a 
subjec t who fulfills all of the following: 
has undergone stem cell transplant, or is considered transplant ineligible, 
has been pretreated with at least the 3 following classes of anti -myeloma 
drugs: alk ylators, proteasome inhibitors and immunomodulators, 
and has demonstrated progression on, or within 60 day s of completion of the 
last therap y. 
AND has measurable disease with at least one of the following:
a.Serum M -protein  0.5 g/dL ( 5 g/L)
b.Urine M -protein  ≥200 mg/24h
c.Serum FLC assay : Involved FLC level ≥5 m g/dL ( ≥50 mg/L) and an 
abnormal serum free light chain ratio (<0.26 or >1.65)
d.Biopsy  proven plasmacy toma (should be measured within 28 day s of 
Screening Visit)
or
Part 2/ BCMA positive Lymphoma cohort: 
a.Subject with one of the following hematologic malign ancies: Diffu se 
Large B -cell Ly mphoma DLBCL or Follicular Lymphoma that 
exhibits positive BCMA expression on tumor cells as determined b y a 
central laboratory  using a validated IHC assay .Eligible subjects with 
BCMA positive lymphomas must also fulfill the prior treatment 
requirements as follows:
b.DLBCL : at least 2 prior lines of sy stemic therapy  containing at least 
one line of chemo -immunotherap y with anti -CD20 antibody , and 
either has undergone stem cell transplant or is considered transplant 
ineligible 
c.FL: at least 2 prior lines of sy stemic therapies. 
5.Subjects with a history  of autologous stem cell transplant are eligible for study  
participation provided the following eligibility  criteria are met:
a.transplant was > 100 days prior to study enrolment
b. no active infection
c.subject meets the remainder of the eligibility  criteria outlined in this 
protocol
6.Adequate organ s yst em functions as defined in Table 14.
2012N155299_05 CONFIDENTIA L
BMA117159
88Table 14 Adequate Organ System Func tion
System Laboratory Values
Hematologic
Absolute neutrophil count (ANC)11.0 X 109/L
Hemoglobin 8.0 g/dL
Platelets 50 X 109/L
Coagulation
INR 1.5 
PTT 1.5 x ULN
Hepatic
Total bilirubin ≤1.5X ULN (isolated bilirubin >1.5xULN is 
acce ptable if bilirubin is fractionated and direct 
bilirubin <35%)
AST and ALT 1.5 X ULN
Renal
Serum creatinine or
Calculated creatinine clearance2
Albuminuria <1.2XULN
≥ 60 mL/min for Part 1;
50 mL/min for Part 2 if data supports loosening 
criteria
500mg/24hr
Cardiac
LVEF (Echo)
Troponin 50%
1xULN
1. Without Growth factor support for the past 14 days, excluding erythropoietin
2. As calculated by Modified Diet in Renal Disease (MDR D) formula ( Appendix 5 )
NOTE:  Laboratory results obtained during Screening should be used to determine 
eligibility  criteria.  In situations where laboratory  results are outside the permitted range, 
the investiga tor may  opt to retest the subject and the subsequent within range screening 
result may be used to confirm eligibility .
7. A female subject is eligible to participate if she is of:
Non-childbearing potential (i.e. ph ysiologically  incapable of becoming pregnant ) 
defined as pre -menopausal females with a documented tubal ligation or 
hysterectom y; or postmenopausal defined as 12 months of spontaneous 
amenorrhea [in questionable cases a blood sample with simultaneous follicle 
stimulating hormone (FSH) > 40 MIU/mL an d estradiol < 40 pg/mL  (<147 
pmol/L) is confirmatory ].  Females on hormone replacement therapy  (HRT) and 
whose menopausal status is in doubt will be required to use one of the 
contraception methods specified if they  wish to continue their HRT during the 
study.  Otherwise, they  must discontinue HRT to allow confirmation of post -
menopausal status prior to study  enrollment.  For most forms of HRT, at least 2-4 
weeks will elapse between the cessation of therap y and the blood draw; this 
interval depends on the t ype and dosage of HRT.  Following confirmation of their 
2012N155299_05 CONFIDENTIA L
BMA117159
89post-menopausal status, they  can resume use of HRT during the study  without use 
of a contraceptive method.
Women of childbearing potential must have a negative serum pregnancy  test 
within 72 hours of first dose of study  treatment and agree to use effective 
contraception, as defined in Section 11.1.1 , during the study  and for 60 days 
following the last dose of study  treatment.
8.Men with a female partner of childbearing potential must have either had a prior 
vasectom y  or agree to use effective contraception as described in Section 11.1.2
from the time of first dose of study  until 60 day s  after the last dose of stud y 
treatment to allow for clearance of an y altered sperm.
9.All prior treatment- related toxicities (defined by  National Cancer Institute -
Common Toxicity  Criteria for Adverse Events (NCI -CTCAE), version 4) must be 
≤Grade 1 at the time of enrollment except for alopecia, and grade 2 neuropathy
5.2.2. Exclusion Criteria
Devi ations from exclusion criteria are not allowed because they  can potentially  
jeopardize the scientific integrit y of the study, regulatory acceptability or subject safet y.  
Therefore, adherence to the criteria as specified in the protocol is essential.
Subje cts meeting an y of the following criteria must not be enrolled in the study :
1.Systemic anti -tumor -therapy  within 14 day s, or plasmapheresis within 7 day s prior 
to the first dose of study  drug.
2.Use of an investigational drug within 14 day s or five half -lives , whichever is 
shorter, preceding the first dose of study  drug.  Prior treatment with a monoclonal 
antibody  within 30 day s of receiving the first dose of study  drug.  
3.History  of an allogeneic stem cell transplant.  Subjects with a history  of an 
autologous stem cell transplant are NOT excluded if they  meet Inclusion Criterion 
#5. 
4.Presence of active renal condition (infection, requirement for dial ysis or any  other 
condition that could affect subject’s safety ). Subjects with isolated proteinuria 
resulting fr om MM are eligible, provided they  fulfil criteria given in Table 14.
5.Evidence of active mucosal or internal bleeding.
6.Any major surgery  within the last four weeks.
7.Any serious and/or unstable pre -existing medical, psychiatric disorder, or other 
conditions (including lab abnormalities) that could interfere with subject’s safet y, 
obtaining informed consent or compliance to the study procedures. 
8.Known active infection requiring antibiotic treatment.
9.Evidence of severe or uncontrolled sy stemic diseases (e.g., unstable or 
uncompensated respiratory , hepatic, renal or cardiac disease ).
10.Subjects with previous or concurrent malignancies are allowed only if the second 
tumor is not contributing to the subject’s illness.  The s ubject must not be receiving 
2012N155299_05 CONFIDENTIA L
BMA117159
90active therap y, other than hormonal therap y for this disease and the disease must be 
considered medicall y stable for at least 2 years.
11.Evidence of cardiovascular risk including an y of the following:
a.QTc interval ≥ 470 msecs.
b.Evidence of current clinically  significant uncontrolled arrh ythmias;
a.including clinicall y significant ECG abnormalities including 2nd 
degree (T ype II) or 3rd degree atrioventricular (AV) block.
c.History  of m yocardial infarction, ac ute coronary  syndromes (including 
unstable angina), coronary  angioplast y, or stenting or bypass grafting 
within six months of Screening.
d.Class III or IV heart failure as defined b y  the New York Heart Association 
functional classification system ( Appendix 4 )
e.Uncontrolled h ypertension
f.Subjects with intra -cardiac defibrillators or permanent pacemakers;
g.Abnormal cardiac valve morphology  (≥Grade 2) documented b y 
echocardiogram (subjects with grade 1 abnormalities [i.e., mild 
regurgitation/stenosis] can be entered on study ).  Subjects with moderate 
valvular thickening should not be entered on stud y.
12.Known immediate or delay ed hy persensitivit y reaction or idiosy ncras y to drugs 
chemicall y related to GSK2857916 or any of the components of the study 
treatment.
13. Pregnant or lactating female.
14.Known HIV infection.
15.Subjects with positive test for Hepatitis B surface (HBS -Ag) or Hepatitis B core 
(HBc)a ntigen  
16.Subjects with positive test for hepatitis C (HCV) infection are excluded regardless 
of viral load.  If hepatitis C antibody  test is positive, a confirmatory  polymerase 
chain reaction (PCR) or recombinant immunoblot assay  (RIBA)test should be 
performed.  If the RIBA test is negative, subject is eligible for this trial.
17. Current active liver or biliary  disease (with the exception of Gilbert's sy ndrome or 
asymptomatic gallstones, liver metastases or otherwise stable chronic liver disease 
per investiga tor’s assessment).
18.Current corneal disease or a history  of corneal disease. 
6. COM PLETION OR WITHDRA WAL OF SUBJECTS
6.1. Screen and Baseline Failures
Data for screen and baseline failures will be collected in source documentation at the site 
but will not be tran smitted to GSK.
2012N155299_05 CONFIDENTIA L
BMA117159
916.2. Subject Completion Criteria
For Part 1 (dose -escalation phase), a completed subject is one who has completed at least 
1 cycle of study  treatment and an End of Study  Visit without events causing them to 
withdraw or discontinue from the study for reasons listed  in Section 6.3  For Part 2 
(expansion cohort), a completed subject is one who has received at least one dose of 
study  treatment without events causing them to withdraw or discontinue study  treatment 
for reasons listed in Section 6.3and completed an End of Study  Visit.
A participant will be considered to have completed the study  if he or she has received at 
least one dose of the study treatment and , has died before the end of the study , has not 
been lost to follow- up, or has not withdrawn consent from study  participation.
6.3. Permanent Discontinuation from Study  Treatment
Subjects will receive study  treatment until disease progression, death or unaccept able 
toxicity , including meeting stopping criteria for significant toxicity  as outlined in Section 
3.10  and other relevant safet y management guidelines outlined in the protocol, or until a 
maximum of 16 treatme nt cy cles.  In addition, study  treatment may  be permanently  
discontinued for an y of the following reasons:
deviation(s) from the protocol
request of the subject or prox y (withdrawal of consent by  subject or proxy )
investigator’s discretion
a dose delay  of >14 day s unless the investigator or GSK Medical Monitor agree 
that subject derives benefit and that further treatment benefits will outweigh the 
risks.   Exceptions apply  to nephrotoxicity  as outlined in Section 3.10.2
intercurrent illness that prevents further administration of study  treatment(s)
subject is lost to follow -up 
study  is closed or terminated
subject completes maximum number of treatment cycles per protocol 
The primary  reason study  treatment was pe rmanently  discontinued must be 
documented in the subject’s medical records and electronic case report form 
(eCRF) 
If the subject voluntaril y discontinues from treatment due to toxicity , ‘adverse event 
(AE)’ will be recorded as the primary  reason for perma nentl y discontinuation on the 
eCRF.
Once a subject has permanently  discontinued from study  treatment, the subject will not 
be allowed to be retreated. 
All subjects who discontinue from stud y treatment will have safet y assessments at the 
time of discontinu ation and during post -study  treatment follow -up as specified in Time 
and Events Tables (see Section 7.1).  
2012N155299_05 CONFIDENTIA L
BMA117159
926.4. Subject Withdrawal
Should a subject fail to attend the clinic for a required study  visit, the site should attempt 
to contact the subject and re -schedule the missed visit as soon as possible. The site should 
also counsel the subject on the importance of maintaining the assigned visit schedule and 
ascertain whether or not the subject wishes to and/or should c ontinue in the study  based 
on previous non- compliance. In cases where the subject does not return for the 
rescheduled visit or cannot be reached to reschedule the missed visit, the site should 
make every  effort to regain contact with the subject (3 telephone calls and if necessary  a 
certified letter to the subject’s last known mailing address) so that they can appropriatel y 
be withdrawn from the study . These contact attempts should be documented in the 
subject’s medical record. Should the subject continue t o be unreachable, then and onl y 
then will he/she be considered to have withdrawn from the study  with a primary  reason of 
“Lost to Follow -up”. For all other subjects withdrawing from the study , an alternative 
reason for discontinuation should be recorded in the eCRF.
6.5. Stud y Completion
A study  will be considered completed, having met the study  objectives, when the last 
subject has received their last dose of study  medication and completed the End of Study  
visit. 
Per the EU Clinical Trial Directive, the end of the study  is defined as the last subject’s 
last visit.
6.6. Treatment after the End of Study
The investigator is responsible for ensuring that consideration has been given for the 
post-study  care of the subject’s medical condition whether or not GSK is providi ng 
specific post -study  treatment.
Subjects’ survival and status of post- study  treatment will be documented via medical 
charts analy sis at 3 months following the last dose of study  drug.
7. STUDY A SSESSMENTS A ND PROCEDURES
A signed, written informed consent fo rm must be obtained from the subject prior to any  
study -specific procedures or assessments being performed.
The timing of each assessment is listed in the Time and Events Tables (Section 7.1).  The 
timing and nu mber of the planned study  assessments may  be altered during the course of 
the study  based on newl y available data (e.g. to obtain data closer to the time of peak 
plasma concentrations) to ensure appropriate monitoring for the following assessments: 
safet y,pharmacokinetic (PK), pharmacody namic (PD)/biomarker or other assessments.  
The change in timing or addition of time points for any  of the planned study  assessments 
listed above must be approved and documented b y GSK, but this will not constitute a 
protoc ol amendment.  The institutional review board (IRB) or ethics committee (EC) will 
be informed of an y safety issues that require alteration of the safet y monitoring scheme.  
The maximum amount of blood collected in Screening and during the first Cy cle 1 fro m 
2012N155299_05 CONFIDENTIA L
BMA117159
93each subject for the Dose Escalation and for the Dose Expansion is no more than 162 ml
of blood (See Appendix 10).
Whenever vital signs, 12 -lead electrocardiograms (ECGs) and blood draws are scheduled 
for the sam e nominal time, the assessments should occur in the following order: 12 -lead 
ECG, vital signs, blood draws.  The timing of the assessments should allow the blood 
draw to occur at the exact nominal time.  Detailed procedures for obtaining each 
assessment ar e provided in the SPM.
7.1. Time and Events Tables
This section consists of the Time and Events Tables and supplemental footnotes to 
describe assessment windows and sequencing of study -specific assessments and 
procedures. 
2012N155299_05 CONFIDENTIA L
BMA117159
947.1.1. Dose Escalation
7.1.1.1. Every  3 Weeks Dosing Schedule for Multiple My eloma
Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1
Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment 3-Month 
Off-study 
Follow -up
Informed Consent X
Baseline Demographics X
Medical History X
Physical Exam X X X At the start of each cycle X
Ocular Exam X3 X4 At the start of each cycle4 X4
ECOG Performance Status X X At the start of each cycle X
Vital Signs (BP, HR, Bod y 
Temperature)X X5 X X X5 At the start of each cycle5 X
Weight and Height XWeight 
onlyWeight 
onlyWeight only -At the start of each cycle Weight only
Hematology X X6 X X X At the start of each cycle X
Clinical chemistry X X6 X X X X At the s tart of each cycle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB, Troponin X7 X7 X7 At the start of each cycle7 X7
BNP X8
UPEP and urine 
Immunof ixationX X At the start of each cycle
SPEP and serum 
Immunofixation, Serum M -
protein CalculationX X At the start of each cycle
Kappa, lambda free LC, FLC 
ratioX X At the start of each cycle
24 hr urine protein and 
albuminX X Atthe start of each cycle
2012N155299_05 CONFIDENTIA L
BMA117159
95Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1
Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment 3-Month 
Off-study 
Follow -up
IgG, IgM, IgA X X At the start of each cycle
CRP, beta2 microglobulin X X At the start of each cycle
Pregnancy Test X9 At the start of cycles 59, 99, 139 X9 X10
Chest X -ray X
12-lead ECG X11 X11 X11 X11 X11 At the start of each cycle11 X11
LVEF and valves assessment 
(ECHO)X12 At the start of cycles 412, 912 X12
Extramedullary plasmacytoma 
imaging X13 At the start of cycles 513, 913, 1313 X13
BM Aspirate (see below for each test re quired within procedure) :
Disease assessment X14 At the time of Complete Response
BCMA assessment and 
PD (flow) X15 X15
FISH testing X16
BM biopsy for disease 
assessment and BCMA 
expression (IHC) X17At the time of CR
(disease assessment only)
Serum (soluble BCMA) X18 X18 X18 X18 X18 Predose at the start of each cycle X18
Serum (cytokines/chemokines) X19 X X19 At predose and EOI on D1 of each cycle X
Serum (anti -drug- antibodies) X X20At the start of cycles 320, 620, 920, 1220and 
1620 X
Plasma -cfDNA X X 
Peripheral blood (flow for 
TBNK)X15 X15 At the start of each cycle15 X15
Serial Pharmacokinetics 
(blood)X21 X21 X21 X21 X21 C3D1 only21 X22
Urine PK X23 X23 Day 1 of cycles 423, 723, 1023, 1323, 1623
Premedication if needed X X At the start of each cycle
GSK2857916  administration X24 X24 X24
Steroid eye drops X25 X25 X25
Adverse Events Continuous
2012N155299_05 CONFIDENTIA L
BMA117159
96Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1
Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment 3-Month 
Off-study 
Follow -up
Concomitant Medications X Continuous
Survival Status X26
Subsequent Treatment X26
1. Assessments scheduled on days of dosing should be done prior to drug administration, unless otherwise specified.  All other a ssessments can be 3 days of scheduled 
occurrence unless otherwise specified.
2. All Scr eening assessments must be performed within 14 days prior to first dose unless otherwise specified. Informed Consent must be signed before any study- specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), s lit lamp examination (with special focus on cornea), intraocular pressure, and dilated fundoscopic 
examination may be performed within 21 days prior to first dose.
4. On-study exams to include BCVA (best -corrected visual acuity) and slit lamp examination (wit h special focus on cornea) ; window for exams is up to 3 days prior to dosing.
5. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes and +30 minutes ( 5 min)  after SOI, EOI, and 1 
hour post EOI.  On subsequent dosing days, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI.  The Sentinel Subject 
must be observed for at least 24 hours post EOI.  On days where vital sign timepoints a lign with PK sampling timepoints, vital signs should be assessed prior to PK 
samples being drawn.
6. If completed within 72 hrs prior to the first dose, this assessment need not be repeated on Day 1 of Cycle 1 .Refer to Table 15 for comprehensive list of lab tests.  
7. Troponin will be measured at the local lab (troponin I or T) and a central lab (troponin I).  CK -MB at the local lab or if not possible by a central laboratory .
8. BNP to be measured locally, or if not availa ble by a central laboratory, at screening; if cardiac workup is required due to safety concerns during the study, BNP should be 
measured.  
9. Perform only in women of child -bearing potential.  A serum pregnancy test should be performed at screening, and subsequent pregnancy tests may be either serum or urine; 
10. Final pregnancy test (serum or urine) must be performed in women of childbearing potential 60 days after last study treat ment.
11. On dosing days, ECG to be performed in triplicate at predose (within 30 min utes prior to SOI) and EOI.  On days where ECG timepoints align with PK sampling 
timepoints, ECGs should be performed prior to PK samples being drawn (PK sample should be taken at the exact nominal time; refer to footnote 21) .  At 
screening, on interim vis its (C1D8 and C1D15) and End of Study obtain a single ECG measurement.
12. At Screening, LVEF may be performed within 30 days prior to first dose. All ECHOs indicated on dosing days may be performed up to 5 days before dosing. All ECHOs to be 
done locally and sent to GSK for central imaging storage.
13. May be performed up to 21 days prior to C1D1 as screening value.  Needs to be performed by the same method throughout the stu dy as was done at baseline (i.e. if PET 
scan was used as baseline, subject needs to be fol lowed by PET scans).  Selected target lesion needs to be measured and followed over time.
14. Samples from within 14 days prior to first dose are acceptable.
15. Sample(s) collected for analysis by central lab .  The same sample will be used for BCMA (flow) and PD during Screening. On D8 only postdose PD assessment will be 
performed
16. FISH testing at least for: t(4;14), t(14;16), 17p13del. FISH results from samples taken within 60 days prior to first dose ar e acceptable.
2012N155299_05 CONFIDENTIA L
BMA117159
9717. Archival tissue from up to 60 days prior to stu dy is acceptable 
18. A single sample for sBCMA will be collected at C1D8, C1D15 and at the End of Study visit. sBCMA samples will also be collecte d on  C1D1 at predose (within 30 minutes 
prior to SOI), at EOI ( 5 minutes) and on C1D2 24h post SOI.  On C2D1 sB CMA will be collected pre -dose (within 30 minutes prior to SOI) and at the EOI ( 5 minutes)
19. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halted) to assess allergic reaction)
20. All ADA sa mples will be collected prior to each infusion
21. PK samples to be taken (in all subjects) for both GSK2857916 and cys -mcMMAF measurement: C1D1 at pre-dose (within 30 minutes prior to SOI), 0.5 h after the start of the 
infusion (SOI) ( 5 min), at the end of i nfusion (EOI) just before EOI), 1 h after EOI, 3 h after EOI ( 5 min), 8 h after EOI ( 15 min), 24h after EOI ( 1h) (Day 2); C1D8 1 
sample; C1D15 1 sample; C2D1, at pre -dose (within 30 minutes prior to SOI) and at the EOI (just before EOI); C3D1 at pre -dose (within 30 minutes prior to SOI) and at the 
EOI (just before EOI).
22. Collect 1 PK sample at each subject’s final visit. 
23. Pre-specified amounts of urine will be collected for PK analysis from the 24 hour urine collection at Screening, C2D1, C4D1, C7D1 , C10D 1, C13D1, and C16D1.  Refer to 
Section 7.4.2 for details.
24. Study drug administration 3 day window only
25. Prophylaxis with prednisolone phosphate 1% or dexamethasone 0.1% 1 drop QID x 4 days starting 1 day prior to treatment
26. Record subject’s survival status and whether subsequent treatment for disease was given.  Subject does not need to come in fo r visit.
Abbreviations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B -type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = 
Circulating free DNA; CK = creatinine kinase;  CRP = C- reactive protein; EM = extramedullary;  EOI = End of Infusion; FLC = free light chain; PD = Pharmacodynamics; PK = 
Pharmacokinetics ; QID = 4 times a day; SOI = start of infusion; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis
7.1.1.2. Weekly  Dosing Schedule (Dose Escalation) for Multiple My eloma
Time and Events Table for Full Study (Cycle = 28 days)
Study Assessm ents1 Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment3-Month Off -
study 
Follow -up
Informed Consent X
Baseline Demographics X
Medical History X
Physical Exam X X X At the start of ea ch cycle X
2012N155299_05 CONFIDENTIA L
BMA117159
98Time and Events Table for Full Study (Cycle = 28 days)
Study Assessm ents1 Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment3-Month Off -
study 
Follow -up
Ocular Exam X3 X4 At the start of each cycle4 X4
ECOG Performance Status X X At the start of each cycle X
Vital Signs (BP, HR, Body 
Temperature)X X5 X X X5 At the start of each cycle5 X
Weight and Height XWeight 
onlyWeight
onlyWeight only -At the start of each cycle Weight only
HematologyX X6 X X X At the start of each cycle X
Clinical Chemistry X X6 X X X X At the start of each cycle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB , Troponin X7 X7 X7 At the start of each cycle7 X7
BNP X8
UPEP and urine 
ImmunofixationX X At the start of each cycle
SPEP and serum 
Immunofixation and Serum -
M protein CalculationX X At the start of each cycle
Kappa, lambda free LC, 
FLC ratioX X At the start of each cycle
24 hr urine protein and 
albuminX X At the start of each cycle
IgG, IgM, IgA X X At the start of each cycle
CRP, beta2 microg lobulin X X X At the start of each cycle
Pregnancy Test X9 At the start of cycles 59, 99, 139 X9 X10
Chest X -ray X
12-lead ECG X11 X11 X11 X11 X11 At the start of each cycle11 X11
LVEF and valves 
assessment (ECHO)X12 At the start of cycles 412, 912 X12
2012N155299_05 CONFIDENTIA L
BMA117159
99Time and Events Table for Full Study (Cycle = 28 days)
Study Assessm ents1 Screen2Day 1 
C1Day 2 
C1Day 8 
C1Day 15 
C1Day 1 
C2D1 of C3 -C16End of Study 
Treatment3-Month Off -
study 
Follow -up
Extramedullary 
Plasmacytoma ImagingX13 At the start of cycles 513, 913, 1313 X13
BM Aspirate (see below for each test required within procedure) :
Disease assessment X14 At the time of Complete Response
BCMA a ssessment and 
PD (flow) X15 X15, 17
FISH testing X16
BM biopsy for disease 
assessment X18At the time of Complete Response 
(disease assessment only)
Serum (soluble BCMA) X19 X19 X19 X19 X19 Predose at the start of each cycle X
Serum 
(cytokines/chemokines)X20 X X20 X20 X20 At predose and EOI on D1 of each cycle X
Serum (anti -drug-
antibodies)X21 X21 X21At the start of cycles 321, 621, 921, 1221and 
1621X
Plasma -cfDNA X X
Peripheral blood (flow for 
TBNK and in tracellular 
cytokine testing)X15 X15 X15 At the start of each cycle15 X15
Serial Pharmacokinetics 
(blood)X22 X22 X22 X22 X22 C3D1 only22 X23
Urine PK X24 X24 Day 1 of cycles 424, 724, 1024, 1324, 1624
Premedication if needed X X X X Each dosing week
GSK2857916 
administrationX25 X25 X25 X25 Each dosing week25
Steroid eye drops X26 X26 X26 X26 Each dosing week26
Adverse Events Continuous
Concomitant Medications X Continuous
Survival Status X27
Subsequent Treatment X27
2012N155299_05 CONFIDENTIA L
BMA117159
1001. Assessments scheduled on days of dosing should be done prior to drug administration, unless otherwise specified.  All other a ssessments can be done 3 days unless otherwise 
specified.
2. All Screening assessments must be performed within 14 day s prior to first dose unless otherwise specified.  Informed Consent must be signed before any study -specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), slit lamp examination (with special focus on corne a), intraocular pressure, dilated fundoscopic examination
may be performed within 21 days prior to first dose
4. On-study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on cornea) ; window for exams is up to 3 days prior to dosing.
5. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes and +30 minutes ( 5 min) after SOI, EOI, and 1 hour 
post EOI.  On subsequent dosing days, vital signs mu st be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI.  On days where vital sign 
time points align with PK sampling timepoints, vital signs should be assessed prior to PK samples being drawn.   
6. If completed within 72 h ours prior to first dose, this assessment need not be repeated on Day 1 of Cycle 1.  Refer to Table 15 for comprehensive list of lab tests.
7. Troponin will be measured at the local (troponin I or T) and central (trop onin I) lab.  CK -MB at the local lab or if not available by a central laboratory . 
8. BNP to be measured locally, or if not available by a central laboratory, at screening; if cardiac workup is required due to safety concerns during the study, BNP should be 
measured.
9. Perform only in women of child -bearing potential.  A serum pregnancy test should be performed at screening, and subsequent pregnancy tests may be either ser um or urine.  
10. Final pregnancy test (serum or urine) must be performed in women of childbea ring potential 60 days after last study treatment.
11. On dosing days, ECG to be performed in triplicate at predose (within 30 minutes prior to SOI) and EOI.  On days where ECG timepoints align with PK sampling timepoints, 
ECGs should be performed prior to PK samples being drawn (PK sample should be taken at the exact nominal time; refer to footnote 22).   At screening and at End of Study, 
obtain a single ECG measurement.
12. At Screening, LVEF may be performed within 30 days prior to fi rst dose ; All ECHOs indicated on dosing days may be performed up to 5 days before dosing .  ECHOs to be done 
locally and sent to GSK for central imaging storage.
13. May be performed up to 21 days prior to C1D1 as screening value.  Needs to be performed by the same method throughout the st udy as was done at baseline (i.e. if PET scan 
was used as baseline, subject needs to be followed by PET scans).  Selected target lesion needs to be measured and followed o ver time.
14. Samples from within 14 days prior to first dose are acceptable.
15. Sample(s) c ollected for analysis by central lab. The same sample collected on Day 1 of cycle 1 prior to dosing will be used for BCMA (flow) and PD u. 
16. FISH testing at least for t(4;14), t(14/16), 17p13del.  FISH results from samples taken within 60 days prior to firs t dose are acceptable.
17. Collect sample prior to dosing.
18. Archival tissue from up to 60 days prior to study is acceptable.
19. A single sample for sBCMA will be collected at C1D8 predose, and at the End of Study visit. sBCMA samples will also  be colle cted on C1D1 at predose (within 30 minutes prior to 
SOI), at EOI ( 5 minutes) and on C1D2 24h post SOI. On C1D15 and C2D1 collect at predose (within 30 minutes prior to SOI) and EOI ( 5 minutes)
20. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halted) to assess allergic reaction
21. All ADA samples will be collected prior to each infusion
22. PK samples to be taken (in all subjects) for both GSK2857916 and cys -mcMMAF measurement: C1D1 at predose (within 30 m inutes prior to SOI), 0.5 h after the start of the 
infusion, at EOI (just before EOI), 1 h after EOI ( 5 min), 3 h after EOI ( 5 min), 8 h after EOI ( 15 min), and 24h after EOI ( 1 h) (Day 2); C1D8 at predose (within 30 minutes 
prior to SOI), and at EOI (just before EOI); C1D15 at predose (within 30 minutes prior to SOI) and at EOI (just before EOI); C2D1 at predose (within 30 minutes prior to SOI), at 
EOI (just before EOI); C3D1 at predose (within 30 minutes prior to SOI) and at EOI (just before EOI).
23. Collect 1 PK sample at each subject’s final visit.
2012N155299_05 CONFIDENTIA L
BMA117159
10124. Pre-specified amounts of urine will be collected for PK analysis from the 24 hour urine collection at Screening, C2D1, C4D1, C7D1 , C10D1, C13D1, and C16D1.  Refer to Section 
7.4.2 for details.
25. Study drug administration 1 day window only.
26. Prophylaxis with prednisolone phosphate 1% or dexamethasone 0.1% 1 drop QID x 4 days starting 1 day prior to treatment
27. Record subject’s survival status and whether subsequent tre atment for disease was given.  Subject does not need to come in for visit.
Abbreviations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B -type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = Circulating 
free DNA; CK = creatinine kinase;  CRP = C -reactive protein; EM = extramedullary;  EOI = End of Infusion; FLC = free light chain; PD = Pharmacodynamics; PK = Pharmacoki netics; 
QID = 4 times a day; SOI = start of infusion; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis
2012N155299_05 CONFIDENTIA L
BMA117159
1027.1.2. Dose Expansion
7.1.2.1. Every  3 Weeks Dosing Schedule for Multiple My eloma
Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1 Screen2Day 1 
C1Day 8 
C1Day 15 
C1Day 1 C2 D1 of C3 -C16End of 
Study 
Treatment34Monthly 
Follow 
up35
Baseline Demographics X
Medical History X
Physical Exam X X X At the start of each cycle X
Ocular Exam X3 X4 At the start of each cycle4 X4X35
ECOG Performance 
StatusX X At the start of each cycle X
Vital Signs (BP, HR, 
Body Temperature)X X5 X X X5 At the start of each cycle5 X
Weight and Height XWeight 
onlyWeight onlyWeight only -At the start of each 
cycleWeight only
HematologyX X6 X X X At the start of eac h cycle X
Clinical chemistry X X6 X X X At the start of each cycle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB , Troponin X7,8 X7,8 X7,8 At the start of each cycle7, 8 X7,8
BNP X9
UPEP and urine 
ImmunofixationX X At the start of each cycle
SPEP and serum 
immunofixation and 
Serum M -protein 
CalculationX X At the start of each cycle
Kappa, lambda free LC, 
FLC ratioX X At the start of each cycle
2012N155299_05 CONFIDENTIA L
BMA117159
103Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1 Screen2Day 1 
C1Day 8 
C1Day 15 
C1Day 1 C2 D1 of C3 -C16End of 
Study 
Treatment34Monthly 
Follow 
up35
24 hr urine protein and 
albuminX X At the start of each cycle
IgG, IgM, IgA X X At the start of each cycle
CRP, beta2 
microglobulinX X At the start of each cycle
Pregnancy Test X10 At the start of cycles 510, 910, 1310 X10 X11
Chest X -ray X
12-lead ECG X12 X12 X12 X12 X12 At the start of each cycle12 X12
LVEF and valves 
assessment (ECHO)X13 At the start of cycles 413, 913 X13
Extramedullary 
Plasmacytoma ImagingX14 At the start of cycles 514, 914, 1314 X14
BM Aspirate (see below for each test required within procedure) :
Disease 
assessmentX15 At the time of Complete Response
BCMA assessment 
and PD (flow)X16 X16, 18
FISH testing X17
BM biopsy for disease
assessment X19At the time of CR (disease 
assessment only)
Serum (soluble BCMA) X20 X20 Predose at the start of each cycle X
Serum 
(cytokines/chemokines)X21 X21Predose and EOI on D1 of each 
cycleX
Serum (anti -drug-
antibodies)X22 X22At the start of cycles 322, 622, 922, 
1222and 1622X
Plasma -cfDNA X X
Peripheral blood (flow 
for TBNK and 
intracellular cytokine 
testing)X23 X X23 At the start of each cycle23 X23
Sparse PK (blood) X24 X24 C3D124and C5D124only X25
Genetics sample X26
2012N155299_05 CONFIDENTIA L
BMA117159
104Time and Events Table for Full Study (Cycle = 21 days)
Study Assessments1 Screen2Day 1 
C1Day 8 
C1Day 15 
C1Day 1 C2 D1 of C3 -C16End of 
Study 
Treatment34Monthly 
Follow 
up35
Premedication if 
neededX X X
GSK2857916  
administrationX27 X27 X27
Steroid eye drops X28 X28 X28
Adverse Events Continuous
Concomitant 
MedicationsX Continuous
e-Diary X X X X X30 X30 X
OSD I X31 X31
NEI-VFQ-25 X31 X31
Exit Interview X32
Follow -up Interview X33
Survival Status X29
Subsequent Treatment X29
1. Assessments scheduled on days of dosing should be done prior to drug administration, un less otherwise specified.  All other assessments can be done 3 days unless otherwise 
specified
2. All Screening assessments must be performed within 14 days prior to first dose unless otherwise specified. Informed Consent m ust be signed before any study- specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), slit lamp examination (with special focus on cornea), intraocular pressure, and dilated fundoscopic
examination may be performed within 21 days prior to first dose.
4. On-study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on cornea); window for exams is up to 3 days prior to dosing. In the 
event that a subject has a dose delay due to a non -ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may be 
omitted if the participant did not have corneal signs on the previous exam and does not have any new corneal symptoms .
5. On initial (first infusion) dos ing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes, +30 minutes (15 min) after SOI, EOI, and 1 hour post 
EOI.  On subsequent dosing days, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI ), +30 minutes after SOI, and EOI.   On days where vital sign 
timepoints align with PK sampling timepoints, vital signs should be assessed prior to PK samples being drawn.
6. If completed within 72 hrs prior to the first dose, this assessment need not be rep eated on Day 1 of Cycle 1.  Refer to Table 15 for a comprehensive list of lab tests.  
7. Troponin will be measured at the local (troponin I or T) and central (troponin I) lab.  
8. CK-MB at the local lab or if not avail able by a central laboratory. 
9. BNP to be measured locally, or if not available by a central laboratory, at screening; if cardiac workup is required due to safety concerns during the study, BNP should be 
measured.
2012N155299_05 CONFIDENTIA L
BMA117159
10510. Perform only in women of child -bearing potential.  A serum pregnancy test should be performed at screening, and subsequent pregnancy tests may be either serum or urine.
11. Final pregnancy test (serum or urine) must be performed in women of childbearing potential 60 days after last study treatment .
12. ECG s to be performed in triplicate.  On dosing days, ECG to be performed at predose (within 30 minutes prior to SOI) and EOI.  A t screening, on interim visits (C1D8 and C1D15) 
and End of Study, obtain a single ECG measurement. On days where ECG timepoints align with PK sampling timepoints, ECGs should be performed prior to PK samples 
being drawn (PK sample should be taken at the exact nomin al time; refer to footnote 24)
13. At Screening, LVEF may be performed within 30 days prior to first dose. All ECHOs indicate d on dosi ng days may be performed up to 5 days before dosing .ECHOs to be done 
locally and sent to GSK for central imaging storage.
14. May be performed up to 21 days prior to C1D1 as screening value.  Needs to be performed with the same method throughout the study as was done at baseline (i.e. if PET scan 
was used as baseline, subject needs to be followed by PET scans).  Selected target lesion needs to be measured and followed o ver time.
15. Samples from within 14 days prior to first dose are acceptable.
16. Sample(s) collected for analysis at central lab. The same sample will be used for BCMA (flow) and PD. On D8 only postdose PD assessment will be performed, if applicable (refer 
to footnote 18).
17. FISH testing at least for: t(4;14), t(14;16), 17p13del. FISH results fro m samples taken within 60 days prior to first dose are acceptable.
18. Additional samples may be collected in some subjects (up to 6) for further exploration of PD.
19. Archival tissue from up to 60 days prior to study is acceptable.
20. Collect sBCMA at C1D1 predose (within 30 minutes prior to SOI) and at EOI ( 5 minutes), C2D1 at predose (within 30 minutes prior to SOI) and at EOI (+ -5 minutes).
21. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halte d) to assess allergic reaction
22. All ADA samples will be collected prior to each infusion
23. Flow cytometry performed central laboratory.
24. PK samples to be taken for both GSK2587916 and cys- mcMMAF measurement on C1D1, C2D1, C3D1, and C5D1 at predose (within 30 m inutes prior to SOI) and at EOI (just 
before EOI).
25. Collect 1 PK sample at each subject’s final visit.
26. Informed consent for optional genetics research should be obtained before collecting a sample.
27. Study drug administration 3 day window only.
28. Prophylaxis w ith prednisolone phosphate 1% or dexamethasone 0.1% 1 drop QID x 4 days starting 1 day prior to treatment
29. All participants should be followed for survival for 1 year from last subject last dose. and whether subsequent treatment for disease was given.  Subj ect does not need to come in 
for visit. Participants who have completed treatment or the 3 month follow up visit (end of study) prior to amendment 5 will be reconsented for further follow up and survival status.
30. e-Diary to be completed at screening, then Days 1- 7, 8, 15 of each treatment cycle. Upon implementation of the e -Diary, these assessments will be required.
31. OSDI and NEI- VFQ- 25 to be administered during end of study treatment visit.  Additional assessments for subjects who are experiencing corneal symptoms to be completed via 
telephone on a monthly basis for up to 1 year, or until resolution of symptoms (whichever comes first) during the follow -up period. 
32. Exit interview to be performed within 21days of end of study visit
33. Optional follow- up telepho ne interview to explore visual symptoms and changes in symptoms and related impacts following treatment discontinuation be performed at least 6 
months following the End of Study Treatment visit .  This interview would only be for those subjects who experien ced corneal symptoms during treatment and consent to 
participate.
34. End of treatment visit should be performed within 30 days (+7 days) after the last dose or prior to the start of new anti -cancer treatment, whichever is earlier. In cases where more 
than 30 days (+7 days) have elapsed from the date of the subject’s last dose due to dosing delays and a subsequent decision to take t he subject off treatment, the end of study 
treatment visit should be scheduled as soon as possible to allow the final assessments t o be performed at the earliest date.
2012N155299_05 CONFIDENTIA L
BMA117159
10635. Participants with corneal signs or symptoms at the end of study treatment visit should be monitored by ophthalmic exam once a month after the last study dose until deemed 
clinically stable by an eye care professional complete resolution or for 12 months (whichever comes first). Corneal exams to include BCVA and slit lamp examination (with sp ecial 
focus on cornea). Participants who have completed treatment or the 3 month follow up visit (end of study) will be reconsented for additional ophthalmology follow up.
Abbreviations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B -type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = 
Circulating free DNA; CK = creatin ine kinase;  CRP = C -reactive protein; EM = extramedullary;  EOI = End of Infusion; FLC = free light chain; PD = Pharmacodynamics; PK = 
Pharmacokinetics; QID = 4 times a day; SOI = start of infusion; SPEP = serum protein electrophoresis; UPEP = urine prote in electrophoresis
2012N155299_05 CONFIDENTIA L
BMA117159
1077.1.2.2. Dose Expansion Weekly  Dosing Schedule for Multiple My eloma
Time and Events Table for Full Study (Cycle = 28 days)
Study Assessments1 Screen2Day 1 
C1Day 8 C1Day 15 
C1Day 1 
C2Day 15 
C2D1 of C3 -C16End of Study 
Treatment3-Month
Off-study 
Follow -up
Informed Consent X
Baseline Demographics X
Medical History X
Physical Exam X X X At the start of each cycle X
Ocular Exam X3 X4 At the start of each cycle4 X4
ECOG Performance 
StatusX X At the start of each cycle X
Vital Signs (BP, HR, Body 
Temperature)X X5 X5 X5 X5 At the start of each cycle5 X
Weight and Height XWeight 
onlyWeight 
onlyWeight only -At the start of each cycle Weight
HematologyX X6 X X X At the start of each cy cle X
Clinical chemistry X X6 X X X X At the start of each cycle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB , Troponin X7 X7 X7 At the start of each c ycle7 X7
BNP X8
UPEP and urine 
immunofixationX X At the start of each cycle
SPEP and serum 
immunofixation and Serum 
M-protein CalculationX X At the start of each cycle
Kappa, lambda free LC, 
FLC ratioX X At the start of each cycle
24 hr urine protein and 
albumin X X At the start of each cycle
IgG, IgM, IgA X X At the start of each cycle
2012N155299_05 CONFIDENTIA L
BMA117159
108Time and Events Table for Full Study (Cycle = 28 days)
Study Assessments1 Screen2Day 1 
C1Day 8 C1Day 15 
C1Day 1 
C2Day 15 
C2D1 of C3 -C16End of Study 
Treatment3-Month
Off-study 
Follow -up
CRP, beta2 microglobulin X X X At the start of each cycle
Pregnancy Test X9 At the start of cycles 59, 99, 139 X9 X10
Chest X -ray X
12-lead ECG X11 X11 X11 X11 X11 At the start of each cycle11 X11
LVEF and valves 
assessment (ECHO)X12 At the start of cycles 412, 912 X12
Extramedullary 
Plasmacytoma ImagingX13 At the start of cycles 513, 913, 1313 X13
BM Aspirate (see below for each test required within procedure) :
Disease assessment X14 At the time of Complete Response
BCMA assessment 
and PD (flow)X15 X15, 17
FISH testing X16
BM biopsy for disease 
assessment X18At the time of Complete Response (disease 
assessment only)
Serum (soluble BCMA) X19 X19 X19 X19 Predose at the start of each cycle X
Serum 
(cytokines/chemokines)X20 X20 X20 X20 Predose and EOI on D1 of each cycle X
Serum (anti -drug-
antibodies)X21 X21 X21 At the start of cycles 321, 621, 921, 1221and 1621 X
Plasma -cfDNA X X X 
Peripheral blood (flow for 
TBNK and intracellular 
cytokine testing)X15 X X15 At the start of each cycle15 X15
Sparse PK (blood) X22 X22 X22 X22 X22 C3D122, C3D1522, and C5D122only X23
Genetics sample X24
Premedication if needed X X X X X Each dosing week
GSK2857916  
administrationX25 X25 X25 X25 X25 Each dosing week25
Steroid eye drops X26 X26 X26 X26 X26 Each dosing wee k26
Adverse Events Continuous
2012N155299_05 CONFIDENTIA L
BMA117159
109Time and Events Table for Full Study (Cycle = 28 days)
Study Assessments1 Screen2Day 1 
C1Day 8 C1Day 15 
C1Day 1 
C2Day 15 
C2D1 of C3 -C16End of Study 
Treatment3-Month
Off-study 
Follow -up
Concomitant Medications X Continuous
e-Diary X X X X X X28 X
Exit Interview X29
Survival Status X27
Subsequent Treatment X27
1. Assessments scheduled on days of dosing should be done prior to drug administration, unless otherwise specified. All other assessments can be done 3 days unless otherwise 
specified 
2. All Screening assessments must be performed within 14 days prior to first dose unless otherwise specified. Informed Consent m ust be sign ed before any study -specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), slit lamp examination (with special focus on cornea), intraocular pressure, and dilated fundoscopic
examination may be performed w ithin 21 days prior to first dose.
4. On-study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on cornea) ; window for exams is up to 3 days prior to dosing.
5. On initial (first infusion) dosing day, vital sign s must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes and +30 minutes ( 5 min) after SOI, EOI, and 1 hour 
post EOI.  On subsequent dosing days, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI.  On days where vital sign 
timepoints align with PK sampling timepoints, vital signs should be assessed prior to PK samples being drawn.   
6. If completed within 72 hrs prior to the first dose, this assessment need not be repeated on Day 1 of Cycle 1.  Refer to Table 15 for comprehensive list of lab tests.   
7. Troponin will be measured at the local (troponin I or T) and central (troponin I) lab.  CK -MB at the local lab , or if not available by a central laboratory . 
8. BNP to be measured locally, or if not available by a central laboratory, at screening; if cardiac workup is required due to safety concerns during the stud y, BNP should be 
measured.
9. Perform only in women of child -bearing potential.  A serum pr egnancy test should be performed at screening, and subsequent pregnancy tests may be either serum or urine
10. Final pregnancy test (serum or urine) must be performed in women of childbearing potential 60 days after last study treatment .
11. ECGs to be performed in triplicate.  On dosing days, ECG to be performed at predose (within 30 minutes prior to SOI) and EOI.  On days where ECG timepoints align with PK 
sampling timepoints, ECGs should be performed prior to PK samples being drawn (PK sample should be taken at the exact nomin al time; refer to footnote 22) .At 
screening and End of Study, obtain a single ECG measurement.
12. At Screening, LVEF may be performed within 30 days prior to first dose.  All ECHOs indicated on dosing days may be performed up to 7 days before dosing . ECHOs to be done 
locally and sent to GSK for central imaging storage.
13. May be performed up to 21 days prior to C1D1 as screening value.  Needs to be performed with the same method throughout the s tudy as was done at baseline (i.e. if PET scan 
was u sed as baseline, subject needs to be followed by PET scans).  Selected target lesion needs to be measured and followed over t ime.
14. Samples from within 14 days prior to first dose are acceptable.
15. Sample(s) collected for analysis at central lab. The same sam ple collected on Day 1 of cycle1 prior to dosing will be used for BCMA (flow) and PD (refer to footnote 17).
2012N155299_05 CONFIDENTIA L
BMA117159
11016. FISH testing at least for: t(4;14), t(14;16), 17p13del. FISH results from samples taken within 60 days prior to first dose ar e acceptable.
17. Addition al samples may be collected from 6 subjects in the MM cohort.  Collect sample prior to dosing.
18. Archival tissue from up to 60 days prior to study is acceptable
19. A single sBCMA sample will be collected at C1D1 predose (within 30 minutes prior to SOI) unless o therwise specified.  On C1D15 and C2D1 collect samples at predose (within 30 
minutes prior to SOI) and at EOI ( 5 minutes).  
20. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halted) to as sess allergic reaction
21. All ADA samples will be collected prior to each infusion
22. PK samples to be taken for both GSK2857916 and cys- mcMMAF measurement at C1D1 predose (within 30 minutes prior to SOI), EOI (just before EOI), 1 hour post EOI ( 5 min), 
and 3 h ours post EOI ( 5 min); predose (within 30 minutes prior to SOI) and EOI (just before EOI) on C1D8, C1D15, C2D1, C2D15, C3D1, C3D15, and C5D1
23. Collect 1 PK sample at each subject’s final visit
24. Informed consent for optional genetics research should be obtain ed before collecting a sample.
25. Study drug administration 1 day window only
26. Prophylaxis with prednisolone phosphate 1% or dexamethasone 0.1% 1 drop QID x 4 days starting 1 day prior to treatment
27. Record subject’s survival status and whether subsequent treat ment for disease was given.  Subject does not need to come in for visit.
28. e-Diary to be completed at screening, then Days 1 -7, 8, 15 of each treatment cycle. Upon implementation of the e -Diary, these assessments will be required.
29. 29.Exit interview to be pe rformed within 14 days of end of study visit
Abbreviations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B -type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = 
Circulating free DNA; CK = cr eatinine kinase;  CRP = C -reactive protein; EM = extramedullary;  EOI = End of Infusion; FLC = free light chain; PD = Pharmacodynamics; PK = 
Pharmacokinetics; QID = 4 times a day; SOI = start of infusion; SPEP = serum protein electrophoresis; UPEP = urine protein electrophoresis
2012N155299_05 CONFIDENTIA L
BMA117159
1117.1.2.3. Dose Expansion Every  3 Weeks Dosing Schedule for Ly mphomas
Study Assessments1
Screen2 Day 1 C1 Day 8 C1 Day 15 C1 Day 1 C2 D1 of C3 -C16End of 
Study 
Treatment26Monthly 
Follow 
up27
Informed Consent X
Baseline Demograp hics X
Medical History X
Physical Exam X X X At the start of each cycle X
Ocular Exam X3 X4 At the start of each cycle4 X4 X27
ECOG Performance 
StatusX X At the start of each cycle X
Vital Signs (BP, HR, 
Body Temperature)X X5 X X X5 At the start of each cycle5 X
Weight and Height X Weight only Weight onlyWeight only -At the start of 
each cycleWeight only
HematologyX X6X XX At the start of each cycle X
Clinical chemistry X X6 X X X At the start of each cy cle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB, Troponin X7,8 X7,8 X7,8 At the start of each cycle7 X7,8
BNP X9
24 hr urine protein and 
album in X X At the start of each cycle
IgG, IgM, IgA X X At the start of each cycle
CRP, beta2 
microglobulinX X At the start of each cycle
Pregnancy Test X10At the start of cycles 510, 910, 
1310X10 X11
Chest X -ray X
12-lead ECG X12 X12 X12 X12 X12 At the start of each cycle12 X12
LVEF and valves 
assessment (ECHO)X13 At the start of cycles 413, 913 X13
Serum (soluble BCMA) X14 X14
2012N155299_05 CONFIDENTIA L
BMA117159
112Study Assessments1
Screen2 Day 1 C1 Day 8 C1 Day 15 C1 Day 1 C2 D1 of C3 -C16End of 
Study 
Treatment26Monthly 
Follow 
up27
Serum 
(cytokines/chemokines)X15 X15Predose and EOI on D1 of 
each cycleX
Serum (anti -drug-
antibodies)X16 X16At the start of cycles 316, 616, 
916, 1216and 1616X
Plasma -cfDNA X X 
Peripheral blood (flow 
for TBNK and 
intracellular cytokine 
testing)X17 X17 X17 At the start of each cycle17 X17
Spars e PK (blood) X18 X18 C3D118and C5D118 X19
Genetics sample X20
CT Scan/PET Scan for 
disease assessments X21At the start of cycles 4, 7, 10, 
13, and 16
Premedication if needed X X At the start of each cycle
GSK2857916  
admini strationX22 X22 X22
Steroid eye drops X23 X23 At the start of each cycle23
Tumor biopsy for BCMA 
expressionX24
Adverse Events Continuous
Concomitant 
MedicationsX Continuous
Survival Status X25
Subsequent Treatment X25
1. Assessments scheduled on days of dosing should be done prior to drug administration, unless otherwise specified.  All other a ssessments can be done 3 days of scheduled 
occurrence unless otherwise specified.
2. All Screening assessments must be performed within 14 days prior to first dose unless otherwise specified. Informed Consent must be signed before any study -specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), slit lamp examination (with special focus on cornea), intraocular pressure, and dilated fundoscopic 
examination may be performed within 21 days prior to first dose .
4. On-study exams to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on cornea) ;window for exams is up to 3 days prior to dosing. In the 
event that a subject has a dose delay due to a non -ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may be 
omitted if the participan t did not have corneal signs on the previous exam and does not have any new corneal symptoms.
2012N155299_05 CONFIDENTIA L
BMA117159
1135. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes, +30 minutes ( ±15 min) after SOI, EOI, and 1 hour post 
EOI.  On subsequent dosing days, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI.  On days where vital sign 
timepoints align with PK sampling timepoints, vital signs should be a ssessed prior to PK samples being drawn.  
6. If completed within 72 hrs prior to the first dose, this assessment need not be repeated on Day 1 of Cycle 1.  Refer to Table 15 for a comprehensive list of lab tests.  
7. Troponin will be measured at the local (troponin I or T) and central (troponin I) lab.  
8. CK-MB at the local lab , or if not available by a central laboratory . 
9. BNP to be measured locally at screening; if cardiac workup is required due to safety concerns duri ng the study, BNP should be measured.
10. Perform only in women of child -bearing potential.  A serum pregnancy test should be performed at screening, and subsequent pregnancy tests may be either serum or urine.
11. Final pregnancy test (serum or urine) must be per formed in women of childbearing potential 60 days after last study treatment.
12. On dosing days, triplicate ECGs to be performed at predose (within 30 minutes prior to SOI) and EOI.  On days where ECG timepoints align with PK sampling timepoints, 
ECGs should be performed prior to PK samples being drawn (PK sample should be taken at the exact no minal time; refer to footnote 18 ).  At screening, on interim visits 
(C1D8 and C1D15) and End of Study, obtain a single ECG measurement.
13. At Screening, LVEF may be perform ed within 30 days prior to first dose.  All ECHOs indicated on dosing days may be performed up to 5 days. ECHOs to be done locally and sent 
to GSK for central imaging storage.
14. A single sBCMA sample will be collected at C1D1 predose (within 30 minutes prior to SOI) .  On C2D1 sBCMA will be collected at predose (within 30 minutes prior to SOI) and at 
EOI (5 minutes).
15. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halted) to assess allergic reaction.
16. All ADA samples will be collected prior to each infusion.
17. Sample(s) collected for analysis by central lab.
18. PK samples to be taken for both GSK2587916 and cys- mcMMAF measurement on C1D1 at pre -dose (within 30 minutes prior to SOI), at EOI (just be fore EOI), 1 h after EOI ( 5 
min), 3 h after EOI ( 5 min); C2D1, C3D1, and C5D1 at pre -dose (within 30 minutes prior to SOI) and at EOI (just before EOI).
19. Collect 1 PK sample at each subject’s final visit.
20. Informed consent for optional genetics research should be obtained before collecting a sample.
21. CT/PET or CT scans from within 21 days prior to first dose are acceptable. CT scans are acceptable at all restaging assessments unless CR is suspected, in which case a 
PET/CT scan will be obtained to confirm CR.
22. Study drug administration 3 day window only.
23. Prophylaxis with prednisolone phosphate 1% or dexamethasone 0.1% 1 drop sQID x 4 days starting 1 day prior to treatment.
24. Archived or fresh tissue required for BCMA testing.  Refer to Section 5.2.1 Inclusion Criterion #4 for eligibility criteria. 
25. Record subject’s survival status until last subject completes or discontinues treatment and whether subsequent treatment for disease was given.  Subject does not need to come 
in for visit .
26. End of treatment visit should be performed within 30 days (+7 days) after the last dose or prior to the start of new anti -cancer treatment, whichever is earlier. In cases where more 
than 30 days (+7 days) have elapsed from the date of the subject’s last dose due to dosing delays and a subsequent decision to take the subject off treatment, the end of study 
treatment visit should be scheduled as soon as possible to allow the final assessments to be performed at the earliest date.
27. All participants should be followed for survival for 1 year from last dose. Participants with corneal signs or symptoms at the end of study treatment visit should be monitored by 
ophthalmic exam every month after the last study dose until deemed clinically stable by an eye care prof essional or for 12 months (whichever comes first). Corneal exams to 
include BCVA and slit lamp examination (with special focus on cornea).
2012N155299_05 CONFIDENTIA L
BMA117159
114Abbreviations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B-type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = 
Circulating free DNA; CK = creatine kinase; CRP = C -reactive protein; EOI = End of Infusion; PD = Pharmacodynamics; PK = Pharmacokinetics; QID = 4 times a day; SOI = start 
of infusion
2012N155299_05 CONFIDENTIA L
BMA117159
1157.1.2.4. Dose Expansion Weekly Dosing Schedule for Ly mphomas
Time and Events Table for Full Study (Cycle = 28 days)
Study Assessments1 Screen2Day 1 
C1Day 8 C1Day 15 
C1Day 1 
C2Day 15 
C2D1 of C3 -C16End of Study 
Treatment3-Month 
Off-study 
Follow -up
Informed Con sent X
Baseline Demographics X
Medical History X
Physical Exam X X X At the start of each cycle X
Ocular Exam X3 X4 At the start of each cycle4 X4
ECOG Performance 
StatusX X At the start of each cycle X
Vital Si gns (BP, HR, Body 
Temperature)X X5 X5 X5 X5 At the start of each cycle5 X
Weight and Height XWeight 
onlyWeight 
onlyWeight only -At the start of each cycle Weight
HematologyX X6 X X X At the start of each cycle X
Clinical chemistry X X6 X X X X At the start of each cycle X
Urine Dipstick X X6 X At the start of each cycle X
INR, PTT X X6 X X X At the start of each cycle
HBV/HCV tests X
CK-MB , Troponin X7 X7 X7 At the start of each cycle7 X7
BNP X8
24 hr u rine protein and 
albumin X X At the start of each cycle
IgG, IgM, IgA X X At the start of every other  cycle
CRP, beta2 microglobulin X X At the start of each cycle
Pregnancy Test X9 At the start of cycles 59, 99, 139 X9 X10
Chest X -ray X
12-lead ECG X11 X11 X11 X11 X11 At the start of each cycle11 X11
LVEF and valves 
assessment (ECHO)X12 At the start of cycles 412, 912 X12
2012N155299_05 CONFIDENTIA L
BMA117159
116Time and Events Table for Full Study (Cycle = 28 days)
Study Assessments1 Screen2Day 1 
C1Day 8 C1Day 15 
C1Day 1 
C2Day 15 
C2D1 of C3 -C16End of Study 
Treatment3-Month 
Off-study 
Follow -up
Serum (soluble BCMA) X13 X13 X13 X13X13
Serum 
(cytokines/chemokines)X14 X14 X14 X14 Predose and EOI on D1 of each cycle X
Serum (anti -drug-
antibodies)X15 X15 X15At the start of cycles 315, 615, 915, 1215and 
1615X
Plasma -cfDNA X X 
Peripheral blood (flow for 
TBNK)X16 X16 X16 At the start of each cycle16 X16
Sparse PK (blood) X17 X17 X17 X17 X17 C3D117, C3D1517and C5D117only X18
Genetics sample X19
CT/PET Scan for disease 
assessments X20At the start of Cycles 3, 5, 7, 9, 11, 13, and 
16
Premedication if needed X X X X24 X Each dosing week
GSK2857916  
administrationX21 X21 X21 X21, 24 X Each dosing week21
Steroid eye drops X22 X22 X22 X22, 24 X22 Each dosing week22
Tumor biopsy for BCMA 
expressionX23
Adverse Events Continuous
Concomitant Medications X Continuous
Survival Status X25
Subsequent Treatment X25
1. Assessments scheduled on days of dosing should be done prior to drug administration, unless otherwise specified.  All other a ssessments can be done 3 days unless otherwise 
specified
2. All Scr eening assessments must be performed within 14 days prior to first dose unless otherwise specified. Informed Consent must be signed before any study- specific 
assessments are performed.
3. Screening examination to include BCVA (best -corrected visual acuity), s lit lamp examination (with special focus on cornea), intraocular pressure, and dilated fundoscopic 
examination may be performed within 21 days prior to first dose.
4. On-study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (wi th special focus on cornea); window for exams is up to 3 days prior to dosing .In the 
event that a subject has a dose delay due to a non -ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may b e 
omitted if the participant did not have corneal signs on the previous exam and does not have any new corneal symptoms.
2012N155299_05 CONFIDENTIA L
BMA117159
1175. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 minutes and +30 minutes after SOI (5 min), EOI, and 1 hour 
post EOI.  On subsequent dosing days, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI .  On days where vital sign 
timepoints align with PK sampling timepo ints, vital signs should be assessed prior to PK samples being drawn.   
6. If completed within 72 hrs prior to the first dose, this assessment need not be repeated on Day 1 of Cycle 1.  Refer to Table 15 for comprehensive list of lab tests.   
7. Troponin will be measured at the local (troponin I or T) and central (troponin I) lab.  CK -MB at the local lab , or if not available by a central laboratory. 
8. BNP to be measured locally, or if not available by a central laboratory ,at screening; if cardiac workup is required due to safety concerns during the study, BNP should be 
measured.
9. Perform only in women of child -bearing potential.  A serum pregnancy test should be performed at screening, and subsequent pregnancy tests may be either serum or urine
10. Final pregnancy test (serum or urine) must be performed in women of childbearing potential 60 days after last study treatment .
11. On dosing days, perform triplicate ECGs at predose (within 30 minutes prior to SOI) and EOI.  On days wher e ECG timepoints align with PK sampling timepoints, ECGs 
should be performed prior to PK samples being drawn (PK sample should be taken at the exact no minal time; refer to footnote 17) .  At screening and End of Study, 
obtain a single ECG measurement.
12. At Sc reening, LVEF may be performed within 30 days prior to first dose. All ECHOs indicated on dosing days may be performed up to 7 days before dosing .ECHOs to be done 
locally and sent to GSK for central imaging storage.
13. A single sample for sBCMA will be collected at C1D8 predose, and at the End of Study visit.  sBCMA samples will also be collected on C1D1 at predose (within 30 minutes prior to 
SOI) and EOI (5 minutes).  On C1D15 and C2D1 collect at predose (within 30 minutes prior to SOI) and EOI ( 5 minutes)
14. Collect cytokines at predose (within 30 minutes prior to SOI) and EOI ( 5 min) (even when infusion is interrupted or halted) to assess allergic reaction.
15. All ADA samples will be collected prior to each infusion.
16. Sample(s) collected for analysis by central lab.
17. PK samples to be taken for both GSK2857916 and cys- mcMMAF measurement at C1D1 predose (within 30 minutes prior to SOI), EOI (just before EOI), 1 hour post EOI ( 5 min), 
and 3 hours post EOI ( 5 min); predose (within 30 minutes prior to SOI) and EOI ( just before EOI) on C1D8, C1D15, C2D1, C2D15, C3D1, C3D15, and C5D1.
18. Collect 1 PK sample at each subject’s final visit.
19. Informed consent for optional genetics research should be obtained before collecting a sample.
20. CT/PET scans from within 21 days prior to first dose are acceptable.
21. Study drug administration 1 day window only.
22. Prophylaxis with prednisolone phosphate 1% or dexamethasone 0.1% 1 drop sQID x 4 days starting 1 day prior to treatment.
23. Archived or fresh tissue required for BCMA testing.  Refer to Section 5.2.1 Inclusion Criterion #4 for eligibility criteria. 
24. Also applies to C2D8.
25. Record subject’s survival status and whether subsequent treatment for disease was given.  Subject does not need to come in fo r visit.
Abbre viations:
ADA = Antibody Drug Antibody; ALP = alkaline phosphatase; BCVA = best corrected visual acuity; BNP = B -type natriuretic peptide; C1D1 = Cycle 1 Day 1, etc.; cfDNA = 
Circulating free DNA; CK = creatine kinase; CRP = C -reactive protein; EOI = End o f Infusion; PD = Pharmacodynamics; PK = Pharmacokinetics; QID = 4 times a day; SOI = start 
of infusion
2012N155299_05 CONFIDENTIA L
BMA117159
1187.2. Demographic/Medical History  and Baseline A ssessments
The following demographic parameters will be captured during Screening: date of birth, 
gender, rac e and ethnicity .
Medical/medication history  assessed as related to the eligibility  criteria listed in Section 
5.2.
Baseline (Screening) assessments obtained will include:
Complete phy sical examination, including height (in cm) and weight (in kg).
Vital signs (blood pressure, temperature, pulse rate)
Chest x -ray
Ocular exam
Eastern Cooperative Oncology  Group (ECOG) performance status
Clinical laboratory  tests outlined in Table 15
Serum beta -human chorionic gonadotropin ( -HCG) pregnancy  test for female 
subjects of childbearing potential only
12-lead electrocardiogram (ECG)
Echocardiogram (ECHO) 
Imaging studies (extramedullary  disease for MM if indicated, or CT/PET scan for
lymphomas)
For MM: BM aspirate for FISH, BCMA (flow cytometry ), PD (target engagement 
and caspase 3) ; BCMA expression (I HC)
For MM: BM biops y for disease assessment 
For Lym phomas : archival or fresh tissue evaluation for BCMA expression
Review of concomit ant medications
Procedures conducted as part of the subject’s routine clinical management (e.g., blood 
count, imaging stud y) and obtained prior to signing of informed consent may be utilized 
for Screening or baseline purposes provided the procedure meets t he protocol -defined 
criteria and has been performed in the timeframe of the study .
7.2.1. Critical Baseline Assessments
Cardiovascular medical history /risk factors will be assessed at baseline.
7.3. Safet y Evaluations
Planned time points for all safety  assessments are provided in the Time and Events 
Tables (Section 7.1).
2012N155299_05 CONFIDENTIA L
BMA117159
1197.3.1. Physical Examinations
At screening and on dosing day s, a full phy sical examination will include assessments of 
the head, ey es, ears, nose, throat, skin, thy roid, lungs, cardiovascular, abdomen (liver and 
spleen), l ymph nodes and extremities.  Height and weight will also be measured and 
recorded.
During interim visits and at the end of stud y, a brief ph ysical examination will include 
assessments of the skin, l ungs, cardiovascular s ystem, and abdomen (liver and spleen).
7.3.2. ECOG Performance Status
The performance status will be assessed using the Eastern Cooperative Oncology  Group 
(ECOG) scale ( Appendix 6 ) as specified in th e Time and Events Tables (Section 7.1).
7.3.3. Vital Signs
Vital sign measurements will include sy stolic and diastolic blood pressure, temperature, 
and pulse rate.  Vital signs should be measured after resting for at l east 5 minutes.  Vital 
signs will be measured more frequentl y if warranted by the clinical condition of the 
subject.  On day s where vital signs are measured multiple times, temperature does not 
need to be repeated unless clinically indicated.  
First Infus ion:
Monitoring intervals:  Vital signs must be monitored at predose (within 30 minutes prior 
to start of infusion), +10 and +30 minutes post start of infusion, and at the end of 
infusion, and 1 hour post end of infusion.  In general, subjects must also be monitored for 
at least 1 hour after the completion of the first infusion and may  be discharged if 
considered clinically  stable and all other study  procedures have been completed.  
Sentinel subject:  Subject must be monitored for at least 24 hours post fi rst infusion.
Subsequent subjects:  Subjects may  be discharged if considered clinically  stable and all 
other study  procedures have been completed.  
Subsequent Infusions:
Monitoring intervals:  Vital signs must be monitored at predose (within 30 minutes pr ior 
to start of infusion), +30 minutes post start of infusion, and at the end of infusion. 
Subjects may  be discharged after the infusion has been completed if considered clinically  
stable and all other stud y procedures have been completed.  
In case of in fusion related reactions or cy tokine storm, monitoring will be performed with 
higher frequency  (as clinically  indicated).
7.3.4. Electrocardiogram
Triple 12- lead electrocardiogram (ECGs) will be obtained at designated time points 
specified in the Time and Events Tables (Section 7.1) during the study  using an ECG 
2012N155299_05 CONFIDENTIA L
BMA117159
120machine that automatically  calculates the heart rate and measures PR, QRS, QT, and 
corrected QT (QTc) intervals.  At each assessment a 12 -lead ECG will be perf ormed b y 
qualified personnel at the site after the subject has at least a 5 minute rest.  
The QT interval should be corrected for heart rate by  Fridericia’s formula (QTcF).  Refer 
to Section 3.9.2 for QTc withd rawal criteria.  Refer to the Study  Procedures Manual 
(SPM) for details regarding ECG procedures.
7.3.5. Echocardiogram
Echocardiograms (ECHOs) will be performed at baseline to assess cardiac ejection 
fraction and cardiac valve morphology  for the purpose of study eligibility , as specified in 
the Time and Events Tables (Section 7.1).  Additional ECHO assessments will be 
performed at specified timepoints indicated in the Time and Events Tables (Section 7.1) 
or if clinically  warranted.  The evaluation of the echocardiographer should include an 
evaluation for left ventricular ejection fraction (LVEF) and both right and left -sided 
valvular lesions.
Copies of all ECHOs performed on subjects will be stored in a central location if further 
evaluation is warranted. 
7.3.6. Ocular Exam
An ocular exam to include BCVA (best -corrected visual acquity ), slit lamp examination 
(with special focus on the cornea), intraocular pressure, and dilated fundu scopic 
examination will be conducte d for all subjects at screening. Additional exams will be 
performed as specified in the Time and Events Tables (Section 7.1) during the treatment 
period and at monthly  follow -up visits as clinically  indicated.
7.3.7. Laboratory  Assessments
All protocol required laboratory  assessments, as defined in ( Table 15), should be 
performed according to the Time and Events Tables (Section 7.1).  Details for the 
preparation and shipment of samples will be provided in the SPM.
Prior to administration of the first dose of stud y treatment, results of laboratory 
assessments should be reviewed.  An y laboratory  test w ith a value outside the normal 
range may  be repeated (prior to the first dose) at the discretion of the investigator.
If additional non -protocol specified laboratory  assessments are performed at the 
institution’s local laboratory  and result in a change in patient management or are 
considered clinical significant by the Investigator (for example SAE or AE or dose 
modification) the results must be recorded in the subject’s CRF. Refer to the SPM for 
appropriate processing and handling of samples to avoid dupl icate and/or additional 
blood draws. 
All laboratory  tests with values that are significantly  abnormal during participation in the 
study  or within 30 day s after the last dose of stud y treatment should be repeated until the 
values return to normal or baseli ne.  If such values do not return to normal within a 
period judged reasonable by  the investigator, the etiology  should be identified and the 
sponsor notified.
2012N155299_05 CONFIDENTIA L
BMA117159
121Hematology , clinical chemistry , urinal ysis and additional parameters to be tested are 
listed in Table 15 :
Table 15 List of Clinical Laboratory  Tests
Hematology
Platelet Count RBC Indices : Automated WBC Differential :
Red blood cell (RBC) Count MCV Neutrophils
White blood cell (WBC) C ount 
(absolute) MCH Lymphocytes
Reticulocyte Count MCHC Monocytes
Hemoglobin Eosinophils
Hematocrit Basophils
Clinical Chemistry
Blood urea nitrogen 
(BUN)Potassium Aspartate aminotransferase 
(AST)Total and direct bilirubin
Creatinine Chloride Alanine aminotransferase 
(ALT)Uric Acid
Glucose Total carbon 
dioxide (CO 2)Gamma glutamyl transferase 
(GGT)Albumin
Sodium Calcium Alkaline phosphatase Total Protein
Magnesium Phosphorous Creatine kinase (CK) LDH
Routine Urinalysis
Specific gravity
pH, glucose, protein, blood and ketones by dipstick
Microscopic examination (if blood or protein is abnormal)
24-hour urine protein and albumin
Other screening tests
Hepatitis B (HBsAg)
Hepatitis C (Hep C antibody --if second generation Hepatitis C ant ibody positive, a hepatitis C antibody 
Chiron RIBA immunoblot assay or a validated HCV PCR viral test should be reflexively performed on the 
same sample to confirm the result) 
Follicle stimulating hormone (FSH) and estradiol (as needed in women of non -child bearing potential only)
FISH analysis1
Other Laboratory Tests
Troponin PTT INR IgG, IgM, IgA
CK-MB B-type natriuretic 
peptideC-reactive protein (CRP) Beta2 microglobulin
Kappa, lambda free LC, 
FLC ratioADA PGx2 Immunofixation
Serum Protein 
Electrophoresis (SPEP) 
and Serum M -protein 
calculationUrine Protein 
Electrophoresis (UPEP)
Biomarker Measurements
BCMA/sBCMA Caspase 3 Serum 
cytokines/chemokinescfDNA
1.FISH testing at least for: t(4;14), t(14/16), 17p13del.  Biopsy samples from wi thin 60 days prior to first dose are 
acceptable.
2.  Samples to be collected from subjects in expansion cohorts only.
2012N155299_05 CONFIDENTIA L
BMA117159
1227.3.8. Pregnancy  Testing and Reporting
The need for a screening pregnancy  test depends on whether a female subject is of 
childbearing potential o r non -childbearing potential.
If a female subject is of childbearing potential, she must have a serum -HCG pregnancy 
test performed within 14 day s prior to the first dose of study  treatment.  Subjects with 
positive pregnancy  test result must be excluded f rom the study .  Subjects with negative 
pregnancy  test result must agree to use an effective contraception method as described 
below during the study  until 60 day s following the last dose of stud y treatment(s).
Any pregnancy  that occurs during stud y partici pation must be reported using a clinical 
trial pregnancy  form.  To ensure subject safet y, each pregnancy  must be reported to GSK 
within 2 weeks of learning of its occurrence.  The pregnancy  must be followed up to 
determine outcome (including premature term ination) and status of mother and child.  
Pregnancy  complications and elective terminations for medical reasons must be reported 
as an adverse event (AE) or serious adverse event (SAE).  Spontaneous abortions must be 
reported as an SAE.
Any SAE occurring i n association with a pregnancy  brought to the investigator’s 
attention after the subject has completed the stud y and considered b y the investigator as 
possibly  related to the study  treatment, must be promptly  reported to GSK.
In addition, the investigator must attempt to collect pregnancy  information on any  female 
partners of male study  subjects who become pregnant while the subject is enrolled in the 
study .  Pregnancy  information must be reported to GSK as described above.
7.3.9. Immunogenicity
Serum samples for determination of anti -GSK2857916 antibodies will be taken from all 
subjects in this study  at the time -points specified in the Time and Events Tables in 
Section 7.1.  Timing of the assessments may  be adjusted bas ed on emerging data.   Details 
ofsample preparation, storage and anal ysis will be provided in the SPM.
Samples will be ana lyzed for the presence of anti- GSK2857916 antibodies by  a validated 
electrochemiluminescen t immunoassay . All samples will be tested by a screening assay ,
and positive samples will be further characterized for specificity  and antibody  titers. 
7.3.10. Visual Functioning Questionnaires
The impact of potential ocular toxicity on function and health -related quality  of life will 
be assessed with the use of 2 visual function questionnaires: the National Ey e Institute 
Visual Function ingQuestionnaire -25 (NE I VFQ -25), and the Ocular Surface Disease 
Index (OSDI).  S ubjects will complete the self -administered version sof these two 
assessments during thei r End of Study  Treatment visit.  Subjects who are unable to 
complete the questionnaire on their own due to blurry  vision, and require assistance can 
have the questionnaire read to them by  an interviewer .  If the questionnaires are 
2012N155299_05 CONFIDENTIA L
BMA117159
123administrated by  an Inter viewer , then the questionnaire should be read to the subjects 
verbatim, and subject responses should be recorded directly  without any  interpretation.  
Subjects who continue to experience visual s ymptoms after discontinuation of study  
treatment will complete additional interviewer -administered assessments via telephone on 
a monthly  basis for up to 1 y ear during the Follow -up period or until the resolution of 
their visual sy mptoms , whichever comes first .
7.3.10.1. National Eye Institute Visual Functioning Questionna ire-25
The NEI -VFQ -25 consists of a base set of 25 vision- targeted questions representing 11 
vision -related constructs, plus an additional single -item general health rating question 
[Mangione, 2001 ].  The NEIVFQ -25 generates the following vision- targeted sub- scales:  
global vision rating , difficulty  with near vision activities; difficulty  with distance vision 
activities; limitations in social functioning due to vision; role limitations due to vision; 
dependency  on others due to vision; mental health sy mptom s due to vision; driving 
difficulties; limitations with peripheral vision, limitations with color vision; and corneal 
pain.  
7.3.10.2. Ocular Surface Disease Index Questionnaire
The Ocular Surface Disease Index (OSDI) is a 12 -item questionnaire designed to assess 
both the frequency  of dry ey e symptoms and their impact on visio n-related functioning 
[Schiffman, 2000]. The OSDI  has demonstrated good reliability , validity , sensitivity , and 
specificit y, and can be used as a complement to other clinical and subjective me asures of 
dry eye disease b y providing a quantifiable assessment of dry eye s ymptom frequency  
and the impact of these symptoms on vision- related functioning.
7.4. Pharmacokinetics
7.4.1. Blood Sample Collection for Pharmacokinetics
Blood samples of approximately  5mLfor pharmacokinetic (PK) anal ysis of 
GSK2857916 (ADC and total antibody ) and cy s-mcMMAF will be collected at the time 
points indicated in the Time and Events Tables (Section 7.1).  Each PK sample should be 
collected as close as possible to the planned time relative to the dose (i.e., time zero) 
administered to the subject on PK day s.  The actual date and time of each blood sample 
collection will be recorded.
Details on PK blood sample collection, processing, sto rage and shipping procedures are 
provided in the Study  Procedures Manual (SPM).   Blood volumes for PK samples are 
outlined in Appendix 10 (Section 16.9).
2012N155299_05 CONFIDENTIA L
BMA117159
1247.4.2. Urine Sample Collection for Pharmacokinetics
Urine samples of approximately  1 mL for pharmacokinetic (PK) anal ysis of cy s-
mcMMAF will be collected from the 24 hour urine collection sample as scheduled in the 
Dose Escalation Time and Events Tables (Section 7.1.1 ).  The actual date and time of 
each urine sample collection as well as the urine volume collected will be recorded.  In 
addition for qualitative analy sis of any  metabolite(s) approximately  20mL of control is 
required prior to dosing and a 400mL  aliquot as described in the Time and Events 
Schedules (Section 7.1.1 )
Details on PK urine sample collection, processing, storage and shipping procedures are 
provided in the Study  Procedures Manual (SPM).
7.4.3. Pharmacokinetic Sample A nalysis
Plasma and urine analy sis will be performed under the control of GSK Platform 
Technologies and Science (PTS) Drug Metabolism and Pharmacokinetics ( DMPK), the 
details of which will be included in the Study  Procedures Manual.  Concentrations of 
GSK2857916 (ADC and total antibody ) and cy s-mcMMAF will be determined in plasma 
and urine (cy s-mcMMAF) samples using the currently  approved bioanaly tical 
methodology .  Raw data will be archived at the bioanal ytical site (detailed in the Study  
Procedures Manual).
Once the plasma and urine has been anal ysed for GSK2857916 (ADC and total antibody ) 
and cy s-mcMMAF any remaining plasma or urine may  be anal ysed for other compound -
related metabolites and the results reported under a separate GSK PTS- DMPK protocol.
7.5. Translational Research
7.5.1. Pharmacody namics
Blood, bone marrow, and tumor tissue samples will be collected during this study  and 
analysed pre and post GSK2857916 at the time points indicated in the Time and Events 
Tables (Section 7.1) to investigate pharmacody namic response to GSK2857916.  The 
timing of the collections may  be adjusted on the basis of emerging PK or 
pharmacod ynamic data from this study  or other new information in order to ensure 
optimal evaluation of the pharmacod ynamic endpoints.  Details on PD blood and bone 
marrow sample collection, processing, storage and shipping procedures are provided in 
the SPM.
Pharmacod ynamic markers may include but will not be limited to the following:
Bone marrow anal ysis of plasma cell BCMA receptor expression by  flow cytometry .  
Flow cytometry measurements to include assessment of free and GSK2857916 drug 
bound receptors as well as measures of cell cy cle/apoptosis  
Additional soluble measurements to include serum level s of free sBCMA and 
sBCMA complexed to GSK2857916 
2012N155299_05 CONFIDENTIA L
BMA117159
125Whole blood count of mononuclear cells (PBMC) and their activation status and 
intracellular cy tokine profile .
Soluble factors, including cy tokine/chemokine analy sis of serum
RNA/DNA and protein analy sis of bone marrow, tumor tissue and blood
7.5.1.1. BCMA  Receptor Occupancy in bone marro w plasma cells
To monitor target engagement, bone marrow aspirates will be evaluated by  flow 
cytometry  for enumeration of plasma cell numbers of free BCMA receptors and the 
number of GSK2857916 bound receptors, BCMA cell cy cle markers, as well as apoptosis 
markers on tumor cells to understand anti -tumor responses.  Flow cy tometry markers 
may include but not be limited to:  BCMA, CD138, CD38, CD45, MMAF, CC3, PH3, 
and MPM -2.  
7.5.1.2. sBCMA  Analysis
Target engagement with soluble BCMA will be assessed.  Serum will be collected to 
measure concentrations of free and GSK2857916 bound sBCMA at the timepoints 
specified in the Time and Events Tables (refer to Section 7.1).
7.5.1.3. Activated TBNK cells
Whole blood will be collected and anal yzed for % and absolute counts of monocy tes, T, 
B and NK cells as well as the expression of activation markers CD107 and CD69 on 
these cell t ypes.
7.5.1.4. Cytokine and Chemokine A nalysis
Clusters of mark ers circulating in the blood have been found to correlate with tumor 
pathway  activation.  A broad panel of cy tokines/chemokines will be evaluated at various 
timepoints as outlined in the Time and Events table (Section 7.1) and correlated with 
clinical outcome to treatment with GSK2857916. In addition to measuring total cy tokine 
levels in serum, activated ly mphocy tes and monocy tes producing involved in the 
cytokine production will be determined via intracellular c ytokine assay . 
7.5.2. Subject stratification/predictive biomarkers
BCMA exhi bits varied expression across B -cell hematologic malignancies and therefore, 
BCMA expression levels at baseline may  be an important predictor of response to 
GSK2857916. To evaluate wheth er BCMA expression has utility  in patient stratification
or selection, malignant plasma cells at baseline will be measured for BCMA expression 
by IHC and/or flow cy tometry .  Because BCMA can also be detected in circulation, the 
soluble form (sBCMA) has the potential to serve as a surrogate for cell surface BCMA 
marker expression. This study  will correlate subject’s sBCMA levels with cell surface 
expression and clinical response to support future validation of sBCMA as a patient 
selection marker, if data war rant. In addition baseline measurements of peripheral blood 
mononuclear cells and cytokines/chemokines will help inform on subject immune status.
2012N155299_05 CONFIDENTIA L
BMA117159
126Blood and bone marrow samples will be collected during this study  and may  be used for 
the purposes of measurin g novel biomarkers to identify  factors that may  influence 
advanced multiple my eloma, hematological malignancies and/or medicall y related 
conditions, as well as the biological and clinical responses to GSK2857916.   If relevant, 
this approach may  be extended to include the identification of biomarkers associated with 
AEs.
Unless stated otherwise, these investigations may  be performed irrespective of whether a 
response to GSK2857916 is observed.
Samples will be collected at the time points indicated in the Tim e and Events Tables 
Section 7.1.  The timing of the collections may  be adjusted on the basis of emerging PK 
or pharmacod ynamic data from this study or other new information in order to ensure 
optimal evaluation of the pharmacod ynamic endpoints.  Novel candidate biomarkers and 
subsequently  discovered biomarkers of the biological response associated with advanced 
multiple my eloma, lymphomas and/or medicall y related conditions, as well as the 
biological and clinical responses to GSK2857916 may  also be evaluated.  These anal yses 
may include but not be limited to:
Tumor /plasma cell BCMA receptor expression b y flow cytometry and/or IHC.    
Soluble factors, including circulating cfDNA analy sisof tumor tissue and plasma and 
cytokine/chemokine analy sis of plasma
Additional soluble measurements to include serum levels of free sBCMA 
Activated PBMC count analy sis of whole blood and intracellular cy tokine assessment
RNA/DNA/gene and protein anal ysis of tumor tissue
7.5.3. Tumor Bi omarker A nalysis
In order to further characterize the subject population biomarkers (e.g. expression of 
genes and proteins) related to the activity  of the investigational compound will be 
assessed in baseline tissue and pre and post treatment biopsies as w ell as cf -DNA 
obtained at disease progression. 
BCMA expression in the plasma cells of bone marrow aspirates or treph ines will be 
evaluated at baseline b y IHC and/or flow cy tometry  for plasma cell expression of free 
BCMA receptors.  IHC and flow cy tometry  markers may  include but not be limited to:  
BCMA, Blimp1, CD138, and CD38.  Additionally, bone marrow tumor tissue may  be 
evaluated for an y DNA /RNA changes correlating with response.
7.5.3.1. Circulating cell free DNA  (cfDNA ) analy sis
Additionally , bone marrow tum or tissue may  be evaluated for any  DNA/RNA changes 
correlating with response.  Tumor – specific circulating nucleic acid (cfDNA) levels 
detected in plasma or serum have been found to correlate with increasing tumor burden 
and decline following therap y.  Furthermore, cfD NA in cancer subjects can harbo r man y 
2012N155299_05 CONFIDENTIA L
BMA117159
127genetic alterations (mutations, microsatellite alterations, aberrant meth ylation), which are 
generall y consistent with the tumor.  Thus, tumor -specific circulating cfDNA has the 
potential to be a useful bi omarker of therapeutic response as well as offering a less 
invasive blood based technique for identify ing and selecting subjects for certain 
treatments.  Given the promise of cfDNA blood based test for subject selection, this test 
will be explored to determine whether mutations in cfDNA correlate with that in the 
tumor tissue from which it is derived.  This test will also be explored to correlate 
increasing cfDNA levels with increasing tumour burden.  
7.6. Genetics
An important exploratory objective of the clin ical study  is genetic research.  Participation 
in genetics research is optional but all subjects who are eligible for the clinical study  and 
are enrolled into part 2 (expansion cohort) will be given the opportunity  to participate.  
Subjects may  decline par ticipation without effect on their medical care or care during the 
clinical study .  A separate consent signature is required for genetic research.
Information regarding genetic research is included in Appendix 7 .  In approving the 
clinical protocol the IEC/IRB and, where required, the applicable regulatory agency  are 
also approving the genetic research described in Appendix 7 unless otherwise indicated.  
Where required b y regulatory  authorities, approval of the genetic assessments can occur 
after approval is obtained for the rest of the study .  If so, then the written approval will 
clearl y indicate approval of the genetic assessments is being deferred and the study , 
except fo r genetic assessments, can be initiated.  When genetic assessments will not be 
approved, then the approval for the rest of the study  will clearl y indicate this and 
therefore, genetic assessments will not be conducted.
7.7. Evaluation of A nti-Cancer Activity
Standard disease assessments for MM will include laboratory  tests, bone marrow aspirate 
(cytology ,flow cy tometry , FLC, etc.) and Bone Marrow biops y for BCMA expression 
(IHC) during screening and at the time of CR.  Evaluation will be according to the 
Interna tional M yeloma Working Group Uniform Response Criteria for Multiple 
Mye loma ( Appendix 1 ).  Disease assessment for subjects with lymphomas will be 
evaluated at screening and every  9 weeks (for subjects on every  3 we ek dosing schedule) 
or every  8 weeks (for subjects on weekl y dosing schedule), and at the end of study.  
Disease assessment for subjects with lymphomas will be according to the Revised 
Response Criteria for Malignant Ly m phoma ( Appendix 2 ).
Clinical activity  measured as Overall Response Rate (ORR) which is defined as 
follows:
For MM: the percentage of subjects with confirmed stringent complete response 
(sCR), complete response (CR), very  good partial response (VGPR ), and partial 
response (PR) as assessed by  2011 recommendation of the International 
Mye loma Working Group (IMWG) Panel I ( Appendix 1 ).  Other comparisons of 
interest may  be considered (see Section 13.5.2 ) 
2012N155299_05 CONFIDENTIA L
BMA117159
128For l ymphomas: the percentage of subjects with confirmed CR, PR, as described 
in the Revised Response Criteria for Malignant Lymphoma ( Appendix 2 ). 
Disease assessment may  include imaging (e.g., computed tomograph y [CT] scan, 
magnetic resonance imaging [MRI ], bone scan, plain radiograph y) and ph ysical 
examination (as indicated for palpable/superficial lesions). Disease assessment will be 
complet ed within 4 weeks prior to the f irst dose of GSK2857916 then every 8 or 9 weeks 
thereafter, and at the final study  visit.  See the Time and Events Tables (Section 7.1) for 
the schedule of assessments of anti -cancer activity.  Assessments must be performed on a 
calendar schedule and should not be affected b y dose interruptions/delay s.  For post -
baseline assessments, a window of  3 day sis permitted to allow for flexible scheduling 
with the exception of dose administration day s where a window of 3 day s for Schedule 
1 (once every  3 weeks) is permitted and 1 day  for Schedule 2 (weekl y) is permitted.  If 
the last radiographic assessment was more than 8 or 9 weeks prior to the subject’s 
withdrawal from study  and progressive disease has not been documented, a disease 
assessment should be obtained at the time of withdrawal from study .
7.8. Health Outcomes: Quality  of Life
7.8.1. Bone Pain/Fatigue A ssessment (eDiary )
The patient reported outcome (PRO) instruments that will be used are the Bone 
Pain/Fatigue Assessment via an e -Diary .In the Part 2 multiple my eloma cohort, the 
implementation of this assessment will occur upon availability  of the instruments. 
Bone Pain/Fatigue Assessment: Bone pain burden will be measured b y e-Diary  consisting 
of certain modified qu estions from Brief Pain Inventory -Short Form (BPI -SF) which 
assesses pain intensity  and the interference of pain with daily  life [ Atkinson, 2010;
Cleeland, 1994] and Brief Fatigue Inventory  (BFI) [ Cleeland, 2010]. The BPI -SF is one 
of the most frequentl y used pain assessments [ Cleeland, 2009] and has been used in 
various disease areas, including cancer pain and neuropathic pain [ Daut , 198 2; 
McDowell , 1996]. The questionnaire has demonstrated both reliability  and validity  across 
cultures and languages [ Cleeland, 1994]. The BFI has also been used in cancer patients to 
measure fatigue [ Mendoza , 1999 ; Chang , 2007 ].
Bone pain and fatigue burden will be measured b y an e -Diary  consisting of 7 short 
questions, including 4 questions to assess pain intensity  (severity ) and one question to 
assess the interference of pain with daily  life activities. The items ask about pain 
experienced within the last 24 hours. It also includes 2 questions on use of pain 
medication. Fatigue will be measured b y 2 short questions – one to assess the level of 
fatigue in the past 24 hours and the second to assess the interference of fatigue with 
general activity . Data from this e -Diary  will be used to understand and characterize 
pain/fatigue experience and explore time to potential pain relief while controlling for the 
use of pain medication.
It is expected that the improvement in intensity  of bone pain/fatigue and the impact of 
bone pain/fatigue on general activity  will take place within the first 8 cy cles of treatment 
2012N155299_05 CONFIDENTIA L
BMA117159
129and the self -completion of the e -Diary  during this period will accuratel y capture the 
changes in bone pain/fatigue.
Upon availability  of the Bone Pain/Fatigue Assessment e -Diary , MM subjects will self -
complete the assessments at the following times:
Starting 2- 4 day s prior to Cy cle 1 Day  1
Daily  from Day 1 through Day  8 for eac h Cycle to time of study  treatment 
discontinuation
Day 15 of each C ycle to time of study  treatment discontinuation
Study  Treatment Discontinuation visit
7.8.2. Exit Interview  and Follow -up Interview
To further evaluate disease and treatment related sy mptoms (including bone pain and 
fatigue, and visual s ymptoms) and associated impacts on function and health -related 
quality -of-life, participants in the Part 2 multiple my eloma cohort will complete an 
optional Exit I nterview conducted via te lephone.  The interview will be conducted by  a 
trained interviewer and will be audio recorded for transcription and anal ysis.  The 
telephone interview should be conducted within 21days following completion of the End 
of Study  Treatment visit.
Subjects who have experienced ocular s ymptoms during the treatment period will have 
the option to also consent to participate in an optional Follow- up interview.  The Follow -
up interview will be conducted b y a trained interview via telephone at least 6 months 
following the End of Study  Treatment visit.  The Follow -up interview will focus on 
visual sy mptoms experienced b y the subject, impacts on function and health -related 
quality -of-life and management and resolution of their visual sy mptoms following 
discontinuation of study  treatment .
Both the Exit I nterview and Follow -Up interview are optional, and the failure to complete 
either interview will not constitute a protocol deviation.
8. ADVERSE EVENTS A ND S ERIOUS ADVERSE EVENT S
The investigator or site staff will be responsible for detecting, documenting and reporting 
events that meet the definition of an adverse event (AE) or serious adverse event (SAE) 
as outlined in Section 8.1and Section 8.2, respectively .
8.1. Definition of an A E
Any untoward medical occurrence in a subject or clinical investigation subject, 
temporally  associated with the use of a medicinal product, whether or not considered 
related to the medicinal product.
Note: An a dverse event (AE) can therefore be any unfavorable and unintended sign 
(including an abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) 
2012N155299_05 CONFIDENTIA L
BMA117159
130temporally  associated with the use of a medicinal product.  For marketed medicinal 
products, this also includes failure to produce expected benefits, abuse, or misuse. 
Examples of events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or grade of the c ondition
New conditions detected or diagnosed after stud y treatment administration even 
though it may  have been present prior to the start of the study
Signs, sy mptoms, or the clinical sequelae of a suspected interaction
Signs, sy mptoms, or the clinical se quelae of a suspected overdose of either study  
treatment or a concomitant medication (overdose per se will not be reported as an 
AE/serious adverse event [SAE]). 
“Lack of efficacy ” or “failure of expected pharmacological action” per se is not to be 
repor ted as an AE or SAE.  However, an y signs and sy mptoms and/or clinical sequelae 
resulting from “lack of efficacy ” will be reported as an AE or SAE, if they  fulfill the 
definition of an AE or SAE. 
Events that do not meet the definition of an AE include:
Medical or surgical procedure (e.g., endoscop y, appendectom y); the condition that 
led to the procedure is an AE.
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuat ions of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
The disease/disorder being studied, or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the subject’s 
condition.
8.2. Definition of an SAE
A serious adverse event (SAE) is any  untoward medical occurrence that, at any  dose:
a.Results in death
b.Is life -threatening
NOTE:   The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the subject was at risk of death at the time of the event.  It does not refer to an 
event, which h ypothetically  might have caused death, if it were more severe.
c.Requires hospitalization or prolongation of existing hospitalization
NOTE:   In general, hospitalization signifies that the subject has been detained 
(usually  involving at least an overnight stay ) at the hospital or emergency  ward for 
observation and/or treatment that would not have been appropriate in the phy sician’s 
office or out -subject setting. Complications that occur during hospitalization are 
adverse events (AEs). If a complication prolongs hospitalization or fulfills any  other 
2012N155299_05 CONFIDENTIA L
BMA117159
131serious criteria, the event is serious.  When in doubt as to whether “hospitalization” 
occurred or was necessary , the AE should be considered serious.
Hospitalization for elective treatment of a pre-existing condition that did not worsen 
from baseline is not considered an AE.
d.Results in disability /incapacity , or
NOTE:   The term disability  means a substa ntial disruption of a person’s ability  to 
conduct normal life functions.  This definition is not intended to include experiences 
of relativel y minor medical significance such as uncomplicated headache, nausea, 
vomiting, diarrhea, influenza, and accidental trauma (e.g. sprained ankle) which may  
interfere or prevent everyday  life functions but do not constitute a substantial 
disruption.
e.Is a congenital anomal y/birth defect. 
f.Medical or scientific judgment should be exercised in deciding whether reporting 
is appropriate in other situations, such as important medical events that may not 
be immediately  life-threatening or result in death or hospitalization but may  
jeopardize the subject or may  require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition.  These should also be 
considered serious.  Examples of such events are invasive or malignant cancers, 
intensive treatment in an emergency  room or at home for allergic bronchospasm, 
blood dy scrasias or convulsions tha t do not result in hospitalization, or 
development of drug dependency  or drug abuse.
g.Protocol -Specific SAEs:
All events of possible study  treatment -induced liver injury  with 
hyperbilirubinemia defined as alanine aminotransferase (ALT) 3 times upper 
limit of normal (UL N) and bilirubin ≥2 times ULN (>35% direct) (or 
ALT≥3times ULN and international normalization ratio (INR) >1.5, if INR is 
measured) or termed ‘Hy’s Law’ events (INR measurement is not required and 
the threshold value stated will not apply  to patients receivin g anticoagulants).
NOTE:   Bilirubin fractionation should be performed.
Any new primary  cancers
8.2.1. Sentinel Events
A Sentinel Event is a GSK- defined SAE that is not necessaril y drug -related but has been 
associated historicall y with adverse reactions for other drugs and is therefore worth y of 
heightened pharmacovigilance.  The GSK Medical Monitor is accountable for reviewing 
all SAEs for possible Sentinel Events which is mandated at GSK.  The GSK medical 
monitor may  request additional clinical information on an urgent basis if a possible 
Sentinel Event is identified on SAE review.  The current GSK- defined Sentinel Events 
are listed below:
Acquired Long QT Sy ndrome
Agranulocy tosis/Severe Neutropenia 
2012N155299_05 CONFIDENTIA L
BMA117159
132Anaph ylaxis & Anaph ylactoid Reactions 
Hepatotoxicity
Acute Rena l Failure
Seizure
Stevens Johnson sy ndrome/Toxic epidermal necrosis
8.3. Laboratory  and Other Safety  Assessment A bnormalities 
Reported as A Es and SA Es
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis), or 
other safet y assessme nts (e.g., electrocardiogram [ECGs], radiological scans, vital signs 
measurements) including those that worsen from baseline, and events felt to be clinically  
significant in the medical and scientific judgment of the investigator are to be recorded as 
an adverse event (AE) or serious adverse event (SAE), in accordance with the definitions 
provided.
In addition, an associated AE or SAE is to be recorded for an y laboratory  test result or 
other safet y assessment that led to an intervention, including permanent discontinuation 
of study  treatment, dose reduction, and/or dose interruption/delay .
Any new primary  cancer must be reported as a SAE. 
However, an y clinicall y significant safet y assessments that are associated with the 
underly ing disease, unless judged by the investigator to be more severe than expected for 
the subject's condition, are not to be reported as AEs or SAEs.
8.3.1. Cardiovascular Events
Investigators will be required to fill out event specific data collection tools for the 
following AEs and SAEs:  
Myocardial infarction/unstable angina
Congestive heart failure
Arrh ythmias
Valvulopathy
Pulmonary  hypertension
Cerebrovascular events/stroke and transient ischemic attack
Peripheral arterial thromboembolism
Deep venous thrombosis/pulmonary  embolism
Revascula risation
This information should be recorded in the specific cardiovascular eCRF within one week 
of when the AE/SAE(s) are first reported.
2012N155299_05 CONFIDENTIA L
BMA117159
1338.4. Disease -Related Events and/or Disease -Related Outcomes 
Not Qualify ing as SAEs
An event which is part of the natural course of the disease under stud y (i.e., disease 
progression or hospitalization due to disease progression) does not need to be reported as 
a serious adverse event (SAE).  Death due to disease under stud y is to be recorded on the 
Death electronic case report form (eCRF).  However, if the underly ing disease (i.e., 
progression) is greater than that which would normally  be expected for the subject, or if 
the investigator considers that there was a causal relationship between treatment with 
study  treatment(s) or protocol design or procedures and the disease progression, then this 
must be reported as a SAE.
8.5. Time Period and Frequency  of Detecting AEs and SA Es
The investigator or site staff is responsible for detecting, documenting and reporting 
events that meet the definition of an adverse event (AE) or serious adverse event (SAE). 
AEs will be collected from the time the first dose of study  treatment is administered until 
30 day s following discontinuation of study  treatment regardless of initiation of a new 
cancer therapy  or transfer to hospice. 
SAEs will be collected over the same time period as stated above for AEs.  In addition, 
any SAE assessed as related to study  participation (e.g., protocol- mandated procedures, 
invasive tests, or change in existing therap y),study  treatment or GSK concomitant 
medication must be recorded from the time a subject consents to participate in the study  
up to and including an y follow -up contact.  All SAEs will be reported to GSK within 
24 hours, as indicated in Section 8.5.2 .
After discontinuation of study  treatment, the investigator will monitor all AEs/SAEs that 
are ongoing until resolution or stabilization of the event or until the subject is lost to 
follow -up.  At an y time after 30 day s the investigator may  report an y AE that they  
believe possibly  related to study  treatment.   
8.5.1. Method of Detecting A Es and SA Es
Care must be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended 
and non-leading verbal questioning of the subject is the preferred method to inquire about 
AE occurrence. Appropriate questions include:
“How are you feeling?” 
“Have you had an y (other) medical problems since y our last visit/contact?” or for 
pediatric studies, “Has your child had an y (other) medica l problems or seem to act 
differentl y in an y wa y since his/her last visit/contact?”
“Have you taken an y new medicines, other than those provided in this study , since your 
last visit/contact?” or for pediatric studies, ”Has your child needed to take any medicines, 
other than those provided in this study , since his/her last visit/contact?”
2012N155299_05 CONFIDENTIA L
BMA117159
1348.5.2. Prompt Reporting of SA Es and Other Events to GSK
Serious adverse events (SAEs), pregnancies, and liver function abnormalities and an y 
other events meeting pre -defined crite ria will be reported promptly  by the investigator to 
GSK as described in the following table once the investigator determines the event meets 
the protocol definition for that event.
Initial Reports Follow -up Information on a Previous 
Report
Type of Even t Time Frame Documents Time Frame Documents
All SAEs 24 hours SAE data collection 
tool24 hours Updated SAE data 
collection tool 
“CV events” and/or 
“death”Initial and 
follow up 
reports to be 
completed 
within one 
week of when 
the 
cardiovascular 
event or death 
is reported“CV events” 
and/or “death” 
data collection 
tool(s) if 
applicableInitial and follow 
up reports to be 
completed within 
one week of when 
the cardiovascular 
event or death is 
reportedUpdated “CV 
events” and/or 
“death” data 
collection tool (s) if 
applicable
Pregnancy 2 Weeks Pregnancy 
Notification Form2 Weeks Pregnancy 
Follow -up Form
Liver chemistry abnormalities:
ALT 3 times ULN and 
bilirubin 2 times ULN 
(>35% direct) (or ALT 
3 times ULN and INR 
>1.5, if INR is 
measured)c24 hoursa SAE data collection 
tool;
Liver Event eCRF 
and liver imaging 
and/or biopsy 
eCRFs if 
applicableb24 hours Updated SAE data 
collection tool. 
Updated Liver Event 
eCRFb
ALT 5 times ULN; ALT 
3 times ULN with 
hepatitis or rash or 3 
times ULN 4weeks24 hoursa Liver Event eCRFb 24 hours Updated Liver Event 
eCRFb
ALT 3 times ULN and 
<5 times ULN and 
bilirubin <2 times ULN24 hoursa Liver Event eCRF 
does not need to be 
completed unless 
elevations persist 
for 4 weeks or 
subject cannot be 
monitored weekly 
for 4 weeksb
a. GSK to be notified at onset of liver chemistry elevations to discuss subject safety.
b. Liver event documents should be completed as soon as possible
c. INR measurement is not required; if measured, the threshold value stated will not apply to subjects receiving 
anticoagulants.
2012N155299_05 CONFIDENTIA L
BMA117159
135Methods for detecting, recording, evaluating, and following up on adverse events (AEs) 
and serious adverse events (SAEs) are provided in the Study  Procedures Manual (SPM).
8.5.3. Regulatory  reporting requirements for SA Es
Prompt notifi cation of serious adverse events (SAEs) by the investigator to GSK is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects are met.
GSK has a legal responsibility  to notify  both the local regulatory  authorit y and other 
regulatory  agencies about the safet y of a product under clinical investigation.  GSK will 
comply  with country  specific regulatory  requirements relating to safet y reporting to the 
regulatory  authority, institutional review board (IRB)/ethics committee (EC) and 
investigators.
Investigator safety  reports are prepared for suspected unexpected serious adverse 
reactions according to local regulatory  requirements and GSK policy  and are forwarded 
to investigators as necessary .
An investigator who receives an investigator safety  report describing a SAE(s) or other 
specific safet y information (e.g., summary or listing of SAEs) from GSK will file it with 
the IB and will notify  the I RB/EC, if appropriate according to local requirements.
9. LIVER CHEMISTRY FOLL OW-UP PROCEDURES
9.1. Liver Chemistry  Testing Procedures
For subjects meeting an y  of the liver chemistry stopping criteria in Section 3.9.1 , make 
every  attempt to carry  out the liver event follow- up assessments described be low:
Viral hepatitis serology , including:
Hepatitis A IgM antibody
Hepatitis B surface antigen and Hepatitis B Core Antibody  (IgM)
Hepatitis C RNA
Cytomegalovirus IgM antibody
Epstein -Barr viral capsid antigen IgM antibod y (or if unavailable, then obtain 
heterophile antibod y or monospot testing)
Blood sample for pharmacokinetic (PK) anal ysis. Record the date and time of 
the PK blood sample draw and the date and time of the last dose of study  drug 
prior the blood sample draw on the eCRF.  If the date or time of the last dose is 
unclear, provide the subject’s best approximation.  If the date or time of the last 
dose cannot be approximated, or if a PK sample cannot be collected within 48 
hours of the liver chemistry  event, do not obtain a PK sample.  I nstructio ns for 
sample handling and shipping are found in the Study  Procedures Manual (SPM).
Serum creatinine phosphokinase (CPK) and lactate deh ydrogenase (LDH)
2012N155299_05 CONFIDENTIA L
BMA117159
136Fractionate bilirubin, if total bilirubin 2 X upper limit of normal (UL N)
Obtain a complete blood coun t (CBC) with differential to assess eosinophilia
Record the appearance or worsening of clinical symptoms indicative of hepatitis 
or hy persensitivity , such as fatigue, nausea, vomiting, right upper quadrant pain 
or tenderness, fever, rash or eosinophilia as relevant on the AE eCRF
Record the use of concomitant medications, including acetaminophen, herbal 
remedies or an y other over the counter (OTC) medications, or an y putative 
hepatotoxins, on the concomitant medication eCRF
Record alcohol use on the liver e vent alcohol intake eCRF
The following assessments are required for subjects with AL T 3 X ULN and bilirubin 
2X ULN (>35% direct) but are optional for other abnormal liver chemistries:
Anti- nuclear antibody , anti -smooth muscle antibody , and Ty pe 1 anti -liver 
kidney  microsomal antibodies
Liver imaging (ultrasound, magnetic resonance imaging [MRI ] or computed 
tomograph y [CT]) to evaluate liver disease
9.2. Liver Chemistry  Monitoring Criteria
For subjects with ALT  3 X ULN but <5X ULN andbilirubin <2 X UL N, witho ut 
symptoms indicative of hepatitis or rash, and who can be monitored safet y for 4 weeks, 
the following actions should be taken:
Notify  the GSK Medical Monitor within 24 hours of learning of the abnormality  
to discuss subject safet y
Continue administration of study  drug
Evaluate liver chemistries (ALT, AST, alkaline phosphatase, bilirubin) weekly  
until they  resolve, stabilize or return to within baseline levels
If at an y time the subject meets an y of the liver chemistry stopping criteria 1 to 5 
(Section 3.9.1 ), then proceed as described in Section 9)
If, after 4 weeks of monitoring, ALT <3X ULN and bilirubin <2 X ULN, then 
monitor subjects twice monthly  until liver chemistries normalize or return to 
within baseline values
9.3. Drug Restart/Rechallenge Following Liver Events that are 
Possibl y Related to Study  Drug
Approval b y the GSK Medical Monitor to restart/rechallenge stud y drug may be 
considered where:
The subject is rece iving compelling benefit, the benefit exceeds the risk, and no 
effective alternative therapy  is available.  Approval of restart/rechallenge by  the 
Institutional Review Board (IRB) or Independent Ethics Committee (I EC) must 
be obtained, as required  
2012N155299_05 CONFIDENTIA L
BMA117159
137If the restart/rechallenge is approved b y GSK in writing, then the subject must 
be provided with a clear description of the possible benefits and risks of 
administration of study  drug, including the possibility  of a recurrence, a more 
severe liver injury  or deat h.
The subject must also provide signed informed consent specificall y for the study  
drug restart/rechallenge.  Documentation of the informed consent must be 
recorded in the subject’s study  chart.
Study  drug must be administered at the dose specified by  theGSK Medical 
Monitor.
Subjects approved b y GS K for restart/rechallenge of study  drug must return to 
the clinic twice a week for evaluation of liver chemistry  tests until stable liver 
chemistries have been demonstrated and laboratory monitoring may  resume per 
protocol.
9.4. Drug Restart Following Transient, Resolving Liver Events 
Not Related to Study  Drug
Approval b y the GSK Medical Monitor to restart study drug(s) may be considered where:
Liver chemistry  abnormalities have a clear underly ing cause (e.g., biliary
obstruction, hy potension) and liver chemistries have improved to normal or are 
within 1.5 X baseline and AL T <3X ULN.  Approval of restart by  the 
Institutional Review Board (IRB) or Independent Ethics Committee (I EC) may  
be required.  
If the restart/rechallenge is approved b y GSK in writing, then the subject must 
be provided with a clear description of the possible benefits and risks of 
administration of study  drug(s), including the possibility  of a recurrence, a more 
severe liver injury  or death.
The subject must also provide signed informed consent specificall y for the study  
drug(s) restart/rechallenge.  Documentation of the informed consent must be 
recorded in the subject’s study  chart.
Study  drug(s) must be administered at the dose specified by  the GSK Medical 
Monitor.
Subjects approved b y GS K for restart/rechallenge of study  drug(s) must return 
to the clinic once a week for evaluation of liver chemistry tests until stable liver 
chemistries have been demonstrated and laboratory monitoring may  resume per
protocol.
If protocol -defined stopping criteria for liver chemistry  abnormalities are met, 
study  drug(s) administration must stop.
2012N155299_05 CONFIDENTIA L
BMA117159
13810. CONCOM ITANT MEDICA TIONS A ND NON -DRUG 
THERA PIES
Subjects will be instructed to inform the investigator prior to starting an y new 
medications from the time of first dose of stud y treatment until the end of the study  (Final 
Study  Visit).  Any  concomitant medication(s), including non -prescription medication(s) 
and herbal product(s), taken during the study  will be recorded in the el ectronic case 
report form (eCRF).  Additionally , a complete list of all prior anti -cancer therapies will 
be recorded in the eCRF.
Concomitant dosing of GSK2857916 with strong Pgp inhibitors should be avoided unless 
considered medicall y necessary (See App endix 11 :  Pgp Inhibitors for list of relevant Pgp 
inhibitors).
If future changes are made to the list of permitted/prohibited medications, formal 
documentation will be provided by  GSK and stored in the study  file.  The SPM will be 
updated to include this information. Any such changes will be communicated to the 
investigative sites in the form of a letter.
10.1. Permitted Medication(s)
Subjects should receive full supportive care during the stud y, including transfusion of 
blood and blood prod ucts, growth factors, and treatment with antibiotics, anti -emetics, 
antidiarrheals, and analgesics, as appropriate.
Steroids are not allowed unless used for pre -medication prior to GSK2857916 infusion.
Concomitant therap y with biphosphonates is allowed.
Concomitant prophy lactic treatment for tumor ly sis sy ndrome (according to local 
standards) in subjects with high tumor load, where TL S may  occur is permitted and 
should be considered.
10.2. Prohibited Medication(s)
Chronic treatment with oral steroids is prohibit ed while the subject is on study . 
A short course (up to 7 day s) of steroids can be used to manage rash, treatment induced 
diarrhea, or other acute complications. Steroids may  be used to treat infusion related 
reactions. Inhaled steroids are allowed.
10.3. Permitted Non -Drug Therapies
Subjects may  receive local irradiation for pain control or stability  control. 
10.4. Prohibited Non -Drug Therapies
Plasmapheresis is prohibited from 7 day s prior to study  entry  through the end of study .  
2012N155299_05 CONFIDENTIA L
BMA117159
13911. LIFESTYLE A ND/OR DIETA RY RESTRICT IONS
11.1. Contraception
11.1.1. Female Subjects
A female of non -childbearing potential (i.e., physiologicall y incapable of becoming 
pregnant) is defined as any  female who has had a hy sterectom y, bilateral oophorectom y 
(ovariectomy ) or bilateral tubal ligation, or is po st-menopausal 
A practical definition accepts menopause after 1 year without menses with an appropriate 
clinical profile, e.g., age appropriate, >45 years in the absence of hormone replacement 
therap y (HRT).  In questionable cases, the subject must have a follicular stimulating 
hormone (FSH) value >40 mI U/mL and an estradiol value < 40pg/mL (<140 pmol/L).
A female of childbearing potential is defined as any  female who does not meet the 
criteria of non -childbearing potential as described in the previous para graph.
Female subjects of childbearing potential must not become pregnant during the study  and 
so must be sexually  inactive by  abstinence or use contraceptive methods with a failure 
rate of <1%.
Abstinence
Sexual inactivity  by abstinence must be consistent with the preferred and usual lifesty le 
of the subject.  Periodic abstinence (e.g. calendar, ovulation, sy mptothermal, post -
ovulation methods) and withdrawal are notacceptable methods of contraception. 
Complete abstinence from sexual intercourse for 14 d ays prior to first dose of study  
treatment, through the dosing period, and for at least 60 day s after the last dose of study  
treatment.
Contraceptive Methods with a Failure Rate of <1%
Oral contraceptives (either combined or progesterone only ) if not contr aindicated for 
this subject population or per local practice. 
Estrogenic vaginal ring if not contraindicated for this subject population or per local 
practice. 
Percutaneous contraceptive patches if not contraindicated for this subject population 
or per l ocal practice. 
Implants of levonorgestrel if not contraindicated for this subject population or per 
local practice.  
Injectable progesterone if not contraindicated for this subject population or per local 
practice. 
Intrauterine device or intrauterine s ystem that meets the <1% failure rate as stated in 
the product label
2012N155299_05 CONFIDENTIA L
BMA117159
140Male partner sterilization (vasectomy with documentation of azoospermia) prior to 
the female subject's entry intothe study , and this male is the sole partner for that 
subject.  For this definition, “documented” refers to the outcome of the 
investigator's /designee’s medical examination of the subject or review of the 
subject's medical history  for study  eligibility , as obtained via a verbal interview with 
the subject or from the subject’s me dical records.
Double- barrier method: condom and occlusive cap (diaphragm or cervical/vault 
caps) plus vaginal spermicidal agent (foam/gel/film/cream/suppository) 
These allowed methods of contraception are only effective when used consistently, 
correctly and in accordance with the product label.  The investigator is responsible 
for ensuring subjects understand how to properly use these methods of 
contraception.
11.1.2. Male Subjects
To prevent pregnancy  in a female partner or to prevent exposure of any  partner to the 
study  treatment from a male subject’s semen, male subjects must use one of the following 
contraceptive methods:
Abstinence, defined as sexual inactivity  consistent with the preferred and usual 
lifesty le of the subject.  Periodic abstinence (e.g. calendar, ovulation, s ymptothermal, 
post-ovulation methods) and withdrawal are not acceptable methods of 
contraception.
Complete abstinence from sexual intercourse from the first dose of study  medication, 
throughout the stud y treatment period and for at least 60 days after the last dose of 
study  treatment.
Condom (during non -vaginal intercourse with any partner -male or female) OR
Double- barrier method: condom and occlusive cap (diaphragm or cervical/vault 
caps) plus spermicidal agent (foam/gel/film/cream/suppos itory ) (during sexual 
intercourse with a female)
11.2. Lactation Restrictions
Female subjects who are lactating must discontinue nursing prior to the first dose of study  
treatment and must refrain from nursing throughout the treatment period and for 4 
months fol lowing the last dose of study treatment.
12. DATA MANAG EMENT
For this study , data will be collected using defined electronic case report forms (eCRFs), 
transmitted electronically to GSK and combined with data provided from other sources in 
a validated data s ystem.
Management of clinical data will be performed in accordance with applicable GSK 
standards and data cleaning procedures to ensure the integrity of the data, e.g. removing 
errors and inconsistencies in the data.  AEs and concomitant medications terms wi ll be 
coded using Medical Dictionary  for Regulatory  Activities (MedDRA) and an internal 
2012N155299_05 CONFIDENTIA L
BMA117159
141validated medication dictionary , GSK Drug.  Electronic CRFs (eCRFs), including queries 
and audit trails, will be retained by  GSK, and copies will be sent to the investi gator to 
maintain as the investigator cop y.
When laboratory samples (i.e., hematology and clinical chemistry ) are analy zed by  a 
central laboratory  the results will be stored in a database maintained b y the central 
laboratory  and transferred to GSK at agree d times.
In all cases, subject initials will not be collected or transmitted to GSK according to GSK 
policy .
12.1. Data Dissemination and Communication Plan
The GSK Medical Monitor will review screening packets to ensure that subjects being 
considered for enrolm ent meet eligibility  criteria prior to entering the study .  Subjects 
will not be assigned a study  number until their screening packet is reviewed and approved 
by the GSK Medical Monitor.  GSK will remain in constant contact with the clinical sites 
during t he enrolment period to ensure that cohort enrolment in Parts 1 and 2 of this study  
are completed as per protocol.  I nvestigators will be informed about available openings 
for enrolment on the trial and will be asked to pre-screen their subjects to determin e 
potential eligibility , and to avoid over -enrolment. Enrol lment will be offered to a given 
site for a limited period of time, and if the site chosen cannot successfull y enrol a subject 
within a pre -specified time period then another site will be offered t he opportunity  to 
enrol a subject.  
During Part 1 of the study , Study  Team Safet y Update Meetings will be held every three 
weeks to review relevant data with the Principal Investigators (or delegates) and site staff. 
These meetings will be held on an “as needed” basis (but no less frequent than once a 
month) during Part 2 (e.g., to share safet y experience and to communicate results of 
scheduled futility anal yses).  Safet y, PK, PD, and clinical outcome data available for all 
subjects at the time of the sche duled Safet y Update Meeting will be reviewed and 
summarized.  I n addition, Dose Escalation Meetings will be scheduled at the conclusion 
of the DLT assessment period for subjects enrolled in each cohort to review safet y PK, 
and PD data and determine the nex t dose level appropriate for study . Dose escalation 
decisions will be made with team and investigator agreement after review of available 
safet y data from at least one cycle of therap y with GSK2867916 (i.e., 21 days for the 
once every  3 weeks schedule and 28 day s for weekly  schedule).  All dose escalation or 
safet y decisions will be documented in writing with copies maintained at each site and 
the Master Study  Files at GSK.  Available data will be provided to participants prior to 
each scheduled Safet y or Dose Escalation Meeting.
Attendees of Safet y Update and Dose Escalation Meetings will include but not limited to 
all clinical investigators (or designees) and site staff, the GSK Medical Monitor, Clinical 
Investigation Lead, Clinical Operations Study  Lead ( USA and Local Operating Company  
designees), Data Quality  Leader, Global Clinical Safet y and Pharmacovigilance 
Representative, Statistician, CPMS representative , and Translational Medicine Lead.
2012N155299_05 CONFIDENTIA L
BMA117159
14213. DATA ANALYSIS AND STA TISTICAL CONSIDERA TIONS
13.1. Hypothesis(es)
13.1.1. Part 1: Dose -Escalation Phase
No formal statistical h ypotheses are being tested in Part 1.  Anal ysis of the data obtained 
from Part 1 will only  utilize descriptive methods.
13.1.2. Part 2: Expansion Cohort
For Part 2, h ypothesized response rates are provided in Sect ion 13.2.2 below .  In this 
case, a test that the ORR is less than or equal to the null hy pothesis rate versus the ORR 
is greater than or equal to the alternative rate will be performed using the stopping rules 
provided in Section 13.6.2 .  Descriptive statistics will be used to describe the observed 
ORRs at the RP2 dose used in the expanded cohorts.
13.2. Sample Size Determination
The sample size planned for Part 1 arises fro m the predefined criteria for dose selection 
and is not driven by  statistical considerations.  Based on simulations, the anticipated size 
of Part 1 will be approximately  20 subjects. See Section 13.2.1 and Secti on 13.2.2 for 
more details.
The additional 50 subjects in the expanded cohort for Part 2 of the study  (which includes 
approximately  40 MM subjects and approximately 10 subjects with other BCMA positive 
malignancies) will provide additional safet y and tolerability  information about the 
treatment and a better precision around the response rate estimate.
13.2.1. Part 1: Dose -Escalation Phase
The total number of subjects to be enrolled in Part 1 will depend on the number of 
subjects needed to characterize the individual dose cohorts for determination of the MTD.    
Simulations were conducted to determine the average sample size and percentage of 
times each dose was selected under three different scenarios.  These scenarios we re 
designed to represent true toxicity  profiles which are lower than expected, higher than 
expected, and in line with expectations. For each scenario, 1000 clinical trials were 
simulated.  Details are provided in Table 16 .  Doses are the projected doses.  Actual 
doses used during the conduct of the trial may  vary .
The specified prior probabilities discussed in Section 3.3.1.2.3   were used to determine an 
explicit equation for the prior distribution using the FACTS software.  The parameters 
(s.d.) of the explicit distribution are =-1.3281 (1.7153), ln( )=-0.795 (1), and ρ=-0.9352 
where and ln( ) are distributed as bivariate normal with correlation ρ.
2012N155299_05 CONFIDENTIA L
BMA117159
143Table 16 Simulation Results Under Various Scenarios
Dose
(mg/kg)Scenario 1: Below  Level of 
ToxicityScenario 2: Expected Level 
of ToxicityScenario 3: Higher Level of 
Toxicity
True DLT 
RatePercent of 
Trials 
Selecting 
Dose as 
MTD (%)True DLT 
RatePercent of 
Trials 
Selecting 
Dose as 
MTD (%)True DLT 
RatePercent of 
Trials 
Selecting 
Dose as 
MTD (%)
No Dose 0 0.7 6.8
0.03 0 0 0.001 0 0.05 0.2
0.06 0.01 0 0.02 0 0.075 0.1
0.12 0.025 0 0.05 0.4 0.1 2.6
0.24 0.05 0.1 0.1 1.4 0.15 5.3
0.48 0.075 0.7 0.15 6.7 0.2 20.3
0.96 0.1 4.3 0.2 20.3 0.3 29.0
1.92 0.125 14.1 0.225 30.3 0.35 24.6
2.8 0.15 22.6 0.275 27.9 0.375 9.5
3.6 0.175 22.4 0.35 9.1 0.45 1.2
4.5 0.225 35.8 0.425 3.2 0.55 0.4
The average sample size over the 1000 clinical trials si mulated under each of Scenarios 
1-3 was 20.55, 20.04, and 19.43 respectivel y.
13.2.2. Part 2: Expansion Cohort
Dose escalation will be used to establish the RP2 dose for GSK2857916 .  Once the RP2 
dose is confirmed, at least 15 and up to 40 subjects in total will b e enrolled into the MM 
cohort using decision rules defined in Table 17.  The sample size and stopping rules are 
based on the methodology  of Lee et al. [ Lee, 2008].  The assumptions underly ing the 
design are detailed below. 
The null hy pothesis is:
H0: p≤20%
The alternative hy pothesis is:
HA:p≥40%
2012N155299_05 CONFIDENTIA L
BMA117159
144For the MM expansion cohort, starting with 15 subjects and allowing for a maximum 
sample size of 40, this design will have a t ype I error rate ( ) of 0.075 and 89.8% power.  
The trial is not designed to stop early for efficacy, but is designed to stop early for futility 
if the predictive probability  of success is less than 5%.  The t ype I error rate, power, and 
predictive probability of success to stop early  for futility  were derived from explicitly  
stating th e minimum and maximum sample size, allowing for the futility  stopping rate to 
range from 5% to 20% within the predictive probability  design software, and selection of 
the optimizing criterion as the maximization of power under the alternative hy pothesis.  
The Bay esian prior probability  used in determining the design was Beta (0.25, 0.75), a 
distribution with a mean response rate of 25%.  Under the null hy pothesis, if the true 
response rate is 20%, the expected sample size of the design is 23.4 subjects and 
probability  of earl y termination (PET) is 88.9%.  Under the alternative h ypothesis, if the 
true response rate is 40%, the expected sample size of the design is 38.6 subjects and 
probability  of earl y termination (PET) is 8.5%.  
13.3. Sample Size Sensitivity
13.3.1. Samp le Size Re -estimation
Sample size re -estimation is not planned for this study .
13.4. Data Analysis Considerations
Data will be listed and summarized according to GSK integrated data standards library  
(IDSL) reporting standards and the Clinical Data Interchange S tandards Consortium 
(CDI SC) where applicable. Complete details will be provided in the Reporting and 
Analy sis Plan (RAP).
13.4.1. Analysis Populations
The ‘ All Treated ’ population is defined as all eligible subjects who receive at least 1dose 
of study  treatment. A n incorrect treatment schedule or drug administration or an earl y 
termination of treatment will not result in exclusion of subjects from this population. 
Subjects with major deviations from the eligibility criteria affecting safet y or from the 
treatment sc hedule at the DL T evaluation period (1 cy cle: 21 day s for once every  3 weeks 
schedule or 28 day s for once weekl y schedule) for reasons other than toxicity may be 
presented in separate tables/listings.
The ‘All Treated’ population will further be classified in the following sub -populations.
oPart 1: all Part 1 subjects of All Treated population. Note, subjects in Part 1 are 
exclusively multiple myeloma patients. 
oPart 2 MM: all Part 2 MM subjects of All Treated population 
oAll Treated MM: comprise of subjects in Part 1 and Part 2 MM.
oPart 2 NHL: all Part 2 lymphoma subjects of All Treated population.
2012N155299_05 CONFIDENTIA L
BMA117159
145The ‘ DLT Evaluable ’ population in Part 1 enables an appropriate evaluation of study  
DLTs. It is defined as those subjects fulfilling the ‘All Treated’ population criteria, and 
having met the following adequate exposure criteria: 
oFor Schedule 1 (once every 3 weeks dosing) subjects received a complete infusion 
in cy cle 1. 
oFor Schedule 2 (once weekly  dosing for 3 consecutive weeks, 1 week rest) 
subjects receive th ree infusions, two of which must be complete infusions, in 
cycle 1. (as increa ses up to ≤30% are implemented between cohorts, less than 2 
complete infusions would result in a total dose closer to the previous dose 
investigated).
Any subject in the “All Treated” population who experiences a DLT, as defined in 
Section 3.3.3 will also be included in the DLT evaluable population regardless of 
exposure.
The ‘Evaluable (MM) ’ population is a subset of the ‘All Treated’ population, who were 
initially treated at RP2D in the expansion cohort and ha ve at least two post -baseline disease 
assessments or they have progressed or died or permanently discontinued treatment. This 
population will be used for the futility analysis of the MM expansion cohort.
The ‘ Pharmacokinetic (PK)Population ’ is defined as those subjects in the “All 
Treated” population from whom at least one PK sample was obtained, analyzed, and was 
measurable. 
The ‘ Pharmacodynamic (PD)Population ’ is defined as those subjects in the “All 
Treated” population from whom at least one PDsample was obtained, analyzed, and was 
measurable.
13.5. Treatment Comparisons
13.5.1. Primary  Comparisons of Interest
No formal h ypothesis testing will be performed. Safet y, PK, PD markers, and efficacy 
summaries will be provided by  initial dose cohort in Part 1 and by  expa nsion cohort in 
Part 2.
13.5.1.1. Primary  Comparison of Interest
All available data, including adverse events, changes in laboratory  values and other safet y 
parameters will be evaluated for each dose cohort in Part 1 and for each expansion cohort 
in Part 2.
13.5.2. Other Co mparisons of Interest
Pharmacokinetic: PK parameters will be evaluated and summarized for each dose cohort 
in Part 1 and in Part 2. 
2012N155299_05 CONFIDENTIA L
BMA117159
146Pharmacod ynamic markers: Changes from baseline in PD markers will be evaluated and 
summarized for each dose cohort in Part 1 and for Part 2.
Clinical anti -cancer activity : The number of Overall Responders (PR, VGPR, CR or sCR) 
for each dose cohort in Part 1 and for each expansion cohort in Part 2 will be listed and 
summarized if data warrant. Clinical Benefit Rate (CBR), as de fined in Appendix 1 , may  
also be explored.  The results from the independently  reviewed scans may  also be 
reported if data are available.
2012N155299_05 CONFIDENTIA L
BMA117159
14713.6. Interim Analysis
13.6.1. Part 1
While no formal interim anal ysis is planned for Par t 1, safet y, pharmacokinetic and 
pharmacod ynamic marker data will be examined on an ongoing basis to support dose 
escalation decisions. Prior to determining the GSK2857916 dose for the next cohort 
enrolled, exploratory  analy sis will be conducted to assess the relationship of 
GSK2857916 dose levels with safet y, PK and PD parameters using all data from 
available cohorts. For more details of the dose escalation procedure, see Section 3.3. 
13.6.2. Part 2
The methodology  utilized is based on the predictive probability  of success if enrollment 
continues to 40 subjects [ Lee, 2008]. The predictive probability  design is similar to a 
Green -Dahlberg design in that it allows for earl y stopping for futility .  The differences 
are that the predictive probability  design allows for evaluation of stopping rules as often 
as after each subject, rather than at onl y two stages.  While the two designs have similar 
type I and t ype II error rates, the probability  of early  termination is greater with the 
predictive probability  design. In this particular study , we will stop only  for futility  and 
evaluate the stopping rules once approximately  15, 22, and 30 subjects are evaluable 
(though additional futility looks a re also controlled for if necessary ). A subject is 
considered evaluable if they  are in the all treated population and have had at least two 
post baseline disease assessments.
For the MM expansion cohort, response data will be reviewed once approximately  15, 22, 
and 30 subjects are evaluable and the number of overall responses (PR, VGPR, CR, and 
sCR) observed will be compared with the stopping rules provided in Table 17below. 
2012N155299_05 CONFIDENTIA L
BMA117159
148Table 17 Futil ity Stopping Region
Number of Overall Responses
Number of Evaluable Subjects 0 1 2 3 4 5 6 7 8 910 11 >11
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Note: The shaded regions are the specific regions for stopping the stud y for futility .  For 
instance, if there are 4 -5 or fewer responses in 25 subjects, then the predictive probability  
for success will be less than the futility  criterion, 5.0%, and the study  will be stopped.
In addition to the considering the recommendations of the futility  anal yses, final 
decisions on stopping enrolment in the MM cohort will depend on the totality  of the data 
collected. Examples of consideration of the totality  of the data include, further 
investigation of the clinical activity  of subgroups of subjects based on their BCMA 
expression levels and evaluation of the quality  of responses (including sCR, CR and 
Clinical Benefit Rate, as de fined in Appendix 1 ). Should the recommendation to stop for 
futility  be disregarded in favor of a decision to continue the trial based on the totality  of 
the data, the overall ty pe I error rate of the expansion pha se will be inflated.  
2012N155299_05 CONFIDENTIA L
BMA117159
149No interim anal yses will be performed on the BCMA+ ly mphomas cohort ;though 
consideration would be given to closing the cohort should the enrol lment be stopped in 
the MM cohort. 
If necessary , a subject may  be replaced if they  are d eemed to be Lost to Follow- Up 
(LTFU) or they  have withdrawn due to a toxicity  deemed to not have been related to 
GSK2857916.
Subjects will not be replaced when they discontinue the study  due to: Progression 
(symptomatic or otherwise), toxicity  related to GSK2857916, or lack of efficacy .
Other administrative interim analy ses may  be performed if needed.
Final anal ysis of MM population may  be performed separatel y, before the NHL cohort 
completes the study . 
13.7. Key Elements of A nalysis Plan
Data will be listed an d summarized according to the GSK reporting standards, where 
applicable.  Complete details will be documented in the Reporting and Analysis Plan 
(RAP).  Any  deviations from, or additions to, the original anal ysis plan described in this 
protocol will be doc umented in the RAP and final study  report.
As it is anticipated that accrual will be spread thinly  across centers and summaries of data 
by center would be unlikely  to be information, data from all participating centers will be 
pooled prior to anal ysis.
Alldata up to the time of study  completion/withdrawal from study  will be included in the 
analysis, regardless of duration of treatment.
As the duration of treatment for a given subject will depend on efficacy  and tolerability , 
the duration of follow -up will vary between subjects.  Consequently  there will be no 
imputation for missing data. 
Demographic and baseline characteristics will be summarized.
13.7.1. Anti-Cancer A ctivity Analyses
The All Treated Population will be used for anti -cancer activity  anal yses. Since this is a 
Phase I study , anti- cancer activity  will be evaluated based on clinical evidence and 
response criteria.  If data warrant, the response data will be summarized by  dose level.  
Correlation anal ysis will be conducted to explore any relationship betw een the tumor 
response based on either the I n ternational M yeloma Working Group Uniform Response 
Criteria (for subjects with MM; see Appendix 1 ) or the Response Criteria for Malignant 
Lym phoma (for subjects with lymphomas, refer to Appendix 2 ). Full details will be 
specified in the Reporting and Anal ysis Plan (RAP). 
2012N155299_05 CONFIDENTIA L
BMA117159
15013.7.2. Safety  Analyses
The All Treated Population will be used for the analy sis of safet y data. All serially 
collecte d safet y endpoints (e.g. laboratory  tests, vital signs, electrocardiogram [ECGs]) 
will be summarized according to the scheduled, nominal visit at which they  were 
collected and across all on- treatment time points using a “worst -case” analysis. Complete 
details of the safety  anal yses will be provided in the Reporting and Anal ysis Plan (RAP).
13.7.2.1. Extent of Exposure
The number of subjects administered study  treatment will be summarized according to 
the duration of therap y.  
13.7.2.2. Adverse Events
Adverse events (AEs) will be coded using the standard MedDRA and grouped by  system 
organ class.  Adverse events (AEs) will be graded by  the investigator according to the 
National Cancer Institute- Common Toxicity  Criteria for Adverse Events (NCI -CTCAE), 
(version 4) .
Events will be summarized by  frequency  and proportion of total subjects, by  system 
organ class and preferred term.  Separate summaries will be given for all AEs, treatment -
related AEs, serious adverse events (SAEs) and AEs leading to discontinuation of study  
treatment. Adverse events (AEs), if listed in the NCI -CTCAE (version 4) will be 
summarized by  the maximum grade.  Otherwise, the AEs will be summarized by  
maximum intensity .
Characteristics (e.g. number of occurrences, action taken, grade, etc) of the following 
AEs of clinical interest will be summarized separately : corneal events, hematologic 
toxicities (including but not limited to thrombocy topenia and neutropenia) , infusion 
related reaction etc. Details will be provided in the RAP.
The incidence of deaths and the primary  cause of death will be summarized.
13.7.2.3. Clinical Laboratory  Evaluations
Hematology  and clinical chemistry  data will be summarized using frequencies and 
proportions according to National Cancer Institute- Common Toxicity  Criteria for 
Adverse Events (NCI -CTCAE) (Version 4.0) .  The evaluation of clinical laboratory tests 
will focus on selected laboratory  analy tes from the hematology  and blood chemistry  
panel.
Descriptive statistics (mean, standard deviation, median, range) will be used to 
summarize observe d laboratory  values and change from baseline in observed value at 
each scheduled visit, as appropriate.
2012N155299_05 CONFIDENTIA L
BMA117159
151The worst -case-toxicity  grade in hematology  and chemistry  result during the treatment 
will be summarized. Shift tables from baseline to the worst tox icity grade during 
treatment will be provided for each laboratory  analy te.
Further details will be provided in the Reporting and Analy sis Plan (RAP).
13.7.2.4. Immunogenicity  Analyses
For each subject, t he results and titers of anti -GSK2857916 binding antibodies will be 
listed for each assessment time point.  The frequency and percentage of subjects with 
positive and negative results will be summarized for each assessment time and overall for 
each subject by  dose cohort.
13.7.2.5. Other Safety  Measures
Data for vital signs, e lectrocardiograms (ECGs), and echocardiograms (ECHOs) will be 
summarized based on predetermined criteria identified to be of potential clinical concern 
(PCI ).  For continuous variables, these summaries will include sample size, mean, median, 
standard devia tion, minimum, and maximum. For categorical variables, the summaries will 
include frequencies and corresponding percentages. Further details will be provided in the 
Reporting and Anal ysis Plan (RAP).
2012N155299_05 CONFIDENTIA L
BMA117159
15213.7.3. Pharmacokinetic A nalyses
13.7.3.1. Raw Plasma Concentrations
Linea r and semi -logarithmic individual plasma concentration- time profiles and mean and 
median profiles (when applicable) b y GSK2857916 dose and schedule will be plotted for 
both GSK2857916 (intact and total) and cy s-mcMMAF in Part 1.
In Part 2, individual model -predicted GSK2857916 plasma concentration -time profiles, 
observed concentrations in individual subjects and population predicted plasma 
concentrations provided by  NONMEM (non -linear mixed effects modelling), will be 
presented graphicall y by subject (semi -log plot) and by  treatment (linear and semi -log 
plots).
Plasma concentrations of GSK2857916 (intact and total) and cy s-mcMMAF will be listed 
for each subject and summarized by  planned time point ,dose cohort and schedule in Part 
1and Part 2.
Derived Plasma Pharmacokinetic Parameters
Pharmacokinetic anal ysis will be the responsibility of the CPMS Department, QSci, 
GSK.
In Part 1 of the stud y, plasma GSK2857916 concentration -time data will be anal yzed by 
non-compartmental methods using WinNonlin. Calculations will be based on the actual 
sampling times recorded during the stud y. From the plasma concentration -time data, the 
following GSK2857916 (intact and total) PK parameters will be determined as data 
permit, for each dose of GSK2857916 , each schedule and for each subject : After single 
dose : area under the plasma concentration- time curve (AUC( 0-t), AUC (0 -tau) and/or 
AUC(0 -∞)), maximum observed plasma concentration (Cmax),time to Cmax (tmax), l ast 
time point where the concentration is above the limit of quantification (tlast), sy stemic 
clearance (CL), Volume of distribution at steady  state (Vss ), terminal phase elimination 
rate constant ( λz), terminal phase half -life (t½). After repeat dose: Cmax and Ctrough.
For cy s-mcMMAF, after single dose, Cmax and AUC(0 -t) will be derived and after 
repeat dose Cmax and Ctrough.
In Part 2 of the stud y, plasma GSK2857916 concentration -time data together with data 
from part 1 will be analysed using a population approach. A nonlinear mixed effects 
model will be used to determine population pharmacokinetic parameters and identify  
relevant covariates (e.g., age, w eight, or disease related covariates). PK parameters will 
be listed and summarized descriptivel y (mean, standard deviation, median, minimum, 
maximum, geometric mean, and the standard deviation, CV% and 95% confidence 
interval of log -transformed parameters) by dose cohort and schedule in Part 1 and Part 2.  
To assess the extent of accumulation following GSK2857916 repeat dosing, the observed 
accumulation ratio (Ro) for both GSK2857916 (intact and total) and cy s-mcMMAF will 
be determined as Cmax and Ctrough a t stead y-state to Cmax and Ctrough after the first 
dose, respectively .
2012N155299_05 CONFIDENTIA L
BMA117159
153Raw urine Concentrations
Urine concentrations of cy s-mcMMAF (part 1 only ) will be listed and summarised by  
GSK2857916 dose , schedule and nominal time range. Plots may  also be produced i f 
deemed necessary .
Derived Urine Pharmacokinetic Parameters
If data permits, the following pharmacokinetic parameters will be determined for each 
GSK2857916 dose, each schedule and for each subject (P art 1 onl y):
Urinary  recovery  of unchanged cy s-mcMMAF w ithin the 24 h period collection (Ae(0-
24)) will be calculated. It will be calculated as the product of the concentration in urine 
and the urine weight, thus assuming a urine density of 1 g/mL.
Fraction of total cy s-mcMMAF dose excreted (Fe) in the 24- h interval will be estimated 
as Ae(0 -24)/(cy s-mcMMAF)Dose, in the Schedule 1only  (i.e. every  3weeks).
Derived cy s-mcMMAF urine pharmacokinetic parameters will be listed and summarised 
by GSK2857916 dose and schedule .
13.7.3.2. Statistical A nalysis of Pharmacokinetic Dat a
Statistical analy ses of the pharmacokinetic (PK) parameters data will be the responsibility  
of Discovery  Biometrics, GSK.
GSK2857916 (intact and total) and cy s-mcMMAF concentration- time data will be listed 
for each subject and summarized by  descriptive s tatistics at each time point by cohort.  
Dose Proportionality : In Part 1, if more than 2 dose cohorts are required to reach RP2 
dose, exploration of dose proportionality  for GSK2857916 (intact and total) and 
Cys-mcMMAFAUC(0 -∞)/AUC(0 -tau) and Cmax followi ng single dose administration 
and GSK2857916 (intact and total) and cy s-mcMMAF Cmax and Ctrough following 
repeat dose administration will be evaluated graphically  and using the power model as 
described below:
where ais the y -intercept and bis the slope.
The power model will be fitted by  restricted maximum likelihood (REML) using SAS 
Proc Mixed. Both the intercept and slope will be fitted as fixed effects. If there is 
sufficient data, the model may  also be fit with the intercept and/or slop e as random 
effects depending on the ability  of the model to converge and on estimation of variance-
covariance matrix. The mean slope and corresponding 90% confidence interval will be 
estimated from the power model.
2012N155299_05 CONFIDENTIA L
BMA117159
15413.7.4. Pharmacokinetic/Pharmacody namic A nalyse s
Exploratory  plots will be presented to examine potential relationships between individual 
and/or pooled plasma concentrations/exposure and relevant safet y and PD endpoints. If 
deemed appropriate, further PK/PD modelling will be performed on the safety  and PD 
endpoints selected based on the results of the exploratory  graphical analy sis showing 
obvious relationships or trends between the dose, concentration/exposure and the safet y 
and PD endpoints. The choice of the structural PK/PD models will be dependent on the 
emerging data. More details of an y exploratory  PK/PD analy ses will be provided in the 
RAP.
The exposure response relationship between GSK2857916 (dose, concentration, Cmax, 
or AUC) and clinical activity  (e.g. ORR) will also be explored combining Pa rt 1 and Part 
2 data together if deemed appropriate.
13.7.4.1. Translational Research A nalyses
The results of translational research investigations will be reported either within or 
separately  from the main clinical study  report (CSR).  All endpoints of interest fro m all 
comparisons will be descriptively  and/or graphically  summarized as appropriate to the 
data.
Further details on the translational research anal yses will be addressed in the Reporting 
and Anal ysis Plan (RAP).
13.7.4.2. Novel Biomarker(s) A nalyses
The results of these biomarker investigations may  be reported separatel y from the main 
clinical study  report.  All endpoints of interest from all comparisons will be descriptivel y 
and/or graphically  summarized as appropriate to the data.
Additional exploratory  analy ses m ay be performed to further characterize the novel 
biomarker.
13.7.5. Genetic A nalyses
Further details on genetic analyses will be addressed in Appendix 7 .
13.7.6. Pharmacody namic Biomarkers and Exploratory  Response 
Prediction Biom arkers
Cell surface BCMA and sBCMA pre dosing will be quantified as a potential predictive 
biomarker for clinical activity.  Post dosing, free surface BCMA and BCMA -drug 
complex will be quantified to assess proportion of target engagement. 
Measurements of sBCMA will include separate assay s for free sBCMA and sBCMA 
complexed with drug. 
Post dose measurements of free and complexed BCMA will be used in conjunction with 
PK data to understand drug/ target interaction during dosing. 
2012N155299_05 CONFIDENTIA L
BMA117159
155If the data permit, an atte mpt will be made to identify  a statisticall y and clinically 
meaningful threshold for BCMA expression which serves as an indicator for potential 
efficacy . Full details of analy sis approaches will be provided in the RAP. 
13.7.6.1. Exploratory  analy ses of DNA , and Pro tein
Exploratory  anal yses may  be performed on remaining study  samples for analy ses of 
DNA, RNA and protein to understand changes in response to GSK2857916 treatment.
The results of exploratory  investigations will be reported separate from the main clinical
study  report (CSR).  All endpoints of interest from all comparisons will be descriptivel y 
and/or graphically  summarized as appropriate to the data. 
13.7.7. Clinical A ctivity Analyses
Overall Response Rate ORR) is one of the secondary endpoints to measure clinica l 
activity  of this study .  
For multiple my eloma, ORR is defined as the percentage of subjects with a confirmed PR 
or better (i.e. PR, VGPR, CR and sCR), according to the I M WG Panel I ( Appendix 1 ), as 
assessed b y the investigator. In addition, Clinical Benefit rate (CBR) is defined as the 
percentage of subjects with a confirmed MR or better (i.e.MR, PR, VGPR, CR and sCR), 
according to the IMWG Panel I  (Appendix 1 ), as assessed b y the investigator.
The number and p ercentage of subject s in the following response categories will be 
presented sCR (stringent complete response), (complete response) CR, (very good partial 
response) VGPR, (partial response) PR, (minimal response) MR, stable disease (SD), 
progressive diseas e (PD), and not evaluable (NE)
sCR+CR+VGPR+PR for overall response (ORR)
sCR+CR+VGPR+PR+MR for Clinical Benefit rate (CBR)
The corresponding exact 95% CI  for ORR and Clinical Benefit Rate (CBR) will also be 
provided.  Subject s with unknown or missing respo nse will be treated as non -responders, 
i.e., these subject s will be included in the denominator when calculating percentages of 
response.
For l ymphoma, ORR is defined as the percentage of subjects with confirmed CR, or PR, 
as described in the Revised Resp onse Criteria for Malignant Ly mphoma ( Appendix 2 ). 
ORR for ly mphomas will be summarized in a similar way  as multiple m y eloma. The 
corresponding exact 95% CI  for ORR will also be provided.
Other exploratory  time -to-event (TTE) endpoints related to clinical activity for Part 2 
(MM) of this study  are TTP, DOR, TTR, and PFS.
Time to disease progression (TTP) is defined as the time from first dose until the 
earliest date of PD per IMWG, or death due to PD. Determination of dates of TTP event 
and dates for censoring will be described in the RAP. Duration of response (DOR) is 
defined as the time from first documented evidence of PR or better until disease 
progression (PD) per IMWG, or death due to PD among subject s who achi eve a response 
2012N155299_05 CONFIDENTIA L
BMA117159
156(i.e. confirmed PR or better ). Responders without disease progression will be censored at 
the censoring time point for TTP. 
Time to response (TTR) is defined as the time between the date of first dose and the 
first documented evidence of re sponse (PR or better). Subject s without confirmed 
response (PR or better) will be censored at the censoring date for TTP. 
Progression -free survival (PFS) is defined as the time from first dose until the earliest 
date of disease progression (PD) per IMWG, or death due to an y cause. Determination of 
dates of PFS event and dates for censoring will be described in the RAP. 
For all the TTE endpoints described above, median TTE with 95% CI  will be estimated 
employ ing the Kaplan- Meier method as data permits. A K aplan -Meier survival curve will 
be generated. The number and percentage of subject s who had the event or were censored 
will also be reported.
Exploratory  subgroup analy ses may  be performed for all endpoints to measure clinical 
activity  as appropriate.
Over all Survival : The protocol is amended to collect long- term survival data (i.e. up to 1 
year after last subject completes or discontinues treatment). Subjects who have alread y 
completed the study  will be contacted to request re -consent .
If all the patients (who were alive at the time of study  completion) can be re -consented, 
OS landmark anal ysis may  be performed at 9 and 12 months using Kaplan -Meier analy sis 
as data permits.
Otherwise, onl y descriptive anal ysis (number and % of deaths and lost to follow -up) will 
be performed.
13.7.8. Health Outcome A nalyses
Symptom impact and HRQoL  will be assessed using the e -Diary . Change from baseline 
and change over time will be summarized. 
The calculation of scores and methods to deal with missing data will be provided in the 
RAP.
Visual Functioning Questionnaire ( NEI VFQ -25and OSDI) : Data will be collected from 
end of treatment (EOT) visit as baseline. Additional data will be collected in follow -up 
visits on a monthly  basis for subjects with ongoing corneal events or signs at EOT for 1 
year or until resolution, whichever occurs first. These data will not be collected for 
subjects who alread y completed the treatment. Methods for calculation of scores will be 
provided in the RAP. Due to limited number of on -treatment subjects at the time of 
protocol amendment, only  individual subject data will be presented .
2012N155299_05 CONFIDENTIA L
BMA117159
15714. STUDY CONDUCT CONSIDERA TIONS
14.1. Posting of Information on Clinicaltrials.gov
Study  information from this protocol will be posted on publicly  available clinical trial 
registers before enrolment of subjects begins.
14.2. Regulatory  and Ethical Considerations, Including the 
Informed Consent Process
Prior to initiation of a study  site, GSK will obtain approval from the appropriate 
regulatory  agency  to conduct the study in accordance with I nternational Conference on 
Harmonization Good Clinical Practice (ICH GCP) and applicable country -specific 
regulatory  requirements.
The study  will be conducted in accordance with all applicable regulatory  requirements.
The study  will be conducted in accorda nce with ICH GCP, all applicable subject privacy  
requirements, and the ethical principles that are outlined in the Declaration of Helsinki 
2008, including, but not limited to:
Institutional review board (IRB)/ethics committee (EC) review and approval of st udy 
protocol and an y subsequent amendments
Subject informed consent
Investigator reporting requirements
GSK will provide full details of the above procedures, either verball y, in writing, or both.
Written informed consent must be obtained from each subject prior to participation in the 
study .
14.3. Urgent Safety  Measures
If an event occurs that is related to the conduct of the study  or the development of the I P, 
and this new event is likely  to affect the stud y of subjects, the Sponsor, and the 
investigator will take appropriate urgent safet y measures to protect subjects against an y 
immediate hazard.
The Sponsor will work with the investigator to ensure the Institutional review board 
(IRB)/ethics committee (EC) is notified.
14.4. Qualit y Control (Study  Monitoring)
In acc ordance with applicable regulations, Good Clinical Practice (GCP) and GSK 
procedures, the site will be contacted prior to the start of the study  to review with the site 
staff the protocol, stud y requirements, and their responsibilities to satisfy regulator y, 
ethical, and GSK requirements.  When reviewing data collection procedures, the 
discussion will include identification, agreement and documentation of data items for 
which the electronic case report form (eCRF) will serve as the source document.
2012N155299_05 CONFIDENTIA L
BMA117159
158The inve stigator and the head of the medical institution (where applicable) agrees to 
allow the monitor direct access to all relevant documents and to allocate their time and 
the time to their staff to monitor to discuss findings and an y issues.
Monitoring visits will be conducted in a manner to ensure that the:
Data are authentic, accurate, and complete.
Safety  and rights of subjects are being protected.
Study  is conducted in accordance with the currently  approved protocol and any  other 
study  agreements, ICH GCP, and all applicable regulatory requirements.
14.5. Qualit y Assurance
To ensure compliance with I nternational Conference on Harmonization Good Clinical 
Practice (I CH GCP) and all applicable regulatory  requirements, GSK may  conduct 
quality  assurance audits of the s ite.  Regulatory  agencies may  conduct a regulatory  
inspection at an y time during or after completion of the study.  In the event of an audit or 
inspection, the investigator (and institution) must agree to grant the auditor(s) and 
inspector(s) direct access to all relevant documents and to allocate their time and the time 
of their staff to discuss any findings/relevant issues.
14.6. Stud y and Site Closure
The end of the stud y will be defined as the date of the last visit of the last subject 
enrolled.
Upon completi on or termination of the study , the monitor will conduct site closure 
activities with the investigator or site staff (as appropriate), in accordance with applicable 
regulations, International Conference on Harmonization Good Clinical Practice (ICH 
GCP), and GSK Standard Operating Procedures.
GSK reserves the right to temporaril y suspend or terminate the stud y at an y time for 
reasons including (but not limited to) safety  issues, ethical issues, or severe 
noncompliance.  If GSK determines that such action is required, GSK will discuss the 
reasons for taking such action with the investigator or head of the medical institution 
(where applicable).  When feasible, GSK will provide advance notice to the investigator 
or head of the medical institution of the impending action.
If a stud y is suspended or terminated for safet y reasons, GSK will promptly  inform all 
investigators, heads of the medical institutions (where applicable),and/or institutions 
conducting the study .  GSK will also promptly  inform the relevant regu latory  authorities 
of the suspension/termination along with the reasons for such action.  Where required b y 
applicable regulations, the investigator or head of the medical institution must inform the 
IRB/EC promptly  and provide the reason(s) for the suspen sion/termination.
GSK may  also close study  sites which fail to recruit subjects within a predefined 
timeframe, as defined within the Study  Procedures Manual (SPM).
2012N155299_05 CONFIDENTIA L
BMA117159
15914.7. Records Retention
Following closure of the study , the investigator or head of the medical in stitution (where 
applicable) must maintain all site study records (except for those required by  local 
regulations to be maintained elsewhere) in a safe and secure location.  The records must 
be easil y accessible when needed (e.g., for a GSK audit or regula tory inspection) and 
must be available for review in conjunction with assessment of the facility , supporting 
systems, and relevant site staff.
Where permitted b y local laws/regulations or institutional policy, some or all of the 
records may  be maintained i n a format other than hard cop y (e.g., microfiche, scanned, 
electronic); however, caution must be exercised before such action is taken.  The 
investigator must ensure that all reproductions are legible and are a true and accurate 
copy  of the original.  In addition, they  must meet accessibility  and retrieval standards, 
including regeneration of a hard cop y, if required.  The investigator must also ensure that 
an acceptable back -up of the reproductions exists and that there is an acceptable quality  
control pr ocedure in place for creating the reproductions.
GSK will inform the investigator of the time period for retaining the site records in order 
to comply  with all applicable regulatory  requirements.  The minimum retention time will 
meet the strictest standard applicable to a particular site, as dictated b y local 
laws/regulations, GSK standard operating procedures, and/or institutional requirements.
The investigator must notify  GSK of any  changes in the archival arrangements, including, 
but not limited to archi val of records at an off -site facility  or transfer of ownership of the 
records in the event that the investigator is no longer associated with the site.
14.8. Provision of Study  Results to Investigators, Posting of 
Information on Publicly  Available Clinical Tria ls Registers 
and Publication
Where required b y applicable regulatory  requirements, an investigator signatory  will be 
identified for the approval of the clinical study  report.  The investigator will be provided 
reasonable access to statistical tables, figur es, and relevant reports and will have the 
opportunity  to review the complete study  results at a GSK site or other mutually -
agreeable location.
GSK will also provide the investigator with the full summary  of the stud y results.  The 
investigator is encourag ed to share the summary  results with the study  subjects, as 
appropriate.
The results summary  will be posted to the GSK Clinical Study  Register no later than 
eight months after the final primary  completion date, the date that the final subject was 
examined or received an intervention for the purposes of final collection of data for the 
primary  outcome.  In addition, a manuscript will be submitted to a peer reviewed journal 
for publication no later than 18 months after the last subject’s last visit (L SLV).  W hen 
manuscript publication in a peer reviewed journal is not feasible, a statement will be 
added to the register to explain the reason for not publishing.
2012N155299_05 CONFIDENTIA L
BMA117159
16015. REFERENCES
Alley  S, Okeley  N, Senter P.  Antibody -drug conjugates: targeted drug delivery  for 
cancer.  Curr Opin  Chem Biol.  2010; 13:529 -537.
Alley  S, Zhang X, Okeley  N, Anderson M, Law C, Senter P, Benjamin D.  The 
pharmacologic basis for antibody -auristatin conjugate activity .  J Pharmacol  Exp Ther.  
2009 ;330:932-938.
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug -induced liver injury :the 
attractive hazard. Expert Opin Drug Safet y 2009;8:709–714.
Atkinson TM, Mendoza TR, Sit L , et al. The Brief Pain I nventory  and its "pain at its 
worst in the last 24 hours" item: clinical trial endpoint conside rations . Pain Med. 
2010;11:337 -346.
Basso K, Margolin AA, Stolovitzky  G, Klein U, Dalla -Favera R, Califano A. Reverse 
engineering of regulatory networks in human B cells. Nat Genet. 2005; 37:382 -390.
Beck A, Lambert J, Sun M, Kedan L. Fourth World Antibody -Drug Conjugate Summit. 
mAbs 4:6, 637 –647; 2012.
Chang YJ, Lee JS, L ee CG, et al. Assessment of clinical relevant fatigue level in c ancer. 
Support Care Cancer. 2007; 15: 891 -896.
Cleeland C.  The Brief Fatigue Inventory User’s Guide.  2010.  
http://www.mda nderson.org/education -andreseach/departments -programs -and-
labs/departments- and-divisions/sy mptom -research/sy mptom -assessment -
tools/MDASI _userguide.pdf
Cleeland C.  The Brief Pain I nventory  User’s Guide.  2009.  
http://www.mdanderson.org/education -andreseac h/departments- programs -and-
labs/departments- and-divisions/sy mptom -research/sy mptom -assessment -
tools/BPI _userguide.pdf
Cleeland CS, Ry an KM. Global use of the Brief Pain I nventory . Ann Acad Med 
Singapore. 1994; 23: 129-138.
Darce JR, Arendt BK, Wu X, Jeline k DF. Regulated expression of BAFF -binding 
receptors during human B cell differentiation. J Immunol. 2007 Dec 1;179(11):7276 -86.
Daut RL , Cleeland CS.  The prevalence and severity  of pain in cancer.  Cancer.  1982; 
50(9):1913-1918.
Devine, BJ.  Case Number 25 Gentamicin Therapy : Clinical Pharmacology Case Studies.  
Drug Intell  Clin Pharm. 1974; 8:650 -655.
2012N155299_05 CONFIDENTIA L
BMA117159
161Elsawa S, Novak A, Grote D, Ziesmer S, Witzig T, Ky le R, et al. B -lymphocy te 
stimulator (BLy S) stimulates immunoglobulin production and malignant B -cell growth in 
Waldenstrom macroglobulinemia. Blood. 2006;107:2882-2888.
Endo T, Mitsufumi N, Enzler T, Cottam HB, Fukuda T, James DF, et al. BAFF and 
APRIL support chronic ly mphocy tic leukemia B -cell survival through activation of the 
canonical NF -B pathway . Blood . 2007;109:703-710.
GlaxoSmithKline Document Number 2013N175128_02 .  GSK2857916 Investig ator’s 
Brochure.  Report Date 14- April 2016
Hallek M, Cheson B, Catovsky  D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, 
et al.  Response: Defining respon se criteria in CLL patients treated in clinical research 
trials.  Blood. 2008;111:5446-56.
James L P, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Protein Adducts in Adults with 
Acetaminophe n Overdose and Acute L iver Failure. Drug Metab Dispos 2009; 37(8): 
1779 -1784.
Kyle RA and Rajkumar SV. Criteria for diagnosis, staging, risk stratification and 
response assessment of multiple my eloma. Leukemia. 2009;23:3 -9.
Lee J, L iu D. A predictive proba bility  design for phase II cancer clinical trials. Clinical 
Trials 2008;5:93-106.
Mangione, C. M., P. P. Lee, P. R. Gutierrez, K. Spritzer, S. Berry , R. D. Hay s and I. 
National Ey e Institute Visual Function Questionnaire Field Test. "Development of the 
25-item National Ey e Institute Visual Function Questionnaire." Arch Ophthalmol 2001; 
119(7): 1050-1058.
McDowell I, Newel C.  Measuring health: a guide to rating scales and questionnaires.  
3rd edition.  New York: Oxford University  Press, Pain measurements. 1 996; 470-519.
Mendoza T, Wang XS, Cleeland CS, et al.  The rapid assessment of fatigue severit y in 
cancer patients: use of the B rief Fatigue Inventory.  Cancer. 1999;5: 1186 -96.
Montes -Moreno S, Montalban C, Piris M. L arge B -cell ly mphomas with plasmablasti c 
differentiation: a biological and therapeutic challenges. Leuk Ly mph. 2012;53(2):185 -
194.
NCI-CTCAE (NCI Common Terminology  Criteria for Adverse Events), Version 4, 
DCTD, NCI , NIH, DHHS, May  28, 2009.
Neuenschwander B, Branson M, Gsponer T. Critical aspe cts of the Bay esian approach to 
phase I cancer trials. Stat Med. 2008 Jun 15; 27(13):2420 -39.
O’Quigley  J, Pepe M, Fisher L. Biometrics 46;1;11-48, 1990.
2012N155299_05 CONFIDENTIAL  
  BMA117159 
 162 
 Oken, M.M., Creech, R.H., Tormey, D.C., Horton, J., Davis, T.E., McFadden, E.T., 
Carbone, P.P.: Toxicity And Response Criter ia Of The Eastern Cooperative Oncology 
Group. J Clin Oncol 5:649-655, 1982. 
Palumbo A and Anderson K. Multiple Myeloma. N Engl J Med. 2011; 364:1046-60. 
Papay JI, Clines D, Rafi R, Yuen N, Britt SD , Walsh JS, et al. Drug-induced liver injury 
following positive drug rechallenge. Re gul Toxicol Pharmacol 2009;54:84-90. 
Rajkumar SV. Multiple myeloma: 2011 update  on diagnosis, risk stratification, and 
management. Am J Hematol. 2011b;86:57-65. Rajkumar SV. Treatment of multiple myel oma. Nat Rev Clin Oncol. 2011a;8:479-491. 
Sanchez E, Li M, Kitto A, Li J, Wang SJ , Kirk DT, et al. Serum B-cell maturation 
antigen is elevated in multiple myeloma and co rrelates with disease status and survival. 
Brit J Haematol. 2012;158:727-738. Schiffman, R. M., M. D. Christianson, G. Jacobsen, J. D. Hirsch and B. L. Reis . 
"Reliability and validity of the Ocular Su rface Disease Index." Arch Ophthalmol. 2000; 
118(5): 615-621. 
Sullivan P and Salmon S. Kinetics of Tumor Growth and Regression in IgG Multiple 
Myeloma. J Clin Investigation, 1972, 51: 1697-1708. 
Thompson, J, Forero A, Heath E, Pal S, Ansell S, Infante J, et al.  SGN-75 in the 
treatment of patients with CD70-positive mali gnancies including metastatic renal cell 
carcinoma. J Clin Oncol 2013;31 (suppl 6; abstr 368). 
Tomoyuki E, Mitsufumi N, Enzler T, Cottam H, Fukuda T, James D, et al.  BAFF and 
APRIL support chronic lymphocytic leukemia B-cell survival  through activation of the 
canonical NF- κB pathway.  Blood 2007:109:703-710. 
  
 
2012N155299_05 CONFIDENTIA L
BMA117159
16316. APPENDICES
16.1. Appendix 1: Inter national My eloma Working Group Uniform
Response Criteria for Multiple My eloma
Response IMWG Criteria
sCR CR as defined below plus normal FLC ratio and absence of clonal
cells in bone marrow3by immunohistochemistry  or 
immunofluorescence4
CR Negative immu nofixation on the serum and urine and 
disappearance of an y soft tissue plasmacytomas and < 5% plasma 
cells in bone marrow3
VGPR Serum and urine M -protein detectable by  immunofixation but not 
on electrophoresis
or
≥ 90% reduction in serum M -protein plus urine M -protein level 
<100 mg/24 h
PR ≥ 50% reduction of serum M -protein and reduction in 24 hours 
urinary  M-protein by  ≥90% or to < 200 mg/24 h
If the serum and urine M -protein are unmeasurable,5a ≥ 50% 
decrease i n the difference between involved and uninvolved FL C 
levels is required in place of the M -protein criteria
If serum and urine M- protein are not measurable, and serum free 
light assay  is also not measureable, ≥ 50% reduction in plasma cells 
is required in place of M- protein, provided baseline bone marrow 
plasma cell percentage was ≥ 30%
In addition to the above listed criteria, if present at baseline, a ≥ 
50% reduction in the size of soft tissue plasmacy tomas is also 
required
MR 25% but <49% reduction of serum M protein and reduction in 24 
hour urine M protein b y 50-89%, which still exceeds 200 mg per 24 
hour
In addition to the above criteria, if present at baseline, 25 -49% 
reduction in the size of soft tissue plasmacy tomas is also required
No increase in size or number of l ytic bone lesions (development of 
compression fracture does not exclude response)
No 
change/Stable 
diseaseNot meeting criteria for CR, VGPR, PR, or progressive disease
Progressive 
DiseaseIncrease of ≥ 25% from lowest response value in any  one or more 
of the following:
oSerum M -component and/or (the absolute increase must be 
≥ 0.5 g/dL)6
oUrine M -component and/or (the absolute increase must be 
≥200 mg/24 h)
2012N155299_05 CONFIDENTIA L
BMA117159
164Response IMWG Criteria
Only  in patients without measurable serum and urine M -protein 
levels; the difference between involved and uninvolved FLC levels. 
The absolute increase must be > 10 mg/dL
Bone marrow plasma cell percentage; the absolute percentage must 
be ≥ 10%7
Definite development of new bone lesions or so ft tissue 
plasmacy tomas or definite increase in the size of existing bone 
lesions or soft tissue plasmacy tomas
Development of h ypercalcaemia (corrected serum calcium > 11.5 
mg/dL or 2.65mmol/L) that can be attributed solely  to the plasma 
cell proliferative disorder
Relapse Clinical relapse requires one or more of:
Direct indicators of increasing disease and/or end organ d ysfunction 
(CRAB features).6It is not used in calculation of time to 
progression or progression -free survival but is listed here as 
some thing that can be reported optionally  or for use in clinical 
practice
Development of new soft tissue plasmacy tomas or bone lesions
Definite increase in the size of existing plasmacy tomas or bone 
lesions. A definite increase is defined as a 50% (and at leas t 1 cm) 
increase as measured serially  by the sum of the products of the 
cross -diameters of the measurable lesion
Hypercalcemia (> 11.5 mg/dL) [2.65 mmol/L ]
Decrease in haemoglobin of ≥ 2 g/dL [1.25 mmol/L ]
Rise in serum creatinine by  2 mg/dL or more [177 mol/L  or more]
Relapse from 
CR5(to be 
used only if 
the endpoint 
studied is 
DFS)8Any one or more of the following:
Reappearance of serum or urine M -protein by immunofixation or 
electrophoresis
Development of ≥ 5% plasma cells in the bone marrow7
Appearance of an y other sign of progression (i.e., new 
plasmacy toma, ly tic bone lesion, or hy percalcaemia)
Overall Responders:  PR, VGPR, CR, sCR
Clinical Benefit Rate:  Overall responders + MR
Adapted from Durie BGM, et al. Leukemia 2006; 20: 1467 -1473; and Ky le RA, 
Rajkumar SV. Leukemia
2008;23:3 -9.
Note: A clarification to IMWG criteria for coding CR and VGPR in patients in whom the 
only measurable
disease is b yserum FL C levels: CR in such patients is defined as a normal FL C ratio of 
0.26–1.65 in
addition to CR criteria listed above. VGPR in such patients is defined as a >90% decrease 
in the difference
between involved and uninvolved free light chain (FLC) level s.
3 Confirmation with repeat bone marrow biopsy  not needed.
2012N155299_05 CONFIDENTIA L
BMA117159
1654 Presence/absence of clonal cells is based upon the kappa/lambda ratio. An abnormal 
kappa/lambda ratioby  immunohistochemistry  and/or immunofluorescence requires a 
minimum of 100 plasma cells for analy sis. An abnormal ratio reflecting presence of an 
abnormal clone is kappa/lambda of > 4:1 or < 1:2.
5 All relapse categories require two consecutive assessments made at an y time before 
classification as relapse or disease progression and/or the institu tion of any  new therap y. 
In the IMWG criteria, CR patients must also meet the criteria for progressive disease 
shown here to be classified as progressive disease for the purposes of calculating time to 
progression and progression -free survival. The definit ions of relapse, clinical relapse and 
relapse from CR are not to be used in calculation of time to progression or progression 
free survival
6 For progressive disease, serum M -component increases of ≥1 gm/dL are sufficient to 
define relapse if starting M-component is ≥5 g/dL.
7 Relapse from CR has the 5% cut -off versus 10% for other categories of relapse.
8 For purposes of calculating time to p rogression and progression -free survival, CR 
patients should also be evaluated using criteria listed above for progressive disease.
2012N155299_05 CONFIDENTIA L
BMA117159
16616.2. Appendix 2: Revised Response Criteria for Malignant 
Lymphoma
Response Criteria for Malignant Lymphoma
Response Definition N odal Masses Spleen, L iver Bone Marrow
CR Disappearance of 
all evidence of 
disease(a). FDG -avid or 
PET positive prior 
to therapy; mass 
of any size 
permitted if PET 
negative
(b). Variably 
FDG -avid or Pet 
negative; 
regression to 
normal size on CTNot palpab le, 
nodules 
disappearedInfiltrate cleared on 
repeat biopsy; if 
indeterminate by 
morphology, 
immunohistochemistry 
should be negative
PR Regression of 
measurable 
disease and no 
new sites50% decrease in 
SPD of up to 6 
largest dominant 
masses; no 
increase in size of 
other nodes
(a). FDG -avid or 
PET positive prior 
to therapy; one or 
more PET 
positive at 
previously 
involved site
(b). Variably 
FDG -avid or PET 
negative; 
regression on CT50% decrease 
in SPD of 
nodules (for 
single nodule 
in greatest 
transverse 
diameter); no 
increase in size 
of liver or 
spleenIrrelevant if positive 
prior to therapy; cell 
type should be 
specified
SD Failure to attain 
CR/PR or PD(a). FDG -avid or 
PET positive prior 
to therapy; PET 
positive at prior 
sites of disease 
and no new site s 
on CT or PET
(b). Variably 
FDG -avid or PET 
negative; no 
change in size of 
previous lesions 
on CT
2012N155299_05 CONFIDENTIA L
BMA117159
167Response Criteria for Malignant Lymphoma
Response Definition N odal Masses Spleen, L iver Bone Marrow
Relapsed 
Disease or 
PDAny new lesion 
or increase by 
50% of 
previously 
involved sites 
from nadirAppearance of a 
new lesion(s) >1.5 
cm in any axis, 
50% increase in 
SPD of more than 
one node, or 
50% increase in 
longest diameter 
of a previously 
identified node >1 
cm in short axis
Lesions PET 
positive if FDG -
avid lymphoma or 
Pet positive prior 
to therapy>50% increase 
from nadir in 
the SPD or any 
previous 
lesionsNew or recurrent 
involvement
Abbreviations: CR = complete remission; FDG = [18F]fluorodeox yglucose; PET = 
positron emission tomography ; CT = computed tomography ; PR = partial remission; SPD 
= sum of the product of the diameters; SD = stable disease ; PD = progressive disease
2012N155299_05 CONFIDENTIA L
BMA117159
16816.3. Appendix 4: NYHA  Functional Classification Sy stem
The New York Heart Association (NYHA) Functional Classification: Class I, II, III 
or IV Heart Failure [NYHA , 1994] provides a simple way  of classify ing the extent of 
heart failure.  It places subjects in one of 4 categories based on the level of limitation 
experienced during ph ysical activity :
Class Symptoms
Class I
(Mild)No limitation of phy sical activity .  Ordinary  physical activity does 
not cause undue fatigue, palpitation or dyspnea (shortness of 
breath).
Class II
(Mild)Slight limitation of phy sical activity .  Comfortable at rest, but 
ordinary  physical activity results in fatigue, palpitation or dy spnea.
Class III
(Moderate)Marked lim itation of physical activity .  Comfortable at rest, but less 
than ordinary  physical activity  results in fatigue, palpitation or 
dyspnea.
Class I V
(Severe)Unable to carry  out any physical activity without discomfort.  
Symptoms of cardiac insufficiency  at rest.  If an y physical activity  is 
undertaken, discomfort is increased.
Reference:
The Criteria Committee of the New York Heart Association (NYHA).  Nomenclature and 
Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th Ed. Boston, Mass:   
Little, Brown & Co.;  1994:253 -256.
2012N155299_05 CONFIDENTIA L
BMA117159
16916.4. Appendix 5: Modified Diet in Renal Disease Formula
MDRD eGFR = 175× (S cr)-1.154× (Age)-0.203× (0.742 if female) × (1.212 if 
African American)
GFR is expressed in mL /min/1.73 m2, SCr is serum creatinine 
expressed in mg/dL, and age is expressed in years.
The link below will auto- calculate the creatinine clearance:
http://nephron.org/cgi -bin/MDRD_GFR/cgi
2012N155299_05 CONFIDENTIA L
BMA117159
17016.5. Appendix 6: ECOG Performance Status1
Grade Descriptions
0Normal activity .  Full y active, able to carry on al l pre-disease performance 
without restriction.
1Symptoms, but ambulatory .  Restricted in phy sically  strenuous activity , but 
ambulatory  and able to carry  out work of a light or sedentary  nature ( e.g., 
light housework, office work).
2In bed <50% of the time.  Ambulatory  and capable of all self -care, but 
unable to carry  out an y work activities.  Up and about more than 50% of 
waking hours.
3In bed >50% of the time.  Capable of onl y limited self -care, confined to 
bed or chair more than 50% of waki ng hours.
4100% bedridden.  Completely  disabled.  Cannot carry  on an y self-care.  
Totally  confined to bed or chair.
5 Dead.
1. [Oken , 1982]
Reference:
Oken, M.M., Creech, R.H., Tormey , D.C., Horton, J., Davis, T.E., McFadden, E.T., 
Carbone, P.P.: Toxicity  And Response Criteria Of The Eastern Cooperative Oncology  
Group. Am J Clin Oncol 5:649-655, 1982.
2012N155299_05 CONFIDENTIA L
BMA117159
17116.6. Appendix 7: Genetics
Genetics –Background
Naturall y occurring genetic variation may  contribute to inter -individual variability in 
response to medicines, as well as an individual's risk of developing specific diseases. 
Genetic factors associated with disease characteristics may  also be associated with 
response to therap y, and could help to explain some clinical study outcomes. For
example, genetic variants associated with age- related macular degeneration (AMD) are 
reported to account for much of the risk for the condition [ Gorin , 2012] with certain 
variants reported to influence treatment response [ Chen, 2012]. Thus, knowledge of the 
genetic etiology  of disease may  better inform understanding of disease and the 
development of medicines. Additionally , genetic variability  may  impact the 
pharmacokinetics (absorption, distribution, metabolism, and elimination), or 
pharmacod ynamics (relationship between concentration and pharmacologic effects or the 
time course of pharmacologic effects) of a specific medicine and/or clinical outcomes 
(efficacy  and/or safet y) observed in a clinical study.
Genetic Research Objectives and A nalyses
The objectives of the genetic research are to investigate the relationship between genetic 
variants and: 
Response to medicine, including GSK2857916 or any  concomitant medicines;
Multiple my eloma and l ymphomas e xpressing BC MAsusceptibility , severity , and 
progression and related conditions
Genetic data may  be generated while the study  is underway  or following completion of 
the study .  Genetic evaluations may  include focused candidate gene approaches and/or 
examination of a large number of genetic variants throughout the genome (whole genome 
analyses). Genetic anal yses will utilize data collected in the study  and will be limited to 
understanding the objectives highlighted above.  Analy ses may  be performed using data 
from mult iple clinical studies to investigate these research objectives.
Appropriate descriptive and/or statistical analy sis methods will be used. A detailed 
description of an y planned anal yses will be documented in a Reporting and Analy sis Plan 
(RAP) prior to init iation of the anal ysis. Planned analy ses and results of genetic 
investigations will be reported either as part of the clinical RAP and study  report, or in a 
separate genetics RAP and report, as appropriate.
Study Population
Any subject who is enrolled in p art 2 (expansion cohort) of the clinical study  can 
participate in genetic research.  An y subject who has received an allogeneic bone marrow 
transplant must be excluded from the genetic research.
Subject participation in the genetic research is voluntary  and refusal to participate will 
not indicate withdrawal from the clinical study .  Refusal to participate will involve no 
penalty  or loss of benefits to which the subject would otherwise be entitled.
2012N155299_05 CONFIDENTIA L
BMA117159
172Study Assessments and Procedures
A key  component of successful genetic research is the collection of samples during 
clinical studies. Collection of samples, even when no a priori hypothesis has been 
identified, may  enable future genetic anal yses to be conducted to help understand 
variability  in disease and medicin e response.  
A 6 ml blood sample will be taken for Deox yribonucleic acid (DNA) extraction. 
A blood sample is collected at the baseline visit, after the subject has been 
randomized and provided informed consent for genetic research. Instructions for 
collec tion and shipping of the genetic sample are described in the laboratory  
manual. The DNA from the blood sample may  undergo quality  control analy ses to 
confirm the integrit y of the sample. If there are concerns regarding the quality  of 
the sample, then the s ample may  be destroy ed. The blood sample is taken on a 
single occasion unless a duplicate sample is required due to an inabilit y to utilize 
the original sample.  
The genetic sample is labelled (or “coded”) with the same stud y specific number used to 
label other samples and data in the study .   This number can be traced or linked back to 
the subject by  the investigator or site staff. Coded samples do not carry  personal 
identifiers (such as name or social security  number). 
Samples will be stored securel y and may  be kept for up to 15 y ears after the last subject 
completes the study , or GSK may  destroy  the samples sooner.  GSK or those working 
with GSK (for example, other researchers) will only use samples collected from the study  
for the purpose stated in thi s protocol and in the informed consent form.  Samples may  be 
used as part of the development of a companion diagnostic to support the GSK medicinal 
product.
Subjects can request their sample to be destro yed at any  time.
Informed Consent
Subjects who do not wish to participate in the genetic research may  still participate in the 
study .  Genetic informed consent must be obtained prior to any blood being taken.
Subject Withdrawal from Study
If a subject who has consented to participate in genetic research with draws from the 
clinical study  for any  reason other than being lost to follow -up, the subject will be given a 
choice of one of the following options concerning the genetic sample, if already  
collected:
Continue to participate in the genetic research in whic h case the genetic DNA 
sample is retained
Discontinue participation in the genetic research and destroy  the genetic DNA 
sample 
2012N155299_05 CONFIDENTIA L
BMA117159
173If a subject withdraws consent for genetic research or requests sample destruction for an y 
reason, the investigator must complet e the appropriate documentation to request sample 
destruction within the timeframe specified b y GSK and maintain the documentation in 
the site study  records . 
Genoty pe data may  be generated during the study  or after completion of the study  and 
may be anal yzed during the study  or stored for future anal ysis. 
If a subject withdraws consent for genetic research and genot ype data has not been 
analyzed, it will not be analy zed or used for future research.  
Genetic data that has been anal yzed at the time of with drawn consent will 
continue to be stored and used, as appropriate. 
Screen and Baseline Failures
If a sample for genetic research has been collected and it is determined that the subject 
does not meet the entry  criteria for participation in the study , then the investigator should 
instruct the subject that their genetic sample will be destro yed. No forms are required to 
complete this process as it will be completed as part of the consent and sample 
reconciliation process.  In this instance a sample destructi on form will not be available to 
include in the site files.
Provision of Study Results and Confidentiality  of Subject’s Genetic Data
GSK may  summarize the genetic research results in the clinical study  report, or 
separately  and may  publish the results in scientific journals. 
GSK may  share genetic research data with other scientists to further scientific 
understanding in alignment with the informed consent. GSK does not inform the subject, 
family  members, insurers, or employ ers of individual genoty ping resu lts that are not 
known to be relevant to the subject’s medical care at the time of the study , unless 
required b y law. This is due to the fact that the information generated from genetic 
studies is generall y preliminary in nature, and therefore the signific ance and scientific 
validity  of the results are undetermined.  Further, data generated in a research laboratory  
may not meet regulatory  requirements for inclusion in clinical care.
References
Chen H, Yu KD, Xu GZ. Association between Variant Y402H in Age-R elated Macular 
Degeneration (AMD) Susceptibility  Gene CFH and Treatment Response of AMD: A 
Meta -Anal ysis. PloS ONE 2012; 7: e42464
Gorin MB. Genetic insights into age -related macular degeneration: Controversies 
addressing risk, causality, and therapeutics . Mol. Asp. Med. 2012; 33: 467-486.
2012N155299_05 CONFIDENTIA L
BMA117159
17416.7. Appendix 8: Liver Safety  Drug Restart Guidelines
Drug restart may  be considered for a subject exhibiting compelling benefit for a critical 
medicine following drug -induced liver injury , if there is favorable benefit: risk ratio and 
no alternative medicine available.
Background Information on Drug Restart/Rechallenge
Following drug -induced liver injury , drug restart or rechallenge is associated with a 
13% mortality across all drugs in prospective studies.1  Clinical outcome s vary  by 
drug, with nearl y 50% fatality  with halothane readministered in one month of initial 
injury . However, some drugs seldom result in recurrent liver injury  or fatality .  Risk 
factors for a fatal drug restart/rechallenge outcome include: hy persensiti vity1with initial 
liver injury  (e.g. fever, rash, eosinophilia), jaundice or bilirubin  2xULN or INR>1.5 
suggesting severe liver injury , prior I P-related severe or fatal drug restart/rechallenge2,3 or 
evidence of drug- related preclinical liability  / mitoc hondrial impairment3.
Drug Restart/Rechallenge Process (also see Figure 1)
6.Principal I nvestigator (PI) requests consideration of drug restart for a subject 
receiving compelling benefit from a critical or life- saving drug , who exhibits liver 
chemistry  elevation meeting subject stopping criteria, with no alternative 
treatment.
GSK Medical Monitor & Clinical Safety  Physician.to review the subject’s 
restart/rechallenge risk factors & complete checklist ( Table 18 ).
Table 18 Checklist for drug restart/rechallenge for critical medicine
(Following drug -induced liver injury, drug rechallenge is associated with 13% mortality 
across all drugs in prospective studi es)
Yes No
Compelling benefit of the investigational product (IP) for this subject 
andno alternative therapy .  Provide brief explanation :
Relative benefit -risk favorable for drug restart/rechallenge , after 
considering the follo wing high risk factors :
•Initial liver injury event included: 
–fever, rash, eosinophilia, or hypersensitivity
–or bilirubin 2xULN (direct bilirubin >35% of total)
•Subject currently exhibits ALT 3xULN, bilirubin 2xULN (direct 
bilirubin >35% of total), orINR1.5
•Severe or fatal restart/rechallenge has earlier been observed 
with IP If yes, please provide brief explanation :
•IP associated with known preclinical hepatic liability/ injury 
2012N155299_05 CONFIDENTIA L
BMA117159
175If GSK provides written approval for restart/rechallenge following the ab ove review, 
the Principal Investigator (PI) must ensure the following:
The PI  is to obtain Ethics Committee or I nstitutional Review Board review of 
drug re -initiation, as required. 
PI must discuss the possible benefits and risks of drug re- initiation with the 
subject.
The subject must sign informed consent with a clear description of possible 
benefits and risks of drug administration, including recurrent liver injury  or death. 
Consent specificall y for the I P restart must be recorded in the study  chart.
Thedrug must be reinitiated at GSK approved dose(s). 
Subjects approved b y GS K for restart of IP must return to the clinic twice a week 
for liver chemistry  tests until stable, liver chemistries have been demonstrated and 
then laboratory  monitoring may  resume as per protocol.  If protocol defined 
stopping criteria for liver chemistry  elevations are met, study  drug must be 
stopped.
The Ethics Committee or I nstitutional Review Board is to be informed of the 
subject’s outcome, as required.
GSK is to be notified of any  adverse events, as per Section 8.5.2.
2012N155299_05 CONFIDENTIA L
BMA117159
176
References:
Andrade RJ, Robles M, Lucena MI. Rechallenge in drug -induced liver injury :the 
attractive hazard. Expert Opin Drug Saf 2009;8:709– 714.
Hunt CM. Mitochondrial and immunoallergic injury  increase risk of positive drug 
rechallenge after drug -induced liver injury : a systematic review. Hepatology  
2010;52:2216–2222
Papay  JI, Clines D, Rafi R, Yuen N, Britt SD, Walsh JS, et al. Drug- induced liver injury  
following positive drug rechallenge. Regul Toxicol Pharmacol 2009;54:84-90.
2012N155299_05 CONFIDENTIA L
BMA117159
177

2012N155299_05 CONFIDENTIA L
BMA117159
17816.8. Appendix 9: Urine Protein Creatinine (UPC) Ratio Clinical 
meaning of UPC
There is a good correlation between the ratio of protein concentration to creatinine 
concentration in a random urine sample and the amount of protein excreted over 
24 hours.  Creatinine excretion is fairl y constant throughout the day  regardless of changes 
in urine flow rate.
Normal protein excretion is <150 mg/24 hours and is similar for men and women.
Men excrete 20 mg to 25 mg of creatinine/kg of body  weight/day .
Women excrete 15 mg to 20 mg of creatinine/kg of body  weight/day .
Calculating UPC
UPC ratio = Urine protein (mg/dL) / Urine creatinine (mg/dL). 
UPC ratio ≈ equivalent to grams of protein excreted in urine over 24 hrs. 
Example:   Patient has a urine protein = 90 mg/dL and urine creatinine = 30 mg/dL.  
UPC ratio= (90 mg/dL) / (30 mg/dL) =  3  
The calculated UPC ratio is 3, which correlates to roughl y 3 g protein excretion in a 24 -
hour period.
Units for UPC ratio
Note: To calculate UPC, protein and creatinine concentrations must be expressed in the 
same units (mg/dL, g/L, or μmol/L). If, for example, protein concentration is expressed 
in mg/dL  and creatinin e concentration is expressed in µmol/L , conversion of one of the 
concentration values is required.  Conversion factors are: 
From To Conversion Factor 
Conventional Units: mg/dL SI Units: µmol/L Multiply by 88.4
SI Units: µmol/L Conventional Units: mg/dL Divide 88.4 
References:
NKF: NKF KDOQI Guidelines [I nternet].  National Kidney  Foundation; nd.  KDOQI 
Clinical Practice Guidelines for Chronic Kidney  Disease: Evaluation, Classification, and 
Stratification.  Available from 
http://www.kidney .org/profe ssionals/KDOQI/guidelines_ckd/p5_lab_g5.htm
Xin G, Wang M, Jian L , Xu F, Wang H.  Protein -to-creatinine ratio in spot urine samples 
as a predictor of quantitation of proteinuria 2004. Clinica Chimica Acta 350:35 -39.
2012N155299_05 CONFIDENTIA L
BMA117159
17916.9. Appendix 10: Blood Requirements
16.9.1. Blood R equirements for A ll Lab Tests, Except PK
16.9.1.1. Dose Escalation: Every 3 Weeks for Multiple Myeloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 15-20 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda 
free LC, FLC1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 5 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Total 59.5 ml 51.5-66.5 ml 45.5-51.5 ml
1. Required for women of childbearing potential
16.9.1.2. Dose Escalation:  Weekly  for Multiple My eloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 15-20 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
2012N155299_05 CONFIDENTIA L
BMA117159
180Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 6ml 6 ml 6ml
sBCMA 1 ml 6 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Total 43.5 ml 73.5-88.5 ml 48.5-54.5 ml
1. Required for women of childbearing potential
16.9.1.3. Dose Expansion:  Every 3 Weeks for Multip le Myeloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 6ml 6 ml 6ml
sBCMA 1 ml 2 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Genetics Sample 6 ml 6 ml
Total 43.5 ml 68.5-83.5 ml 48.5-54.5 ml
1. Required for women of childbearing potential
2012N155299_05 CONFIDENTIA L
BMA117159
18116.9.1.4. Dose Expansion:  Weekly  for Multiple My eloma
Test Sampl e Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5-10 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 6ml 6 ml 6ml
sBCMA 1 ml 1 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Genetics Sample 6 ml 6 ml
Total 43.5 ml 68.5-83.5 ml 48.5-59.5 ml
1.Required for w omen of childbearing potential
16.9.1.5. Dose Expansion:  Every 3 Weeks for Ly mphomas
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 6ml 6ml 6ml
2012N155299_05 CONFIDENTIA L
BMA117159
182Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
sBCMA 1 ml 1 ml 0-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Genetics Sample 6 ml 6ml
Total 36.5 ml 67.5-82.5 ml 40.5-47.5 ml
1. Required for w omen of childbearing potential
16.9.1.6. Dose Expansion:  Weekly  for Ly mphomas
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5-10 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 6ml 6ml 6ml
sBCMA 1 ml 5 ml 0-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Genetics Sample 6 ml 6 ml
Total 36.5 ml 74.5-89.5 ml 40.5-51.5 ml
1. Required for w omen of childbearing poten tial
16.9.2. Blood Requirements for PK
PK Schedule Sample 
VolumeCycle 1 Cycle 2 Cycle 3 Cycle 5 Total 
Volume
Escalation Every 3 Weeks 5ml 60ml 10ml 10ml 80ml
Escalation Weekly 5ml 80ml 10ml 10ml 100ml
Expansion Every 3 Weeks 
MM5ml 20ml 20 ml 20 ml 20ml 80ml
Expansion Weekly MM 5ml 20ml 10ml 10ml 10ml 50ml
Expansion Every 3 Weeks 
Lymphomas5ml 40ml 20ml 20ml 10ml 90ml
Expansion Weekly 
Lymphomas5ml 40ml 20ml 20ml 10ml 90ml
2012N155299_05 CONFIDENTIA L
BMA117159
18316.9.3. Total Blood Requirements
Schedule Screeni ng Cycle 1 Each Subsequent 
Cycle
Escalation Every  3 Weeks 
MM59.5 ml 51.5-66.5 ml 45.5-51.5 ml
Escalation Weekl y MM 43.5 ml 73.5-88.5 ml 48.5-54.5 ml
Expansion Every  3 Weeks 
MM43.5 ml 68.5-83.5 ml 48.5-54.5 ml
Expansion Weekly  MM 43.5 ml 68.5-83.5 ml 48.5-59.5 ml
Expansion Every  3 Weeks 
Lym phomas36.5 ml 67.5-82.5 ml 40.5-47.5 ml
Expansion Weekly  
Lym phomas36.5 ml 74.5-89.5 ml 40.5-51.5 ml
The Study  Procedures Manual will be updated with new information if changes in blood 
volumes are required.
2012N155299_05 CONFIDENTIA L
BMA117159
18416.10. Appendix 11:  Pgp Inhibitors
Amiodarone
Atorvastatin
Azithromy cin
Carvedilol
Clarithromy cin
Dronedarone
Fluvoxamine
Indinavir
Indinavir and Ritonavir
Itraconazole
Ketonazole
Lapatinib
Lopinavir and Ritonavir
Nicardipine
Quinidine
Ranolazine
Ritonavir
Saquinavir and R itonavir
Telaprevir
Verapamil
Valspodar
The Study  Procedures Manual will be updated if changes to the Pgp inhibitor list is 
required.
2012N155299_05 CONFIDENTIA L
BMA117159
18516.11. Appendix 1 2: Protocol A mendment Changes
16.11.1. Amendment 1
Where the A mendment A pplies
United Kingdom
Summary  of A mendme nt Changes with Rationale
1.Regulatory  Agency  Identify ing Number(s): Corrected EudraCT Number
Rationale:  Ty pographical error corrected.
2.Protocol Sy nopsis, Exclusion Criteria, page 25; Section 5.2.2, Exclusion Criteria, 
page 85: Added #18
Rationale: MHRA req uested the exclusion of subjects with current or history  
of corneal pathology  given the corenal necrosis seen in rat studies.
3. Section 3.3, Part 1: Dose- Escalation Phase, page 47; Section 3.3.1.2.1, Planned 
Dose Levels, pages 50 and 51; Section 3.3.3, Dose- Limiting Toxicity  –Part 1 
only, page 54; Section 3.4, RP2 Dose and Administration Schedule Selection for 
Part 2, page 56: Added reference to new Section 12.1, Data Dissemination and 
Communication Plan.
Rationale:  References to new section on data dissemi nation and 
communication to sites requested b y MHRA added.  
4. Section 3.9.2, QTc Stopping Criteria, page 67; Section 3.10.3, Dose 
Modifications Table 13, page 77.
Rationale: MHRA requested subjects with increase in QTc > 60 msec from 
baseline be withdrawn f rom study  treatment.
5.Section 12.1, Data Dissemination and Communication Plan, page 132.
Rationale: MHRA requested a detailed communication plan be included in the 
protocol.  This plan should address the assignment of subjects to a cohort with 
consideration of cohort size and number of sites, and should address how 
dissemination of safet y data to all sites will be handled.
2012N155299_05 CONFIDENTIA L
BMA117159
186List of Specific Changes
Regulatory  Agency  Identifying Number(s):
OLD TEXT
Compound Number IND Number EudraCT Number
GSK2857916 119333 2003-004549 -18
NEW TEXT
Compound Number IND Number EudraCT Number
GSK2857916 119333 2003 2013 -004549 -18
Protocol Sy nopsis, Exclusion Criteria
NEW TEXT
18. Current corneal disease or a history  of corneal disease.
Section 3.3 Part 1: Dose -Escalation Phase
NEW TEXT
Note:  For details on data dissemination and communication with sites (dose escalation 
meetings and safet y update meetings), refer to Section 12.1.
Section 3.3.1.2.1 Planned Dose Levels, 2ndParagraph
PREVI OUS TEXT
Description of the New Continua l Reassessment Method : After each cohort, a dosing 
recommendation for the next cohort will be made using the N-CRM [Neuenschwander, 
2008].  All available data, including safet y, PK and PD data from current and prior 
cohorts will be reviewed at the dose esc alation meeting. Although the N- CRM will be 
used to recommend the next dosing level, clinical judgment b y the Medical Monitor and 
internal dose -escalation committee in consultation with the investigators can halt 
enrolment into lower dose cohorts as deemed appropriate at any  time during the trial.
REVI SED TEXT
Description of the New Continual Reassessment Method : After each cohort, a dosing 
recommendation for the next cohort will be made using the N-CRM [Neuenschwander, 
2008].  All available data, including safet y, PK and PD data from current and prior 
cohorts will be reviewed at the dose escalation meeting (see Section 12.1) . Although the 
2012N155299_05 CONFIDENTIA L
BMA117159
187N-CRM will be used to recommend the next dosing level, clinical judgment by  the 
Medical Monitor and internal dose -escala tion committee in consultation with the 
investigators can halt enrolment into lower dose cohorts as deemed appropriate at any  
time during the trial.
Section 3.3.1.2.1 Planned Dose Levels, 6thParagraph
PREVI OUS TEXT
The recommended dose will be the dose wi th the highest posterior probability  of ly ing in 
the target toxicity  interval with the additional requirement that the sum of the posterior 
probabilities of the DLT rate l ying in the excessive toxicity  or unacceptable toxicity  
range is less than 25%.  Selection of the next dose cohort to be enrolled is also subject to 
the constraint that the next dose level can be no more than two times that of the current 
dose level. An updated estimate of the toxicity  curve will be provided at the time of each 
dose escala tion meeting.
REVI SED TEXT
The recommended dose will be the dose with the highest posterior probability  of ly ing in 
the target toxicity  interval with the additional requirement that the sum of the posterior 
probabilities of the DLT rate l ying in the excessive toxicity  or unacceptable toxicity  
range is less than 25%.  Selection of the next dose cohort to be enrolled is also subject to 
the constraint that the next dose level can be no more than two times that of the current 
dose level. An updated estimate of the toxicity  curve will be provided at the time of each 
dose escalation meeting (see Section 12.1) .
Section 3.3.3, Dose Limiting Toxicity  –Part 1 Only
PREVI OUS TEXT
Any subject in Part 1 (Dose Escalation) who received at least one dose of the drug 
(regardless of schedule) will be evaluated for DLTs 
REVI SED TEXT
Any subject in Part 1 (Dose Escalation) who received at least one dose of the drug 
(regardless of schedule) will be evaluated for DLTs.  Safety data together with DLTs 
will be reviewed during the dose escalation meetings prior to opening enrollment 
into subsequent cohorts (see Section 12.1).
Section 3.4, RP2 Dose and A dministration Schedule Selection for Part 2
NEW TEXT
Note:  For details on data dissemination and communication with sites (s afety  update 
meetings), refer to Section 12.1.
2012N155299_05 CONFIDENTIA L
BMA117159
188Section 3.9.2, QTc Stopping Criteria
PREVI OUS TEXT
If a subject that meets the corrected QT (QTc)1 interval duration criteria below, study  
treatment(s) will be withheld.  
QT interval corrected for heart rate by Fridericia’s formula (QTcF) >530 msec
1Based on average QTc value of triplicate electrocardiograms (ECGs) to include manual 
over-read.  For example, if an ECG demonstrates a prolonged QT interval, obtain 2 
additional ECGs over a brief period (e.g., within approximately  10 minutes of the 
abnormal ECG, if possible, and approximately  10 minutes apart from each other), and 
then use the averaged QTc values of the 3 ECGs to determine whether the subjects 
should have study  treatment withheld.
If the QTc prolon gation resolves to Grade 1 or baseline, the subject may  be re -started on 
the study  treatment if the investigator and GSK Medical Monitor agree that the subject 
will benefit from further treatment.
REVI SED TEXT
Study treatment will be withheld in Ifa subje ct thatwho meets the corrected QT 
(QTc)1 interval duration criteria below, study  treatment(s) will be withheld.  
QT interval corrected for heart rate b y Fridericia’s formula (QTcF) > 530500msec
or
Increase in QTc of > 60 msec from baseline
1Based on aver age QTc value of triplicate electrocardiograms (ECGs) to include manual 
over-read.  For example, if an ECG demonstrates a prolonged QT interval, obtain 2 
additional ECGs over a brief period (e.g., within approximately  10 minutes of the 
abnormal ECG, if possible, and approximately  10 minutes apart from each other), and 
then use the averaged QTc values of the 3 ECGs to determine whether the subjects 
should have study  treatment withheld.
If the QTc prolongation resolves to Grade 1 or baseline, the subject may  be re -started on 
the study  treatment if the investigator and GSK Medical Monitor agree that the subject 
will benefit from further treatment.
2012N155299_05 CONFIDENTIA L
BMA117159
189Section 3.10.3, Dose Modifications
PREVI OUS TEXT
Table 13 Dose A djustment/Stopping Criteria
Toxicity GradeaDose Modification of GSK2857916
Grade 1Continue at current dose level. Consider supportive care 
recommendations 
Grade 2If toxicity is considered not clinically relevant, continue with 100% 
scheduled dose
If toxicity is considered clinically relevant withhol d the dose until 
toxicity resolves to Grade 1 or baseline. If resolved within 14 days, 
then restart at current dose level. Consider supportive care 
recommendations
If not resolved within 14 days, discuss with GSK Medical Monitor 
Grade 3Withhold dose u ntil toxicity resolves to Grade 1 or baseline, unless 
condition fits exceptions noted below. If resolved within 14 days, 
resume treatment at dose reduced by 25% (first dose reduction), or 50% 
(second dose reduction). Consider supportive care recommenda tions.  
If not resolved within 14 days, discuss with GSK Medical Monitor  
Exceptions :
Subjects who develop G3 toxicities which respond to standard treatment 
and resolve to G1 within 48 hours may continue treatment at 
scheduled or reduced dose
Permanen tly discontinue for grade 3 or greater QTc prolongation ie, 
QTcF >530 msec 
Troponin elevations: See Section 3.9.3 for troponin stopping criteria
Grade 4Permanently discontinue study medication
Exceptions:
G4 thrombocytopenia with no sign of bleeding, i f recovered within 
14 days.  For dose reductions see Section 3.10
G4 lymphopenia (dose reductions by 25 -50% may be considered
b.Considered related to investigational drug.
2012N155299_05 CONFIDENTIA L
BMA117159
190REVI SED TEXT
Toxicity GradeaDose Modification of GSK2857916
Grade 1Continue at current dose level. Consider supportive care 
recommendations 
Grade 2If toxicity is considered not clinically relevant, continue with 100% 
scheduled dose
If toxicity is considered clinically relevant withhold the dose until 
toxicity resolves to Grade 1 or baseline. If resolved within 14 days, 
then restart at current dose level. Consider supportive care 
recommendations
If not resolved within 14 days, discuss with GSK Medical Monitor 
Grade 3Withhold dose until toxicity resolves to Grade 1 or baseline, unless 
condition fits exceptions noted below. If resolved within 14 days, 
resume treatment at dose reduced by 25% (first dose reduction), or 50% 
(second dose reduction). Consider supportive care recommendations.  
If not resolved within 14 days, discu ss with GSK Medical Monitor  
Exceptions :
Subjects who develop G3 toxicities which respond to standard treatment 
and resolve to G1 within 48 hours may continue treatment at 
scheduled or reduced dose
Permanently discontinue for grade 3 or greater QTc pr olongation ie, 
QTcF > 500 500 msec or QTcF increase by > 60 msec from baseline
Troponin elevations: See Section 3.9.3 for troponin stopping criteria
Grade 4Permanently discontinue study medication
Exceptions:
G4 thrombocytopenia with no sign of bleedin g, if recovered within 
14 days.  For dose reductions see Section 3.10
G4 lymphopenia (dose reductions by 25 -50% may be considered
c.Considered related to investigational drug.
Section 5.2.2, Exclusion Criteria
NEW TEXT
18. Current corneal disease or a h istory  of corneal disease.
Section 12.1, Data Dissemination and Communication Plan
NEW TEXT
The GSK Medical Monitor will review screening packets to ensure that subjects being 
considered for enrollment meet eligibility  criteria prior to entering the study .  Subjects 
will not be assigned a study  number until their screening packet is reviewed and approved 
by the GSK Medical Monitor.  GSK will remain in constant contact with the clinical sites 
during the enrolment period to ensure that cohort enrolment in Par ts 1 and 2 of this study  
2012N155299_05 CONFIDENTIA L
BMA117159
191are completed as per protocol.  I nvestigators will be informed about available openings 
for enrolment on the trial and will be asked to pre- screen their subjects to determine 
potential eligibility , and to avoid over -enrolment. Enrolment will be offered to a given 
site for a limited period of time, and if the site chosen cannot successfull y enrol a subject 
within a pre -specified time period then another site will be offered the opportunity  to 
enrol a subject.  
During Part 1 of the s tudy, Study  Team Safet y Update Meetings will be held every three 
weeks to review relevant data with the Principal Investigators (or delegates) and site staff. 
These meetings will be held on an “as needed” basis (but no less frequent than once a 
month) during Part 2 (eg, to share safet y experience and to communicate results of 
scheduled futility anal yses).  Safet y, PK, PD, and clinical outcome data available for all 
subjects at the time of the scheduled Safet y Update Meeting will be reviewed and 
summarized. In addition, Dose Escalation Meetings will be scheduled at the conclusion 
of the DLT assessment period for subjects enrolled in each cohort to review safet y PK, 
and PD data and determine the next dose level appropriate for study . Dose escalation 
decisions will be made with team and investigator agreement after review of available 
safet y data from at least one cycle of therap y with GSK2867916 (ie, 21 days for the once 
every  3 weeks schedule and 28 day s for weekl y schedule).  All dose escalation or safet y 
decisions will be documented in writing with copies maintained at each site and the 
Master Study  Files at GSK.  Available data will be provided to participants prior to each 
scheduled Safety  or Dose Escalation Meeting.
Attendees of Safet y Update and Dose Esc alation Meetings will include but not limited to 
all clinical investigators (or designees) and site staff, the GSK Medical Monitor, Clinical 
Investigation Lead, Clinical Operations Study  Lead (USA and Local Operating Company  
designees), Data Quality  Leader , Global Clinical Safet y and Pharmacovigilance 
Representative, Statistician, Pharmacokineticist, and Translational Medicine Lead.
2012N155299_05 CONFIDENTIA L
BMA117159
19216.11.2. Amendment 2
Where the A mendment A pplies
Canada, United Kingdom, United States
Summary  of A mendment Changes with Rationale
1. Pag e 1, Subject
Rationale: updated key  words of subject
2.Page 2, Amendment 1 Rationale
Rationale:  updated wording of Amendment 1 rationale for clarit y
3.Page 12, List of Abbreviations
Rationale:  removed abbreviations no longer being used in the protocol and 
made corrections to ty pographical errors
4.Page 18, Stud y Objectives, Endpoints and Hy potheses and Section 2
Rationale:  corrected definition of MR from Minor Response to Minimal 
Response
5.Page 20, Protocol Sy nopsis I nclusion Criteria and Section 5.2.1 I nclusio n Criteria
Rationale:  updated Inclusion Criterion #2 to add minimum weight requirement 
to ensure subjects do not exceed maximum blood volume sampled for research 
tests within a month
6.Page 27, Clinical Activity  Assessment
Rationale: corrected definition of MR from Minor Response to Minimal 
Response
7.Section 1.2.3.4.1 and Section 10
Rationale:  added restriction for use of Pgp inhibitors per FDA request
8.Section 3.1, Table 3
Rationale:  added “serial” to add clarity on PK samples required for subjects in 
Dose Escalation
Per FDA request, added text that maxmimum dose to be administered will not 
exceed 5mg/kg
9. Section 3.3.1.1
Rationale:  Per FDA request, removed specification of “clinicall y significant” 
in reference to toxicities
10. Section 3.1, Section 3.3.1.2.1, and Section 3.8
2012N155299_05 CONFIDENTIA L
BMA117159
193Rationale:  Per FDA request, added the maximum dose of drug to be 
administered in the study
11. Section 3.3.3
Rationale:  Per FDA request, removed specification of “clinicall y significant” 
in reference to toxicities.  Clarified the DLT definiti ons of thrombocy topenia 
and skin reactions
12. Section 3.8
Rationale: Per FDA request, added text that maxmimum dose to be 
administered will not exceed 5mg/kg
13. Section 3.9.5
Rationale: Added clarification on use of premedication before the first dose if 
warrant ed.  Added clarification on management of subjects with grade 3 
allergic reactions or cy tokine release s yndrome
14. Section 3.9.6
Rationale:  Added further clarification on management of subjects with allergic 
reactions per FDA request
15. Section 3.9.8
Rationale:   Per FDA request, added stopping criteria for subjects with corneal 
toxicity
16. Section 3.10.2
Rationale: Clarifications added on dose adjustments and stopping criteria for 
serum creatinine, thrombocy topenia, INR prolongation, and ocular toxicity.
17. Section 4
Rationale:  Added Lot # restrictions per FDA request. Updated storage 
conditions of prepared drug.
18. Section 6.3
Rationale:  Per FDA request, added clarification on discontinuation from study
19. Section 7.1
Rationale:  Updated all Time and Events tables for Dos e Escalation and Dose 
Expansion to add Hepatitis B and C testing at Screening, removal of sBCMA 
and cy tokine samples at Screening, and clarification on PD samples
20.Section 7.3.6, Table 15
Rationale:  Updated clinical laboratory  test table to remove tests no t required in 
the study
21. Section 7.4.1
Rationale:  Updated blood volume for PK samples
22.Appendix 10
2012N155299_05 CONFIDENTIA L
BMA117159
194Rationale:  updated blood volume tables
23.Appendix 11
Rationale:  New appendix added per FDA request to list Pgp I nhibitors
List of Specific Changes
Example hea ding is listed below, and should be modified as appropriate.
Title Page, Subject
PREVI OUS TEXT
Multiple My eloma, BCMA expressing, Advanced Hematologic Malignancies
REVI SED TEXT
Multiple My eloma, BCMA expressing ,Advanced Hematologic Malignancies
Revision C hronology
PREVI OUS TEXT
2012N155299_01 2014 -MAR -01 Amendment 01: Country specific 
Amendment for the United Kingdom to 
address required changes per MHRA.  
Updated Exclusion Criteria to exclude 
subjects with current or medical history  
of corneal pathology .  Updated QTc 
withdrawal criterion to modify  QTc 
withdrawal for QTc 500msec and to 
include > 60 msec increase from 
baseline.  Updated Data Management 
Section 12 to include details on 
dissemination of data and 
communication plan.  
2012N155299_05 CONFIDENTIA L
BMA117159
195REVI SED TEXT
2012 N155299_01 2014 -MAR -01 Amendment 01: Country specific 
Amendment for the United Kingdom to 
address required changes per MHRA.  
Updated Exclusion Criteria to exclude 
subjects with current or medical corneal 
disease or history  of corneal pathology
disease .  Updated QTc withdrawal 
criterion to modify  QTc withdrawal for 
QTc 500msec and to include > 60 
msec increase from baseline.  Updated 
Data Management Section 12 to 
include details on dissemination of data 
and communication plan.  
List of A bbreviations
PREVIOUS TEXT
CPK Creatine Phosphokinase
CK Creatinine kinase
CK-MB Creatin ine kinase MB -isoenzy me
MR Minor response
REVI SED TEXT
CPK Creatine Phosphokinase
CK Creatin ine kinase
CK-MB Creatin ine kinase MB -isoenzy me
MR Minor Minimal response
2012N155299_05 CONFIDENTIA L
BMA117159
196Protocol Sy nopsis, Study Objectives
PREVI OUS TEXT
Secondary
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and other BCMA 
expressing hematologic 
malignanciesClinical activity  measured as Overall Respons e 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minor response (MR) will be assessed for 
clinical benefit rate (CBR) (Appendix 1)
oFor Other Hematologic Malignancies: the 
percentage of subjects achieving PR or 
better ( PR) (Appendix 2 and Appendix 3) 
REVI SED TEXT
Secondary
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and othe r BCMA 
expressing hematologic 
malignanciesClinical activity  measured as Overall Response 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subje cts with 
minor minimal response (MR) will be 
assessed for clinical benefit rate (CBR) 
(Appendix 1)
oFor Other Hematologic Malignancies: the 
percentage of subjects achieving PR or 
better ( PR) (Appendix 2 and Appendix 3) 
Protocol Sy nopsis, Inclusion Crit eria
PREVI OUS TEXT 
2.Male or female, 18 yearsor older (at the time consent is obtained).
2012N155299_05 CONFIDENTIA L
BMA117159
197REVI SED TEXT
2.Male or female, 18 years or older (at the time consent is obtained) and must have a 
body  weight of at least 45 kg (99 lb).
Protocol Sy nopsis, Clinical A ctivity  Assessment
PREVI OUS TEXT
CLINICAL ACTIVITY 
ASSESSMENTClinical activity  will be measured as Overall Response Rate 
(ORR) which is defined as follows:
For MM: the percentage of subjects with confirmed 
stringent complete response (sCR), complete resp onse 
(CR), very  good partial response (VGPR), and partial 
response (PR) as assessed by  2011 recommendation of 
the International M yeloma Working Group (IMWG) 
Panel I .   Clinical benefit rate (CBR), including minor 
response (MR), may be considered in addition to ORR.
(Appendix 1 ).  
For Other Hematologic Malignancies: the percentage of 
subjects with confirmed CR, PR, as described in the 
Revised Response Criteria for Malignant Ly mphoma 
(Appendix 2 ) and for CLL Appendix 3 ). 
REVI SED TEXT
CLINICAL ACTIVITY 
ASSESSMENTClinical activity  will be measured as Overall Response Rate 
(ORR) which is defined as follows:
For MM: the percentage of subjects with confirmed 
stringent complete response (sCR), complete response 
(CR), very  good partial response (VGPR), and part ial 
response (PR) as assessed by  2011 recommendation of 
the International M yeloma Working Group (IMWG) 
Panel I .   Clinical benefit rate (CBR), including minor
minimal response (MR), may be considered in addition 
to ORR. (Appendix 1 ).  
For Other Hematologi c Malignancies: the percentage of 
subjects with confirmed CR, PR, as described in the 
Revised Response Criteria for Malignant Ly mphoma 
(Appendix 2 ) and for CLL Appendix 3 ). 
2012N155299_05 CONFIDENTIA L
BMA117159
198Section 1.2.3.4.1, Victim interaction potential
NEW TEXT
Concomitant dosing of GSK2857916 with strong Pgp inhibitors should be avoided unless 
considered medicall y necessary ( See Appendix 11:  Pgp Inhibitors for list of relevant Pgp 
inhibitors).
Section 2, Objective(s), Endpoint(s) and Hypothesis
PREVI OUS TEXT
Secondary
Objective Endpoint
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and other BCMA 
expressing hematologic 
malignanciesClinical activity  measured as Overall Response 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minor response (MR) will be assessed for 
clinical benefit rate (CBR) ( Appendix 1 )
oFor Other Hematologic Malignancies: the 
percentage of subjects achieving PR or 
better ( PR) ( Appendix 2 and Appendix 3 ) 
REVI SED TEXT
Secondary
Objective Endpoint
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and other BCMA 
expressing hematologic 
malignanciesClinical activity  measured as Overall Response 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minor minimal respons e (MR) will be 
assessed for clinical benefit rate (CBR) 
(Appendix 1 )
oFor Other Hematologic Malignancies: the 
percentage of subjects achieving PR or 
better ( PR) ( Appendix 2 and Appendix 3 ) 
2012N155299_05 CONFIDENTIA L
BMA117159
199Section 3.1, Discussion of Study Design, Table 3 Study  Design
PREVI OUS TEXT
Part 1 Dose Escalation (n=up to 30 subjects )
Population:   relapsed/refractory MM
Characterize safety, PK, PD, immunogenicity and establish RP2 dose of GSK2857916
Schedule 1 : GSK2587916 once every 3 weeks (21 -day cycle) (n=~20)
Schedule 2 :GSK2587916 once weekly for 3 consecutive weeks, 1 -week rest (28- day cycle) 
(n=~9)
PK samples will be collected from all subjects in Part 1
REVI SED TEXT
Part 1 Dose Escalation (n=up to 30 subjects )
Population:   relapsed/refractory MM
Characterize saf ety, PK, PD, immunogenicity and establish RP2 dose of GSK2857916
Schedule 1 : GSK2587916 once every 3 weeks (21 -day cycle) (n=~20)
Schedule 2 : GSK2587916 once weekly for 3 consecutive weeks, 1 -week rest (28- day cycle) 
(n=~9)
Serial PK samples will be col lected from all subjects in Part 1
Section 3.1, Discussion of Study Design
PREVI OUS TEXT
This is a First Time in Human (FTIH), open -label, dose escalation trial consisting of two 
parts: a Part 1 dose escalation phase and a Part 2 expansion phase for s afety, and clinical 
activity  testing ( Table 3and Section 3.2). The study will enroll a total of approximately  
80 subjects with relapsed/refractory  MM or other BCMA -expressing hematologic 
malignancies.  
REVI SED TEXT
This is a First Time in Human (FTIH), open -label, dose escalation trial consisting of two 
parts: a Part 1 dose escalation phase and a Part 2 expansion phase for safet y, and clinical 
activity  testing ( Table 3and Section 3.2). The study will enroll a total of approximately  
2012N155299_05 CONFIDENTIA L
BMA117159
20080 subjects with rela psed/refractory  MM or other BCMA -expressing hematologic 
malignancies.  The maximum dose to be administered in this trial will not exceed 5 
mg/kg.
Section 3.3.1.1, Single Subject Cohort Run- in (Schedule 1 only )
PREVI OUS TEXT
A single subject will be enrolle d at each dose level as outlined in Table 4 until 
occurrence of a clinically significant ≥ Grade 2 toxicity  for which relationship to 
the investigational agent cannot be ruled out.
Initiall y, GSK2857916 will be administered (IV) via 60 min infusion once ev ery 
three weeks (21 day s = 1 cy cle) on Schedule 1. One subject or the sentinel 
subject ie, the very  first subject on the study ; will initially  be enrolled at the 
starting dose of 0.03 mg/kg in Cohort 1 (Refer to Section 3.6.4 for starting dose 
rationale). The initial dose will be given to the sentinel subject.  Serial blood 
samples will be collected for PK.  The sentinel subject must remain under 
observation for at least 24 hours after dosing before discharge.  GSK2857916 
(intact and total [intact + unconj ugated antibod y]) and cy s-mcMMAF plasma 
concentrations will be analy zed and reviewed together with the safet y data (DL T 
period). If the first dose is considered tolerated, the sentinel subject will be 
allowed to stay  on the study  and receive subsequent doses at the same dose level 
(ie, 0.03 mg/kg) as scheduled, every  three weeks (21 day s interval) for up to 16 
doses (or until disease progression, toxicity  or withdrawal of consent). 
If the sentinel subject does not experience a ≥ clinically  significant Grade 2 
toxicity  for which relationship to the investigational agent cannot be ruled out
during the first cycle (within 21 day s), the next subject will be allowed to enroll 
in the next cohort at a dose increased b y ≤100% of the starting dose.  Dose 
escalation with increments up to 100% of the previous dose will continue with 
enrolment of 1 subject per cohort until the occurrence of the first clinically  
significant ≥ Grade 2 toxicity  forwhich relationship to the investigational agent 
cannot be ruled out. (run in procedure outlined  in Table 4 )
The single subject (small cohort) run -in will be halted when the first clinically  
significant ≥ Grade 2 toxicity  for which relationship to the inv estigational agent 
cannot be ruled out occurs in one subject in Cy cle 1 (21 day s).  At this point, the 
cohort will be expanded to 3 or more subjects at the same dose level and the 
escalation will continue to follow the N-CRM procedure as outlined in Table 4
2012N155299_05 CONFIDENTIA L
BMA117159
201Table 19 Single Subject (Small Cohort) Run -InProcedure for GSK2857916 given 
on Schedule 1 (once every  21 day s)
Dose Level Number of subjects 
with ≥G2 toxicityDose Escalation/Action
Dose Level 1/Cohort 1 0 out of 1 subject
(Sentinel subject)Predicted starting dose 0.03 mg/kg every 21 
days
Dose Level 2/Cohort 2 0 out of 1 subject Escalate to the next dose level with increase   
≤100%  of the starti ng dose
Dose Level 3 and 
beyond/Cohort 3 and 
beyond0 out of 1 subject Escalate to the next dose level with increase of 
≤100% of the dose tested in the previous cohort 
1 out of 1 subject* Switch to Cohort size of 3 or more subjects 
*Increase of doses up to 100% of the previous dose may continue until the first clinically 
significant ≥Grade 2 toxicity  for which relationship to the investigational agent cannot be 
ruled out occurs in one subject in Cycle 1 (21 days).  At this point the single subject (small 
cohort) run -in is halted.  Continue with N -CRM, with cohort sizes of 3 or more subjects.  Increase 
of doses 100% will be considered for subsequent cohorts of 3 or more subjects. 
REVI SED TEXT
A single subject will be enrolled at each dose level as outlined in Table 4 until 
occurrence of a clinically significant ≥ Grade 2 toxicity  for which relationship to 
the investigational agent cannot be ruled out.
Initiall y, GSK2857916 will be administered (IV) via 60 min infusion once every 
three weeks (21 day s = 1 cy cle) on Schedule 1. One subject or the sentinel 
subject ie , the very  first subject on the study ; will initially  be enrolled at the 
starting dose of 0.03 mg/kg in Cohort 1 (Refer to Section 3.6.4 for starting dose 
rationale).  The initial dose will be given to the sentinel subject.  Serial blood 
samples will be co llected for PK.  The sentinel subject must remain under 
observation for at least 24 hours after dosing before discharge.  GSK2857916 
(intact and total [intact + unconjugated antibod y]) and cy s-mcMMAF plasma 
concentrations will be analy zed and reviewed toge ther with the safet y data (DL T 
period). If the first dose is considered tolerated, the sentinel subject will be 
allowed to stay  on the study  and receive subsequent doses at the same dose level 
(ie, 0.03 mg/kg) as scheduled, every  three weeks (21 day s inter val) for up to 16 
doses (or until disease progression, toxicity  or withdrawal of consent). 
If the sentinel subject does not experience a ≥ clinically  significant Grade 2 
toxicity  for which relationship to the investigational agent cannot be ruled out
during the first cycle (within 21 day s), the next subject will be allowed to enroll 
in the next cohort at a dose increased b y ≤100% of the starting dose.  Dose 
escalation with increments up to 100% of the previous dose will continue with 
enrolment of 1 subject per cohort until the occurrence of the first clinically  
significant ≥ Grade 2 toxicity  for which relationship to the investigational agent 
cannot be ruled out. (run in procedure outlined  in Table 4 )
2012N155299_05 CONFIDENTIA L
BMA117159
202The single subject (small cohort) run -in will be halted when the first clinically  
significant ≥ Grade 2 toxicity  for which relationship to the inve stigational agent 
cannot be ruled out occurs in one subject in Cy cle 1 (21 day s).  At this point, the 
cohort will be expanded to 3 or more subjects at the same dose level and the 
escalation will continue to follow the N-CRM procedure as outlined in Table 4
Table 20 Single Subject (Small Cohort) Run -InProcedure for GSK2857916 given 
on Schedule 1 (once every  21 day s)
Dose Level Number of subjects 
with ≥G2 toxicityDose Escalation/Action
Dose Level 1/Cohort 1 0 out of 1 subject
(Sentinel subject)Predicted starting dose 0.03 mg/kg every 21 
days
Dose Level 2/Cohort 2 0 out of 1 subject Escalate to the next dose level with increase   
≤100%  of the starti ng dose
Dose Level 3 and 
beyond/Cohort 3 and 
beyond0 out of 1 subject Escalate to the next dose level with increase of 
≤100% of the dose tested in the previous cohort 
1 out of 1 subject* Switch to Cohort size of 3 or more subjects 
*Increase of doses up to 100% of the previous dose may continue until the first clinically 
significant ≥Grade 2 toxicity  for which relationship to the investigational agent cannot be 
ruled out occurs in one subject in Cycle 1 (21 days).  At this point the single subject (s mall 
cohort) run -in is halted.  Continue with N -CRM, with cohort sizes of 3 or more subjects.  Increase 
of doses 100% will be considered for subsequent cohorts of 3 or more subjects. 
Section 3.3.1.2.1, Planned Dose Levels
NEW TEXT
Prior to the start of the study , projected dose levels on Schedule 1 (in mg/kg) are 0.03, 
0.06, 0.12, 0.24, 0.48, 0.96, 1.92, 2.88, 3.6, and 4.5 mg/kg.  Additional doses and 
schedules may  be explored based on emerging safety , PK, and PD data. The maximum 
dose to be administer ed in this trial will not exceed 5 mg/kg.
Section 3.3.3, Dose Limiting Toxicity –Part 1 only
PREVIOUS TEXT
Subjects who have been withdrawn from the study  for reasons other than toxicity  but 
prior to completion of DLT observation period will be replaced. An event will be 
considered a DLT if it is clinically  significant and its relationship to the investigational 
agent cannot be ruled out occurs within the DLT reporting period (first 21 day s of 
treatment for schedule 1, and first 28 day s for schedule 2) a nd meets one of the following 
criteria:
2012N155299_05 CONFIDENTIA L
BMA117159
203Albuminuria ≥2000 mg/24 hr which has been confirmed by  repeat test at least 7 
days apart and is not considered to be related to disease progression based on 
consultation of investigator with GSK medical monitor
Grad e 4 neutropenia (without fever) lasting 7 day s 
Febrile neutropenia lasting 72 hours 
Grade 3 thrombocy topenia associated  with clinically  significant bleeding or
Grade 4 thrombocy topenia lasting >7 day s and not responding to platelet 
transfusions 
Any Grade 3 or greater non -hematologic toxicity  as described in Common 
National Cancer Institute- Terminology  Criteria for Adverse Events (NCI -
CTCAE) version 4.0 [NCI , 2009]  with the exception of the following Grade 3 
events that can be controlled within 48 ho urs with routine supportive measures
oNausea and vomiting that can be controlled with anti -emetics
oDiarrhea that can be controlled with anti- diarrheals
oRash or allergic reactions that can be controlled with antihistamines and 
steroids
oClinically  asymptomati c electrol yte abnormalities which can be corrected 
within 48 hours)
Liver toxicity meeting pre -specified GSK liver stopping criteria (see Liver in 
Section 3.9.1 )
Tumor ly sis sy ndrome does NOT constitute a DLT (Section 3.9.7 ).
REVISED TEXT
Subjects who hav e been withdrawn from the study  for reasons other than toxicity  but 
prior to completion of DLT observation period will be replaced. An event will be 
considered a DLT if it is clinically  significant and its relationship to the investigational 
agent cannot be ruled out occurs within the DLT reporting period (first 21 day s of 
treatment for schedule 1, and first 28 day s for schedule 2) and meets one of the following 
criteria:
Albuminuria ≥2000 mg/24 hr which has been confirmed by  repeat test at least 7 
days apart and is not considered to be related to disease progression based on 
consultation of investigator with GSK medical monitor
Grade 4 neutropenia (without fever) lasting 7 day s 
Febrile neutropenia lasting 72 hours 
Grade 3 thrombocy topenia associated  with clinically  significant bleeding or
where estimated blood loss is > 10mL or Grade 4 thrombocy topenia lasting >7 
days and not responding to platelet transfusions 
Any Grade 3 or greater non -hematologic toxicity  as described in Common 
National Cancer Institute- Terminology  Criteria for Adverse Events (NCI -
2012N155299_05 CONFIDENTIA L
BMA117159
204CTCAE) version 4.0 [NCI , 2009]  with the exception of the following Grade 3 
events that can be controlled within 48 ho urs with routine supportive measures
oNausea and vomiting that can be controlled with anti -emetics
oDiarrhea that can be controlled with anti- diarrheals
oRash or allergic other skin reactions that can be controlled with 
antihistamines and steroids
oClinically  asymptomatic electrol yte abnormalities which can be corrected 
within 48 hours)
Liver toxicity meeting pre -specified GSK liver stopping criteria (see Liver in 
Section 3.9.1 )
Tumor ly sis sy ndrome does NOT constitute a DLT (Section 3.9.7 ).
A subject who devel ops a DLT will be allowed to stay  on study  only if the toxicity  did 
not meet stopping criteria and recovered to Grade 1 within 14 day s, or after a longer 
recovery  time if benefit to subject can be demonstrated and if the investigator and 
medical monitor agree that for a given subject the benefits may  outweigh the risks.
Section 3.8, Dosage and A dministration of Study Treatment(s)
NEW TEXT
The maximum dose to be administered to subjects in this trial is 5 mg/kg.
Section 3.9.5, Infusion -related Reactions an d Cytokine Release Sy ndrome
PREVI OUS TEXT
Premedication is not allowed prior to first infusion . Premedication should be considered 
in any  subject who experienced an infusion related reaction at first or any  subsequent 
infusion with GSK2857916.
REVI SED TEX T
Premedication is not allowed prior to first infusion unless deemed medically  appropriate 
by the GSK Medical Monitor in consultation with investigators following evaluation of 
infusion related reactions across cohorts. Premedication should be considered i n any  
subject who experienced an infusion related reaction at first or an y subsequent infusion 
with GSK2857916.
Section 3.9.6, A llergic and A naphy lactic reaction
PREVI OUS TEXT
As GSK2857916 is a fully  humanized ADC, it is considered unlikel y for acute alle rgic 
reactions to occur in response to GSK2857916 exposure; however, all subjects will be 
monitored carefully  for evidence of allergic response. A subject that exhibits signs or 
symptoms of severe hy persensitivity  or anaphy laxis will receive appropriate me dical 
2012N155299_05 CONFIDENTIA L
BMA117159
205treatment and remain on study  at the discretion of the investigator and after discussion 
with the GSK medical monitor. 
oFurther treatment with GSK2857916 needs to be discussed with MM prior 
to next dose administration.
REVI SED TEXT
As GSK2857916 i s a fully humanized ADC, it is considered unlikel y for acute allergic 
reactions to occur in response to GSK2857916 exposure; however, all subjects will be 
monitored carefully  for evidence of allergic response. A subject that exhibits signs or 
symptoms of severe h ypersensitivity  or anaphy laxis will receive appropriate medical 
treatment and remain on study  at the discretion of the investigator and after discussion 
with the GSK medical monitor. be withdrawn from the study .
oSubjects who experience Grade 3 all ergic reaction will be withdrawn 
from study  
oFurther treatment with GSK2857916 in subjects who experience a Grade 
3 infusion related reaction needs to be discussed with MM prior to next 
dose administration. Those subjects will be allowed to continue on s tudy 
after recovery  of the reaction to Grade 1 but will have to receive pre -
medication prior to each subsequent dose of GSK2857916, and their 
infusion time will be extended to 2- 4 hours (depending on severity  of the 
reaction).
Section 3.9.8, Ocular Toxi city
NEW TEXT
Section 3.9.8, Ocular Toxicity  and Stopping Criteria
All subjects will be advised to use prednisolone phosphate 1% or dexamethasone 0.1% 
eye drop 4 times a day  (QID) for 4 days starting 1 day  prior to each dose. Additional use 
of lubrication eye drops (artificial tears) QID PRN throughout the trial is recommended, 
especiall y if subject develops any ocular s ymptoms. Subjects who develop Grade 3 
ocular or corneal toxicity  will be permanentl y removed from stud y.
2012N155299_05 CONFIDENTIA L
BMA117159
206Section 3.10.2, Predicted Toxicities and Proposed Dose 
Adjustments/Stopping Criteria
PREVI OUS TEXT
Thrombocytopenia Grade 3: >25 and 
<50x109/LWith clinically significant bleeding:  Withhold 
the: 
No clinically significant bleeding: continue 
treatment with  25% dose reduction 
Ocula r/corneal 
toxicityGrade 2 /Grade 3 First occurrence:
oInterrupt treatment with 
GSK2857916
oConsult ophthalmologist immediately
oWhen recovered to G 1 Re-start 
treatment with GSK2857916 at 25%  
dose reduction upon resolution to 
G1 
Second occurrence:
oInterrupt treatment with 
GSK2857916
oConsult ophthalmologist immediately
oOnce resolved to G1 or less: Restart 
treatment with GSK2857916 at 
additional 25% dose reduction
Third occurrence:
Permanently discontinue treatment with 
GSK2857916 and withdraw subject from s tudy
Grade 4 Consult ophthalmologist immediately
Permanently discontinue treatment with 
GSK2857916
REVI SED TEXT
Thrombocytopenia Grade 3: >25 and 
<50x109/LWith clinically significant bleeding Where 
estimated blood loss is 10 mL : withhold the
treatment :
No clinically significant bleeding: continue 
treatment with  25% dose reduction 
Ocular/corneal 
toxicityGrade 2 /Grade 3 First occurrence:
oInterrupt treatment with 
GSK2857916
oConsult ophthalmologist immediately
oWhen recovered to G 1 Re-start 
treatm ent with GSK2857916 at 25%  
dose reduction upon resolution to 
G1 
Second occurrence:
2012N155299_05 CONFIDENTIA L
BMA117159
207oInterrupt treatment with 
GSK2857916
oConsult ophthalmologist immediately
oOnce resolved to G1 or less: Restart 
treatment with GSK2857916 at 
additional 25% dose reduction
Third occurrence:
Permanently discontinue treatment with 
GSK2857916 and withdraw subject from study
Grade 3/ Grade 4 Consult ophthalmologist immediately
Permanently discontinue treatment with 
GSK2857916
NEW TEXT
Serum 
creatinine 
Grade 3>3.0mg/dL from
baseline
or
3.0-6.0xULNProvide appropriate medical treatment. 
Withdraw permanently from trial
INR prolongation >2.5 Evaluate and provide medical treatment if 
necessary
If INR prolongation is not related to use of 
anticoagulants withdraw subject from study
Section 3.10.3,   Dose Modifications, Table 13 Dose A djustment/Stopping 
Criteria
PREVI OUS TEXT
Toxicity GradeaDose Modification of GSK2857916
Grade 3Withhold dose until toxicity resolves to Grade 1 or baseline, unless 
condition fits exceptions n oted below. If resolved within 14 days, 
resume treatment at dose reduced by 25% (first dose reduction), or 50% 
(second dose reduction). Consider supportive care recommendations.  
If not resolved within 14 days, discuss with Medical Monitor.  
Exceptions :
Subjects who develop G3 toxicities which respond to standard treatment 
and resolve to G1 within 48 hours may continue treatment at 
scheduled or reduced dose
Permanently discontinue for grade 3 or greater QTc prolongation ie, 
QTcF >500 msec or QTcF i ncrease by > 60 msec from baseline
Troponin elevations: See Section 3.9.3 for troponin stopping criteria
aConsidered related to investigational drug.
2012N155299_05 CONFIDENTIA L
BMA117159
208REVI SED TEXT
Toxicity GradeaDose Modification of GSK2857916
Grade 3Withhold dose until toxicity resol ves to Grade 1 or baseline, unless 
condition fits exceptions noted below. If resolved within 14 days, 
resume treatment at dose reduced by 25% (first dose reduction), or 50% 
(second dose reduction). Consider supportive care recommendations.  
If nottoxicity is resolved within period longer than 14 days, discuss 
with Medical Monitor. continuation of treatment may be considered on 
an individual basis if benefit to subject can be demonstrated and if 
the investigator and medical monitor agree that for a give n subject 
the benefits may  outweigh the risks   
Exceptions :
Subjects who develop G3 toxicities which respond to standard treatment 
and resolve to G1 within 48 hours may continue treatment at 
scheduled or reduced dose
Permanently discontinue for grade 3 or greater QTc prolongation ie, 
QTcF >500 msec or QTcF increase by > 60 msec from baseline
Troponin elevations: See Section 3.9.3 for troponin stopping criteria
aConsidered Possibly related to investigational drug.
Section 4.1, Description of Investigat ional Product
NEW TEXT
Lot number 132373860
GSK2857916 will be provided to sites by  GSK.  The contents of the label will be in 
accordance with all applicable regulatory  requirements. Only Lot#132373860 of drug 
product will be used for this trial.
Sectio n 4.2, Preparation/Handling/Storage of GSK2857916 Investigational 
Product
PREVI OUS TEXT
Preparation
GSK2857916 Solution for Infusion, 20 mg/mL is supplied as a frozen liquid.  Before use, 
thaw each vial of GSK2857916 for Infusion, 20mg/mL, 1.5mL for up to 4 hours under 
refrigerated conditions, protected from light.  Following thawing, gently  swirl the vial to 
ensure uniformit y.  GSK2857916 should be diluted in normal saline (0.9%) to no more 
than 2 mg/mL and no less than 0.2 mg/mL.
2012N155299_05 CONFIDENTIA L
BMA117159
209The dosing solution of G SK2857916 can be held up to 8 hours at room temperature 
(diluted drug product in bag) from a stability  perspective, but should be used as soon as 
possible as the product does not contain an antimicrobial preservative.
Administration
GSK2857916 is compatibl e with poly vinylchloride -lined or pol yolefin -lined intravenous 
infusion administration sets, 0.2 micron poly ethersulfone filters, or optionally  a 
polyurethane catheter.   Doses of GSK2857916 are to be administered as an IV infusion 
via an infusion pump that can ensure precision to the decimal point of a mL for the 
infusion rate at lower doses. It is recommended to prime the IV tubing with at least 15 
mL prior to dosing.
Storage
GSK2857916 must be stored in a secure area under the appropriate ph ysical conditi ons 
for the product.  Access to and administration of the GSK2857916 will be limited to the 
investigator and authorized site staff.  GSK2857916 must be dispensed or administered 
only to subjects enrolled in the study  and in accordance with the protocol.  
GSK2857916 is to be stored at a temperature range of -50C to -15C.  Maintenance of a 
temperature log is required. 
The expiry  date, where required, is stated on the product label.
REVI SED TEXT
Preparation
GSK2857916 Solution for Infusion, 20 mg/mL is s upplied as a frozen liquid (Lot# 
132373860).   Before use, thaw each vial of GSK2857916 for Infusion, 20mg/mL, 1.5mL 
for up to 4 hours under refrigerated conditions, protected from light.  Following thawing, 
gentl y swirl the vial to ensure uniformity.  GSK2 857916 should be diluted in normal 
saline (0.9%) to no more than 2 mg/mL and no less than 0.2 mg/mL.
The dosing solution of GSK2857916 can be held up to 24 hours under refrigerated 
conditions or 4 8 hours at room temperature (diluted drug product in bag) from a stability  
perspective, but should be used as soon as possible as the product does not contain an 
antimicrobial preservative.
Administration
GSK2857916 is compatible with poly vinylchloride -lined or pol yolefin -lined intravenous 
infusion administration sets, 0.2 micron polyethersulfone filters, or optionally  a 
polyurethane catheter.   Doses of GSK2857916 are to be administered as an IV infusion 
via an infusion pump that can ensure precision to the decimal point of a mL for the 
infusion rate at lower dose s.It is recommended to prime the IV tubing with at least 15 
mL prior to dosing.
2012N155299_05 CONFIDENTIA L
BMA117159
210Administration of drug product in this trial is restricted to L ot#132373869.
Storage
GSK2857916 must be stored in a secure area under the appropriate ph ysical conditions 
for the product.  Access to and administration of the GSK2857916 will be limited to the 
investigator and authorized site staff.  GSK2857916 must be dispensed or administered 
only to subjects enrolled in the study  and in accordance with the protocol.  
GSK28579 16 is to be stored at a temperature range of -50C to -15C.  Maintenance of a 
temperature log is required. 
The expiry  date, where required, is stated on the product label. Only Lot#132373860 of 
drug product is acceptable for use in this trial.
Section 5 .2.1, Inclusion Criteria
PREVI OUS TEXT
2.Male or female, 18 years or older (at the time consent is obtained ).
REVI SED TEXT
2.Male or female, 18 years or older (at the time consent is obtained) and must have a 
body  weight of at least 45 kg (99 lb). 
Section 6.3 , Permanent Discontinuation fro Study  Treatment
PREVI OUS TEXT
a dose delay  of >14 day s unless the investigator or GSK Medical Monitor agree 
that further treatment may benefit the subject. Exceptions apply  to 
nephrotoxicity  as outlined in Section 3.10.2
REVISED TEXT
a dose delay  of >14 day s unless the investigator or GSK Medical Monitor agree 
that subject derives benefit and that further treatment benefits will outweigh the 
risks may  benefit the subject .   Exceptions apply  to nephrotoxicity  as outlined in 
Section 3.10.2
2012N155299_05 CONFIDENTIA L
BMA117159
211Section 7.1.1.1, Every 3 Weeks Dosing Schedule for Multiple Myeloma
PREVI OUS TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
(flow) X15
Study 
Assessments1Screen2DAY 
1 C1Day 
2 
C1Day 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X X
Serum (soluble BCMA) X18 X18X18 X18 X18 X18 Predose at the start 
of each cycleX18
Serum 
(cytokin es/chemokines)X19 X19 X X19At predose and EOI 
on D1 of each cycleX
15. Sample(s) collected for analysis by central lab.    
18. A single sample for sBCMA will be collected at screening, C1D8, C1D15 and at the End of Study visit. 
sBCMA samples will also be c ollected on  C1D1 at EOI ( 5 minutes) and on C1D2 24h post SOI.  On C2D1 
sBCMA will be collected pre -dose (within 30 minutes prior to SOI) and at the EOI ( 5 minutes)
REVI SED TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
and PD (flow) X15 X15
2012N155299_05 CONFIDENTIA L
BMA117159
212Study 
Assessments1Screen2DAY 
1 C1Day 
2 
C1Day 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X15 X
Serum (soluble BCMA) X18 X18X18 X18 X18 X18 Predose at the start 
of each cycleX18
Serum 
(cytokines/chemokines)X19 X19 X X19At predose and EOI 
on D1 of each cycleX
15. Sample(s) collected for analysis by central lab.   The same sample will be used for BCMA (flow) and PD 
during Screening. 
18. A single sample for sBCMA will be collected at screening, C1D8, C1D15 and at the End of Study visit. 
sBCMA samples will also be collected on  C1D1 at predose (within 30 minutes prior to SOI), at EOI ( 5 
minutes) and on C1D 2 24h post SOI.  On C2D1 sBCMA will be collected pre -dose (within 30 minutes prior to 
SOI) and at the EOI ( 5 minutes)
NEW TEXT
Study 
Assessments1
Screen2Day 
1 
C1Day 
2 
C1Day 
8 
C1Day 
15 
C1Day 
1 
C2D1 of C3 -C16End of 
Study3-
Month 
Off-
study 
Follow -
up
HBV/HCV tests X
Section 7.1.1.2,  Weekly  Dosing Schedule (Dose Escalation) for Multiple 
Myeloma
PREVI OUS TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCM A 
assessment 
(flow) X15
2012N155299_05 CONFIDENTIA L
BMA117159
213Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X X17
Serum (soluble BCMA) X19 X19X19
X19 X19 X19Predose at the 
start of each cycleX
Serum 
(cytokines/chemokines)X20 X20 X X20 X20 X20At predose and 
EOI on D1 of 
each cycleX
15. Sample(s) collected for analysis by central lab.
19. A single sample for sBCMA will be collected at screening and on C1D8 predose, and at the End of Study visit. 
sBCMA samples will also  be collected on C1D1 at EOI ( 5 minutes) and on C1D2 24h post SOI. On C1D15 and 
C2D1 collect at predose (within 30 minutes prior to SOI) and EOI ( 5 minutes)
REVI SED TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
and PD (flow) X15X15, 
17
Study 
Assessments1Screen2DAY 
1 C1DAY 
2 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X15 X17
Serum (soluble BCMA) X19 X19X19
X19 X19 X19Predose at the 
start of each cycleX
Serum 
(cytokines/chemokines)X20 X20 X X20 X20 X20At predose and 
EOI on D1 of 
each cycleX
15. Sample(s) collected for analysis by central lab. The s ame sample will be used for BCMA (flow) and PD during 
Screening.
19. A single sample for sBCMA will be collected at screening and on C1D8 predose, and at the End of Study visit. 
sBCMA samples will also  be collected on C1D1 at predose (within 30 minutes prior to SOI), at EOI ( 5 minutes) 
and on C1D2 24h post SOI. On C1D15 and C2D1 collect at predose (within 30 minutes prior to SOI) and EOI ( 5 
minutes)
2012N155299_05 CONFIDENTIA L
BMA117159
214NEW TEXT
Study 
Assessments1Screen2Day 
1 
C1Day 
2 
C1Day 
8 
C1Day 
15 
C1Day 
1 
C2D1 of C3 -C16End of 
Study3-
Month 
Off-
study 
Follow -
up
HBV/HCV tests X
Section 7.1.2.1, Every 3 Weeks Dosing Schedule for Multiple Myeloma
PREVI OUS TEXT
Study 
Assessments1Screen2DAY 
1 
C1DAY 
8 
C1DAY 
15 
C1DAY 1 C2 D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
(flow)X16
Study 
Assessments1Screen2DAY 
1 C1DAY 
8 
C1DAY 
15 
C1DAY 1 C2 D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X X18
Serum (soluble BCMA) X20 X20 X20Predose at the 
start of each cycleX
Serum 
(cytokines/chemokines)X21 X21 X21Predose and EOI 
on D1 of each 
cycleX
16. Sample(s) collected for analysis at central lab. 
20. Collect sBCMA at screening (single sample), C1D1 at EOI ( 5 minutes), C2D1 at predose (within 30 minutes prior 
to SOI) and at EOI (+ -5 minutes).
2012N155299_05 CONFIDENTIA L
BMA117159
215REVI SED TEXT
Study 
Assessments1Screen2DAY 
1 
C1DAY 
8 
C1DAY 
15 
C1DAY 1 C2 D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
and PD (flow)X16X16, 
18
Study 
Assessments1Screen2DAY 
1 C1DAY 
8 
C1DAY 
15 
C1DAY 1 C2 D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X16 X18
Serum (soluble BCMA) X20 X20 X20Predose at the 
start of each cycleX
Serum 
(cytokines/chemokines)X21 X21 X21Predose and EOI 
on D1 of each 
cycleX
16. Sample(s) collected for analysis at central lab. The same sample will be used for BCMA (flow) and PD during 
Screening. On D8 only postdose PD assessment will be performed , if applicable (refer to footnote 18).
20. Collect sBCMA at screening (single sample), C1D1 predose (within 30 minutes prior to SOI) and at EOI ( 5 
minutes), C2D1 at predose (within 30 minutes prior to SOI) and at EOI (+ -5 minutes).
NEW TEXT
Study 
Assessments1Screen2Day 
1 
C1Day 
8 
C1Day 
15 
C1Day 1 C2 D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study
Follow -
up
HBV/HCV 
testsX
2012N155299_05 CONFIDENTIA L
BMA117159
216Section 7.1.2.2,  Dose Expansion Weekly  Dosing Schedule for Multiple 
Myeloma
PREVI OUS TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
8 C1DAY 
15 
C1DAY 
1 C2Day 
15 
C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
and PD (flow)X15
Study 
Assessments1Screen2DAY 
1 C1Day 
8 
C1DAY 
15 
C1DAY 
1 C2Day 
15 
C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
PD X X17
Serum (soluble BCMA) X19 X19 X19 X19 X19Predose at the st art 
of each cycleX
Serum 
(cytokines/chemokines)X20 X20 X20 X20 X20Predose and EOI on 
D1 of each cycleX
15. Sample(s) collected for analysis at central lab. The same sample will be used for BCMA (flow) and PD during 
Screening.
19. A single sBCMA sample will be collected at Screening or predose (within 30 minutes prior to SOI) unless 
otherwise specified.  On C1D15 and C2D1 collect samples at predose (within 30 minutes prior to SOI) and at EOI 
(5 minutes).  
REVI SED TEXT
Study 
Assessments1Screen2DAY 
1 C1DAY 
8 
C1DAY 
15 
C1DAY 
1 C2Day 
15 
C2D1 of C3 -C16END 
OF 
STUDY3-MONTH 
OFF-
STUDY 
FOLLOW -
UP
BCMA 
assessment 
and PD (flow)X15X15, 
17
2012N155299_05 CONFIDENTIA L
BMA117159
217Study 
Assessments1Screen2DAY 
1 C1Day 
8 
C1DAY 
15 
C1DAY 
1 C2Day 
15 
C2D1 of C3 -C16END 
OF 
STUDY3-MONTH
OFF-
STUDY 
FOLLOW -
UP
PD X15 X17
Serum (soluble BCMA) X19 X19 X19 X19 X19Predose at the start 
of each cycleX
Serum 
(cytokines/chemokines)X20 X20 X20 X20 X20Predose and EOI on 
D1 of each cycleX
15. Sample(s) collected for analysis at centr al lab. The same sample will be used for BCMA (flow) and PD during 
Screening. On D8 only postdose PD assessment will be performed , if applicable (refer to footnote 17).
19. A single sBCMA sample will be collected at Screening or C1D1 predose (within 30 minutes prior to SOI) unless 
otherwise specified.  On C1D15 and C2D1 collect samples at predose (within 30 minutes prior to SOI) and at EOI 
(5 minutes).  
NEW TEXT
Study 
Assessments1Screen2Day 
1 
C1Day 
8 C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
HBV/HCV tests X
Section 7.1.2.3,  Dose Expansion Every 3 Weeks Dosing Schedule for Other 
Hematologic Malignancies
PREVI OUS TEXT
Study Assessments1 Screen2Day 1 
C1Day 8 
C1Day 15 
C1
Day 1 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Serum (soluble BCMA) X14 X14
Serum 
(cytokines/chemokines)X15 X15 X15Predose and EOI 
on D1 of each 
cycleX
2012N155299_05 CONFIDENTIA L
BMA117159
218Study 
Assessments1Screen2
Day 1 C1Day 8 C1Day 15 
C1
Day 1 C2 D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Survival Status X24
Subsequent 
TreatmentX24
14. A single sBCMA sample will be collected at screening.  On C2D1 sBCMA will be collected at predose (within 
30 minutes prior to SOI) and at EOI ( 5 minutes).
REVI SED TEXT
Study Assessments1 Screen2Day 1 
C1Day 8 
C1Day 15 
C1
Day 1 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Serum (soluble BCMA) X14 X14 X14
Serum 
(cytokines/chemokines)X15 X15 X15Predose and EOI 
on D1 of each 
cycleX
Study 
Assessments1Screen2
Day 1 C1Day 8 C1Day 15 
C1
Day 1 C2 D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Survival Status X25
Subsequent 
TreatmentX25
14. A single sBCMA sample will be collected at screening.   C1D1 predose (within 30 minutes prior to SOI).   On 
C2D1 sBCMA will be collected at predose (within 30 minutes prior to SOI) and at EOI ( 5 minutes).
NEW TEXT
Study 
Assessments1Screen2 Day 1 C1Day 8 C1Day 15 
C1
Day 1 C2 D1 of C3 -C16End of 
Study3-
Month 
Off-
study 
Follow -
up
HBV/HCV tests X
2012N155299_05 CONFIDENTIA L
BMA117159
219Tumor biopsy 
for BCMA 
expressionX24
24. Archival or fresh tissue required for BCMA testing.  Refer to Section 5.2.1 Inclusion Criterion #4 for eligibility 
criteria. 
Section 7.1.2.4,  Dose Expansion Weekly  Dosing Schedule fo r Other 
Hematologic Malignancies
PREVI OUS TEXT
Study Assessments1 Screen2Day 
1 
C1Day 
8 
C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Serum (soluble BCMA) X13 X13 X13 X13 X13 X13
Serum 
(cytokines/chemokines)X14 X14 X14 X14 X14Predose and EOI on D1 of 
each cycleX
Study 
Assessments1Screen2
Day 
1 
C1Day 
8 C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Survival Status X23
Subsequent 
TreatmentX23
13. A single sample for sBCMA will be collected at screening, on C1D8 predose, and at the End of Study visit.  
sBCMA samples will also be collected on C1D1 at EOI (5 minutes).  On C1D15 and C2D1 collect at 
predose (within 30 minutes prior to SOI) and EOI ( 5 minutes)
REVI SED TEXT
Study Assessments1 Screen2Day 
1 
C1Day 
8 
C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Serum (soluble BCMA) X13 X13 X13 X13 X13X13
Serum 
(cytokines/chemokines)X14 X14 X14 X14 X14Predose and EOI on D1 of 
each cycleX
2012N155299_05 CONFIDENTIA L
BMA117159
220Study 
Assessments1Screen2
Day 
1 
C1Day 
8 C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Survival Status X2325
Subsequent 
TreatmentX2325
13. A single sample for sBCMA will be collected at screening, on C1D8 predose, and at the End of Study visit.  
sBCMA samples will also be collected on C1D1 at predose (within 30 minutes prior to SOI) and EOI (5 
minutes).  On C1D15 and C2D1 collect at predose (within 30 minutes prior to SOI) and EOI ( 5 minutes)
NEW TEXT
Study 
Assessments1Screen2Day 
1 
C1Day 
8 C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
HBV/HCV tests X
Study 
Assessments1Screen2Day 
1 
C1Day 
8 C1Day 
15 
C1Day 
1 
C2Day 
15 
C2D1 of C3 -C16End 
of 
Study3-
Month 
Off-
study 
Follow -
up
Tumor biopsy 
for BCMA 
expressionX23
23. Arcived or fresh tissue required for BCMA testing.  Refer to Section 5.2.1 Inclusion Criterion #4 for eligibility 
criteria. 
Section 7.3.6,  Laboratory  Assessments, Table 15, List of Clinical 
Laboratory  Tests
PREVI OUS TEXT
Glucose, fasting Total carbon 
dioxide (CO 2)Gamma glutamyl transferase 
(GGT)Albumin
Magnesium Phosphorous Creatinine kinase (CK) LDH
2012N155299_05 CONFIDENTIA L
BMA117159
221Serum Creatine Phos phokinase (CPK)
Human Immunodeficiency virus (HIV)
REVI SED TEXT
Glucose , fasting Total carbon 
dioxide (CO 2)Gamma glutamyl transferase 
(GGT)Albumin
Magnesium Phosphorous Creatin ine kinase (CK) LDH
Serum Creatine Phosphokinase (CPK)
Human Immu nodeficiency virus (HIV)
Section 7.4.1, Blood Sample Collection for Pharmacokinetics
PREVI OUS TEXT
Blood samples of approximately  1mL for pharmacokinetic (PK) anal ysis of 
GSK2857916 (ADC and total antibody ) and cy s-mcMMAF will be collected at the time
points indicated in the Time and Events Tables (Section 7.1 ).  Each PK sample should be 
collected as close as possible to the planned time relative to the dose (i.e., time zero) 
administered to the subject on PK day s.  The actual date and time of each blood sample 
collection will be recorded.
Details on PK blood sample collection, processing, storage and shipping procedures are 
provided in the Study  Procedures Manual (SPM).   
REVI SED TEXT
Blood samples of approximately  1 5mL for pharmacokinetic (PK) anal ysis of 
GSK2857916 (ADC and total antibody ) and cy s-mcMMAF will be collected at the time 
points indicated in the Time and Events Tables (Section 7.1 ).  Each PK sample should be 
collected as close as possible to the planned time relative to the dose (i.e., time zero) 
administered to the subject on PK day s.  The actual date and time of each blood sample 
collection will be recorded.
Details on PK blood sample collection, processing, storage and shipping procedures are 
provided in the Study  Procedures Manual (S PM).   Blood volumes for PK samples are 
outlined in Appendix 10 (Section 17.10 ).
2012N155299_05 CONFIDENTIA L
BMA117159
222Section 10, Concomitant Medications and Non- Drug Therapies
NEW TEXT
Concomitant dosing of GSK2857916 with strong Pgp inhibitors should be avoided unless 
considered medicall y necessary  (See Appendix 11 for list of relevant Pgp inhibitors).
If future changes are made to the list of permitted/prohibited medications, formal 
documentation will be provided by  GSK and stored in the study  file.  The SPM will be 
updated to include this information. Any such changes will be communicated to the 
investigative sites in the form of a letter.
Section 17.10, A ppendix 10: Blood Requirements
PREVI OUS TEXT
Blood Requirements in Dose Escalation and Dose Expansion Cohorts for All Lab 
Tests, Except P K
Test Sample Sample 
VolumeRequirements for 
Screening – Cycle 1Requirements for 
Subsequent Cycles
Hematology 5 ml 10-25 ml 5 ml
Chemistry 5 ml 15-20 ml 5 ml
Coagulation 5 ml 10-20 ml 5 ml
Hgb A1c 5 ml 5 ml
SPEP/UPEP 6 ml 6 ml 6 ml
CRP 1 ml 1-2 ml 1 ml
B2 microglobulin 1 ml 1-2 ml 1 ml
Kappa, lambda free LC, FLC 1 ml 1 ml 1 ml
Immunoglobulin levels (IgG, 
IgA, IgM)6 ml 6 ml 6 ml
Plasma collection for cfDNA 
and circulating cytokines5 ml 5 ml 5 ml
Hepatitis B, Hepatitis C 3 ml 3 ml
HIV 5 ml 5 ml
CK-MB 3 ml 6 ml 3 ml
Anti- Drug Antibody 3 ml 3 ml 3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA11 ml 6 ml 6 ml
PGx26 ml 6 ml
Total Volume 100-13 2ml 52.5 ml
1Calculation reflects blood drawn for sBCMA measurem ent in a MM subject
2Dose expansion only
2012N155299_05 CONFIDENTIA L
BMA117159
223Blood Requirements for PK
PK Schedule Sample 
VolumeCycle 1 Cycle 2 Cycle 3 Cycle 5 Total 
Volume
Escalation Every 3 Weeks 3ml 27ml 6 ml 6 ml 39ml
Escalation Weekly 3ml 33ml 6 ml 6 ml 45ml
Expansion Every 3 Weeks 
MM3ml 6ml 6 ml 6 ml 6 ml 24ml
Expansion Every 3 Weeks 
Other Hematologic 
Malignancies3ml 12ml 6 ml 6 ml 6 ml 30ml
Expansion Weekly MM 3ml 24ml 12ml 12 ml 6 ml 54ml
Expansion Weekly 
Other Hematologic 
Malignancies3ml 24ml 12ml 12 ml 6 ml 54ml
Total Blood Requirements
Schedule Screening + Cycle 1 Subsequent Cycles
Escalation Every  3 Weeks 127-159 ml 58.5 ml
Escalation Weekl y 133-165 ml 58.5 ml
Expansion Every  3 Weeks 106-144 ml 58.5 ml
Expansion Weekly 124-156 ml 58.5-64.5 ml
REVI SED TEXT
Blood Requirements in Dose Escalation and Dose Expansion Cohorts for All Lab 
Tests, Except PK
Test Sample Sample 
VolumeRequirements for 
Screening – Cycle 1Requirements for 
Subsequent Cycles
Hematology 5 ml 10-25 ml 5 ml
Chemist ry 5 ml 15-20 ml 5 ml
Coagulation 5 ml 10-20 ml 5 ml
Hgb A1c 5 ml 5 ml
SPEP/UPEP 6 ml 6 ml 6 ml
CRP 1 ml 1-2 ml 1 ml
B2 microglobulin 1 ml 1-2 ml 1 ml
Kappa, lambda free LC, FLC 1 ml 1 ml 1 ml
Immunoglobulin levels (IgG, 
IgA, IgM)6 ml 6 ml 6 ml
Plasma collection for cfDNA 
and circulating cytokines5 ml 5 ml 5 ml
2012N155299_05 CONFIDENTIA L
BMA117159
224Test Sample Sample 
VolumeRequirements for 
Screening – Cycle 1Requirements for 
Subsequent Cycles
Hepatitis B, Hepatitis C 3 ml 3 ml
HIV 5 ml 5 ml
CK-MB 3 ml 6 ml 3 ml
Anti- Drug Antibody 3 ml 3 ml 3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA11 ml 6 ml 6 ml
PGx26 ml 6 ml
Total Volume 100-132 ml 52.5 ml
1Calculation reflects blood drawn for sBCMA measurement in a MM subject
2Dose expansion only
Blood Requirements for PK 
PK Schedule Sample 
VolumeCycle 1 Cycle 2 Cycle 3 Cycle 5 Total 
Volume
Escalation Every 3 Weeks 3 ml 27 ml 6 ml 6 ml 39 ml
Escalation Weekly 3 ml 33 ml 6 ml 6 ml 45 ml
Expansion Every 3 Weeks 
MM3 ml 6 ml 6 ml 6 ml 6 ml 24 ml
Expansion Every 3 Weeks 
Other Hematologic 
Malignancies3 ml 12 ml 6 ml 6 ml 6 ml 30 ml
Expansion Weekly MM 3 ml 24 ml 12 ml 12 ml 6 ml 54 ml
Expansion Weekly 
Other Hematologic 
Malignancies3 ml 24 ml 12 ml 12 ml 6 ml 54 ml
Total Blood Requirements
Schedule Screening + Cycle 1 Subsequent Cycles
Escalation Every  3 Weeks 127-159 ml 58.5 ml
Escalation Weekl y 133-165 ml 58.5 ml
Expansion Every  3 Weeks 106-144 ml 58.5 ml
Expansion Weekly 124-156 ml 58.5-64.5 ml
2012N155299_05 CONFIDENTIA L
BMA117159
225Blood Requirements for A ll Lab Tests, Except PK
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 15-20 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 5 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Total 59.5 ml 51.5-66.5 ml 45.5-51.5 ml
1. Required for women of childbearing potential
Dose Escalation:  Weekly  for Multiple My eloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 15-20ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 3 ml 0-3 ml
2012N155299_05 CONFIDENTIA L
BMA117159
226Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 6 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
Total 59.5 ml 57.5-72.5 ml 45.5-51.5 ml
1. Required for women of childbearing potential
Dose Expansion:  Every 3 Weeks for Multiple My eloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 2 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
PgX 6 ml 6 ml
Total 59.5 ml 49.5-64.5 ml 45.5-51.5 ml
1. Required for women of chi ldbearing potential
2012N155299_05 CONFIDENTIA L
BMA117159
227Dose Expansion:  Weekly  for Multiple My eloma
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5-10 ml
SPEP 6 ml 6 ml 6 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
Kappa, lambda free 
LC, FL C1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 1 ml 1-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
PgX 6 ml 6 ml
Total 59.5 ml 49.5-64.5 ml 45.5-56.5 ml
1. Required for women of childbearing potential
Dose Expansion:  Every 3 Weeks for Other Hematologic Malignancies
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
CRP 1 ml 1 ml 1 ml
B2 M icroglobulin 1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
2012N155299_05 CONFIDENTIA L
BMA117159
228Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
sBCMA 1 ml 1 ml 0-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
PgX 6 ml 6 ml
Total 52.5 ml 48.5-63.5 ml 37.5-44.5 ml
1. Required for women of childbearing potential
Dose Expansion:  Weekly  for Other Hematologic Malignancies
Test Sample Sample 
VolumeScreening Cycle 1 Each 
Subsequent 
Cycle
Hematology 5 ml 5 ml 10-15 ml 5 ml
Chemistry 5 ml 5 ml 10-15 ml 5-10 ml
Coagulation 5 ml 5 ml 10-15 ml 5 ml
CRP 1 ml 1 ml 1 ml
B2 Microglobulin 1 ml 1 ml 1 ml
IgG, IgA, IgM 6 ml 6 ml 6 ml
cfDNA 10 ml 10 ml
Cytokines 3 ml 6 ml 6 ml
HBV/HCV 3 ml 3 ml
CK-MB 3 ml 3 ml 3 ml 3 ml
ADA 3 ml 3 ml 3 ml 0-3 ml
BNP 3 ml 3 ml
Troponin 2.5 ml 2.5 ml 2.5 ml 2.5 ml
TBNK 3 ml 3 ml 3 ml
sBCMA 1 ml 5 ml 0-2 ml
Pregnancy  Test12 ml 2 ml 0-2 ml
PgX 6 ml 6 ml
Total 52.5 ml 55.5-70.5 ml 37.5-49.5 ml
1. Required for women of childbearing potential
2012N155299_05 CONFIDENTIA L
BMA117159
229Blood Requirements for PK
PK Schedule Sample 
VolumeCycle 1 Cycle 2 Cycle 3 Cycle 5 Total 
Volume
Escalation Every 3 Weeks 5ml 60ml 10ml 10ml 80ml
Escala tion Weekly 5ml 80ml 10ml 10ml 100ml
Expansion Every 3 Weeks 
MM5ml 20ml 20ml 20ml 20ml 80ml
Expansion Weekly MM 5ml 20ml 10ml 10ml 10ml 50ml
Expansion Every 3 Weeks 
Other Hematologic 
Malignancies5ml 40ml 20ml 20ml 10ml 90ml
Expansion Weekly 
Other Hematologic 
Malignancies5ml 40ml 20ml 20ml 10ml 90ml
Total Blood Requirements
Schedule Screening Cycle 1 Each Subsequent 
Cycle
Escalation Every  3 Weeks 
MM59.5 ml 111.5 -126.5 ml 45.5-61.5 ml
Escalation Weekl y MM 59.5 ml 137.5-152.5 ml 45.5-61.5 ml
Expansion Every  3 Weeks 
MM59.5 ml 69.5-84.5 ml 45.5-61.5 ml
Expansion Weekly  MM 59.5 ml 69.5-84.5 ml 45.5-66.5 ml
Expansion Every  3 Weeks 
Other Hematologic 
Malignancies52.5 ml 88.5-103.5 ml 37.5-64.5 ml
Expansion Weekly  Other
Hematologic Malignancies52.5 ml 95.5-110.5 ml 37.5-69.5 ml
The Study  Procedures Manual will be updated with new information if changes in blood 
volumes are required.
2012N155299_05 CONFIDENTIA L
BMA117159
230Section 17.11, A ppendix 11: Pgp Inhibitors
NEW TEXT
Amiodarone
Atorvastatin
Azithro mycin
Carvedilol
Clarithromy cin
Dronedarone
Fluvoxamine
Indinavir
Indinavir and Ritonavir
Itraconazole
Ketonazole
Lapatinib
Lopinavir and Ritonavir
Nicardipine
Quinidine
Ranolazine
Ritonavir
Saquinavir and R itonavir
Telaprevir
Verapamil
Valspodar
The Stud y Procedures Manual will be updated if changes to the Pgp inhibitor list is 
required.
2012N155299_05 CONFIDENTIA L
BMA117159
23116.11.3. Amendment 3
Where the A mendment A pplies
Canada
Summary  of A mendment Changes with Rationale
1.Section 4.2, Preparation/Handling/Storage of GSK2867916 Investigational 
Product
Rationale: Health Canada requested change to the amount of time prepared 
product can be kept under refrigerated conditions from 24 hours to 8 hours as 
the product does not contain an antimicrobial preservative
List of Specific Changes
Section 4.2,  Prepar ation/Handing/Storage of GSK2857916 Investigational 
Product
PREVI OUS TEXT
Preparation
GSK2857916 Solution for Infusion, 20 mg/mL is supplied as a frozen liquid (Lot# 
132373860) .  Before use, thaw each vial of GSK2857916 for Infusion, 20mg/mL , 1.5mL 
for up to 4 hours under refrigerated conditions, protected from light.  Following thawing, 
gentl y swirl the vial to ensure uniformity.  GSK2857916 should be diluted in normal 
saline (0.9%) to no more than 2 mg/mL and no less than 0.2 mg/mL.
The dosing solution o f GSK2857916 can be held up to 24 hours under refrigerated 
conditions or 4hours at room temperature (diluted drug product in bag) from a stability  
perspective, but should be used as soon as possible as the product does not contain an 
antimicrobial preserv ative.
REVI SED TEXT
Preparation
GSK2857916 Solution for Infusion, 20 mg/mL is supplied as a frozen liquid (Lot# 
132373860) .  Before use, thaw each vial of GSK2857916 for Infusion, 20mg/mL , 1.5mL 
for up to 4 hours under refrigerated conditions, protected fr om light.  Following thawing, 
gentl y swirl the vial to ensure uniformity.  GSK2857916 should be diluted in normal 
saline (0.9%) to no more than 2 mg/mL and no less than 0.2 mg/mL.
The dosing solution of GSK2857916 can be held up to 24 8 hours under refrigerated 
conditions or 4hours at room temperature (diluted drug product in bag) from a stability  
perspective, but should be used as soon as possible as the product does not contain an 
antimicrobial preservative.
2012N155299_05 CONFIDENTIA L
BMA117159
23216.11.4. Amendment 4
Where the Amendment Applies
Amend ment 4 applies to all sites in Canada, United Kingdom, and United States
Amendment Changes with Rationale
The protocol Amendment 2 dated 20 March 2014 (applied to all sites) and protocol 
Amendment 3 dated 05 May  2014 (applied to sites in Canada) are replac ed by  
Amendment 4 with the effective date of 05 MAY 2016.
The following protocol changes have been implemented to include patient reported 
outcome instruments in the Part 2 multiple my eloma cohort and refine the ly mphoma 
histologies eligible in Part 2 BCMA -expressing lymphoma cohort (the prior cohort name 
of “other hematologic malignancies” will be replaced with “l ymphomas”; this revision 
will be referenced throughout the protocol. Additionally the requirement for 60% of 
tumor cells staining positive for BC MA expression was removed. The total number of 
subjects that may  be enrolled is presented by  a range of 80 to 95 to provide an updated 
estimate based on the number of subjects who enrolled at the time of the amendment.  
Additional modifications include: ch anging the time -point specific blood specimens are 
collected for baseline/pre -treatment immunogenicity  and biomarker measurements, and 
the visit window for certain assessments. The primary  and secondary  medical monitors 
were updated and stud y treatment dose modification revisions were made for Grade 3 
ocular toxicities. 
Original text display ed as strikethrough indicates replaced or removed text. New text is 
display ed as underline. Revisions within tables will either be presented with the entire 
table or di splay ed as text (i.e., for larger tables). Revisions to figures will be display ed 
first by  the old figure and then followed by  the new figure. Ty pos or minor word changes 
will not be presented.
Summary of Changes
1.Medical Monitor/Sponsor Contact Information
Role Name Day Time 
Phone 
NumberAfter -hours 
Phone/Cell/
Pager 
NumberGSK Address
Primary 
Medical 
Monitor MDGlaxoSmithKline
1250 South Collegeville Road
Mailstop UP1450 UP-4300
Collegeville, PA 19426 , USA
Secondary 
Medical 
MonitorMD  
MDGlaxoSmithKline
1250 South Collegeville Road
Mailstop UP4315UP4300
Collegeville, PA 19436, USA
PPD
PPD
PPD
PPD
PPD
PPD
2012N155299_05 CONFIDENTIA L
BMA117159
2332.Protocol Synposis
RATIONALE: This is a FTIH study  that will assess the safet y, pharmacokinetics (PK), 
pharmacod ynamics (PD) and therapeutic potential of GSK2857916 in multiple my eloma 
(MM) and other hematologic malignancies lymphomas that express BCMA.
The hy pothesis is that GSK2857916 can be safely  administered to subjects with BCMA 
positive malignancies at doses where target engagement can be demonstrated.  This study  
will determine if adequate target engagement of BCMA receptors translates into clinical 
benefit for subjects with MM and other BCMA positive hematologic malignancies
lymphomas.
OBJECTIVES: 
Secondary
To evaluate the 
pharmacokinetic (PK) 
profile of GSK2857916 and 
the breakdown product cys -
mcMMAF) after 
intravenous (IV) single and 
repeat dose administration 
in subjects with 
relapsed/refractory  MM and 
other BCMA expressing 
hematologic malignancies
lymphomasGSK2857916 and cy s-mcMMAF PK parameters 
following IV single and repeat dose administration 
during dose escalation as data permit (e. g., AUCs 
Cmax, tmax, CL , VSS, t½ [single dose], Cmax and 
Ctrough [repeat dose]). GSK2857916 population 
PK parameters in expansion cohorts at the RP2 
dose (e.g. clearance (CL), volume of distribution 
(Vd)), and relevant covariates which may  
influence exposure (e.g. age, weight, or disease-
related covariates e.g. BCMA expression) 
To assess anti -drug 
antibody  (ADA)formation 
after IV single and repeat 
dose administration of 
GSK2857916ADA incidence and titers after single and repeat 
IV dosing of GSK2857916
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refractory  
MM and other BCMA 
expressing hematologic 
malignancies lymphomasClinical activity  measured as Overall Response 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minimal response (MR) will be assessed 
for clinical benefit rate (CBR) (Appendix 
1)
oFor Other Hematologic Malignancies 
Lym phomas : the percentage of subjects 
achieving PR or better ( PR) (Appendix 
2012N155299_05 CONFIDENTIA L
BMA117159
2342Appendix 2 ) (Appendix 3)
Exploratory 
To evaluate PD markers in 
MM after treatment with 
GSK2857916sBCMA levels, BCMA receptor occupancy  and 
cell death markers in subjects with MM. 
Toexplore relationships of 
GSK2857916 plasma 
concentrations/exposure 
with pharmacod ynamics 
(PD), safet y and clinical 
activity  Relationship between receptor occupancy , tumor 
cell death markers, sBCMA and GSK2857916 
plasma PK parameters;
Relationship betwee n safety /clinical activity  (e.g. 
ORR) and GSK2857916  PK parameters 
To characterize the 
relationship between 
clinical response and other 
biologic tumor 
characteristics (DNA, 
protein anal ysis)BCMA expression levels on malignant cells as 
measured b y IHC a nd/or flow cy tometry  in tumor 
tissue, serum sBCMA levels and their relationship 
to clinical response
To investigate the 
relationship between genetic 
variants in the host and 
response to GSK2867916
study  medicine, or 
susceptibility , severit y and 
progressio n of disease.Relationship between host genetic variation and 
response to GSK2867916 study  medicine or 
susceptibility , severit y and progression of disease
To explore the effect of 
GSK2857916 on bone 
pain/fatigue and HRQoL in 
subjects with 
relapsed/refract ory MM
(Part 2)Changes from baseline in bone pain/fatigue and 
analgesic use as measured by  the eDiary
Interviews with subjects to further characterize 
changes in bone pain/fatigue and impacts on 
HRQoL
Rationale for Change : update the objectives and endpoints to align with the other 
hematologic malignancies to be restricted to l ymphomas and the inclusion of fatigue and 
bone pain quality  of life instruments in Part 2 multiple my eloma cohort. Also allow for 
genetic research to include anal yses of genetic va riants with disease susceptibility , 
severit y, and progression of disease. 
2012N155299_05 CONFIDENTIA L
BMA117159
235STUDY DESIGN: This study  is an open -label, dose escalation Phase I FTIH study  to 
determine the RP2 dosing regimen of GSK2857916.  The recommended dose and 
schedule will be selected based on the safet y, pharmacokinetic (PK), and 
pharmacod ynamic (PD) profiles observed after administering the study  drug to subjects 
with multiple my eloma (MM).  The study  will consist of two parts and will enroll 
approximately  80-95subjects.  The Part 1 dose escalation phase will characterize the 
safet y and tolerability of respective dosing regimen for GSK2857916 utilizing the model 
based on the Neuenschwander continual reassessment method (N -CRM).  Initiall y, 
GSK2857916 will be administered via 60 min in travenous (IV) infusion once every  three 
weeks (21 day s = 1 cy cle). After a MTD or recommended phase 2 dose (RP2D ) has been 
established on the once every  three weeks schedule, the safety , tolerability , and PK of 
once -weekl y dosing of GSK2857916 for three c onsecutive weeks with 1 week rest (28 
days = 1 cy cle) may  be explored in an additional cohort(s). Part 2 will explore the safet y, 
tolerability , PK, PD, and clinical activity  of the RP2 dose of GSK2857916 identified in 
Part 1.  Subjects with MM (n=40) and l ymphomas expressing BCMA (n=10) will be 
enrolled inexpansion cohort in Part 2. Futility  analy ses will be performed on the MM 
cohort after approximately 15, 22, 30 subjects have been enrolled. Sparse PK sampling 
will be collected to further characterize GSK 2857916 exposures for the selected dose 
schedule.  Although not required for MM, subjects with other BCMA -positive 
hematologic malignancies lymphomas will be enrolled in Part 2 based upon the detection 
of positive BCMA staining of tumor cells in a prospect ive immunohistochemistry  
screening assay  performed at a central laboratory .
NUMBER OF SUBJECTS : Approximately  80-95subjects will be enrolled.
Up to 30 subjects with relapsed/refractory MM will be enrolled in Part 1, Schedule 1; 
Schedule 2, if explored, wi ll enroll up to 15 additional subjects in Part 1.
Up to 40 subjects with relapsed/refractory MM and up to 10 subjects with other 
hematologic malignancies l ymphomas expressing BCMA will be enrolled in Part 2.
INCLUSION CRITERIA
2.Male or female, 18 years or older (at the time consent is obtained) and must have a 
body  weight of at least 45 kg (99 lb).
4.Part 2/Other BCMA positive Hematologic Malignancies cohort: 
a.Subject with one of the following hematologic malignancies lymphomas:
Waldenstrom’s Macroglobuline mia (WM), Diffuse Large B -cell Ly mphoma 
(DLBCL) ,orand chronic ly mphocy tic leukemia (CLL) follicular l ymphoma 
(FL) that exhibits positive BCMA expression on tumor cells as determined by  a 
central laboratory  using a validated IHC assay .The BCMA positivity is defined 
as having approximately  60% of tumor cells staining positive for BCMA, and 
the staining intensity  must be 2 on IHC scale 0- 3.
Eligible subjects with BCMA positive malignancies ly mphomas must also fulfill the 
prior treatment requirements as follows:
2012N155299_05 CONFIDENTIA L
BMA117159
236b.DLBCL and WM: at least 2 prior lines of sy stemic therapy  containing at least 
one line of chemo -immunotherap y with anti -CD20 antibody , and either has 
undergone stem cell transplant or is considered transplant ineligible .
c.FL: at least 2 prior lines of systemic therapy CLL: at least 2 prior lines of 
systemic therapies, and who are refractory  to fludarabine, and failed (or are 
ineligible) for rituximab, ofatumumab and bendamustine.
6.Adequate organ s ystem functions as defined in Table below:
General
Ca 1.1xULN 
Exclusion Criteria:
1.Systemic anti -myeloma tumor therap y within 14 days, or plasmapheresis within 7 
days prior to the first dose of study  drug.
17. Subjects with positive test for hepatitis C (HCV) infection are excluded regardless 
of viral load.   If hepatitis C antibody  test is positive, a confirmatory  polymerase chain 
reaction (PCR) or recombinant immunoblot assay (RIBA)test should be performed.  If 
the PCR or RIBA test is negative, subject is eligible for this trial.
Rationale for Changes: removed the minimum weight in Inclusion criterion 2 as that 
was required for the lowest doses administered during dose escalation. The Part 2 
hematologic malignancies were refined to include DLBCL and FL onl y based on the 
frequency  of BCMA expression and the intensity  of expression observed. 
PHARMACOKINETIC/ PHARMACODYNAMIC ASSESSMENT(S) : 
In the Part 2 dose expansion phase in subjects with other BCMA positive lymphomas   
hematologic malignancies PK samples will be taken for both GSK2587916 and cy s-
mcMMAF meas urement according to the Time and Events Tables in Section 7.17.1.
CLINICAL ACTIVITY ASSESSMENT:
For Other Hematologic Malignancies Lym phomas : the percentage of subjects with 
confirmed CR, PR, as described in the Revised Response Criteria for Malignant 
Lym phoma (Appendix 2) .and for CLL Appendix 3).
TRANSLATIONAL RESEARCH
Pharmacod ynamic assessments will include evaluation of tumor tissue by flow cytometry 
and immunohistochemistry  (IHC) for plasma cell expression of free BCMA receptors and 
GSK2857916 bound receptors, cell cy cle markers, as well as apoptosis markers on tumor 
cells, to understand anti -tumor responses. IHC markers may  include but will not be 
limited to BCMA, Blimp1, CD38, CD45, cy s-mcMMAF, CC3, PH3, and MPM -2.  
Additionally , tumor tissue may  beevaluated for any  DNA /RNA changes correlating with 
response.  Serum levels of free and GSK2857916 bound sBCMA will be assessed b y 
Meso -Scale Discovery  immunoassay  and correlated with clinical outcome to treatment 
with GSK2857916.  Cy tokines and, chemokin es, and cfDNA will alsobe measured; cell-
free deox yribonucleic acid (cfDNA) may be measured.   
2012N155299_05 CONFIDENTIA L
BMA117159
237Leukocy te population will be characterized and may  be correlated with clinical outcome.
Pharmacogenetic A genetics samples will be collected in Part 2 and may  be used to 
investigate variability  in response that may  be attributable to host genetic variation, if it 
emerges during this clinical study or a series of clinical studies of GSK2857916 
(Appendix 7). Further, the genetic sample may  be used to investigate th e relationship 
between genetic variation and disease (susceptibility , severity  or progression) .
Rationale for Changes : as cfDNA anal yses may  not occur the language was revised 
accordingl y. Sample collected for genetic anal ysis may  be used to investigate 
relationships between genetic variations and disease associated parameters in addition to 
response to GSK2857916.
PATIENT REPORTED OUTCOMES
Part 2/MM cohort: changes in sy mptoms and health -related quality  of life (HRQoL) will 
be assessed with the use of the Bone Pain/Fatigue diary .
Rationale for Change: inclusion of HRQoL assessments in Part 2 MM cohort will 
provide a preliminary  assessement of patient report for affects of GSK2857916 on bone 
pain and fatigue. 
3.Section 1.1 Background
BCMA is expressed in var ious B -cell malignancies, including MM.  The expression 
levels in MM vary  from patient to patient, but our studies demonstrate that all patients 
tested express detectable levels of BCMA protein on their tumor cells. BCMA expression 
varies between MM patients and GlaxoSmithKline (GSK) studies have shown that in 
samples taken from MM patients (N=45), 31% have low expression, 38% moderate 
expression and 31% high expression of BCMA as detected b y immunohistochemistry 
(IHC).  BCMA was also anal yzed by flow cy tometry in tumor cells from 48 MM patients 
which aligned well with IHC results. In addition, other B -cell malignancies including 
Follicular Ly mphoma (FL) [ Basso, 2005; GSKin -house data], Diffuse Large B -Cell 
Lym phoma (DLBCL), Large B -Cell Ly mphoma (LBC L), Ch ronic Ly mphocy tic 
Leukemia (CLL) and Waldenstrom’s Macroglobulinemia (WM) [ Montes -Moreno , 2012] 
[Elsawa , 2006] [ Endo, 2007] were reported to express BCMA at varying 
frequencies;DLBCL and FL were among the B-cell hematologic malignancies exhibiting 
the high est frequency  of BCMA expression.
A soluble form of BCMA has also been reported [ Sanchez , 2012].  Higher amounts of 
this soluble form were found in supernatants isolated from cultures of MM -containing 
peripheral blood and bone marrow mononuclear cells comp ared to normal cells.  
Moreover, soluble BCMA (sBCMA) was higher in the sera of MM patients (n=209) 
compared to sera from age -matched, health y controls (n=40; P< 0.0001).  Measurement 
of serum levels of BCMA was conducted b y immunoassay to confirm the pre valence and 
level of sBCMA expression in MM.  Soluble BCMA is present in serum at a median 
concentration of 9.28 ng/mL  (range 6.10- 14.09 ng/mL ) in healthy  volunteers (N=38) and 
is elevated in the serum of MM patients (N = 44) to median of 148.64 ng/mL (ran ge 2.40 -
1062.48 ng/mL). 
2012N155299_05 CONFIDENTIA L
BMA117159
238In addition, other B -cell malignancies including Diffuse Large B- Cell Lymphoma 
(DLBCL), Large B -Cell Ly mphoma (LBCL), Chronic Ly mphocy tic Leukemia (CLL) 
and Waldenstrom’s Macroglobulinemia (WM) [Montes -Moreno , 2012] [ Elsawa , 2006]
[Endo, 2007] have been reported to express BCMA at varying frequencies. 
The restricted normal tissue expression profile of BCMA, along with its upregulation and 
survival function in MM and other BCMA -positive cancers makes it an attractive target 
for a t herapeutic antibody  with direct cell killing activity . 
4. Section 1.3.2 Benefit Assessment
Currently  there is no clinical evidence that treatment with GSK2857916 will result in 
any benefit to subjects.  However, based on data from non clinical studies there is a 
possibility  that GSK2857916 might reduce tumor burden in subjects with MM and 
other BCMA positive hematologic malignancies lymphoma s.
5. Section 1.3.3 Overall Benefit:Risk Conclusion
Overall, due to lack of any limited clinical experience with GSK2857916 benefit/risk 
cannot be asseesesed at this time.  The safet y of subject is the primary objective of 
this study  and adequate monitoring and guidance for dose reductions/stopping criteria 
are provided in the protocol to minimize risks associated with exposur e to 
GSK2857916. 
6.Objectives(s), Endpoint(s) and Hypothesis
Objective Endpoint
Primary
To determine safet y, 
tolerability , maximum 
tolerated dose (MTD), and 
recommended phase (RP2) 
dose and schedule of 
GSK2857916 administeredAdverse events (AE) and chang es in clinical signs 
and laboratory  parameters 
Secondary 
To evaluate the 
pharmacokinetic (PK) 
profile of GSK2857916 and 
the breakdown product cys -
mcMMAF) after 
intravenous (IV) single and 
repeat dose administration 
in subjects with 
relapsed/refractory MM and 
BCMA expressing 
lymphomasGSK2857916 and cy s-mcMMAF PK parameters 
following IV single and repeat dose administration 
during dose escalation as data permit (e.g., AUCs 
Cmax, tmax, CL , VSS, t½ [single dose], Cmax and 
Ctrough [repeat dose]). GSK28579 16 population 
PK parameters in expansion cohorts at the RP2 
dose (e.g. clearance (CL), volume of distribution 
(Vd)), and relevant covariates which may  
influence exposure (e.g. age, weight, or disease-
related covariates e.g. BCMA expression) 
2012N155299_05 CONFIDENTIA L
BMA117159
239Objective Endpoint
To assess an ti-drug 
antibody  (ADA)formation 
after IV single and repeat 
dose administration of 
GSK2857916ADA incidence and titers after single and repeat 
IV dosing of GSK2857916
To explore the initial anti -
tumor activity  of 
GSK2857916 in subjects 
with relapsed/refr actory  
MM and BCMA expressing 
lymphomasClinical activity  measured as Overall Response 
Rate (ORR) which is defined as follows:
oFor MM: the percentage of subjects 
achieving confirmed partial response or 
better ( PR) 
oIn addition, the percentage of subjects with 
minimal response (MR) will be assessed 
for clinical benefit rate (CBR) ( Appendix 
1)
oFor Other HematologicMalignancies
Lym phomas: the percentage of subjects 
achieving PR or better ( PR) ( Appendix 2
and Appendix 3)
Exploratory 
To evaluate PD marker s in 
MM after treatment with 
GSK2857916sBCMA levels, BCMA receptor occupancy  and 
cell death markers in subjects with MM. 
To explore relationships of 
GSK2857916 plasma 
concentrations/exposure 
with pharmacod ynamics 
(PD), safet y and clinical 
activity  Relationship between receptor occupancy , tumor 
cell death markers, sBCMA and GSK2857916 
plasma PK parameters;
Relationship between safety /clinical activity  (e.g. 
ORR) and GSK2857916  PK parameters 
To characterize the 
relationship between 
clinical response a nd other 
biologic tumor 
characteristics (DNA, 
protein anal ysis)BCMA expression levels on malignant cells as 
measured b y IHC and/or flow cy tometry  in tumor 
tissue, serum sBCMA levels and their relationship 
to clinical response
To investigate the 
relationship between genetic 
variants in the host and 
response to GSK2857916 
study  medicine or 
susceptibility , severit y and Relationship between host genetic variation and 
response to GSK2857916 study  medicine or 
susceptibility , severit y and progression of disease
2012N155299_05 CONFIDENTIA L
BMA117159
240Objective Endpoint
progression of disease
To explore the effect of 
GSK2857916 on bone 
pain/fatigue and HRQoL in 
subjects with 
relapsed/refractory  MMChanges from baseline in bone pain/fatigue and 
analgesic use as measured by  the eDiary
Interviews with subjects to further ch aracterize 
changes in bone pain/fatigue and impacts on 
HRQoL
7. Section 3.1 Discussion of Study Design
This is a First Time in Human (FTIH), open -label, dose escalation trial consisting of two 
parts: a Part 1 dose escalation phase and a Part 2 expansion pha se for safet y, and clinical 
activity  testing ( Table 3and Section 3.2). The study will enroll a total of approximately  
80-95subjects with relapsed/refractory  MM or other BCMA- expressing hematologic 
malignanciesly mphoma s.  The maximum dose to be administer ed in this trial will not 
exceed 5 mg/kg.
Part 1 : Dose -escalation cohorts will characterize the safet y, tolerability , PK, and PD of 
GSK2857916 given on a once every  21 day s or a once weekl y schedule. Only  subjects 
with MM will be enrolled in Part 1 based o n an N -CRM dose escalation model until 
MTD(s) or RP2D is/are established on an appropriate schedule(s).
Once an MTD1 or RP2D has been established on the once every  21-day (Schedule 1), the 
safet y, tolerabilit y, PK, and PD of once -weekl y dosing (Schedule 2) of GSK2857916 
may be explored asan additional cohort(s). 
A smaller cohort of subjects with other BCMA positive hematologic malignancies
lymphomas (up to 10 subjects) will be enrolled based upon prospective detection of 
positive BCMA tumor cell expressio n as determined by a central laboratory using a 
validated IHC screening assay .  BCMA staining intensity  of 2 (on scale 0 -3) in 
approximately  60% tumor cells vs. control slides will be assessed for stud y entry at a 
central laboratory ). Enrollment into the cohort for other hematologic malignancies will be 
initiated once the safety  of the selected dose and schedule have been confirmed in the 
MM expansion cohort (i.e. when at least >15 MM patients have enrolled and been 
evaluated for at least one cycle).
8.Section 3.2 Study Schematic
Old Figure
2012N155299_05 CONFIDENTIA L
BMA117159
241
New Figure
MTD1
4
3
12
25% of MTD1 /RP2 D1MTD 2/RP2D2BCMA -positive Lymphomas (n =≈10)Multiple myeloma  (n ≈ 40)PART 1: Dose Escala tion
(n≈30)PART 2: Expa nsion Coho rts 
(n≈50)
23
1
*Cohort s ize to i ncrease, n≈3 i f ≥Grade 2 
drug related toxi city reported5-9
4RP2D1
2012N155299_05 CONFIDENTIA L
BMA117159
242Abbreviations: MTD=maximum tolerated dose; N- CRM= Neuenschwander Continual Reassessment 
Method; RP2D=recommended phase 2 dose
1.Part 2 to initiate after  once every 3 week recommended dose is determined
2.Dose escalation with once weekly schedule may commence in parallel to Part 2 expansion
Rationale for Changes : the figure was revised to illustrate that Part 2 will be initiated 
after a recommended dose for the once every  three weeks schedule is determined. Dos e 
escalation of the once weekly  schedule if investigated may  commence at any  time during 
the conduct of the stud y.
9.Section 3.3 Part 1: Dose -Escalation Phase
After the MTD1 or RP2D is established for the once every  three weeks Schedule 1, once 
weekl y dosing of GSK2857916 (Schedule 2) may  be evaluated prior to, or in parallel 
with the expansion phase as described in Section 3.3.2 .  A weekl y dosing regimen may be 
chosen for further evaluation if toxicity  is felt to be related to Cmax and that equivalent 
or gre ater exposures in terms of AUC can be safely  achieved with weekl y dosing 
compared with the once every  3weeks dosing regimen.  
10. Section 3.3.1.2.1 Planned Dose Levels
Prior to the start of the study , projected dose levels on Schedule 1 (in mg/kg) are 0.03, 
0.06, 0.12, 0.24, 0.48, 0.96, 1.92, 2. 8, 3.6, and 4.5 mg/kg ; actual dose levels will be 
determined b y N-CRM (Neuenschwander -Continuous Reassessment Method ).  
Additional doses and schedules may  be explored based on emerging safet y, PK, and PD 
data. The maxi mum dose to be administered in this trial will not exceed 5 mg/kg.
11.Section 3.3.1.2.3 Bayesian Prior
A graphical presentation of the initial prior is displayed in Figure 1.  Doses are the 
projected doses.  Actual doses used during the conduct of the trial m ay vary .An 
intermediate prior will be derived based on the initial prior by  FACTS (Version 2.3 or 
higher) from Tessella. The final prior is determined based on the intermediate prior and 
all available data.
12. Section 3.3.2 Dose Escalation on Schedule 2 (GSK 2857916 administered once 
weekly x3, 1 week rest; 28 days = 1 cycle)
The once weekl y dosing cohorts may  be explored prior to, or in parallel with, 
enrollment to the expansion cohorts (Part 2).
Depending on emerging safet y signals, the proposed weekl y start ing dose will be 
25% of MTD1 or RP2D1 .  If the initial dose of 25% of MTD1 or RP2D1 is not 
tolerated, dose escalation on the weekl y schedule will be terminated and enrollment 
into Schedule 2 will be closed.  If the starting dose is tolerated, escalation on the 
weekl y schedule will continue at increments of 30% and will follow the N -CRM 
procedure until MTD2 or RP2D2 is reached. 
13. Section 3.4 RP2 Dose and Administration Schedule Selection for Part 2
This lower dose level, or an intermediate dose considered the BED, may  be tested as the 
RP2 dose for further evaluation in Part 2.  Part 2 may start enrolling once Part 1 has 
completed enrollment of Schedule 1 (once every  three weeks) and after the preliminary  
2012N155299_05 CONFIDENTIA L
BMA117159
243PK and relevant PD data ha vebeen anal yzed. The schedule selection for Part 2 (weekl y 
vs. once every  3 weeks vs. an intermediate schedule) will be based on the information 
collected following administration of GSK2857916 on the respective schedules evaluated 
in Part 1. The once weekly schedule may  be explore d prior to or in parallel with the 
expansion cohorts. Data considered will include, but not be limited to,  relationships 
between safet y and exposure, the PK profiles, as well as an y emerging PD information, 
and earl y signs of clinical activity  observed for each schedule evaluated in Part 1. If the 
once weekl y schedule is explored prior to initiating Part 2 , the chosen dosing regimen 
would need to provide evidence of the following in order to be the preferred schedule in 
Part 2:  a better safet y and tolerab ility profile at an equivalent or higher dose, or greater 
clinical activity , or a more desirable PK profile (i.e. no evidence of target- mediated 
disposition observed over the dosing interval).  A preference might be given to the 
weekl y schedule if at MTD1, thereceptor occupancy  levels are considered sub- optimal 
and/or saturation of soluble sBCMA is not maintained long enough on the every  3 weeks 
dosing schedule .
Part 2: Expansion Cohort :
(Note: For details on scheduled procedures in subjects given GSK28579 16 in Part 2, refer 
to Time and Events Tables Section 7.1.2 .The Time and Events Table for GSK2857916 
administered to MM subjects on Schedule 1 is represented in Section 7.1.2.1 , and the 
Time and Events Table for GSK2857916 administered to MM subjects on Schedule 2 is 
represented in Section 7.1.2.2 . Refer to Time and Events Tables Section 7.1.2.3 and 
Section 7.1.2.4 for GSK2857916 administered to subjects with other hematologic 
malignancies lymphomas on Schedule 1 or Schedule 2, respectively ).
Once the RP2 dose and schedule ha vebeen selected , expansion cohort swill be enrolled 
in order to better characterize the safet y profile of the selected dose and schedule.  
The Part 2 expansion will enroll up to 50 subjects as summarized below:
oMultiple My eloma cohor t (up to 40 subjects)- no prospective screening of 
BCMA is required for enrollment
Futility  anal yses based on ORR will take place after approximately  
15, 22 and 30 subjects have been evaluated for response. Full 
details can be found in Section 13.6.2   
BCM A expression data and retrospective anal ysis will be 
performed on samples collected in the MM population
PRO will be collected via eDiary  in the MM population in Part 2 
only
Other BCMA positive lymphomas (defined as BCMA positive 
staining b y IHC) hematologi c malignancies (up to 10 subjects) –
prospective screening of  BCMA expression is required for 
enrollment
2012N155299_05 CONFIDENTIA L
BMA117159
24414. Section 3.6.1 Rationale for Study; Section 3.6.2 Rationale for Populations
This study  will assess the safet y, PK, PD and the therapeutic potential o f 
GSK2857916 in subjects with MM and other hematologic malignancies lymphomas 
that express BCMA.
This study  will determine if adequate target engagement of BCMA receptors 
translates into clinical benefit for subjects with MM and other BCMA positive 
hematolo gic malignanciesly mphomas .
Subjects with ly mphomas that exhibit BCMA expression have been selected as an 
exploratory  cohort in this FTIH study ; the frequency  of BCMA expression in 
lymphomas is lower than that observed in MM, therefore prospective selection is 
required.  
The target population for this study  includes subjects with relapsed/refractory MM to 
establish the dose and characterize safety , PK and PD of GSK2857916.  Subjects with 
other BCMA expressing hematologic malignancies lymphomas will also be a llowed 
on study  after prospective screening b y IHC demonstrates that BCMA is expressed on 
tumor cells. Potential subjects with other B-cell malignanciesly mphomas who will be 
tested for BCMA expression prior to study  entry  include, subjects with the following 
diseases:  Diffuse Large B -Cell Ly mphoma (DLBCL ), , Folicullar Ly mphoma (FL), 
Chronic Ly mphocy tic Leukemia (CLL) and Waldenstrom’s Macroglobulinemia who 
have that have failedprogressed after 2 prior lines of sy stemic therapy  for a given 
disease.  
15.Secti on 3.6.4 Rationale for Endpoints
Markers showing significant correlation between baseline levels and clinical outcome 
may have predictive value and may be further explored for utility  in patient selection 
in future trials.
Anti- tumor activity  will be explor ed to evaluate the potential for clinical benefit from 
GSK2857916 treatment. In addition, patient report outcomes will also be studied in 
Part 2 (MM subjects only)
Rationale for Changes: QoL measurements were included as exploratory  endpoints 
In Part 2 mul tiple my eloma cohort in order to provide preliminary  analy ses of affects 
of treatment on fatigue and bone pain. Additionally, biomarker anal yses in the 
BMA117159 may  uncover markers that may  be implemented for patient selection in 
future trials.
16. Section 3. 9.8. Ocular Toxicity  and Stopping Criteria
All subjects will be advised to use prednisolone phosphate 1% or dexamethasone 
0.1% ey e drop 4 times a day  (QID) for 4 day s starting 1 day  prior to each dose. 
Additional use of lubrication ey e drops (artificial te ars) QID PRN throughout the trial 
is recommended, especially  if subject develops any  ocular sy mptoms. Subjects who 
develop Grade 3 ocular or corneal toxicity  will be allowed to continue study  
2012N155299_05 CONFIDENTIA L
BMA117159
245treatment after resolution to Grade 1; each case will be discu ssed individually  
between the investigator and the Medical Monitor. Subjects who develop Grade 3 4 
ocular or corneal toxicity  will be permanentl y removed from stud y. Refer to Section 
3.10.2 for futher guidance.
Rationale for Change: The requirement to pe rmanently  discontinue GSK2857916 
for Grade 3 ocular toxicity was revised to require study  treatment to be interrupted 
and to allow for these events to be discussed with regard to t ype of event and the 
duration of time for the event to resolve to Grade 1 or to baseline. If stud y treatment 
resumes, the dose will be reduced b y at least 25% of the dose that was administered 
when event occurred.
17.Section 3.10.2  Predicted Toxicities and Proposed Dose Adjustments/Stopping 
Criteria
Grade 2 Ocular Toxicity: Further treatment Permanently discontinue treatment with 
GSK2857916 only allowed after discussion and in agreement with medical monitor and 
withdraw subject from study
Grade 3 
First occurrence
oConsult ophthalmologist immediately
oInterrupt treatment with GSK28579 16
oOnce resolved to G1: Restart treatment with GSK2857916 at 25% - 50%  dose 
reduction if the investigator and Medical Monitor agree that the potential benefits 
outweigh the risks
Second occurrence
oConsult ophthalmologist immediately
Permanently discontin ue treatment with GSK2857916
Grade 3/Grade 4
Rationale for Changes: The requirement to permanently  discontinue GSK2857916 
for Grade 3 ocular toxicity was revised to require study  treatment to be interrupted 
and to allow for these events to be discussed wi th regard to t ype of event and the 
duration of time for the event to resolve to Grade 1 or to baseline. If stud y treatment 
resumes, the dose will be reduced b y at least 25% of the dose that was administered 
when event occurred.
18.Section 4.1 Description of I nvestigation Product; Section 4.2 
The lot number indicated on the label refers to labelled lot number; the batch 
Lot#132373860 may not be provided on the label.
Before use, thaw each vial of GSK2857916 for Infusion, 20mg/mL , 1.5mL for up to 4 
hours under refrigerated conditions (2-8C), protected from light.  Following thawing, 
gentl y swirl the vial to ensure uniformity.  GSK2857916 should be diluted in normal 
saline (0.9%) to no more than 2 mg/mL and no less than 0.2 mg/mL. Refer to the Study  
Procedures M anual (SPM) for further details on preparation of GSK2857916.
2012N155299_05 CONFIDENTIA L
BMA117159
246The dosing solution of GSK2857916 can be held under refrigerated conditions (2-8C),
for up to 24 hours ( NOTE : For centers in Canada up to 8 hours only ) or 4 hours at 
ambient temperature (dilute d drug product in bag) from a stability  perspective, but should 
be used as soon as possible as the product does not contain an antimicrobial preservative.
Rationale for Change: Clarify  that lot number 132373860 refers to manufacturer batch 
lot number. 
19. Sec tion 5.1 Number of Subjects
An adequate number of subjects will be enrolled into the study  to establish the 
recommended dose(s) for further stud y.  It is estimated that approximately  30 subjects 
will be enrolled into Part 1 , Schedule 1 (dose -escalation) of the study .  Up to 40 subjects 
with MM and up to 10 subjects with other BCMA positive hematologic malignancies
lymphomas ( 50 subjects total) will be enrolled in Part 2 (expansion cohort).  The 
number of subjects in the expansion cohort has been estimated based on expected 
variable expression of BCMA in those subjects (about 1/3 low, 1/3 medium, 1/3 high 
expression; approximately 13 subjects/group).  The level of BCMA expression in a given 
subject is expected to impact target -mediated clearance, which as a consequence might be 
reflected in the PK/PD variability  and safet y profile of individual subjects.  I n addition, 
the sample size of 40 subjects in the MM cohort will allow for assessment of earl y signals 
of clinical activit y and its relationship (if an y) to variable target expression levels.  A total 
of approximately  80subjects will be enrolled in the study .If Part 1, Schedule 2 (once 
weekl y schedule) is explored, up to 15 additional subjects will be enrolled; then a total of 
approximately  95 subjects will be enrolled in the study .
Rationale for Change : The number of subjects in dose escalation is increased to allow 
for the weekl y dosing schedule to be investigated as the estimated 30 subjects in dose 
escalation were allocated to the Q3week schedule. 
20.Secti on 5.2.1 Inclusion Criteria
2. Male or female, 18 years or older (at the time consent is obtained) andmust have a 
body  weight of at least 45 kg (99 lb). 
4.Part 2/Other BCMA positive Hematologic Malignancies cohort: 
d.Subject with one of the following hematologic malignancies lymphomas:
Waldenstrom’s Macroglobulinemia (WM), Diffuse Large B -cell Ly mphoma 
(DLBCL) ,orand chronic ly mphocy tic leukemia (CLL) follicular l ymphoma 
(FL) that exhibits positive BCMA expression on tumor cells as determined by  a 
centra l laboratory  using a validated IHC assay .The BCMA positivity  is defined 
as having approximately  60% of tumor cells staining positive for BCMA, and 
the staining intensity  must be 2 on IHC scale 0- 3.
Eligible subjects with BCMA positive malignancies ly mpho mas must also fulfill the 
prior treatment requirements as follows:
e.DLBCL and WM: at least 2 prior lines of sy stemic therapy  containing at least one 
line of chemo- immunotherap y with anti -CD20 antibody , and either has 
undergone stem cell transplant or is con sidered transplant ineligible .
2012N155299_05 CONFIDENTIA L
BMA117159
247f.FL: at least 2 prior lines of sy stemic therapy CLL: at least 2 prior lines of 
systemic therapies, and who are refractory  to fludarabine, and failed (or are 
ineligible) for rituximab, ofatumumab and bendamustine.
6.Adequate orga n system functions as defined in Table below:
General
Ca 1.1xULN 
21.Section 5.2.2 Exclusion Criteria
1. Systemic anti -myeloma tumor therap y within 14 days, or plasmapheresis within 7 day s 
prior to the first dose of study  drug.
17. Subjects with positiv e test for hepatitis C (HCV) infection are excluded regardless of 
viral load.  If hepatitis C antibody test is positive, a confirmatory  polymerase chain 
reaction (PCR) or recombinant immunoblot assay (RIBA)test should be performed.  If 
the PCR or RIBA tes t isnegative, subject is eligible for this trial.
Rationale for Changes: removed the minimum weight in Inclusion criterion 2 as that 
was required for the lowest doses administered during dose escalation. The Part 2 
hematologic malignancies were refined to include DLBCL and FL onl y based on the 
frequency  of BCMA expression and the intensity  of expression observed. 
22.Section 7 Study Assessments and Procedures and Time and Events Tables
The maximum amount of blood collected in Screening and during the first Cy cle 1 from 
each subject for the Dose Escalation and for the Dose Expansion is no more than 158 162
mlof blood (See Appendix 10 ).
The following changes were made to all Time and Events Tables in Section 7.1.1.2, and 
all Tables in Section 7.1.2; selected ch anges made to Table in Section 7.1.1.1 are 
indicated in parentheses:
End of Study  visit was clarified as End of Study  Treatmen t visit (also Section 
7.1.1.1)
Study  Assessment: CK -MB (local), Troponin; BM biopsy  for disease assessment 
and BCMA expression (IH C); Peripheral blood (flow for TBNK and intracellular 
cytokine testing ). For Tables referring to Part 2 study  assessment: PGxGenetics 
sample . For Part 2 MM cohort study  assessments: e- Diary  and Exit I nterview and 
all associated visits.
Serum for ADA, Plasm a for cfDNA, and whole blood for TBNK analy sis at 
screening was moved to Day  1 cy cle 1 pre -dose. 
C1 D8 visit added for whole blood for TBNK/intracellular cy tokine anal yses
Footnotes (note footnote number provided as the number may  not be consistent 
across all tables: 
oScreening examination to include BCVA (best- corrected visual acuit y), 
slit lamp examination (with special focus on cornea), intraocular pressure, 
2012N155299_05 CONFIDENTIA L
BMA117159
248dilated fundoscopic examination may be performed within 21 day s prior to 
first dose . (also Secti on 7.1.1.1)
oOn-study  exams to include BCVA (best- corrected visual acuity ) and slit 
lamp examination (with special focus on cornea); window for exams is up 
to 3 day s prior to dosing. (also Section 7.1.1.1)
oDescription of change: BNP and CK -MB can be measure d by central or 
local lab. (also Section 7.1.1.1)
oOn day s where ECG timepoints align with PK sampling timepoints, ECGs 
should be performed prior to PK samples being drawn (PK sample should 
be taken at the exact nominal time) . (also Section 7.1.1.1)
oAt Scre ening, LVEF may be performed within 30 days prior to first dose. 
All ECHOs indicated on dosing day s may  be performed up to 5 day s 
before dosing. All ECHOs to be done locall y and sent to GSK for central 
imaging storage. (also Section 7.1.1.1)
oDescription of change for TBNK blood sample: no longer collected at 
Screening but collected C1D1 predose.
oFor Part 2 Tables: 26.Informed consent for optional PGx 
(pharmacogenetics) genetics research should be obtained before collecting 
a sample.
oFor Part 2 MM: e- Diary  to be completed at screening, then Day s 1-7, 8, 15 
of each treatment cy cle. Upon implementation of the e -Diary , these 
assessments will be required. Exit interview to be performed within 14 
days of end of study  visit.
Rationale for Changes: Ocular and ECHOs assessments window increased at 
Screening for ocular and on dosing day s to allow flexibility  for scheduling of 
these assessments prior to dosing. Baseline blood samples for ADA and 
biomarker tests moved to C1D1 to only  collect those samples from eligible 
subjects who receive study  treatment. Allow for BNP and CK- MB testing by  
central laboratory  as not all site local laboratories perform these tests. 
23.Section 7.2 Baseline Assessments
Baseline (Screening) assessments obtained will include:
Imaging studies (e xtramedullary  disease for MM if indicated, or CT/PET scan for 
other hematologic malignancies lymphomas )
For MM: BM aspirate for FISH, BCMA (flow cytometry ), PD (target engagement 
and caspase 3) ; BCMA expression (I HC)
Serum (soluble BCMA, cytokines, and anti -drug-antibodies)
Plasma cfDNA
Peripheral blood (flow for TBNK)
For MM: BM biops y for disease assessment and BCMA expression (I HC)
For other hematologic malignancies Lym phomas: archival or fresh tissue evaluation 
for BCMA expression
24.Section 7.3.6 Laboratory Assessments
2012N155299_05 CONFIDENTIA L
BMA117159
249Table 15:
Hepatitis C (Hep C antibody --if second generation Hepatitis C antibody positive, a hepatitis 
C antibody Chiron RIBA immunoblot assay or a validated HCV PCR viral test should be 
reflexively performed on the same sample to confirm t he result)
25. Section 7.3.8 Immunogenicity 
Serum samples for determination of anti- GSK2857916 antibodies will be taken from 
all subjects in this study  at the time -points specified in the Time and Events Tables in 
Section 7.1.  Timing of the assessments may be adjusted based on emerging data.  
Details of sample preparation, storage and anal ysis will be provided in the SPM.
Samples will be analy zed for the presence of anti- GSK2857916 antibodies by  a 
validated electrochemiluminescent immunoassay . All samples w ill be tested in 
ascreening assay , and positive samples will be further characterized for specificity  
and antibody  titers. 
Rationale for Change : Included section to describe specifics on the immunogenicity 
assessments. 
26.Section 7.5 Translation Research
Section 7.5.1: 
Whole blood count of mononuclear cells (PBMC) and their activation status and 
intracellular cy tokine profile.
Section 7.5.1.4: 
Clusters of markers circulating in the plasma blood have been found to correlate with 
tumor pathway  activation.  A broad panel of cy tokines/chemokines will be evaluated at 
various timepoints as outlined in the Time and Events table (Section 7.1) and correlated 
with clinical outcome to treatment with GSK2857916. In addition to measuring total 
cytokine levels in serum, a ctivated l ymphocy tes and monocy tes producing involved in 
the cy tokine production will be determined via intracellular cy tokine assay. 
Section 7.5.2:
Baseline measurements of BCMA expression on tumour tissue plasma cells will be 
measured BCMA exhibits vari ed expression across B -cell hematological malignancies 
and therefore, BCMA expression levels at baseline may  be an important predictor of 
response to GSK2857916. To evaluate whether BCMA expression has utility  in patient 
stratification or selection, malign ant plasma cells at baseline will be measured for BCMA 
expression by I HC and/or flow cy tometry .since this may  be important for potential 
retrospective stratification of subjects more likel y to respond to GSK2857916.  Because 
BCMA can also be detected in ci rculation, the soluble form (sBCMA) has the potential to 
serve as a surrogate for cell surface BCMA marker expression. This study  will correlate 
2012N155299_05 CONFIDENTIA L
BMA117159
250subject’s sBCMA levels with cell surface expression and clinical response to support 
future validation of sBCMA as a patient se lection marker, if data warrant.
Novel candidate biomarkers and subsequently  discovered biomarkers of the biological 
response associated with advanced multiple my eloma, hematological 
malignanciesly mphomas and/or medicall y related conditions , as well as the biological 
and clinical responses to GSK2857916 may  also be evaluated.  These anal yses may 
include but not be limited to:
Tumor /plasma cell BCMA receptor expression b y flow cytometry and/or IHC.    
Soluble factors, including circulating c fDNA analy sisof tumor tissue and plasma and 
cytokine/chemokine analy sis of plasma
Additional soluble measurements to include serum levels of free sBCMA 
Activated PBMC count analy sis of whole blood and intracellular cy tokine assessment
27.Section 7.6 Pharmac ogenetics Genetics
An important exploratory objective of the clinical study  is pharmacogenetic (PGx)
genetic research.  Participation in PGx is optional but all subjects who are eligible for the 
clinical study  and are enrolled into part 2 (expansion cohort) will be given the 
opportunity  to participate.  Subjects may  decline participation without effect on their 
medical care or care during the clinical study .  A separate consent signature is required 
for PGx genetic research.
Subjects who provide consent wil l have a blood sample taken for anal ysis.  The 
presence/absence of genetic variations in host DNA will be anal yzed to determine their 
relationship with response (safety, tolerability , pharmacokinetics (PK) and efficacy ) to 
treatment with GSK2857916.
Inform ation regarding PGx research genetic research is included in Appendix 7 .  In 
approving the clinical protocol the IEC/IRB and, where required, the applicable 
regulatory  agency  are also approving the PGx genetic research described in Appendix 7
unless otherw ise indicated.  Where required b y regulatory authorities, approval of the 
PGxgenetic assessments can occur after approval is obtained for the rest of the study .  If 
so, then the written approval will clearl y indicate approval of the PGx genetic
assessments is being deferred and the study , except for PGx genetic assessments, can be 
initiated.  When PGx genetic assessments will not be approved, then the approval for the 
rest of the stud y will clearly .
Rationale for Change: Also allow for genetic research to inc lude anal yses of genetic 
variants with disease susceptibility , severity , and progression of disease.
28.Section 7.8 Health Outcome s:Quality of Life
Health Outcomes Endpoints
2012N155299_05 CONFIDENTIA L
BMA117159
251The patient reported outcome (PRO) instruments that will be used are the Bone 
Pain/F atigue Assessment via an e- Diary .In the Part 2 multiple my eloma cohort, the 
implementation of this assessment will occur upon availability  of the instruments.
Bone Pain/Fatigue Assessment: Bone pain burden will be measured b y e-Diary  consisting 
of certain modified questions from Brief Pain Inventory -Short Form (BPI -SF) which 
assesses pain intensity  and the interference of pain with daily  life [Atkinson, 2010; 
Cleeland, 1994] and Brief Fatigue Inventory  (BFI) [Cleeland, 2010]. The BPI -SF is one 
of the most frequentl y used pain assessments [Cleeland, 2009] and has been used in 
various disease areas, including cancer pain and neuropathic pain [ Daut, 1982; McDowell 
1996 ]. The questionnaire has demonstrated both reliability  and validity  across cultures 
and languages [ Cleeland, 1994 ]. The BFI has also been used in cancer patients to 
measure fatigue [ Mendoza, 1999].
Bone pain and fatigue burden will be measured b y an e -Diary  consisting of 7 short 
questions, including 4 questions to assess pain intensity  (severity )and one question to 
assess the interference of pain with daily life activities. The items ask about pain 
experienced within the last 24 hours. It also includes 2 questions on use of pain 
medication. Fatigue will be measured b y 2 short questions – one to a ssess the level of 
fatigue in the past 24 hours and the second to assess the interference of fatigue with 
general activity . Data from this e -Diary  will be used to understand and characterize 
pain/fatigue experience and explore time to potential pain relief while controlling for the 
use of pain medication.
It is expected that the improvement in intensity  of bone pain/fatigue and the impact of 
bone pain/fatigue on general activity  will take place within the first 8 cy cles of treatment 
and the self -completion of the e -Diary  during this period will accuratel y capture the 
changes in bone pain/fatigue.
Upon availability  of the Bone Pain/Fatigue Assessment e -Diary , MM subjects will self -
complete the assessments at the following times:
Starting 2- 4 day s prior to Cy cle 1 Day  1
Daily  from Day  1 through Day  8 for each C ycle to time of study  treatment 
discontinuation
Day 15 of each C ycle to time of study treatment discontinuation
Study  Treatment Discontinuation visit
Samples of the paper versions of the PRO questionnaire s are included in SPM.
29.Section 13. 7.2.3 Immunogenicity Analyses (Section 14 deleted)
For each subject, the results and titers of anti- GSK2857916 binding antibodies will be 
listed for each assessment time point.  The frequency  and percentage of subjects wi th 
positive and negative results will be summarized for each assessment time and overall for 
each subject by  dose cohort.
Rationale for Change: Section was placed in Safety  Anal yes sections.
2012N155299_05 CONFIDENTIA L
BMA117159
25230.Section 13.7.8 Health Outcome Analyses
Symptom imact and HRQoL  will be assessed using the e -Diary . Chage from baseline and 
change over time will be summarized. 
31.The calculation of scores and methods to deal with missing data will be provided in 
the RAP. Section 16.3 Appenidx 3: Response Definition after Treatment for 
Patients with CLL
Entire section deleted as CLL is no longer a hematologic malignancy  under investigator 
in Part 2. 
32. Section 16.6 Appendix 7 Pharmacogenetics (PGx) Genetics
Updated with current template language which allows for analyses of genetic variants
with disease susceptibility , severit y, and progression of disease.
2012N155299_05 CONFIDENTIA L
BMA117159
25316.11.5. Amendment 5
Amendment 5 applies to all sites in Canada, United Kingdom, and United States
The protocol Amendment 4 dated 05 May  2016 (applied to all sites) is replaced b y 
Amendment 5 with the effective date of DD MMM YYYY .
Summary of Changes
The following protocol changes have been implemented to include additional follow up 
of multiple my eloma subjects for ocular exams (for those whose corneal signs or 
symptoms have not resolved), additional patient reported outcome instruments, addition 
of time -to-event endpoints as exploratory  objectives. Subjects who have completed 
treatment or the 3 month follow up visit (end of study ) prior to amendment 5 will be 
reconsented for further follow up and survival status. Other administrative changes are 
also included
Original text display ed as strikethrough indicates replaced or removed text. New text is 
display ed as underline. Revisions within tables is either presented with the entire table or 
display ed as text (i.e., for larger tables). Ty pos or minor word changes are not presented.
List of Changes
1.List of Abbreviations
CI Confidence interval
DOR Duration of response
NEI-VFQ -25 National Ey e Institute Visual Functioning Questionnaire - 25
OSDI Ocular S urface Disease Index
PFS Progression- free survival
SD Stable disease
TTP Time to progression
Rationale for Change : Updated to include new abbreviations used within the 
amendment.
2012N155299_05 CONFIDENTIA L
BMA117159
2542.Protocol Synopsis
STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES
Objective Endpoint
Exploratory
To explore the effect of GSK2857916 on bone 
pain symptoms (including bone pain, fatigue 
and visual symptoms) and impacts on and 
HRQoL in subjects with relapsed/refractory 
MM (Part 2)Changes from baseline in bone pain/fatigue 
and ana lgesic use as measured by the eDiary
Interviews with subjects to further characterize 
changes in bone pain symptoms (including 
bone pain, fatigue and visual symptoms) and 
impacts on HRQoL
To explore changes in visual symptoms and 
function following discontinuation of treatment 
with GSK2857916 Changes in visual symptoms and impacts as 
measured by the OSDI and NEI -VFQ -25 
following treatment discontinuation
 Follow -up telephone interviews conducted to 
further understand subjects experience w ith 
visual symptom s and changes in symptoms 
and related impacts follow ing treatment 
discontinuation
To explore the initial anti -tumor activity of 
GSK2857916 in subjects with 
relapsed/refractory MM in terms of time -to-
event (TTE) endpoints (Part 2 MM)Time to progression (T TP), defined as: the 
time from first dose until the earliest date of 
PD per International Multiple Myeloma 
Working Group (IMWG), or death due to PD.
Duration of response (DOR), defined as: the 
time from first documented evidence of PR or 
better; until the time when disease progression 
(PD) is documented per IMWG; or death due 
to PD occurs in participants who achieve a 
response, i.e. confirmed PR or better.
Time to response (TTR), defined as: the time 
betw een the date of first dose and the first 
documented evidence of response (PR or 
better).
Progression -free survival (PFS), defined as: the 
time from first dose until the earliest date of 
disease progression (PD) per IMWG, or death 
due to any cause.
Rationale for Change :To align with changes made in the mai n Objectives and 
Endpoints table.
PATIENT REPORTED OUTCOMES
Part 2/ MM cohort : changes in sy mptoms and health -related qualit y of life (HRQoL) will 
be assess ed with the use of the Bon e Pain/Fatigue diary .
Changes in visual s ymptoms and impacts with the use of the OSDI and NEI -VFQ -25
2012N155299_05 CONFIDENTIA L
BMA117159
255Rationale for Change :Questionnaires added to obtain additional patient information on 
the resolution of corneal events after the treatment period .
STATISTICAL METHODS
Part1: After each dosing cohort, the N -CRM will be used to recommend the next dose 
level based on observed dose- limiting toxicities (DLTs).  The dose escalation decisions 
will be based on this recommendation as well as the totality  of the safet y, 
pharmacokinetic, and pharmacod ynamic data.
Part 2: Futility  anal yses will be performed on the MM cohort after approximately  15, 22, 
and 30 evaluable subjects have been enrolled. The methodology  utilized is based on the 
predictive probability  of success if enrollment continues to 40 subjects [ Lee, 2008].
Clinical Activity
The exact 95% confidence interval (CI) for overall response rate (ORR) and clinical 
benefit rate (CBR) will be provided. Subjects with unknown or missing response will be 
treated as non -responders, i.e., these subjects will be included in the denominator when 
calculating percentages of response.
For the Part 2 MM population, additional exploratory  time -to-event (TTE) endpoint will 
include TTP, DOR, TTR, and PFS, as data permits. For all the TTE endpoints listed 
above, median TTE with 95% CI  will be estimated employ ing the Kaplan- Meier method 
as data permits. A Kaplan-Meier survival curve will be generated. The number and 
percentage of subjects who had the event or were censored will also be reported.
Adverse Events : Adverse events will be summarized by  frequen cy and proportion of 
total participants, by  system organ class and preferred term. Separate summaries will be 
given for all AEs, treatment-related AEs, SAEs, and AEs leading to discontinuation of 
study  treatment.
The incidence of deaths and the primary  cause of death will be summarized.
Clinical Laboratory Evaluation : The evaluation of clinical laboratory  tests will focus 
on selected laboratory  analy tes from the hematology  and blood chemistry  panel.
Descriptive statistics (mean, standard deviation, median, range) will be used to 
summarize observed laboratory  values and change from baseline in observed value at 
each scheduled visit or worst- case post baseline, as appropriate.
The worst -case-toxicity  grade in hematology  and chemistry  result during the tr eatment 
will be summarized. Shift tables from baseline to the worst toxicity  grade during 
treatment will be provided for each laboratory  analy te.
Other Safety Measures : Data for vital signs, electrocardiograms (ECGs), and 
echocardiograms (ECHOs) will be summarized. For continuous variables, these 
summaries will include sample size, mean, median, standard deviation, minimum, and 
2012N155299_05 CONFIDENTIA L
BMA117159
256maximum.  For categorical variables, the summaries will include frequencies and 
corresponding percentages.   
Rationale for Change :To further clarify and define statistical analy ses.
3. Section 2.0 Objective(S), Endpoint(S) And Hypothesis
Objective Endpoint
Exploratory
To explore the effect of GSK2857916 on bone 
pain/fatigue symptoms (including bone pain, 
fatigue and visual symptoms) and impacts on
and HRQoL in subjects with relapsed/refractory 
MM (Part 2)Changes from baseline in bone pain/fatigue 
and analgesic use as measured by the eDiary
Interviews with subjects to further characterize 
changes in bone pain symptoms (including 
bone pain, fatigue and visual symptoms) and 
impacts on HRQoL
To explore changes in visual symptoms and 
function following discontinuation of treatment 
with GSK2857916 (Part 2 MM) Changes in visual symptoms and impacts as 
measured by the OSDI and NEI -VFQ -25 
following treatment discontinuation
 Follow -up telephone interviews conducted to 
further understand subjects experience w ith 
visual symptoms and changes in symptoms 
and related impacts follow ing treatment 
discontinuation
To explore the initial anti -tumor ac tivity of 
GSK2857916 in subjects with 
relapsed/refractory MM in terms of time -to-
event (TTE) endpoints (Part 2 MM)Time to progression (TTP), defined as: the 
time from first dose until the earliest date of 
PD per International Multiple Myeloma 
Working Grou p (IMWG), or death due to PD.
Duration of response (DOR), defined as: the 
time from first documented evidence of PR or 
better; until the time when disease progression 
(PD) is documented per IMWG; or death due 
to PD occurs in subjects who achieve a 
response , i.e. confirmed PR or better.
Time to response (TTR), defined as: the time 
betw een the date of first dose and the first 
documented evidence of response (PR or 
better).
Progression -free survival (PFS), defined as: the 
time from first dose until the earlies t date of 
disease progression (PD) per IMWG, or death 
due to any cause.
Rationale for Change :To further define and clarify  the objectives of the QoL 
questionnaire and interviews ; to implement follow up questionnaires for patients 
experiencing ocular s ymptoms post dosing; to further define and clari fy statistical 
endpoints.
2012N155299_05 CONFIDENTIA L
BMA117159
2574. Section 5.2.1. Inclusion Criteria
Table 14 Adequate Organ S ystem Function
System Laboratory Values
Total bilirubin ≤1.525X ULN (isolated bilirubin ><1.5xULN is 
acceptable if bilirubin is fractionated and direct 
bilirubin <35%)
Rationale for Change : Clarification as per Note to file submitted to all sites.
5. Section 6.2 Subject Completion Criteria
For Part 1 (dose -escalation phase), a completed subject is one who has completed at least 
1 cycle of study  treatment and an End of Study  Visit without events causing them to 
withdraw or discontinue from the study  for reasons listed   in Section 6.3  For Part 2 
(expansion coho rt), a completed subject is one who has received at least one dose of 
study  treatment without events causing them to withdraw or discontinue study  treatment 
for reasons listed in Section 6.3and completed an End of Study  Visit.
A participant will be consid ered to have completed the study  if he or she has received at 
least one dose of the study treatment and, has died before the end of the study , has not 
been lost to follow- up, or has not withdrawn consent from study  participation.
Rationale for Change : To c larify subject study completion criteria.
2012N155299_05 CONFIDENTIA L
BMA117159
2586. Section 7.1.2.1. Every 3 Weeks Dosing Schedule for Multiple Myeloma
Time and Events Table for Full Study (Cycle = 21 days)
Study 
Assessments1Screen2Day 
1 
C1Day 
8 
C1Day 
15 
C1Day 1 
C2D1 of C3 -C16End of 
Study 
Treatment34Monthly 
Follow 
up353-
Month 
Off-
study 
Follow -
up
Ocular Exam X3 X4At the start of 
each cycle4X4 X35
Pregnancy 
TestX10At the start of 
cycles 510, 910, 
1310X10 X11 X11
OSDI X31 X31
NEI-VFQ- 2531 X31 X31
Exit Int erview X3132
Follow -up 
InterviewX33
Survival Status X29X29
Subsequent 
TreatmentX29
X29
4. On-study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on 
cornea); window for exams is up to 3 days prior to dosing .In the event that a subject has a dose delay due to a non -
ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may 
be omitted if the participant did not have corneal signs on the previous exam and does not have any new corneal 
symptoms.
5. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 
minutes, +30 minutes (515 min) after SOI, EOI, a nd 1 hour post EOI.  On subsequent dosing days, vital signs must 
be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI, and EOI.   On days where vital sign 
timepoints align with PK sampling timepoints, vital signs should be assesse d prior to PK samples being 
drawn.
29. All participants should be followed for survival for 1 year from last subject last dose. Record subject’s survival 
status and whether subsequent treatment for disease was given.  Subject does not need to come in for visit.
Participants who have completed treatment or the 3 month follow up visit (end of study) prior to amendment 5 will be 
reconsented for further follow up and survival status.
31. OSDI and NEI- VFQ- 25 to be administered during end of study treatment visit.  Additional assessments for subjects 
who are experiencing corneal symptoms to be completed via telephone on a monthly basis for up to 1 year, or until 
resolution of symptoms (whichever comes first) during the follow -up period. 
32. Exit interview to b e performed within 14 21 days of end of study visit
33. Optional follow- up telephone interview interview to explore visual symptoms and changes in symptoms and related 
impacts following treatment discontinuation be performed at least 6 months following the End of Study Treatment visit.  
This interview would only be for those subjects who experienced corneal symptoms during treatment and consent to 
participate.
34. End of treatment visit should be performed within 30 days (+7 days) after the last dose or pri or to the start of new 
anti-cancer treatment, whichever is earlier. In cases where more than 30 days (+7 days) have elapsed from the date of 
the subject’s last dose due to dosing delays and a subsequent decision to take the subject off treatment, the end o f 
study treatment visit should be scheduled as soon as possible to allow the final assessments to be performed at the 
earliest date.
35. Participants with corneal signs or symptoms at the end of study treatment visit should be monitored by ophthalmic 
exam once a every month after the last study dose until deemed clinically stable by an eye care professional complete 
resolution or for 12 months (whichever comes first). Corneal exams to include BCVA and slit lamp examination (with 
2012N155299_05 CONFIDENTIA L
BMA117159
259special focus on cornea). Pa rticipants who have completed treatment or the 3 month follow up visit (end of study) will 
be reconsented for further additional ophthalmology follow up.
36. The 3- month off study follow up visit should be performed within 3 months (90 days) (±7 days) afte r the last dose. 
The subject is not required to come to the clinic for this visit (except when a pregnancy test is required). The 
assessments can be performed by phone calls, email or other means of communication.
Rationale for Change :To implement monthl y follow ups and clarify  administrative 
inconsistencies in the Time and Events Table.    Increase the window for performing the 
Exit I nterview in order to allow additional flexibility  in scheduling.
7. Section 7.1.2.3. Dose Expansion Every 3 Weeks Dosing Sche dule for 
Lymphomas
Study 
Assessments1
Screen2Day 
1 
C1Day 
8 C1Day 
15 
C1Day 1 
C2D1 of C3 -C16End of 
Study 
Treatment26Monthly 
Follow 
up273-
Month 
Off-
study 
Follow -
up
Ocular Exam
X3 X4At the start of 
each cycle4X4 X27
Pregnancy 
Test X10At the start of 
cycles 510, 910, 
1310X10 X11 X11
Survival Status
X25 X25
Subsequent 
Treatment X25 X25
4. On-study exams to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on 
cornea) ; window for ex ams is up to 3 days prior to dosing.   In the event that a subject has a dose delay due to a non -
ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may 
be omitted if the participant did not have corneal signs on the previous exam and does not have any new corneal 
symptoms. investigator determines that it is not medically necessary and the subject does not have any new ocular 
symptoms. 
5. On initial (first infusion) dosing day, vital signs must be assessed at pre -dose (within 30 minutes prior to SOI), +10 
minutes, +30 minutes (± 515min) after SOI, EOI, and 1 hour post EOI.  On subsequent dosing days, vital signs must 
be assessed at pre -dose (within 30 minutes prior to SOI), +30 minutes after SOI , and EOI.  On days where vital sign 
timepoints align with PK sampling timepoints, vital signs should be assessed prior to PK samples being 
drawn.  
21. CT/PET or CT scans from within 21 days prior to first dose are acceptable. CT scans are acceptable at a ll 
restaging assessments unless CR is suspected, in which case a PET/CT scan will be obtained to confirm CR.
25. Record subject’s survival status until last subject completes or discontinues treatment and whether subsequent 
treatment for disease was given.   Subject does not need to come in for visit.
26.End of treatment visit should be performed within 30 days (+7 days) after the last dose or prior to the start of new 
anti-cancer treatment, whichever is earlier. In cases where more than 30 days (+7 days) h ave elapsed from the date of 
the subject’s last dose due to dosing delays and a subsequent decision to take the subject off treatment, the end of 
study treatment visit should be scheduled as soon as possible to allow the final assessments to be performed a t the 
earliest date.
27. All participants should be followed for survival for 1 year from last dose. Participants with corneal signs or 
symptoms at the end of study treatment visit should be monitored by ophthalmic exam every month after the last study 
2012N155299_05 CONFIDENTIA L
BMA117159
260dose until deemed clinically stable by an eye care professional or for 12 months (whichever comes first). Corneal 
exams to include BCVA and slit lamp examination (with special focus on cornea).
Rationale for Change :To align with additional follow ups implem ented in the MM 
cohort.
8. Section 7.1.2.4 .Dose Expansion Weekly Dosing Schedule for Lymphomas
4. On -study exams, to include BCVA (best -corrected visual acuity) and slit lamp examination (with special focus on 
cornea); window for exams is up to 3 days pri or to dosing . In the event that a subject has a dose delay due to a non -
ocular toxicity and an ocular exam has been performed for that cycle, a repeat ocular exam 3 days prior to dosing may 
be omitted if the participant did not have corneal signs on the pr evious exam and does not have any new corneal 
symptoms.
Rationale for Change : To clarify  that ocular exams do not need to occur if already  
completed in that cy cle if there are no corneal signs and symptoms after the treatment 
period.
2012N155299_05 CONFIDENTIA L
BMA117159
2619. Section 7.3 Safety E valuations
Section 7.3.6. Ocular Exam
An ocular exam to include BCVA (best -corrected visual acquity ), slit lamp examination 
(with special focus on the cornea), intraocular pressure, and dilated funduscopic 
examination will be conducted for all subjects at screening. Additional exams will be 
performed as specified in the Time and Events Tables (Section 7.1) during the treatment 
period and at monthly  follow -up visits as clinically  indicated. 
Rationale forChange :To add further follow up visits to assess corneal signs and 
symptoms after the treatment period .
Section 7.3.10. Visual Functioning Questionnaires
The impact of potential ocular toxicity on function and health -related quality  of life will 
be assessed with the use of 2 visual function questionnaires: the National Ey e Institute 
Visual Functioning Questionnaire- 25 (NE I VFQ -25), and the Ocular Surface Disease 
Index (OSDI).  Subjects will complete the self- administered versions of these two 
assessments during their End of Study  Treatment visit.  Subjec ts who are unable to 
complete the questionnaire on their own due to blurry  vision, and require assistance can 
have the questionnaire read to them by  an interviewer.  If the questionnaires are 
administrated by  an Interviewer, then the questionnaire should be read to the subjects 
verbatim, and subject responses should be recorded directly  without any  interpretation.  
Subjects who continue to experience visual s ymptoms after discontinuation of study  
treatment will complete additional interviewer -administered assessments via telephone on 
a monthly  basis for up to 1 y ear during the Follow -up period or until the resolution of 
their visual sy mptoms, whichever comes first.
Section 7.3.10. 1. National Eye Institute Visual Functioning Questionnaire-25
The NEI -VFQ -25 consists of a base set of 25 vision -targeted questions representing 11 
vision -related constructs, plus an additional single -item general health rating question 
[Mangione ., 2001 ].  The NEIVFQ -25 generates the following vision- targeted sub -scales:  
global vision rating difficulty  with near vision activities; difficulty  with distance vision 
activities; limitations in social functioning due to vision; role limitations due to vision; 
dependency  on others due to vision; mental health sy mptoms due to vision; dri ving 
difficulties; limitations with peripheral vision, limitations with color vision; and corneal 
pain.  I n addition to the core items from the NEI -VFQ -25, select questions from the 
Appendix of Optional Additional Questions will be administered to further assess the 
impact of corneal events on visual function.  
Section 7.3.10. 2. Ocular Surface Disease Index Questionnaire
The Ocular Surface Disease Index (OSDI) is a 12 -item questionnaire designed to assess 
both the frequency  of dry ey e symptoms and their impact on vision -related functioning 
[Schiffman, 2000]. The OSDI  has demonstrated good reliability , validity , sensitivity , and 
specificit y, and can be used as a complement to other clinical and subjective measures of 
dry eye disease b y providing a quantifi able assessment of dry  eye symptom frequency  
and the impact of these symptoms on vision- related functioning.
2012N155299_05 CONFIDENTIA L
BMA117159
262Rationale forChange :To implement questionnaires at the end of stud y treatment visit 
and during follow -up for patients experiencing ocular sy mptom s, in order to assess 
changes in visual s ymptoms and function following discontinuation of treatment with 
GSK2857916.
10.Section 7.8. Health Outcomes: Quality of Life
Health Outcomes EndpointsSection 7.8.1. Bone Pain/Fatigue Assessment (eDiary)
Section 7.8.2. Exit Interview and Follow -up Interview
To further evaluate disease and treatment related symptoms (including bone pain and 
fatigue, and visual s ymptoms) and associated impacts on function and health -related 
quality -of-life, participants in the Part 2 multiple my eloma cohort will complete an 
optional Exit I nterview conducted via telephone.  The interview will be conducted by  a 
trained interviewer and will be audio recorded for transcription and anal ysis.  The 
telephone interview should be conducted within 21 day s following completion of the End 
of Study  Treatment visit.
Subjects who have experienced ocular s ymptoms during the treatment period will have 
the option to also consent to participate in an optional Follow- up interview.  The Follow -
up interview wi ll be conducted by  a trained interview via telephone at least 6 months 
following the End of Study  Treatment visit.  The Follow -up interview will focus on 
visual sy mptoms experienced b y the subject, impacts on function and health -related 
quality -of-life and management and resolution of their visual sy mptoms following 
discontinuation of study  treatment.
Both the Exit I nterview and Follow -Up interview are optional, and the failure to complete 
either interview will not constitute a protocol deviation.
Rationale forChange :To implement follow up interviews for patients who experienced 
corneal symptoms to further understand changes in visual sy mptoms and function 
experienced during the study  and following discontinuation of treatment with 
GSK2857916.
11. Section 13.4.1 Analysis Populations
The ‘ All Treated ’ population is defined as all eligible subjects who receive at least 1dose 
of study  treatment. An incorrect treatment schedule or drug administration or an earl y 
termination of treatment will not result in exclusi on of subjects from this population. 
Subjects with major deviations from the eligibility criteria affecting safet y or from the 
treatment schedule at the DL T evaluation period (1 cy cle: 21 day s for once every  3 weeks 
schedule or 28 day s for once weekl y schedule) for reasons other than toxicity  may  be 
presented in separate tables/listings.
The ‘All Treated’ population will further be classified in the following sub -populations.
2012N155299_05 CONFIDENTIA L
BMA117159
263oPart 1: all Part 1 subjects of All Treated population. Note, subjects in Part 1 ar e 
exclusively  multiple m yeloma patients. 
oPart 2 MM: all Part 2 MM subjects of All Treated population 
oAll Treated MM: comprise of subjects in Part 1 and Part 2 MM.
oPart 2 NHL : all Part 2 lymphoma subjects of All Treated population.
The ‘ DLT Evaluable ’ population in Part 1 enables an appropriate evaluation of study  
DLTs. It is defined as those subjects fulfilling the ‘All Treated’ population criteria, and 
having met the following adequate exposure criteria: 
oFor Schedule 1 (once every  3 weeks dosing) subje cts received a complete infusion 
in cy cle 1. 
oFor Schedule 2 (once weekly  dosing for 3 consecutive weeks, 1 week rest) 
subjects receive three infusions, two of which must be complete infusions, in 
cycle 1. (as increases up to ≤30% are implemented between cohorts, less than 2 
complete infusions would result in a total dose closer to the previous dose 
investigated).
Any subject in the “All Treated” population who experiences a DLT, as defined in 
Secti on 3.3.3 will also be included in the DLT evaluable population regardless of 
exposure.
The ‘PK’ ‘All Evaluable (MM)’ population is a subset of the ‘All Treated’ population, 
who were initially  treated at RP2D in the expansion cohort and have at least two post-
baseline disease assessments or they  have progressed or died or permanently  
discontinued treatment. This population will be used for the futility  anal ysis of the MM 
expansion cohort.
The ‘ Pharmacokinetic (PK)Population ’ is defined as those subjects in t he “All 
Treated” population from whom at least one PK sample was obtained, analyzed, and was 
measurable. 
The ‘ Pharmacodynamic (PD) Population ’ is defined as those subjects in the “All 
Treated” population from whom at least one P D sample was obtained, anal yzed, and was 
measurable.
Rationale for Change :To further clarify  and define statistical populations.
12. Section 13.6 Interim Analysis ,Section 13.6.2 Part 2
Subjects will not be replaced when they discontinue the study  due to: Progression 
(symptomatic or o therwise), toxicity  related to GSK2857916, or lack of efficacy .
Other administrative interim analy ses may  be performed if needed.
2012N155299_05 CONFIDENTIA L
BMA117159
264Final anal ysis of MM population may  be performed separatel y, before the NHL cohort 
completes the study . 
Rationale forChange : To further define timeframe for MM population in relation to 
NHL cohort.
13. Section 13.7.2.2 Adverse Events
Characteristics (e.g. number of occurrences, action taken, grade, etc) of the following 
AEs of special clinical interest will be summarized separate ly: corneal events, 
hematologic toxicities (including but not limited to thrombocy topenia and neutropenia), 
infusion related reaction etc. Details will be provided in the RAP.
The incidence of deaths and the primary  cause of death will be summarized.
Ratio nale forChange :To further define AEs of clinical interest.
14. Section 13.7.2.3 Clinical Laboratory Evaluations
Hematology  and clinical chemistry  data will be summarized using frequencies and 
proportions according to National Cancer Institute- Common Toxici ty Criteria for 
Adverse Events (NCI -CTCAE) (Version 4.0) .  The evaluation of clinical laboratory tests 
will focus on selected laboratory  analy tes from the hematology  and blood chemistry  
panel. Laboratory  test results outside the reference ranges that do not have associated 
NCI-CTCAE criteria will be summarized using proportions. 
Descriptive statistics (mean, standard deviation, median, range) will be used to 
summarize observed laboratory  values and change from baseline in observed value at 
each scheduled vi sit or worst -case post baseline, as appropriate.
The worst -case-toxicity  grade in hematology  and chemistry  result during the treatment 
will be summarized. Shift tables from baseline to the worst toxicity  grade during 
treatment will be provided for each la boratory  analy te.
Further details will be provided in the Reporting and Analy sis Plan (RAP).
Rationale forChange :To further define anal ysis of clinical laboratory  evaluations.
15. Section 13.7.2.5 Other Safety Measures
Data for vital signs, electrocardiogra ms (ECGs), and echocardiograms (ECHOs) will be 
summarized based on predetermined criteria identified to be of potential clinical concern 
(PCI ).  For continuous variables, these summaries will include sample size, mean, 
median, standard deviation, minimum, and maximum. For categorical variables, the 
summaries will include frequencies and corresponding percentages. Further details will 
be provided in the Reporting and Anal ysis Plan (RAP).
2012N155299_05 CONFIDENTIA L
BMA117159
265Rationale forChange :To further define anal ysis of ECGs and ECHOs. 
16. Section 13.7.7 Clinical Activity Analyses
Clinical activity  will be calculated based on Overall Response Rate (ORR), which is 
defined as the percentage of subjects with confirmed stringent complete response (sCR), 
complete response (CR), very  good partial response (VGPR), and partial response (PR) 
as assessed b y 2011 recommendation of the International Myeloma Working Group 
(IMWG) Panel I ( Appendix 1 ).  Clinical benefit rate may  be considered in addition to 
ORR.
Overall Response Rate (ORR) is one of the se condary  endpoints to measure clinical 
activity  of this study .  
For multiple my eloma, ORR is defined as the percentage of subjects with a confirmed PR 
or better (i.e. PR, VGPR, CR and sCR), according to the I MWG Panel I (Appendix 1), as 
assessed b y the inv estigator. I n addition, Clinical Benefit rate (CBR) is defined as the 
percentage of subjects with a confirmed MR or better (i.e.MR, PR, VGPR, CR and sCR), 
according to the IMWG Panel I  (Appendix 1), as assessed by  the investigator.
The number and percentag e of subjects in the following response categories will be 
presented sCR (stringent complete response), (complete response) CR, (very good partial 
response) VGPR, (partial response) PR, (minimal response) MR, stable disease (SD), 
progressive disease (PD), and not evaluable (NE)
sCR+CR+VGPR+PR for overall response (ORR)
sCR+CR+VGPR+PR+MR for Clinical Benefit rate (CBR)
The corresponding exact 95% CI  for ORR and Clinical Benefit Rate (CBR) will also be 
provided.  Subjects with unknown or missing response will be treated as non -responders, 
i.e., these subjects will be included in the denominator when calculating percentages of 
response.
For l ymphomas, ORR is Clinical activity  for l ymphomas will be calculated based on 
ORR defined as the percentage of subjects with confirmed CR, or PR, as described in the 
Revised Response Criteria for Malignant Ly mphoma ( Appendix 2 ).ORR for ly mphomas 
will be summarized in a similar way  as multiple my eloma. The corresponding exact 95% 
CI for ORR will also be provided.
Other explor atory  time -to-event (TTE) endpoints related to clinical activity for Part 2 
(MM) of this study  are TTP, DOR, TTR, and PFS.
Time to disease progression (TTP) is defined as the time from first dose until the 
earliest date of PD per IMWG, or death due to PD. Determination of dates of TTP event 
and dates for censoring will be described in the RAP. Duration of response (DOR) is 
defined as the time from first documented evidence of PR or better until disease 
progression (PD) per IMWG, or death due to PD among subjects who achieve a response 
2012N155299_05 CONFIDENTIA L
BMA117159
266(i.e. confirmed PR or better ). Responders without disease progression will be censored at 
the censoring time point for TTP. 
Time to response (TTR) is defined as the time between the date of first dose and the 
first documented evidence of response (PR or better). Subjects without confirmed 
response (PR or better) will be censored at the censoring date for TTP. 
Progression -free survival (PFS) is defined as the time from first dose until the earliest 
date of disease progression ( PD) per IMWG, or death due to an y cause. Determination of 
dates of PFS event and dates for censoring will be described in the RAP. 
For all the TTE endpoints described above, median TTE with 95% CI  will be estimated 
employ ing the Kaplan- Meier method as dat a permits. A Kaplan -Meier survival curve will 
be generated. The number and percentage of subjects who had the event or were censored 
will also be reported.
Exploratory  subgroup analy ses may  be performed for all endpoints to measure clinical 
activity  as app ropriate.
Overall Survival : The protocol is amended to collect long- term survival data (i.e. up to 1 
year after last subject completes or discontinues treatment). Subjects who are already  
completed the study will be contacted to request re -consent.
If all the patients (who were alive at the time of study  completion) can be re -consented, 
OS landmark anal ysis may  be performed at 9 and 12 months using Kaplan -Meier analy sis 
as data permits.
Otherwise, onl y descriptive anal ysis (number and % of deaths and lost t o follow -up) will 
be performed.
Rationale forChange :To further define efficacy anal ysis and add anal ysis of time -to-
event endpoints. 
17. Section 13.7.8. Health Outcome Analyses
Symptom impact and HRQoL  will be assessed using the e -Diary . Change from baseli ne 
and change over time will be summarized. 
The calculation of scores and methods to deal with missing data will be provided in the 
RAP.
Visual Functioning Questionnaire ( NEI VFQ -25 and OSDI) : Data will be collected from 
end of treatment (EOT) visit as baseline. Additional data will be collected in follow-up 
visits on a monthly  basis for subjects with ongoing corneal events or signs at EOT for 1 
year or until resolution, whichever occurs first. These data will not be collected for 
subjects who alread y comp leted the treatment. Calculation of scores will be provided in 
the RAP. Due to limited number of on -treatment subjects at the time of protocol 
amendment, only  a listing by  subject will be generated.
Rationale forChange :   To further clarify  how the NEI -VFQ-25 and OSDI will be 
reported .
2012N155299_05 CONFIDENTIA L
BMA117159
26718. Section 15. References
Mangione, C. M., P. P. Lee, P. R. Gutierrez, K. Spritzer, S. Berry , R. D. Hay s and I. 
National Ey e Institute Visual Function Questionnaire Field Test. " Development of the 
25-item National Ey e Institut e Visual Function Questionnaire." Arch Ophthalmol 2001; 
119(7): 1050-1058.
Schiffman, R. M., M. D. Christianson, G. Jacobsen, J. D. Hirsch and B. L. Reis. 
"Reliability  and validity  of the Ocular Surface Disease Index." Arch Ophthalmol 2000; 
118(5): 615-621.
Rationale forChange : References added to align with updates to questionnaires.